<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD001943.pub2" GROUP_ID="SCHIZ" ID="011499092410561218" MERGED_FROM="" MODIFIED="2015-10-14 14:35:21 +0100" MODIFIED_BY="Claire Irving" REVIEW_NO="055" REVMAN_SUB_VERSION="5.3.5 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="11.0">
<COVER_SHEET MODIFIED="2015-10-14 14:27:28 +0100" MODIFIED_BY="[Empty name]">
<TITLE>Loxapine for schizophrenia</TITLE>
<CONTACT>
<PERSON ID="2020219582E26AA20003EB8AEB882A26" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Abhijit</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Chakrabarti</LAST_NAME>
<SUFFIX/>
<POSITION>Consultant</POSITION>
<EMAIL_1>abhijitchakrabarti@yahoo.co.uk</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT/>
<ORGANISATION>Becklin Centre</ORGANISATION>
<ADDRESS_1>Alma Road</ADDRESS_1>
<ADDRESS_2>St James' University Hospital</ADDRESS_2>
<CITY>Leeds</CITY>
<ZIP>LS9 7BE</ZIP>
<REGION/>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CONTACT>
<CREATORS MODIFIED="2015-10-14 14:23:09 +0100" MODIFIED_BY="Claire Irving">
<PERSON ID="2020219582E26AA20003EB8AEB882A26" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Abhijit</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Chakrabarti</LAST_NAME>
<SUFFIX/>
<POSITION>Consultant</POSITION>
<EMAIL_1>abhijitchakrabarti@yahoo.co.uk</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT/>
<ORGANISATION>Becklin Centre</ORGANISATION>
<ADDRESS_1>Alma Road</ADDRESS_1>
<ADDRESS_2>St James' University Hospital</ADDRESS_2>
<CITY>Leeds</CITY>
<ZIP>LS9 7BE</ZIP>
<REGION/>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="14380" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Anne-Marie</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Bagnall</LAST_NAME>
<SUFFIX/>
<POSITION>Reader</POSITION>
<EMAIL_1>A.Bagnall@leedsbeckett.ac.uk</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Faculty of Health and Social Sciences</DEPARTMENT>
<ORGANISATION>Leeds Beckett University</ORGANISATION>
<ADDRESS_1>Calverley Street</ADDRESS_1>
<ADDRESS_2/>
<CITY>Leeds</CITY>
<ZIP>LS1 3NE</ZIP>
<REGION/>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1>+44 113 8124333</PHONE_1>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="1184E61F82E26AA201DC7B3E21933F3B" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Pierre</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Chue</LAST_NAME>
<SUFFIX/>
<POSITION>Clinical Professor</POSITION>
<EMAIL_1>pchue@ualberta.ca</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Psychiatry</DEPARTMENT>
<ORGANISATION>University of Alberta</ORGANISATION>
<ADDRESS_1>3rd Floor 108th Street Building</ADDRESS_1>
<ADDRESS_2>9942-108 Street</ADDRESS_2>
<CITY>Edmonton</CITY>
<ZIP>T5K 2J5</ZIP>
<REGION>AB</REGION>
<COUNTRY CODE="CA">Canada</COUNTRY>
<PHONE_1>+1 780 342 7944</PHONE_1>
<PHONE_2/>
<FAX_1>+1 780 425 9317</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="7447" ROLE="AUTHOR">
<PREFIX>Mr</PREFIX>
<FIRST_NAME>Mark</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Fenton</LAST_NAME>
<SUFFIX/>
<POSITION>Editor</POSITION>
<EMAIL_1>mark.fenton@nice.org.uk</EMAIL_1>
<EMAIL_2>m-fenton@ntlworld.com</EMAIL_2>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Database of Uncertainties about the Effects of Treatments (DUETs)</DEPARTMENT>
<ORGANISATION>National Institute for Health and Clinical Excellence</ORGANISATION>
<ADDRESS_1>Level 1A, City Tower, Piccadilly Plaza</ADDRESS_1>
<ADDRESS_2>Middle Way</ADDRESS_2>
<CITY>Manchester</CITY>
<ZIP>M1 4BD</ZIP>
<REGION/>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1>+44 (0)161 219 3788</PHONE_1>
<PHONE_2>+44(0)1789 552225</PHONE_2>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="0046034D82E26AA201FDBE17163AA314" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Vikram</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Palanisamy</LAST_NAME>
<SUFFIX/>
<POSITION>Consultant Psychiatrist</POSITION>
<EMAIL_1>drpvikram@yahoo.com</EMAIL_1>
<EMAIL_2>drpvikram@gmail.com</EMAIL_2>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>East Cheshire Learning Disability Team</DEPARTMENT>
<ORGANISATION>Cheshire and Wirral Partnership NHS Foundation Trust</ORGANISATION>
<ADDRESS_1>Rosemount Lodge</ADDRESS_1>
<ADDRESS_2>Off Chester Road</ADDRESS_2>
<CITY>Macclesfield</CITY>
<ZIP>SK11 8QA</ZIP>
<REGION>Cheshire</REGION>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1>01625 663 631</PHONE_1>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="2E565EBA82E26AA2004A583DDAE87262" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Winson</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Wong</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>drbywwong@doctors.org.uk</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT/>
<ORGANISATION>Health Education Yorkshire and the Humber</ORGANISATION>
<ADDRESS_1>Ground Floor, Don Valley House</ADDRESS_1>
<ADDRESS_2>Savile Street East</ADDRESS_2>
<CITY>Sheffield</CITY>
<ZIP>S4 7UQ</ZIP>
<REGION/>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="258C268D82E26AA2000C5DBBFFD4E447" ROLE="AUTHOR">
<PREFIX>Ms</PREFIX>
<FIRST_NAME>Jun</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Xia</LAST_NAME>
<SUFFIX/>
<POSITION>Research Associate</POSITION>
<EMAIL_1>Jun.Xia@nottingham.ac.uk</EMAIL_1>
<EMAIL_2>jun-xia@review-solutions.cn</EMAIL_2>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Cochrane Schizophrenia Group</DEPARTMENT>
<ORGANISATION>The University of Nottingham</ORGANISATION>
<ADDRESS_1>Institute of Mental Health</ADDRESS_1>
<ADDRESS_2>University of Nottingham Innovation Park, Triumph Road,</ADDRESS_2>
<CITY>Nottingham</CITY>
<ZIP>NG7 2TU</ZIP>
<REGION/>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1>+44 113 8550686</PHONE_1>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CREATORS>
<DATES MODIFIED="2015-10-14 14:27:28 +0100" MODIFIED_BY="[Empty name]">
<UP_TO_DATE>
<DATE DAY="6" MONTH="8" YEAR="2007"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="12" MONTH="9" YEAR="2012"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="1" MONTH="2" YEAR="2016"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="3" YEAR="1999"/>
<REVIEW_PUBLISHED ISSUE="1" YEAR="2000"/>
<LAST_CITATION_ISSUE ISSUE="4" YEAR="2007"/>
</DATES>
<WHATS_NEW MODIFIED="2015-10-14 14:27:11 +0100" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2015-10-14 14:27:11 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="14" MONTH="10" YEAR="2015"/>
<DESCRIPTION>
<P>The contributions of a previous review author, Jo Wood, have been moved to <LINK TAG="ACKNOWLEDGEMENTS" TYPE="SECTION">Acknowledgements</LINK>.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2015-10-14 14:24:31 +0100" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2015-10-14 14:24:31 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="2" MONTH="12" YEAR="2013"/>
<DESCRIPTION>
<P>32 new references from search (September 12, 2013) were added to 'Classification pending references' section of the review.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2015-10-14 14:24:28 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="26" MONTH="4" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS">
<DATE DAY="6" MONTH="8" YEAR="2007"/>
<DESCRIPTION>
<P>Substantive amendment</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES>
<SOURCE>
<NAME>Leeds Social Services</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>Jansen Cilag</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>Centre for Reviews and Dissemination, University of York</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>Cochrane Schizophrenia Group</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES>
<SOURCE>
<NAME>Centre for Reviews and Dissemination, University of York.</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2015-10-14 14:23:31 +0100" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2008-04-26 13:41:24 +0100" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2008-04-26 13:41:22 +0100" MODIFIED_BY="[Empty name]">Loxapine for schizophrenia</TITLE>
<SUMMARY_BODY MODIFIED="2008-04-26 13:41:24 +0100" MODIFIED_BY="[Empty name]">
<P>Schizophrenia is a chronic and relapsing serious mental illness with a lifetime prevalence of about 1% worldwide.</P>
<P>Typical and atypical antipsychotics provide a treatment for people with schizophrenia, with either a reduction in the episodes of psychosis or a reduction in the severity of the symptoms. However, a proportion of people still do not respond adequately to antipsychotic medication. Typical and atypical antipsychotics are associated with serious adverse effects which are not only uncomfortable for patients, but can also be associated with subsequent reduced compliance with treatment and therefore relapse in the illness.</P>
<P>Loxapine is an antipsychotic drug available in Belgium, Canada, Denmark, France, Germany, Iceland, Ireland, Netherlands, New Zealand, Spain, the UK and the USA. We systematically evaluated the effects of this antipsychotic and were able to include 41 randomised trials following the updates in 2005 and 2007.</P>
<P>Loxapine may be effective for the treatment of schizophrenia but does not differ greatly from the older typical antipsychotics (chlorpromazine, trifluperazine, perphenazine) or other atypicals (risperidone, quetipine) in respect of treatment efficacy. Loxapine, however, may cause more extrapyramidal adverse effects compared with atypical drugs.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT>
<ABS_BACKGROUND>
<P>Some authors have suggested that loxapine is more effective than typical antipsychotics in reducing the negative symptoms of schizophrenia, that extrapyramidal adverse effects are not usually seen at clinically effective antipsychotic doses and that it should therefore be classed as atypical.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES>
<P>To determine the effects of loxapine compared with placebo, typical and other atypical antipsychotic drugs for schizophrenia and related psychoses.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY>
<P>For this 2007 update, we searched the Cochrane Schizophrenia Group's Register (January 2007).</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA>
<P>We included all randomised controlled clinical trials relevant to the care of schizophrenia that compared loxapine to other treatments.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION>
<P>We independently inspected abstracts ordered papers, re-inspected and quality assessed these. For dichotomous data we calculated relative risks (RR) and their 95% confidence intervals (CI) on an intention-to-treat basis based on a fixed effects model. We calculated numbers needed to treat/harm (NNT/NNH) where appropriate. For continuous data, we calculated weighted mean differences (WMD) again based on a fixed effects model.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS>
<P>We were able to include 41 studies in this review. Compared with placebo, loxapine has an antipsychotic effect (Global effect - not improved at six weeks: n=78, 2 RCTs, RR 0.30 CI 0.1 to 0.6 NNT 3 CI 3 to 5). It is as effective as typical drugs in the short term (4 -12 weeks) (Global effect: n=580, 13 RCTs, RR 0.86 CI 0.7 to 1.1; mental state: n=915, 6 RCTs, RR 0.89 CI 0.8 to 1.1). Very limited heterogeneous data suggest that, given intramuscularly (IM), loxapine may be at least as sedating as IM haloperidol and thiothixene. Loxapine is also as effective as atypicals (risperidone, quetiapine) (n=468, 6 RCTs, RR mental state not improved 1.07 CI 0.8 to 1.5). Adverse effect profile is similar to typicals but loxapine may cause more extrapyramidal adverse effects when compared with atypicals (n=340, 4 RCTs, RR 2.18 CI 1.6 to 3.1).</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS>
<P>Loxapine is an antipsychotic which is not clearly distinct from typical or atypical drugs in terms of its effects on global or mental state. Loxapines profile of adverse effects is similar to that of the older generation of antipsychotic drugs.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2013-12-02 11:37:09 +0000" MODIFIED_BY="[Empty name]">
<BACKGROUND>
<P>For schizophrenia, choosing the most appropriate, effective and tolerable antipsychotic drug is key to maximising the usefulness of medication. According to recent treatment guidelines, both conventional/typical and atypical antipsychotic drugs may be reasonable choices in the treatment of schizophrenia (<LINK REF="REF-APA-1994" TYPE="REFERENCE">APA 1994</LINK>). </P>
<P>Typical antipsychotic drugs, such as haloperidol, chlorpromazine, and trifluoperazine are widely used as the first line treatment for people with schizophrenia, in the acute as well as in chronic forms of the illness (<LINK REF="REF-APA-1994" TYPE="REFERENCE">APA 1994</LINK>, <LINK REF="REF-Silverstone-1995" TYPE="REFERENCE">Silverstone 1995</LINK>). However, the atypical class of antipsychotic drugs, most of which have been formulated relatively recently, have made important inroads into this traditional approach (<LINK REF="REF-Wood-MacKenzie-1998" TYPE="REFERENCE">Wood MacKenzie 1998</LINK>, <LINK REF="REF-Adams-1999" TYPE="REFERENCE">Adams 1999</LINK>). </P>
<P>Atypical is a term widely used to describe some antipsychotics which have a low propensity to produce movement disorders, sedation and raised serum prolactin (<LINK REF="REF-Kerwin-1994" TYPE="REFERENCE">Kerwin 1994</LINK>). The pharmacokinetic profiles of the atypical drugs are either clozapine-like or risperidone-like (<LINK REF="REF-Kerwin-1996" TYPE="REFERENCE">Kerwin 1996</LINK>). There is some suggestion that the different adverse effect profiles of the atypical antipsychotic group make them more acceptable to people with schizophrenia (<LINK REF="REF-Casey-1997" TYPE="REFERENCE">Casey 1997</LINK>). Certainly, the adverse effects of the typical drugs, such as movement disorders and sedation, are problematic and can result in poor compliance with treatment (<LINK REF="REF-CWG-1998" TYPE="REFERENCE">CWG 1998</LINK>). </P>
<P>The positive symptoms (delusions, hallucinations, and disordered thinking) of schizophrenia seem more responsive to the typical antipsychotic drugs than the negative symptoms. This latter cluster of symptoms (poverty of speech, lack of motivation, apathy and inability to express emotions (<LINK REF="REF-Carpenter-1994" TYPE="REFERENCE">Carpenter 1994</LINK>)), is very disabling and may respond better to the atypical antipsychotic drugs (<LINK REF="REF-APA-1994" TYPE="REFERENCE">APA 1994</LINK>, <LINK REF="REF-Silverstone-1995" TYPE="REFERENCE">Silverstone 1995</LINK>), although this too has not been adequately established (<LINK REF="REF-Kane-1996" TYPE="REFERENCE">Kane 1996</LINK>).</P>
<P>Atypical antipsychotics are more expensive than conventional drugs (<LINK REF="REF-Wood-MacKenzie-1998" TYPE="REFERENCE">Wood MacKenzie 1998</LINK>), but it has been suggested that if they do indeed reduce a person's need for inpatient services their use would result in a net reduction of costs (<LINK REF="REF-Buckley-1997" TYPE="REFERENCE">Buckley 1997</LINK>, <LINK REF="REF-Glazer-1997" TYPE="REFERENCE">Glazer 1997</LINK>). Loxapine is an old, inexpensive D2/D3 receptor antagonist with a higher affinity for D3 than D2. It also has histamine (H1), serotonin (5-HT2) and adrenergic (alpha 1)-blocking activities. Structurally it is related to clozapine. Some authors have suggested that loxapine is more effective than other 'typical' antipsychotics in reducing the negative symptoms of schizophrenia (<LINK REF="REF-Vanelle-1994" TYPE="REFERENCE">Vanelle 1994</LINK>), that extrapyramidal side-effects are not usually seen at clinically effective antipsychotic doses (<LINK REF="REF-Thomas-1998" TYPE="REFERENCE">Thomas 1998</LINK>) and that it should therefore be classed as an atypical antipsychotic.</P>
<P>Technical background<BR/>Former designation: oxilapine (<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>). Dopamine D2/D3 receptors antagonist with higher affinity for D3 than for D2. Also 5-HT2 antagonist. Structurally related to clozapine. Used in the treatment of schizophrenic disorders. Dosage 50 to 200 mg/day. First French reports in 1965. Plasma half-life after oral administration to healthy people three to four hours; terminal half-life of a major 8-hydroxy-metabolite about eight hours. Loxapine as been known as oxilapine, LW 3170, SUM 3170, CL 71.563 (succinate), CL 62362 and S 805. It is sold as Desconex (Spain); Loxapac (Belgium, Canada, Denmark, France, Germany, Iceland, Ireland, Netherlands, New Zealand, UK); Loxitane (USA).</P>
</BACKGROUND>
<OBJECTIVES>
<P>To determine the clinical effects and safety of loxapine compared with placebo, typical and atypical antipsychotics, for treating schizophrenia and related psychoses. </P>
<P>As secondary objectives, we proposed to investigate:<BR/>i. whether people with schizophrenia described as 'treatment resistant' differed in their response from those whose illnesses were not designated as such;<BR/>ii. whether people having predominantly positive or negative symptoms of schizophrenia were more responsive to loxapine than those without this designation; and <BR/>iii. whether people experiencing their first episode of schizophrenia differed in their response from those at a later stage of their illness.</P>
</OBJECTIVES>
<METHODS MODIFIED="2013-12-02 11:37:09 +0000" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA>
<CRIT_STUDIES>
<P>We included randomised controlled trials. Where a trial was described as 'double-blind', but it was only implied that the study was randomised, we included these trials in a sensitivity analysis. If there was no substantive difference within primary outcomes (see types of outcome measures) when these 'implied randomisation' studies were added, then we included these in the final analysis. If there was a substantive difference, we only used clearly randomised trials and described the results of the sensitivity analysis in the text. We excluded quasi-randomised studies, such as those allocating by using alternate days of the week.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS>
<P>We included people with schizophrenia and other types of schizophrenia-like psychosis (e.g. schizophreniform and schizoaffective disorders), irrespective of the diagnostic criteria used. There is no clear evidence that the schizophrenia-like psychoses are caused by fundamentally different disease processes or require different treatment approaches (<LINK REF="REF-Carpenter-1994" TYPE="REFERENCE">Carpenter 1994</LINK>). If possible, people with dementing illnesses, depression and primary problems associated with substance misuse were excluded.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS>
<P>1. Loxapine: any dose.<BR/>2. Placebo.<BR/>3. Any other antipsychotic agent, divided into the atypical antipsychotics (amisulpiride, aripiprazole, clozapine, olanzapine, risperidone, quetiapine, sertindole, zotepine) and the typical antipsychotics (chlorpromazine, flupenthixol, fluphenazine, haloperidol, pericyazine, sulpiride, thioridazine, trifluperazine, zuclopenthixol).</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES>
<P>1. Death - suicide or natural causes</P>
<P>2. Leaving the study early</P>
<P>3. Clinical response<BR/>3.1 Clinically significant response in global state - as defined by each of the studies<BR/>3.2 Average score/endpoint or change in global state<BR/>3.3 Clinically significant response in mental state - as defined by each of the studies<BR/>3.4 Average score/endpoint or change in mental state<BR/>3.5 Clinically significant response on positive symptoms - as defined by each of the studies<BR/>3.6 Average score/endpoint or change in positive symptoms<BR/>3.7 Clinically significant response on negative symptoms- as defined by each of the studies<BR/>3.8 Average score/endpoint or change in negative symptoms</P>
<P>4. Extrapyramidal adverse effects<BR/>4.1 Incidence of use of antiparkinson drugs<BR/>4.2 Clinically significant extrapyramidal adverse effects- as defined by each of the studies<BR/>4.3 Average score/change in extrapyramidal adverse effects</P>
<P>5. Other adverse effects, general and specific</P>
<P>6. Service utilization outcomes<BR/>6.1 Hospital admission<BR/>6.2 Days in hospital<BR/>6.3 Change in hospital status</P>
<P>7. Economic outcomes</P>
<P>8. Quality of life/satisfaction with care for either recipients or carers by directly asking participants<BR/>8.1. Significant change as defined by each of the studies<BR/>8.2 Average score/change in quality of life/ satisfaction.</P>
<P>We grouped outcomes into the short term (up to six weeks), medium term (seven to 26 weeks) and long term (over 26 weeks).</P>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2013-12-02 11:37:09 +0000" MODIFIED_BY="[Empty name]">
<P>1. Searches for the 2005 and 2007 update</P>
<P>1.1 Electronic searching<BR/>We searched the Cochrane Schizophrenia Group Trials Register (February 2005, February 2007, and September 12, 2013) using the phrase:</P>
<P>[(*loxapin* or *oxilapin* or *loxpac* or *loxitane* or *desconex* or *cloxazepin* or *amoxapin* or *cl-71*) in REFERENCE and (*loxapin* or *oxilapin* or *loxpac* or *loxitane* or *desconex* or *cloxazepin* or *amoxapin*) in STUDY]</P>
<P>This register is compiled by systematic searches of major databases, hand searches and conference proceedings (see Group Module).</P>
<P>1.2 Reference searching<BR/>We inspected the references of all identified studies, included or excluded, for more studies.</P>
<P>2. Searches for past versions of this review (<LINK REF="REF-Murphy-2000" TYPE="REFERENCE">Murphy 2000</LINK>).<BR/>2.1 Electronic searches</P>
<P>2.1.1 We searched Biological Abstracts (January 1980 - February 1999) using the Cochrane Schizophrenia Group's phrase for both randomised controlled trials and schizophrenia (see Group search strategy) combined with the phrase:</P>
<P>[and (loxapine or LW-3170 or SUM-3170 or CL-71.563 or Loxpac or Loxitane or Desconex or oxilapine)]</P>
<P>2.1.2 We searched the Cochrane Library (Issue 1, 1999) using the phrase:</P>
<P>[loxapine or LW-3170 or SUM-3170 or CL-71.563 or loxpac or loxitane or desconex or oxilapine]</P>
<P>2.1.3 We searched the Cochrane Schizophrenia Group's Register (January 1999) using the phrase:</P>
<P>[loxapine or LW-3170 or SUM-3170 or CL-71.563 or Loxpac or Loxitane or Desconex or oxilapine or #42 =149 or #42=692]</P>
<P>(#42 is the field within this register that contains the intervention code and 149 and 692 is loxapine).</P>
<P>2.1.4 We searched CINAHL (1982 - 1999) using the phrase:</P>
<P>[(explode "Psychotic-Disorders"/all topical subheadings/all age subheadings or (schizo* in ti,ab) or (psychoti* in ti,ab) or (psychosis in ti,ab) or (psychoses in ti,ab) or ((chronic* or sever*) with mental* with (ill or illness* or disorder*))) and (loxapine or LW-3170 or SUM-3170 or CL-71.563 or Loxpac or Loxitane or Desconex or oxilapine)]</P>
<P>2.1.5 We searched EMBASE (BIDS) (January 1980 - February 1999) using the Cochrane Schizophrenia Group's phrase for both randomised controlled trials and schizophrenia (see Group search strategy) combined with the phrase:</P>
<P>[and (loxapine or LW-3170 or SUM-3170 or CL-71.563 or Loxpac or Loxitane or Desconex or oxilapine or explode "LOXAPINE"/ all subheadings)]</P>
<P>2.1.6 We searched MEDLINE (January 1966 - February 1999) using the Cochrane Schizophrenia Group's phrase for both randomised controlled trials and schizophrenia (see Group search strategy) combined with the phrase:</P>
<P>[and (loxapine or LW-3170 or SUM-3170 or CL-71.563 or Loxpac or loxitane or desconex or oxilapine]</P>
<P>2.1.7 We searched PsycLIT (January 1974 - February 1999) using the Cochrane Schizophrenia Group's phrase for both randomised controlled trials and schizophrenia (see Group search strategy) combined with the phrase:</P>
<P>[and (loxapine or LW-3170 or SUM-3170 or CL-71.563 or loxpac or loxitane or desconex or oxilapine)]</P>
<P>2.1.8 We searched LILACS (January 1982 - February 1999) using the Cochrane Schizophrenia Group's phrase for both randomised controlled trials and schizophrenia (see Group search strategy) combined with the phrase:</P>
<P>[and (loxapine or LW-3170 or SUM-3170 or CL-71.563 or loxpac or loxitane or desconex or oxilapine)]</P>
<P>2.1.9 We searched PSYNDEX (January 1977 - February 1999) using the Cochrane Schizophrenia Group's phrase for both randomised controlled trials and schizophrenia (see Group search strategy) combined with the phrase:</P>
<P>[and (loxapine or LW-3170 or SUM-3170 or CL-71.563 or loxpac or loxitane or desconex or oxilapine)]</P>
<P>2.1.10 We performed specific searches for randomised trials of loxapine in the following databases:</P>
<P>Pharmaceutical databases available on the Dialog Corporation Datastar service (July 1999):<BR/>ADIS Inpharma; ADIS LMS drug alerts; IDIS Drug File; PharmLine; Pharma Marketing Service.</P>
<P>Pharmaceutical databases available on the Dialog Corporation Dialog service (July 1999):<BR/>CAB Health (international coverage of health journal and non-journal material); Conference Papers Index; Derwent Drug File; Dissertation Abstracts; Extramed; Federal Research in Progress (US federally funded research); International Pharmaceutical Abstracts; JICST-EPLus (Japanese Science and Technology); Mental Health Abstracts; NTIS (national Technical Information Service); Pascal; Pharmaprojects; USP-DI - Drug information for the health care professional</P>
<P>using the following schizophrenia search terms:<BR/>schizo$<BR/>psychotic$<BR/>psychoses<BR/>psychosis<BR/>((chronic$ or sever$) near2 mental$) near2 (ill$ or disorder$)</P>
<P>combined with the following search terms:<BR/>trial$<BR/>random$<BR/>(singl$ or doubl$ or trebl$ or tripl$) near (blind$ or mask$)<BR/>placebo or standard adj treatment<BR/>study or studies<BR/>rct$<BR/>crossover$<BR/>control or controlled or controls</P>
<P>and the phrase:</P>
<P>[and (loxapine or LW-3170 or SUM-3170 or CL-71.563 or loxpac or loxitane or desconex)]</P>
<P>2.1.11 We performed citation searches on key authors.</P>
<P>2.2 Reference lists<BR/>We searched all references of selected articles for further relevant trials.</P>
<P>2.3 Authors of studies<BR/>We contacted the first authors of included studies when necessary to clarify data, and asked for additional studies.</P>
<P>2.4 Pharmaceutical company<BR/>We contacted Wyeth Pharmaceuticals to obtain data on unpublished trials.</P>
</SEARCH_METHODS>
<DATA_COLLECTION>
<P>1. Selection of trials<BR/>We independently inspected citations identified in the search. We identified potentially relevant abstracts and ordered full papers to be reassessed for inclusion and methodological quality. We discussed and reported any disagreement. For the update in 2005 and 2007, we (AC and VP) were involved in inspecting the citations from the additional search.</P>
<P>2. Assessment of methodological quality<BR/>We assessed the methodological quality of included studies using the criteria described in The Cochrane Handbook (<LINK REF="REF-Higgins-2005" TYPE="REFERENCE">Higgins 2005</LINK>), which is based on the degree of allocation concealment. Poor concealment has been associated with overestimation of treatment effect (<LINK REF="REF-Schulz-1995" TYPE="REFERENCE">Schulz 1995</LINK>). Category A includes studies in which allocation has been randomised and concealment is explicit. Category B studies are those which have randomised allocation but in which concealment is not explicit. Category C studies are those in which allocation has neither been randomised nor concealed. Only trials that are stated to be randomised (categories A or B of the handbook) were included in this review. The categories are defined below: </P>
<P>A. Low risk of bias (adequate allocation concealment)<BR/>B. Moderate risk of bias (some doubt about the results) <BR/>C. High risk of bias (inadequate allocation concealment).</P>
<P>3. Data management<BR/>3.1 Data extraction<BR/>We (MF, BM, JW) independently extracted data from selected trials. When disputes arose we attempted to resolve these by discussion. When this was not possible and further information was necessary to resolve the dilemma, we did not enter data and added the trial to the list of those awaiting assessment. Data from French studies were extracted by PC. For the update in 2005 and 2007, AC and VP extracted data, and (WW and JX) extracted data from Chinese papers, JW data extracted French papers, and EC Brazilian papers.</P>
<P>4. Data analysis<BR/>4.1 Binary data<BR/>For binary outcomes we calculated the relative risk (RR) and its 95% confidence interval (CI) based on the fixed effects model. Relative Risk is more intuitive (<LINK REF="REF-Boissel-1999" TYPE="REFERENCE">Boissel 1999</LINK>) than odds ratios and odds ratios tend to be interpreted as RR by clinicians (<LINK REF="REF-Deeks-2000" TYPE="REFERENCE">Deeks 2000</LINK>). This misinterpretation then leads to an overestimate of the impression of the effect. When the overall results were significant we calculated the number needed to treat (NNT) and the number- needed- to- harm (NNH). Where people were lost to follow up at the end of the study, we assumed that they had had a poor outcome, except for the event of death, and once they were randomised they were included in the analysis (intention-to-treat /ITT analysis). </P>
<P>Where possible, we made efforts to convert outcome measures to binary data. This can be done by identifying cut off points on rating scales and dividing participants accordingly into "clinically improved" or "not clinically improved". It was generally assumed that if there had been a 50% reduction in a scale-derived score such as the Brief Psychiatric Rating Scale (BPRS, <LINK REF="REF-Overall-1962" TYPE="REFERENCE">Overall 1962</LINK>) or the Positive and Negative Syndrome Scale (PANSS, <LINK REF="REF-Kay-1986" TYPE="REFERENCE">Kay 1986</LINK>), this could be considered as a clinically significant response (<LINK REF="REF-Leucht-2005a" TYPE="REFERENCE">Leucht 2005a</LINK>, <LINK REF="REF-Leucht-2005b" TYPE="REFERENCE">Leucht 2005b</LINK>). It was recognised that for many people, especially those with chronic or severe illness, a less rigorous definition of important improvement (e.g. 25% on the BPRS) would be equally valid. If individual patient data were available, the 50% cut-off was used for the definition in the case of non-chronically ill people and 25% for those with chronic illness. If data based on these thresholds were not available, we used the primary cut-off presented by the original authors.</P>
<P>4.2 Continuous data<BR/>4.2.1 Skewed data: <BR/>Continuous data on outcomes in trials relevant to mental health issues are often not normally distributed. To avoid the pitfall of applying parametric tests to non-parametric data we applied the following standards to continuous final value endpoint data before inclusion: (a) standard deviations and means were reported in the paper or were obtainable from the authors; (b) when a scale started from zero, the standard deviation, when multiplied by two, should be less than the mean (otherwise the mean is unlikely to be an appropriate measure of the centre of the distribution - <LINK REF="REF-Altman-1996" TYPE="REFERENCE">Altman 1996</LINK>); In cases with data that are greater than the mean we entered these into 'Other data' table as skewed data. If a scale starts from a positive value (such as PANSS, which can have values from 30 to 210) the calculation described above in (b) should be modified to take the scale starting point into account. In these cases skewness is present if 2SD&gt;(S-Smin), where S is the mean score and Smin is the minimum score. We reported non-normally distributed data (skewed) in the 'other data types' tables.</P>
<P>For change data (mean change from baseline on a rating scale) it is impossible to tell whether data are non-normally distributed (skewed) or not, unless individual patient data are available. After consulting the ALLSTAT electronic statistics mailing list, we entered change data in RevMan analyses and reported the finding in the text to summarise available information. In doing this, we assumed either that data were not skewed or that the analysis could cope with the unknown degree of skew.</P>
<P>4.2.2 Summary statistic: For continuous outcomes we estimated a weighted mean difference (WMD) between groups based on a fixed effects model.</P>
<P>4.2.3 Valid scales: A wide range of instruments are available to measure mental health outcomes. These instruments vary in quality and many are not valid, and are known to be subject to bias in trials of treatments for schizophrenia (<LINK REF="REF-Marshall-2000" TYPE="REFERENCE">Marshall 2000</LINK>). Therefore we only included continuous data from rating scales if the measuring instrument had been described in a peer-reviewed journal.</P>
<P>4.2.4 Endpoint versus change data<BR/>Where both final endpoint data and change data were available for the same outcome category, we only presented final endpoint data. We acknowledge that by doing this much of the published change data may be excluded, but argue that endpoint data is more clinically relevant and that if change data were to be presented along with endpoint data, it would be given undeserved equal prominence. Authors of studies reporting only change data are being contacted for endpoint figures. </P>
<P>4.3 Cluster trials<BR/>Studies increasingly employ cluster randomisation (such as randomisation by clinician or practice) but analysis and pooling of clustered data poses problems. Firstly, authors often fail to account for intra class correlation in clustered studies, leading to a unit-of-analysis error (<LINK REF="REF-Divine-1992" TYPE="REFERENCE">Divine 1992</LINK>) whereby p values are spuriously low, confidence intervals unduly narrow and statistical significance overestimated. This causes Type I errors (<LINK REF="REF-Bland-1997" TYPE="REFERENCE">Bland 1997</LINK>, <LINK REF="REF-Gulliford-1999" TYPE="REFERENCE">Gulliford 1999</LINK>).</P>
<P>Where clustering was not accounted for in primary studies, we presented the data in a table, with a (*) symbol to indicate the presence of a probable unit of analysis error. In subsequent versions of this review we will seek to contact first authors of studies to obtain intra-class correlation co-efficients of their clustered data and to adjust for this using accepted methods (<LINK REF="REF-Gulliford-1999" TYPE="REFERENCE">Gulliford 1999</LINK>). Where clustering has been incorporated into the analysis of primary studies, we will also present these data as if from a non-cluster randomised study, but adjusted for the clustering effect.</P>
<P>We have sought statistical advice and have been advised that the binary data as presented in a report should be divided by a design effect. This is calculated using the mean number of participants per cluster (m) and the intraclass correlation co-efficient (ICC) [Design effect=1+(m-1)*ICC] (<LINK REF="REF-Donner-2002" TYPE="REFERENCE">Donner 2002</LINK>). If the ICC was not reported it was assumed to be 0.1 (<LINK REF="REF-Ukoumunne-1999" TYPE="REFERENCE">Ukoumunne 1999</LINK>). If cluster studies had been appropriately analysed taking into account intra-class correlation coefficients and relevant data documented in the report, we synthesised these with other studies using the generic inverse variance technique.</P>
<P>5. Test for heterogeneity<BR/>Firstly, we considered all the included studies within any comparison to judge for clinical heterogeneity. Then we visually inspected graphs to investigate the possibility of statistical heterogeneity. We supplemented this by using primarily the I-squared statistic. This provides an estimate of the percentage of variability due to heterogeneity rather than chance alone. Where the I-squared estimate was greater than or equal to 50%, we interpreted this as indicating the presence of considerable levels of heterogeneity (<LINK REF="REF-Higgins-2003" TYPE="REFERENCE">Higgins 2003</LINK>). Where heterogeneity was present, reasons for this were investigated. If it substantially altered the results, we did not summate data, but presented the data separately and investigated reasons for heterogeneity.</P>
<P>6. Addressing publication bias <BR/>We entered data from all identified and selected trials into a funnel graph (trial effect versus trial size) in an attempt to investigate the likelihood of overt publication bias (<LINK REF="REF-Egger-1997" TYPE="REFERENCE">Egger 1997</LINK>). </P>
<P>7. Sensitivity analyses<BR/>We analysed the effect of including studies with high attrition rates in a sensitivity analysis, and we also investigated, where possible, whether there were differences between:<BR/>i. people with schizophrenia described as 'treatment-resistant' and those whose illness was not designated as such;<BR/>ii. people having predominantly positive or negative symptoms of schizophrenia and those without this designation; and <BR/>iii. people experiencing their first episode of schizophrenia and those at a later stage of their illness.</P>
<P>8. General<BR/>Where possible, we entered data in such a way that the area to the left of the line of no effect indicated a favourable outcome for loxapine.</P>
</DATA_COLLECTION>
</METHODS>
<RESULTS>
<STUDY_DESCRIPTION>
<P>For substantive descriptions of studies please see Included and Excluded Studies table. </P>
<P>1. Excluded studies<BR/>We excluded twenty nine studies, mainly because they were not randomised controlled trials (RCTs), or controlled clinical trials (CCTs).</P>
<P>We excluded two studies, <LINK REF="STD-Jones-2006" TYPE="STUDY">Jones 2006</LINK> and <LINK REF="STD-Lewis-2006" TYPE="STUDY">Lewis 2006</LINK> because they randomised first generation antipsychotics against second generation antipsychotics rather than loxapine versus another treatment. One excluded study, <LINK REF="STD-Leone-1982" TYPE="STUDY">Leone 1982</LINK>, randomised people who had borderline personality problems and two trials, <LINK REF="STD-Lourido-1979" TYPE="STUDY">Lourido 1979</LINK> and <LINK REF="STD-Versiani-1980" TYPE="STUDY">Versiani 1980</LINK>, included those who had both a psychosis and an organic illness. Finally, one trial, <LINK REF="STD-Serafetinides-1971" TYPE="STUDY">Serafetinides 1971</LINK>, reported only electroencephalogram (EEG) readings as the main outcome and another, <LINK REF="STD-Maes-1996" TYPE="STUDY">Maes 1996</LINK>, only drug plasma levels. No clinically relevant outcomes could be gleaned from these studies. We were unable to extract any usable outcome measures in <LINK REF="STD-Bueno-1979" TYPE="STUDY">Bueno 1979</LINK> and <LINK REF="STD-Rainaut-1975" TYPE="STUDY">Rainaut 1975</LINK> and they were added to the list of excluded studies.<BR/> <BR/>2. Awaiting assessment<BR/>No studies await assessment. </P>
<P>3. Ongoing studies<BR/>We identified no ongoing studies from the search.</P>
<P>4. Included studies<BR/>We included a total of 41 studies. One included study (<LINK REF="STD-Moyano-1975" TYPE="STUDY">Moyano 1975</LINK>) did not state if they used random allocation but did report using "double blind" methodology. All data within this study suggested that randomisation did occur so it is included. All except two trials were both randomised and double blind. <LINK REF="STD-Dubin-1996" TYPE="STUDY">Dubin 1996</LINK> and <LINK REF="STD-Tuason-1986" TYPE="STUDY">Tuason 1986</LINK> used "modified" blinding. Staff administering the injection knew what treatment they were giving, whilst staff undertaking outcome rating were blind to treatment. Three studies seemed to be independent of assistance from the two main companies involved, Cynamid (India) and Lederle (US) (<LINK REF="STD-Shopsin-1972" TYPE="STUDY">Shopsin 1972</LINK>, <LINK REF="STD-Schiele-1975" TYPE="STUDY">Schiele 1975</LINK>, <LINK REF="STD-Simpson-1976" TYPE="STUDY">Simpson 1976</LINK>). All other trials either received assistance from industry, either in the form of study drugs, grants, or by, at least, study authorship. Thirteen studies were conducted in China.</P>
<P>4.1 Length of trials<BR/>Most rapid tranquillisation studies were of very short duration, lasting between 72 hours and 10 days. The remainder were between 21 days and 12 weeks for the typical comparison. One study (<LINK REF="STD-Vyas-1980" TYPE="STUDY">Vyas 1980</LINK>) evaluated participants for six months (<LINK REF="STD-Vyas-1980" TYPE="STUDY">Vyas 1980</LINK>).</P>
<P>4.2 Participants<BR/>Six studies employed operationalised diagnoses of schizophrenia and six others confirmed diagnoses by having had two psychiatrists work independently. Eight trials classed participants as chronically ill, with a minimum duration of illness being two years but three specifically randomised those who had been admitted for psychiatric emergencies (<LINK REF="STD-Dubin-1996" TYPE="STUDY">Dubin 1996</LINK>, <LINK REF="STD-Fruensgaard-1977" TYPE="STUDY">Fruensgaard 1977</LINK>, <LINK REF="STD-Tuason-1986" TYPE="STUDY">Tuason 1986</LINK>). Studies comparing loxapine in rapid tranquillisation all operationalised their definition of disturbed as '...characterized by symptoms such as agitation, excitement, aggressiveness, delusions and hallucinations'. <LINK REF="STD-Dubin-1996" TYPE="STUDY">Dubin 1996</LINK> required a Brief Psychiatric Rating Scale (BPRS) inclusion score of six to seven, and <LINK REF="STD-Tuason-1984" TYPE="STUDY">Tuason 1984</LINK> a score of eight, on the BPRS symptom categories of anxiety, conceptual disorganisation, tension, hostility, suspiciousness, hallucinatory behaviour, uncooperativeness, unusual thought content and excitement. <LINK REF="STD-Malik-1980" TYPE="STUDY">Malik 1980</LINK> included participants whose ages ranged between 14 and 19 years but all other studies included people over the age of 18. </P>
<P>4.3 Setting<BR/>All but one study, <LINK REF="STD-Xue-2004" TYPE="STUDY">Xue 2004</LINK>, involved people in, or newly admitted to hospital. </P>
<P>4.4 Study size<BR/>There were three larger studies involving more than 200 patients in each study (<LINK REF="STD-Tu-2004" TYPE="STUDY">Tu 2004</LINK>, <LINK REF="STD-Xue-2004" TYPE="STUDY">Xue 2004</LINK>, <LINK REF="STD-Huang-1997" TYPE="STUDY">Huang 1997</LINK>), otherwise most trials included between 50 and 100 people.</P>
<P>4.5 Interventions<BR/>Seven studies used a placebo control group (<LINK REF="STD-Clark-1972" TYPE="STUDY">Clark 1972</LINK>, <LINK REF="STD-Clark-1975" TYPE="STUDY">Clark 1975</LINK>, <LINK REF="STD-Clark-1977" TYPE="STUDY">Clark 1977</LINK>, <LINK REF="STD-Charalampous-1974" TYPE="STUDY">Charalampous 1974</LINK>, <LINK REF="STD-Pool-1976" TYPE="STUDY">Pool 1976</LINK>, <LINK REF="STD-Selman-1976" TYPE="STUDY">Selman 1976</LINK>, <LINK REF="STD-Van-Der-Velde-1975" TYPE="STUDY">Van Der Velde 1975</LINK>). Nine studies used trifluperazine (<LINK REF="STD-Bagadia-1980" TYPE="STUDY">Bagadia 1980</LINK>, <LINK REF="STD-Bishop-1970" TYPE="STUDY">Bishop 1970</LINK>, <LINK REF="STD-Clark-1975" TYPE="STUDY">Clark 1975</LINK>, <LINK REF="STD-Gallant-1971" TYPE="STUDY">Gallant 1971</LINK>, <LINK REF="STD-Kiloh-1976" TYPE="STUDY">Kiloh 1976</LINK>, <LINK REF="STD-Malik-1980" TYPE="STUDY">Malik 1980</LINK>, <LINK REF="STD-Moyano-1975" TYPE="STUDY">Moyano 1975</LINK>, <LINK REF="STD-Seth-1979" TYPE="STUDY">Seth 1979</LINK>, <LINK REF="STD-Simpson-1976" TYPE="STUDY">Simpson 1976</LINK>), 14 studies used chlorpromazine, four used thiothixene, three used haloperidol, four used risperidone, two used perphenazine, two clozapine, one quetiapine, one sulpride, and one used thioridazine. Loxapine was given as two relatively low fixed doses in <LINK REF="STD-Clark-1977" TYPE="STUDY">Clark 1977</LINK> (100 mg and 50 mg). In trials from India, low doses of loxapine were also compared with low doses of comparator drugs (<LINK REF="STD-Dube-1976" TYPE="STUDY">Dube 1976</LINK>, <LINK REF="STD-Malik-1980" TYPE="STUDY">Malik 1980</LINK>, <LINK REF="STD-Seth-1979" TYPE="STUDY">Seth 1979</LINK>, <LINK REF="STD-Vyas-1980" TYPE="STUDY">Vyas 1980</LINK>). In other studies, loxapine was given in mean doses of about 100 mg/day (range 20 to 150 mg/day). Chlorpromazine was given in doses ranging from 200-1500 mg/day, trifluoperazine from 5-60 mg/day, and oral thiothixene 20-60 mg/day. In trials from China, five used chlorpromazine as a comparator, four used risperidone, two used clozapine, one used quetiapine and another sulpiride and perphenazine. </P>
<P>4.6 Outcomes<BR/>4.6.1 Improvement: Definition of improvement consisted of an analysis of variance from the Brief Psychiatric Rating Scale (BPRS), Clinical Global Impression (CGI) and Nurse's Observation Scale for In-patient Evaluation (NOSIE) in 14 studies. Discharge rates were used in <LINK REF="STD-Shopsin-1972" TYPE="STUDY">Shopsin 1972</LINK>; <LINK REF="STD-Tuason-1986" TYPE="STUDY">Tuason 1986</LINK> gave BPRS endpoint scores. Many studies used BPRS but data were either impossible to extract from graphs or so limited as to render them unusable. Nine studies reported binary results for the CGI. Again many trials employed this simple scale but data were often reported inadequately making outcomes unusable. Only <LINK REF="STD-Shopsin-1972" TYPE="STUDY">Shopsin 1972</LINK> and <LINK REF="STD-Simpson-1976" TYPE="STUDY">Simpson 1976</LINK> reported discharge from hospital. Information collected on adverse events and adverse effects were not standardised. For example, one study (<LINK REF="STD-Selman-1976" TYPE="STUDY">Selman 1976</LINK>) reported five separate forms of muscle cramp, yet others ignored this outcome. Satisfaction with care came from a single study (<LINK REF="STD-Malik-1980" TYPE="STUDY">Malik 1980</LINK>). Of the 13 Chinese studies, common outcome measures were BPRS and CGI scales. </P>
<P>4.6.2 Missing outcomes: As most participants were hospitalised there are no data relating to outcomes such as admission. No study reported usable behaviour data as rated by the commonly used NOSIE scale. Such short trials are also not focusing on clinically relevant outcomes such as quality of daily functioning, 'employed', 'trouble with the police', satisfaction with care. Unfortunately no cost data were reported. No study reassured the reader as regards mortality. </P>
<P>4.6.3 Continuous data: Details of the scales that supplied usable data for this review are shown below. Reasons for exclusion of data from other instruments are given under 'Outcomes' in the 'Included studies' table. </P>
<P>4.6.3.1Global state<BR/>4.6.3.1.1 Clinical Global Impression Scale - CGI Scale (<LINK REF="REF-Guy-1976" TYPE="REFERENCE">Guy 1976</LINK>)<BR/>This is used to assess both severity of illness and clinical improvement, by comparing the conditions of the person standardised against other people with the same diagnosis. A seven-point scoring system is usually used with low scores showing decreased severity and/or overall improvement. <LINK REF="STD-Bishop-1970" TYPE="STUDY">Bishop 1970</LINK>, <LINK REF="STD-Clark-1972" TYPE="STUDY">Clark 1972</LINK>, <LINK REF="STD-Clark-1975" TYPE="STUDY">Clark 1975</LINK>, <LINK REF="STD-Dube-1976" TYPE="STUDY">Dube 1976</LINK>, <LINK REF="STD-Fruensgaard-1978" TYPE="STUDY">Fruensgaard 1978</LINK>, <LINK REF="STD-Kiloh-1976" TYPE="STUDY">Kiloh 1976</LINK>, <LINK REF="STD-Malik-1980" TYPE="STUDY">Malik 1980</LINK>, <LINK REF="STD-Moore-1975" TYPE="STUDY">Moore 1975</LINK>, <LINK REF="STD-Moyano-1975" TYPE="STUDY">Moyano 1975</LINK>, <LINK REF="STD-Pool-1976" TYPE="STUDY">Pool 1976</LINK>, <LINK REF="STD-Schiele-1975" TYPE="STUDY">Schiele 1975</LINK> and <LINK REF="STD-Vyas-1980" TYPE="STUDY">Vyas 1980</LINK> reported data from this scale. </P>
<P>4.6.3.2 Mental state<BR/>4.6.3.2.1 Brief Psychiatric Rating Scale - BPRS (<LINK REF="REF-Overall-1962" TYPE="REFERENCE">Overall 1962</LINK>)<BR/>This is used to assess the severity of abnormal mental state. The original scale has 16 items, but a revised 18-item scale is commonly used. Each item is defined on a seven-point scale varying from 'not present' to 'extremely severe', scoring from 0-6 or 1-7. Scores can range from 0 to 126, with high scores indicating more severe symptoms. <LINK REF="STD-Du-2003" TYPE="STUDY">Du 2003</LINK>, <LINK REF="STD-Tuason-1986" TYPE="STUDY">Tuason 1986</LINK>, <LINK REF="STD-Wang-1996" TYPE="STUDY">Wang 1996</LINK>, <LINK REF="STD-Huang-1997" TYPE="STUDY">Huang 1997</LINK>, <LINK REF="STD-Xue-2004" TYPE="STUDY">Xue 2004</LINK> reported data from this scale.</P>
<P>4.6.3.2.2 Positive and Negative Syndrome Scale - PANSS (<LINK REF="REF-Kay-1986" TYPE="REFERENCE">Kay 1986</LINK>)<BR/>This schizophrenia scale has 30 items, each of which can be defined on a seven-point scoring system varying from 1 - absent to 7 - extreme. This scale can be divided into three sub-scales for measuring the severity of general psychopathology, positive symptoms (PANSS-P), and negative symptoms (PANSS-N). A low score indicates lesser severity. <LINK REF="STD-Li-2004" TYPE="STUDY">Li 2004</LINK>, <LINK REF="STD-Li-2005a" TYPE="STUDY">Li 2005a</LINK>, <LINK REF="STD-Li-2005b" TYPE="STUDY">Li 2005b</LINK>, <LINK REF="STD-Liu-2005" TYPE="STUDY">Liu 2005</LINK>, <LINK REF="STD-Lu-2003" TYPE="STUDY">Lu 2003</LINK>, <LINK REF="STD-Zhang-2005" TYPE="STUDY">Zhang 2005</LINK> reported data from this scale. </P>
<P>4.6.3.3 Adverse effects: general <BR/>4.6.3.3.1 Dosage Record and Treatment Emergent Symptoms Scale - DOTES (<LINK REF="REF-Guy-1976" TYPE="REFERENCE">Guy 1976</LINK>)<BR/>This side effect tool seems less of a scale, where the degree and severity of a symptom is recorded, and more of a checklist. The DOTES seems to record the presence or absence of a list of adverse effects. These dichotomous outcomes are then easily and usefully employed within a systematic review. </P>
<P>4.6.3.3.2 Treatment Emergent Symptom Scale -TESS (<LINK REF="REF-Guy-1976" TYPE="REFERENCE">Guy 1976</LINK>) <BR/>This checklist assesses a variety of characteristics for each adverse event, including severity, relationship to the drug, temporal characteristics (timing after a dose, duration and pattern during the day), contributing factors, course, and action taken to counteract the effect. Symptoms can be listed a priori or can be recorded as observed by the investigator. <LINK REF="STD-Du-2003" TYPE="STUDY">Du 2003</LINK>, <LINK REF="STD-Liu-2005" TYPE="STUDY">Liu 2005</LINK>, <LINK REF="STD-Xue-2004" TYPE="STUDY">Xue 2004</LINK> <LINK REF="STD-Wang-1996" TYPE="STUDY">Wang 1996</LINK> reported data from this scale.</P>
</STUDY_DESCRIPTION>
<STUDY_QUALITY>
<P>1. Randomisation<BR/>Two studies, <LINK REF="STD-Clark-1975" TYPE="STUDY">Clark 1975</LINK> and <LINK REF="STD-Dubin-1996" TYPE="STUDY">Dubin 1996</LINK> fall into quality category A (adequate concealment of allocation). The others were category B as it was not clear exactly how randomisation had been conducted. The reader, therefore, is not assured that the introduction of bias was minimised at this crucial stage. It has been shown that poor reporting of randomisation increases the risk of presenting 'significant' outcomes (<LINK REF="REF-Chalmers-1983" TYPE="REFERENCE">Chalmers 1983</LINK>, <LINK REF="REF-Schulz-1995" TYPE="REFERENCE">Schulz 1995</LINK>).</P>
<P>2. Blinding to interventions and outcomes<BR/>Only <LINK REF="STD-Bishop-1970" TYPE="STUDY">Bishop 1970</LINK>, and <LINK REF="STD-Shopsin-1972" TYPE="STUDY">Shopsin 1972</LINK> did not clearly describe adequate precautions for blinding of treatment. Two studies in the rapid tranquillisation comparison did reassure the reader that they used staff independent of the study to evaluate the outcomes, although those giving the interventions were not blind (<LINK REF="STD-Dubin-1996" TYPE="STUDY">Dubin 1996</LINK>, <LINK REF="STD-Tuason-1986" TYPE="STUDY">Tuason 1986</LINK>). No included trial tested the adequacy of the blindness of those rating outcomes.</P>
<P>3. Follow-up<BR/>In placebo studies 25% of people left the studies early, in comparison to trials where a typical antipsychotic was the control. The latter lost 32% of people before completion. In the rapid tranquillisation studies, 29% left early and in the high dose versus 8% in the low dose group (<LINK REF="STD-Clark-1977" TYPE="STUDY">Clark 1977</LINK>). In <LINK REF="STD-Tuason-1984" TYPE="STUDY">Tuason 1984</LINK> and <LINK REF="STD-Tuason-1986" TYPE="STUDY">Tuason 1986</LINK> participants were discharged if better and not followed up. This added significantly to drop out, and contributed to <LINK REF="STD-Tuason-1984" TYPE="STUDY">Tuason 1984</LINK> being excluded from analysis within this review other than for the outcome 'leaving the study early'. <LINK REF="STD-Kramer-1978" TYPE="STUDY">Kramer 1978</LINK> also reported attrition of over 50%, so only data for the outcome of 'leaving the study early' were entered into the review. <LINK REF="STD-Tuason-1986" TYPE="STUDY">Tuason 1986</LINK> had exactly 50% dropout, and as the review protocol described how to manage studies above and below that threshold, but not exactly 50%, we decided to include it. Many studies actively excluded participants from analysis. Reporting of the explicit reasons for study attrition or exclusion from analyses was poor. Of the 13 Chinese studies, six reported participants dropping out of the study early in both loxapine and control groups.</P>
<P>The barely adequate reporting of randomisation, possible lack of double blindness for these outcomes and unclear reasons for loss to follow up would suggest that all estimates of effect of the experimental intervention may be exaggerated (<LINK REF="REF-Moher-1998" TYPE="REFERENCE">Moher 1998</LINK>).</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS>
<P>1. The search<BR/>The original search resulted in the inclusion of 28 studies. Following the updates in 2005 and 2007, we have been able to include an additional 13 studies. The total of trials in this review now stands at 41. Of the additional 13 studies in the update, all were from China. Following the update, an additional four studies were placed in the exclusion table, therefore giving a total of 29 excluded studies.</P>
<P>2. COMPARISON 1. LOXAPINE versus PLACEBO</P>
<P>2.1 Leaving the study early/removal from analysis<BR/>The numbers of people leaving the study early by six weeks were equivocal (n=82, 2 RCTs, RR 0.43 CI 0.2 to 1.1), although, significantly fewer people left early in medium term studies (n=96, 2 RCTs, RR 0.52 CI 0.3 to 1.0, NNT 5 CI 4 to 117). </P>
<P>A few people were removed from analyses, mostly because they did not complete the first two weeks of the trial, but there were no apparent differences between loxapine and placebo (n=151, 3 RCTs, RR 0.74 CI 0.3 to 2.2).</P>
<P>2.2 Global effect - Not improved<BR/>We found short term data significantly favoured loxapine, with fewer participants not responding to treatment (n=78, 2 RCTs, RR 0.30 CI 0.1 to 0.6, NNT 3 CI 3 to 5) compared with placebo. Medium term data also significantly favoured loxapine (n=71, 2 RCTs, RR 0.54 CI 0.4 to 0.8, NNT 3 CI 3 to 8) with more participants in the placebo group not improving.</P>
<P>No clear differences were demonstrated for the outcome of needing additional antipsychotic/sedative medication both short and medium term data.</P>
<P>2.3 Mental state<BR/>We found only limited mental state data. For the outcome of increased anxiety/tension, no significant differences were found between loxapine and placebo.</P>
<P>2.4 Adverse effects<BR/>Those taking loxapine (short term) were more likely to experience an adverse event than those allocated to placebo (n=67, 2 RCTs, RR 1.51 CI 1.0 to 2.2, NNH 4 CI 3 to 48). Medium term data also revealed loxapine users had a worse outcome (n=38, 1 RCT, RR 2.60 CI 1.1 to 6.0, NNH 3 CI 2 to 33).</P>
<P>2.4.1 Anticholinergic effects<BR/>We found reports of blurred vision were equivocal. We found participants taking placebo were more likely to suffer constipation (n=54, 1 RCT, RR 0.27 CI 0.1 to 0.9, NNH 3 CI 2 to 11). Dry mouth (short term) data were not significantly different.</P>
<P>2.4.2 Cardiovascular problems<BR/>ECG abnormalities and hypotension are reported in selected small studies and neither outcome showed clear differences between groups. We found the loxapine group were significantly more likely to experience tachycardia compared with placebo (<LINK REF="STD-Clark-1972" TYPE="STUDY">Clark 1972</LINK> n=36, RR 9.00 CI 1.3 to 63.9, NNH 3 CI 2 to 68).</P>
<P>2.4.3 Gastrointestinal problems<BR/>Frequency of abdominal pain favoured loxapine compared with placebo (<LINK REF="STD-Van-Der-Velde-1975" TYPE="STUDY">Van Der Velde 1975</LINK>, n=54, RR 0.33 CI 0.1 to 0.9), although the high dropout from the placebo group heavily influences this outcome. Similarly, fewer people taking loxapine experienced nausea/vomiting than those on placebo, but the high dropout from the placebo group adds 75% weighting to this outcome (nausea/vomiting: n=119, 3 RCTs, RR 0.41 CI 0.2 to 1.0, NNH 4 CI 2 to 8).</P>
<P>2.4.4 Movement disorders<BR/>Generally data were very limited but showed that there were no statistically significant difference between loxapine and placebo in terms of akathisia, akinesia, bradykinesia, drooling, dyskinesia, dystonia, muscle cramp, oculogyric crisis, thick speech and tremor. Loxapine resulted in significantly more participants experiencing extrapyramidal symptoms compared with placebo (n=89, RR 9.68 CI 3.2 to 29.6, NNH 2 CI 2 to 7). We found the loxapine group needed significantly more antiparkinsonian medication than the placebo group (n=67, 2 RCTs, RR 4.11 CI 1.6 to 10.8, NNH 3 CI 2 to 15) during short term evaluation. However, 12 weeks data (<LINK REF="STD-Clark-1977" TYPE="STUDY">Clark 1977</LINK>) were not significantly different (loxapine 8/25, placebo 0/13), although a clear trend is present, favouring placebo. Short term data for rigidity were not significantly different, but 12 week evaluation showed those given placebo had significantly fewer incidences of rigidity (n=74, 2 RCTs, RR 9.78 CI 1.3 to 75.6, NNH 4 CI 2 to 124).</P>
<P>2.4.5 Neurological problems<BR/>There are limited data on ataxia, dizziness and seizures. Data tend to favour loxapine but, are heavily influenced by high dropout in the placebo. For the outcome weakness we found data significantly favoured loxapine (<LINK REF="STD-Van-Der-Velde-1975" TYPE="STUDY">Van Der Velde 1975</LINK>, n=54, RR 0.33 CI 0.1 to 0.9), although this is again heavily influenced by high drop out in the placebo group. </P>
<P>2.4.6 Sleep problems<BR/>We found drowsiness (short term, n=67, 2 RCTs, RR 2.46 CI 1.1 to 5.6, NNH 4 CI 2 to 60) and medium term data (n=74, 2 RCTs, RR 6.75 CI 1.6 to 27.9, NNH 3 CI 2 to 25) significantly favoured placebo. No significant differences were found for insomnia.</P>
<P>2.4.7 Weight changes<BR/>From limited short and medium term data participants given loxapine did not gain more weight than those allocated to placebo (n=102, 3 RCTs, RR 2.18 CI 0.7 to 6.6), although weight loss did occur more frequently in the loxapine group (n=74, 2 RCTs, RR 0.24 CI 0.1 to 0.9, NNH 5 CI 4 to 27) at the end of 12 weeks evaluation.</P>
<P>2.4.8 Other problems<BR/>Most results in this category are influenced by the dropout rate of the placebo group in <LINK REF="STD-Van-Der-Velde-1975" TYPE="STUDY">Van Der Velde 1975</LINK>, and as a consequence results tend to favour loxapine. </P>
<P>3. COMPARISON 2. LOXAPINE versus TYPICAL ANTIPSYCHOTICS</P>
<P>3.1 Leaving the study early / removed from analysis<BR/>Sixteen percent (100/638) of those taking loxapine and 14% (91/667) allocated typical drugs left before the completion of the trials (short and medium term data) that contribute to this review (n=1305, 16 RCTs, RR 1.11 CI 0.9 to 1.4). Small numbers were removed from the analysis, usually because they did not complete the first few days of the study, but there were no differences between loxapine and other typical drugs (n=793, 11 RCTs, RR 0.99 CI 0.5 to 1.8).</P>
<P>3.2 Global effect<BR/>We found all global outcomes (not improved, not ready for discharge, needing additional antipsychotic/sedative medication) were not significantly different between loxapine and typical antipsychotics. Both short term (6 RCTs) and medium term (7 RCTs) data showed that in terms of CGI 'not improved' loxapine does not differ from typicals (n=580, RR 0.86 CI 0.7 to 1.1). We found participant's global impression of their illness were also equivocal, and showed no clear differences between loxapine and trifluoperazine.</P>
<P>3.3 Mental state <BR/>As for the loxapine versus typical antipsychotic comparison, we found dichotomous mental state data measured by BPRS or PANSS, from six studies revealed no significant difference between loxapine and typical antipsychotics (n=915, RR 0.89, CI 0.8 to 1.1). We found BPRS endpoint data favoured loxapine (n=465, 3 RCTs, WMD -1.80 CI -2.9 to -0.7) compared with those given typical antipsychotics. However, data from a single study measuring mental state PANSS scores did not support this finding (<LINK REF="STD-Liu-2005" TYPE="STUDY">Liu 2005</LINK>, n=80, WMD -1.75 CI -8.6 to 5.1). Average change scores from the BPRS scale significantly favoured loxapine (n=465, 3 RCTs, WMD -1.38 CI -2.6 to -0.2). Specific mental state outcomes, anxiety, behaviour changes, depression, excitement, restlessness, and violence/aggression came from small studies and no significant differences were found.</P>
<P>3.4 Adverse effects</P>
<P>3.4.1 TESS<BR/>We found side effects from treatments were significantly lower in the loxapine group, but data are heterogeneous (I squared=76%).</P>
<P>3.4.2 Any adverse effect<BR/>We found both short and medium term data to be equivocal between loxapine and typical antipsychotics - 'any adverse event'. When analysed together (n=627, 14 RCTs) we found the risk of such an event to be identical in each group (RR 0.96 CI 0.9 to 1.1).</P>
<P>3.4.3 Anticholinergic effects<BR/>We found no significant differences for the outcomes, blurred vision, constipation, dry mouth and unspecified anticholinergic effects between loxapine and the other active drugs.</P>
<P>3.4.4 Cardiovascular problems<BR/>Similarly for hypertension, ECG abnormalities, hypotension, syncope, and tachycardia, we found no significant differences between loxapine and the typical antipsychotic groups.</P>
<P>3.4.5 Gastrointestinal<BR/>We found no significant differences between loxapine and typical antipsychotic drugs for outcomes such as abdominal pain, loss of appetite, diarrhoea, constipation, stomach trouble and nausea and vomiting.</P>
<P>3.4.6 Movement disorders<BR/>Several symptoms including, agitation, akathisia, dyskinesia, dystonia, extrapyramidal, excess salivation, fixed stare, heavy muscles, muscle cramp, oculogyric crisis, rigidity, thick speech, tremor, akinesia, twisting movement are reported, but we did not find any significant differences between loxapine and typical antipsychotic drugs. About half the people on either loxapine or a typical antipsychotic drug experienced an extrapyramidal effect and 40% needed supplementary anticholinergic medication. For the outcome 'needing antiparkinsonian medication' we found no difference between loxapine and those given typical antipsychotics (n=302, 7 RCTs, RR 1.04 CI 0.8 to 1.3). </P>
<P>3.4.7 Neurological<BR/>When outcomes such as confusion, ataxia, clumsiness, dizziness and seizures are reported, we found no significant differences between loxapine and typical antipsychotics.</P>
<P>3.4.8 Sleep problems<BR/>We found some suggestion that loxapine is more sedating than typical drugs (medium term) (n=408, 6 RCTs, RR 1.38 CI 1.0 to 1.9, NNH 13 CI 6 to 244). Short term data, however, did not reveal any significant differences (n=279, 6 RCTs, RR 1.14 CI 0.8 to 1.7). Overall, data on fatigue (n=54, 1 RCT, RR 0.65 CI 0.2 to 2.4) and lethargy (n=108, 2 RCTs, RR 1.69 CI 0.8 to 3.8) revealed no significant differences. For insomnia, we found medium term data favoured the loxapine group (n=189, 2 RCTs, RR 0.30 CI 0.1 to 0.7) compared with those given typical antipsychotics (NNH 6 CI 5 to 13). However, short term outcomes (n=137, 2 RCTs) were equivocal.</P>
<P>3.4.9 Weight changes<BR/>We found no significant differences between loxapine and typical drugs for outcomes related to weight change.</P>
<P>3.4.10 Others<BR/>None of the abnormal blood results were serious and there we found no differences in their rate of occurrence between groups. Other limited data for anxiety, headache, ringing in ears and libidinal decrease were equivocal. Only medium term data on rash were significantly different (n=184, 4 RCTs, RR 0.20 CI 0.1 to 0.8, NNH 11 CI 9 to 37). Four week data for rash were not significantly different (n=95, 2 RCTs, RR 0.34 CI 0.1 to 1.3) between loxapine and typical antipsychotics. </P>
<P>4. COMPARISON 3. LOXAPINE IM versus TYPICAL ANTIPSYCHOTICS IM FOR RAPID TRANQUILLISATION</P>
<P>4.1 Withdrawn from analysis or leaving the study early by 72 hours<BR/>More people allocated to the intramuscular (IM) haloperidol or thiothixene left or were withdrawn early than those given IM loxapine, although the data were not statistically significant (n=115, 2 RCTs, RR 0.58 CI 0.3 to 1.1).</P>
<P>4.2 General effect - tranquillisation<BR/>When rapid tranquillisation is necessary, data favoured IM loxapine when comparing with IM haloperidol and thiothixene at one hour (not sedated n=145, 3 RCTs, RR 0.62 CI 0.5 to 0.8, but data are heterogeneous I-squared 77%); homogeneous data at six to 24 hours (n=54, 1 RCT, RR 0.39 CI 0.04 to 3.5), and requiring further sedation (n=115, 2 RCTs, RR 1.21 CI 0.6 to 2.4) did not reveal any significant differences. </P>
<P>4.3 Mental state - BPRS<BR/>
<LINK REF="STD-Tuason-1986" TYPE="STUDY">Tuason 1986</LINK> reported mean BPRS endpoint scores and the standard deviation of these means. We felt that these standard deviations were in fact standard errors and converted them to deviations. In any event, we found no suggestion of a significant difference between IM loxapine and IM haloperidol.</P>
<P>4.4 Adverse effects<BR/>No differences were found between IM loxapine and comparator drugs for outcomes such as 'any adverse event' and various movement disorders, for example dyskinesia, dystonia, oculogyric crisis, rigidity tremor, and dizziness. Other physiological effects showed no significant difference between groups. </P>
<P>5. COMPARISON 4. LOXAPINE HIGH DOSE versus LOXAPINE LOW DOSE<BR/>One small (n=25) study compared a higher fixed dose to a lower fixed dose and placebo (<LINK REF="STD-Clark-1977" TYPE="STUDY">Clark 1977</LINK>). Low dose was considered 50 mg/day, and high, 100 mg/day. Unsurprisingly, because of the limited power of a study of 25 participants no differences are seen in global effect, leaving the study early and a variety of adverse effects. The high dose group did not need any additional sedating drugs than those on the low dose (RR 1.30 CI 0.5 to 3.2) and were no more likely to leave the study early (RR 0.22 CI 0.01 to 4.1) or experience any adverse event (RR 1.55 CI 0.9 to 2.7).</P>
<P>6. COMPARISON 5. LOXAPINE versus ATYPICAL ANTIPSYCHOTICS</P>
<P>6.1 Leaving the study early / removed from analysis<BR/>Three percent (3/110) of those taking loxapine and 2% (2/108) allocated atypical drugs left before the completion of the trials that contribute to this review (n=218, 3 RCTs, RR 1.26 CI 0.3 to 5.0). Small numbers were removed from the analysis, because they did not complete the first week of the study, but there were no differences between loxapine and atypical antipsychotic drugs (n=68, 1 RCT, RR 5.00 CI 0.3 to 100.4).</P>
<P>6.2 Mental state<BR/>As for the loxapine versus atypical antipsychotic comparison, mental state data, from BPRS and PANSS scales, revealed no significant difference: (PANSS, 'not improved' n=468, 6 RCTs, RR 1.07 CI 0.8 to 1.5) and (BPRS, 'endpoint score' n=60, 1 RCT, WMD 1.38 CI -5.8 to 8.6). Also, we found PANSS endpoint scores to be equivocal (n=408, 5 RCTs, WMD -1.13 CI -4.1 to 1.8).</P>
<P>6.3 Adverse effects <BR/>Seven studies (n=528) examined the difference in adverse effects between loxapine and atypical antipsychotics and adverse effects. </P>
<P>6.3.1 TESS<BR/>We found no significant difference between loxapine and atypical antipsychotics (<LINK REF="STD-Du-2003" TYPE="STUDY">Du 2003</LINK>, n=60, WMD 0.05 CI -0.04 to 0.1) when treatment emergent side effects were measured. </P>
<P>6.3.2 Movement disorder<BR/>There were no statistically significant differences between loxapine and atypical antipsychotics for symptoms of tremor (n=123, 2 RCTs, RR 1.08 CI 0.8 to 1.4), increased activity (n=68, 1 RCT, RR 0.11 CI 0.01 to 2.0), agitation (n=87, 1 RCT, RR 0.11 CI 0.01 to 2.0) and akathisia (n=63, 1 RCT, RR 6.79 CI 0.4 to 126.2). However, four studies reported extrapyramidal adverse effects, and we found this occurred more often in the loxapine group compared with atypicals (n=340, RR 2.18 CI 1.6 to 3.1, NNH 5 CI 3 to 9). </P>
<P>6.3.3 Cardiovascular<BR/>
<LINK REF="STD-Li-2005b" TYPE="STUDY">Li 2005b</LINK> and <LINK REF="STD-Li-2005a" TYPE="STUDY">Li 2005a</LINK> reported data on ECG abnormalities and we found no significant difference between groups (n=165, 2 RCTs, RR 1.80 CI 0.7 to 4.6).</P>
<P>6.3.4 Sleep<BR/>
<LINK REF="STD-Li-2005b" TYPE="STUDY">Li 2005b</LINK> and <LINK REF="STD-Li-2005a" TYPE="STUDY">Li 2005a</LINK> also reported on insomnia, and we found that those given the atypical risperidone were significantly more likely to experience insomnia compared with the loxapine group (n=165, RR 0.18 CI 0.04 to 0.8, NNH 9 CI 8 to 33). Also, we found the risperidone group had significantly greater 'sleep disturbance' compared with the loxapine group (<LINK REF="STD-Wang-2005b" TYPE="STUDY">Wang 2005b</LINK>, n=63, RR 0.19 CI 0.1 to 0.8, NNH 4 CI 4 to 17).</P>
<P>6.3.5 Other adverse effects<BR/>We found data from <LINK REF="STD-Wang-2005b" TYPE="STUDY">Wang 2005b</LINK> showed no significant differences between the loxapine and atypical (risperidone) group regarding anxiety (n=63, RR 0.97, CI 0.3 to 3.5), dermatitis (n=63, RR 0.32 CI 0.01 to 7.7), amenorrhea (n=63, RR 0.32 CI 0.01 to 7.7) and enuresis (n=63, RR 0.32 CI 0.01 to 7.7). Both <LINK REF="STD-Lu-2003" TYPE="STUDY">Lu 2003</LINK> and <LINK REF="STD-Wang-2005b" TYPE="STUDY">Wang 2005b</LINK> reported on leucopoenia and we found that the atypical group (clozapine) had a statistically higher proportion of leucopoenia compared with the loxapine group (n=185, RR 0.12 CI 0.02 to 1.0, NNH 15 CI 14 to 264). </P>
<P>7. Sensitivity analysis<BR/>We were unable to undertake the proposed sensitivity analysis for people with schizophrenia described as 'treatment resistant', people having predominantly positive or negative symptoms of schizophrenia and people experiencing their first episode of schizophrenia.</P>
<P>8. Funnel plot for publication bias<BR/>With only two studies in the placebo comparison, three in the rapid tranquillisation studies and one in the high versus low dose comparison, it was impossible to undertake the proposed funnel plot for publication bias. Within the loxapine versus typical antipsychotics, for the outcomes of 'Global effect: 1. Not improved' and 'Leaving the study early' funnel plots were possible and there is no suggestion of asymmetry.</P>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION>
<P>1. Generalisability<BR/>Eighteen of the included studies were set in the USA and randomised people mostly without operationally diagnosed disorders uncomplicated by co-morbidity or ill health. Four studies were from India (<LINK REF="STD-Dube-1976" TYPE="STUDY">Dube 1976</LINK>, <LINK REF="STD-Malik-1980" TYPE="STUDY">Malik 1980</LINK>, <LINK REF="STD-Seth-1979" TYPE="STUDY">Seth 1979</LINK>, <LINK REF="STD-Vyas-1980" TYPE="STUDY">Vyas 1980</LINK>) and used relatively low doses of drugs. <LINK REF="STD-Dube-1976" TYPE="STUDY">Dube 1976</LINK> reported no adverse effects what so ever, whilst <LINK REF="STD-Malik-1980" TYPE="STUDY">Malik 1980</LINK> recorded that every participant (all adolescents) has experienced adverse effects. Following the update in 2005 and 2007, 13 studies were added from China, all of which used the Chinese Classification of Mental Disorders (CCMD) as a means of diagnosing disorders. With limited operationalisation of diagnosis, varied groups of participants, and intervention regimens, the results of this review should be more generalisable than if very strict definitions and care regimens had been employed (<LINK REF="REF-Elwood-1982" TYPE="REFERENCE">Elwood 1982</LINK>). </P>
<P>2. Limited data<BR/>The collection and quality of reporting of data were disappointing. Most trials report only three to 12 week outcomes, with the exception of <LINK REF="STD-Vyas-1980" TYPE="STUDY">Vyas 1980</LINK>, a six month study. No studies reported on economic outcomes or quality of life and only one gave data on satisfaction with care (<LINK REF="STD-Malik-1980" TYPE="STUDY">Malik 1980</LINK>). Only two of the included studies reported on discharge from hospital (<LINK REF="STD-Shopsin-1972" TYPE="STUDY">Shopsin 1972</LINK>, <LINK REF="STD-Simpson-1976" TYPE="STUDY">Simpson 1976</LINK>). Many included trials reported 'efficacy' as an analysis of variance from the BPRS, CGI and NOSIE endpoint scores, or a maximum percentage improvement, and therefore much valuable data were unusable. Frequently mean scores were reported without a standard deviation or standard error, rendering data useless for a quantitative review such as this. The removal of people from analysis within a trial can rarely be justified (<LINK REF="REF-Hollis-1999" TYPE="REFERENCE">Hollis 1999</LINK>). We have reported the rate of attrition and the rate of withdrawal from the analyses where this has happened. It is easy to criticise studies from the 1970s, by 2007 standards and knowledge, but this review is one where poor reporting of outcomes does seem to do a disservice to all concerned. </P>
<P>3. COMPARISON 1. LOXAPINE versus PLACEBO</P>
<P>3.1 Leaving the study early<BR/>That fewer people in the loxapine group (medium term) left the study early than those on placebo may suggest that loxapine had a favourable effect on mental state and behaviour. Alternatively, it is possible that the sedation that loxapine affords may have made study attrition less likely. Even in the control group only about 30% of people left the studies early, which is considerably less than many more recent trials. </P>
<P>3.2 Global improvement<BR/>People taking loxapine were more likely to have a global improvement than those allocated placebo (NNT 3); about 60% of people taking loxapine improved. It is surprising, however, that the need for additional antipsychotic/sedative medication did not mirror this result. It may be that those within these studies were not severe enough to be likely to ever need additional sedation.</P>
<P>3.3 Mental state<BR/>Mental state data relating to loxapine versus placebo is almost non-existent. The outcome of increased anxiety/tension is reported and data is in favour of those allocated to loxapine but, especially in a drug introduced into use over 20 years ago, more data would have been expected.</P>
<P>3.4 Adverse effects<BR/>Those allocated loxapine were more likely to experience 'any adverse event' than those randomised to placebo (NNH 3). In any event, it is difficult to know how to interpret 'any adverse event' but the suggestion is that loxapine is an active compound. Limited data (<LINK REF="STD-Clark-1972" TYPE="STUDY">Clark 1972</LINK>, n=36) suggests that loxapine may cause tachycardia (NNH 3), although ECG data did not indicate loxapine disrupted cardio-function over a 12 week period. Because of high dropout from the placebo group on one dominant study (<LINK REF="STD-Van-Der-Velde-1975" TYPE="STUDY">Van Der Velde 1975</LINK>), it is difficult to comment on the results favouring loxapine over placebo. It is possible that loxapine may have caused movement disorders and these outcomes would have been masked by the increased use of antiparkinsonian medication in the loxapine group.</P>
<P>4. COMPARISON 2. LOXAPINE versus TYPICAL ANTIPSYCHOTICS<BR/>These results were characterised by the similarity in outcomes between the various loxapine doses and comparison drugs.</P>
<P>4.1 Leaving the study early / removal from analysis<BR/>The loxapine group were no different to typical drugs for causing study attrition. About 16% of people left these studies early and again, this is considerably better than would be expected in more recent studies. Most trials were conducted in the 1970s and 1980s. Three, however, also with very low attrition, were undertaken between 2004 and 2005. It is possible that those designing studies could learn from these trials. <BR/> <BR/>4.2 Global effect<BR/>Whilst the CGI data, a measure of global impairment, were used within all studies, none reported it as a continuous outcome. Nine included studies reported a binary result based on the CGI and we found no suggestion of a difference between loxapine and the drugs of comparison. Global effects were also reported as readiness for discharge (<LINK REF="STD-Shopsin-1972" TYPE="STUDY">Shopsin 1972</LINK>, <LINK REF="STD-Simpson-1976" TYPE="STUDY">Simpson 1976</LINK>), needing additional antipsychotic or sedative medication (<LINK REF="STD-Clark-1975" TYPE="STUDY">Clark 1975</LINK>, <LINK REF="STD-Moore-1975" TYPE="STUDY">Moore 1975</LINK>) and participant's impression of change (<LINK REF="STD-Malik-1980" TYPE="STUDY">Malik 1980</LINK>). Although data for these latter outcomes are based on very small numbers they are consistent with the dichotomised CGI. Loxapine is not clearly less or more effective than typical antipsychotics. Overall, in the short to medium term, over 70% of people given loxapine do experience global improvement. </P>
<P>4.3 Mental state<BR/>Four studies (<LINK REF="STD-Huang-1997" TYPE="STUDY">Huang 1997</LINK>, <LINK REF="STD-Tu-2004" TYPE="STUDY">Tu 2004</LINK>, <LINK REF="STD-Wang-1996" TYPE="STUDY">Wang 1996</LINK>, <LINK REF="STD-Xue-2004" TYPE="STUDY">Xue 2004</LINK>) using dichotomous mental state data measured by BPRS, showed no statistically significant difference between loxapine and typical antipsychotics. Of these four studies, three also used continuous data measured by BPRS, in addition to reporting dichotomous data (<LINK REF="STD-Huang-1997" TYPE="STUDY">Huang 1997</LINK>, <LINK REF="STD-Wang-1996" TYPE="STUDY">Wang 1996</LINK>, <LINK REF="STD-Xue-2004" TYPE="STUDY">Xue 2004</LINK>). The continuous data measured by <LINK REF="STD-Huang-1997" TYPE="STUDY">Huang 1997</LINK> and <LINK REF="STD-Tu-2004" TYPE="STUDY">Tu 2004</LINK> revealed no statistically significant difference between loxapine and typical antipsychotics. However, the dichotomous and continuous mental state data measured by <LINK REF="STD-Xue-2004" TYPE="STUDY">Xue 2004</LINK> showed contradictory results, with the dichotomous data showing no statistical significance and the continuous data favouring loxapine in a statistically significant manner. This was, perhaps, a chance result. Again, as for the global outcomes, loxapine seems little different to the typical group of antipsychotic drugs. </P>
<P>4.4 Adverse effects<BR/>Comment must be made about what appears to be fairly unsystematic approach to collecting data on adverse effects, with only five studies reporting on the tools used for collecting data (<LINK REF="STD-Kramer-1978" TYPE="STUDY">Kramer 1978</LINK>, <LINK REF="STD-Liu-2005" TYPE="STUDY">Liu 2005</LINK>, <LINK REF="STD-Shopsin-1972" TYPE="STUDY">Shopsin 1972</LINK>, <LINK REF="STD-Wang-1996" TYPE="STUDY">Wang 1996</LINK>, <LINK REF="STD-Xue-2004" TYPE="STUDY">Xue 2004</LINK>). Other studies are suspected to have used a treatment emergent symptoms checklist, but they do not make this clear.<BR/> <BR/>Fourteen studies provided data on the outcome of 'any adverse event'. Although it is difficult to know what this outcome means in clinical terms, it is reassuring to know that loxapine seemed no different to the other typical drugs; about two thirds of both groups experience an adverse event. The limited and patchy adverse event data are, nevertheless, consistent. Loxapine is not clearly different from other drugs in its adverse effect profile. It does not clearly cause less movement disorders or need for anticholinergic medication than the typical drugs (~50%). Sedation revealed no differences in short term evaluation, but medium term data did suggest that loxapine is more sedating (NNH 13); more data is needed however to support this finding, as this was heavily influenced by one study (<LINK REF="STD-Zhang-2005" TYPE="STUDY">Zhang 2005</LINK>). Two studies (<LINK REF="STD-Kiloh-1976" TYPE="STUDY">Kiloh 1976</LINK>, <LINK REF="STD-Zhang-2005" TYPE="STUDY">Zhang 2005</LINK>) indicate that loxapine causes less insomnia compared with typicals. Measures of weight change came mostly from small studies conducted up to no more than 12 weeks, and we found no significant differences between loxapine and typical antipsychotics. Other adverse effects also proved equivocal with the exception of skin rash which occurred significantly more in the loxapine group. However, the data (4 RCTs) were influenced by the <LINK REF="STD-Clark-1972" TYPE="STUDY">Clark 1972</LINK> study, otherwise no difference in rates of rash would have occurred, and this is possibly a spurious finding. </P>
<P>4.5 Missing outcomes<BR/>In such short term explanatory studies data on service utilisation, economic outcomes, quality of life and satisfaction with care are commonly not recorded. The long term effects of loxapine are currently unknown. This is no different than other more recently formulated drugs but loxapine has been used for nearly a quarter of a century with minimal long term data.</P>
<P>5. COMPARISON 3. LOXAPINE versus TYPICAL ANTIPSYCHOTICS FOR RAPID TRANQUILLISATION<BR/>All three studies in this comparison started with a rapid tranquillisation phase followed by an oral extension stage. <LINK REF="STD-Dubin-1996" TYPE="STUDY">Dubin 1996</LINK> did not report any data other than tranquillisation and adverse effects, <LINK REF="STD-Fruensgaard-1977" TYPE="STUDY">Fruensgaard 1977</LINK> did not report on the extension phase, and <LINK REF="STD-Tuason-1986" TYPE="STUDY">Tuason 1986</LINK> had 50% loss to follow up.</P>
<P>5.1 Withdrawn from analysis or leaving the study early by 72 hours<BR/>Even if there is no clear difference in levels of sedation and mental state outcomes, fewer participants given loxapine were withdrawn from the study than those given typical antipsychotics, which may suggest that loxapine may be more acceptable to clinicians, if not patients, than either haloperidol or thiothixine.</P>
<P>5.2 General effect - tranquillisation / sedation<BR/>Data are poor and it is unclear why they are heterogeneous. In any effect there is no clear differences demonstrated between IM loxapine and haloperidol or thiothixene. </P>
<P>5.3 Mental state<BR/>We are waiting confirmation that the trialists (<LINK REF="STD-Tuason-1986" TYPE="STUDY">Tuason 1986</LINK>) did erroneously report standard errors as deviations but, in any event, there is no difference between IM loxapine and IM haloperidol. This probably is to be expected at such a short follow up period of 72 hours, where sedation/ tranquillisation would have been expected but not necessarily an antipsychotic effect. The other two studies used the BPRS but did not report data.</P>
<P>5.4 Adverse effects<BR/>From the small studies no statistically significant difference were found between IM loxapine and haloperidol or thiothixene regarding adverse effects. Perhaps, had there been larger trials conducted over a longer period differences may have become apparent.</P>
<P>6. COMPARISON 4. LOXAPINE HIGH DOSE versus LOXAPINE LOW DOSE<BR/>Only 25 people have been randomised to high or low dose loxapine (<LINK REF="STD-Clark-1977" TYPE="STUDY">Clark 1977</LINK>). Such a small study would be likely to miss real differences so all data should be considered hypothesis-generating. <BR/> <BR/>There were no differences at all for global effect, study attrition and adverse effects. Perhaps these data do support generation of the hypothesis that there is no real difference in terms of effect between high and low dose loxapine.</P>
<P>7. COMPARISON 5. LOXAPINE versus ATYPICAL ANTIPSYCHOTICS <BR/>Four studies used risperidone, two clozapine, and one used quetiapine as comparator. </P>
<P>7.1 Leaving the study early / removed from analysis<BR/>There were no differences between loxapine and atypical drugs. However, very few people left these recent three Chinese studies (~3%). This may not simply reflect good trial design, but also a difference in health care culture between China and the rest of the world. However, 1.3 billion people live in this large country.</P>
<P>7.2 Mental state<BR/>There were no statistical differences found between loxapine and atypical antipsychotics in each of the seven studies all from China. Four hundred and sixty eight people have entered this comparison and still there is no suggestion of a difference between this inexpensive drug and risperidone, clozapine, or quetiapine.</P>
<P>7.3 Adverse effects<BR/>Seven studies (n=528) examined the difference in adverse effects between loxapine and atypical antipsychotics. </P>
<P>There were no statistically significant differences between loxapine and atypical antipsychotics for symptoms of tremor, increased activity, and akathisia. However, we did find that extrapyramidal adverse effects in four studies (<LINK REF="STD-Li-2005a" TYPE="STUDY">Li 2005a</LINK>, <LINK REF="STD-Li-2005b" TYPE="STUDY">Li 2005b</LINK>, <LINK REF="STD-Lu-2003" TYPE="STUDY">Lu 2003</LINK>, <LINK REF="STD-Wang-2005b" TYPE="STUDY">Wang 2005b</LINK>) were more frequent and of statistical significance, in the loxapine treatment group compared with the atypicals risperidone and clozapine. This would fit with the impression that loxapine is a valuable antipsychotic but with an adverse effect profile not much different from the older generation of antipsychotic drugs. </P>
<P>ECG abnormalities were more common in the loxapine group, but not significantly different compared with atypical risperidone. Also, we found in the studies by <LINK REF="STD-Li-2005a" TYPE="STUDY">Li 2005a</LINK> and <LINK REF="STD-Li-2005b" TYPE="STUDY">Li 2005b</LINK> that those given risperidone were more likely to experience insomnia compared with the loxapine, while in the <LINK REF="STD-Wang-2005b" TYPE="STUDY">Wang 2005b</LINK> study the risperidone group were significantly associated with 'sleep disturbance' compared with those given loxapine. There were no significant differences found between loxapine and quetiapine regarding anxiety, dermatitis, amenorrhea and enuresis. Two studies (<LINK REF="STD-Lu-2003" TYPE="STUDY">Lu 2003</LINK>; <LINK REF="STD-Wang-2005b" TYPE="STUDY">Wang 2005b</LINK>) reported incidences of leucopoenia in the atypical clozapine group, and we found this to be statistically significant compared with loxapine. </P>
<P>7.4 Missing outcomes<BR/>In such short term explanatory studies data on service utilisation, economic outcomes, quality of life and satisfaction with care are commonly not recorded. The medium or long term effects of loxapine are currently unknown. This is no different than other more recently formulated drugs but loxapine has been used for nearly a quarter of a century with minimal long term data.</P>
</DISCUSSION>
<CONCLUSIONS>
<IMPLICATIONS_PRACTICE>
<P>1. For people with schizophrenia<BR/>Loxapine is an antipsychotic drug. For those whose illness results in situations where rapid tranquillisation is needed, loxapine is an option. When loxapine is compared with typical and atypical drugs, most data relate to six to 12 weeks, with very little being known beyond that period. Limited data suggest that in terms of global outcomes or mental state ratings, loxapine is as effective as these drugs. Loxapine does appear to produce a similar degree of adverse effects compared with typicals and atypical drugs but loxapine may cause more extrapyramidal adverse effects than some atypicals. </P>
<P>2. For clinicians<BR/>Very limited trial data suggest that loxapine has very similar effects to typical and atypical drugs and its intramuscular preparation may be as acutely sedating as IM haloperidol or thiothixene. It may be under-used for the care of those with schizophrenia and be a real option when idiosyncratic intolerance to other compounds has occurred.</P>
<P>3. For managers or policy makers<BR/>There are almost no data on service utilisation for loxapine. This is probably a function of the studies having been undertaken when there was less emphasis on these outcomes.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH>
<P>1. General<BR/>All except one study considerably preceded the first CONSORT statement (<LINK REF="REF-Begg-1996" TYPE="REFERENCE">Begg 1996</LINK>), so quality of data reporting might be expected to be lower than at present. However, clear and full reporting of all outcomes that were in fact measured would have resulted in this review being more informative. Denominator data were not always clearly presented. Authors should present raw data rather than in graphical format. If p-values are used, the exact value and test should be reported.</P>
<P>2. Specific<BR/>Loxapine seems to be a potent antipsychotic drug. In the context of all other research priorities it is hard to know if further trials of loxapine are possible. Certainly, the use of loxapine in the acute situation may be worth investigating within the context of a well planned, conducted and reported randomised controlled trial. This should only take place in areas where loxapine is used in this way and, at present, we know of no places where this happens. A reasonable comparison intervention would be haloperidol plus promethazine (<LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>).</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2015-10-14 14:23:31 +0100" MODIFIED_BY="[Empty name]">
<P>Thanks to Julie Glanvile from the Centre for Reviews and Dissemination, University of York who undertook all electronic searches of the original search in 1999 and to Judy Wright from the Cochrane Schizophrenia group who undertook electronic searches for the 2007 update. Thanks to Evandro Coutinho who provided translation for a Brazilian study and Tessa Grant who provided translation for a French study. Thanks to Professor Clive Adams and Ajit Kumar for their support.</P>
<P>Jo Wood helped select studies, extract data, summate data and produce the original report in 2008. She has not been involved in the writing of subsequent versions. We would like to thank her for these previous contributions.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>Mark Fenton has lead Janssen, Lilly and Zeneca sponsored workshops for clinicians.</P>
<P>Jo Wood is Medical Information Officer for Janssen Cilag UK, and worked on this review to increase her knowledge of the process of systematic reviewing.</P>
<P>The Cochrane Schizophrenia Group has received general support funding from Eli Lilly during the years 1996-9 (see Group Module).</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2015-10-14 14:21:02 +0100" MODIFIED_BY="[Empty name]">
<P>Contributions:<BR/>Mark Fenton - prepared protocol, selected and acquired studies, extracted data, summated data, produced report.</P>
<P>Brendan Murphy -protocol writing, selected studies, extracted data, summated data.</P>
<P>Anne-Marie Bagnall - prepared protocol, undertook searches, selected and acquired studies, extracted data, summated data, produced report..</P>
<P>Pierre Chue - data extraction from French studies, report writing.</P>
<P>Maria Leitner - finding funding, inital input into the protocol and searches.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES>
<P>Cochrane Schizophrenia Group internal peer review complete (see Module).<BR/>External peer review scheduled.</P>
</PUBLIC_NOTES>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2015-10-14 14:24:02 +0100" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2015-10-14 14:24:02 +0100" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2015-10-14 14:24:02 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Bagadia-1980" MODIFIED="2015-10-14 14:24:02 +0100" MODIFIED_BY="[Empty name]" NAME="Bagadia 1980" YEAR="1980">
<REFERENCE MODIFIED="2015-10-14 14:24:02 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bagadia VN, Shah LP, Abhyankar RR</AU>
<TI>A double-blind controlled trial of loxapine and trifluoperazine in adolescent schizophrenia</TI>
<SO>Current Therapeutic Research, Clinical and Experimental</SO>
<YR>1980</YR>
<VL>27</VL>
<NO>6</NO>
<PG>886-96</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="79044730"/>
<IDENTIFIER TYPE="OTHER" VALUE="PMID 361345"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bishop-1970" NAME="Bishop 1970" YEAR="1970">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Bishop MP, Gallant DM</AU>
<TI>Loxapine: a controlled evaluation in chronic schizophrenic patients</TI>
<SO>Current Therapeutic Research - Clinical and Experimental</SO>
<YR>1970</YR>
<VL>12</VL>
<NO>9</NO>
<PG>594-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Charalampous-1974" NAME="Charalampous 1974" YEAR="1974">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Charalampous KD, Freemesser GF, Malev J, Ford K</AU>
<TI>Loxapine succinate: A controlled double blind study in schizophrenia</TI>
<SO>Current Therapeutic Research</SO>
<YR>1974</YR>
<VL>6</VL>
<NO>8</NO>
<PG>829-37</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Clark-1972" MODIFIED="2015-10-14 14:24:02 +0100" MODIFIED_BY="[Empty name]" NAME="Clark 1972" YEAR="1972">
<REFERENCE MODIFIED="2015-10-14 14:24:02 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Clark ML, Huber WK, Sullivan J, Wood F, Costiloe JP</AU>
<TI>Evaluation of loxapine succinate in chronic schizophrenia</TI>
<SO>Diseases of the Nervous System</SO>
<YR>1972</YR>
<VL>33</VL>
<PG>783-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Clark-1975" NAME="Clark 1975" YEAR="1975">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Clark ML, Paredes A, Costiloe JP, Wood F, Barrett A</AU>
<TI>Loxapine in newly admitted chronic schizophrenic patients</TI>
<SO>Journal of Clinical Pharmacology</SO>
<YR>1975</YR>
<VL>15</VL>
<NO>4</NO>
<PG>286-94</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Clark-1977" MODIFIED="2015-10-14 14:24:02 +0100" MODIFIED_BY="[Empty name]" NAME="Clark 1977" YEAR="1977">
<REFERENCE MODIFIED="2015-10-14 14:24:02 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Clark ML, Paredes A, Costiloe JP, Fulkerson FG, Wood F</AU>
<TI>Evaluation of two dose levels of loxapine succinate in chronic schizophrenia</TI>
<SO>Diseases of the Nervous System</SO>
<YR>1977</YR>
<VL>38</VL>
<NO>1</NO>
<PG>7-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Du-2003" NAME="Du 2003" YEAR="2003">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Du B-G, Fang R-L</AU>
<TI>Control studies on curative effects of loxapine succinate and risperidone in schizophrenics</TI>
<SO>Journal of Clinical Psychosomatic Diseases</SO>
<YR>2003</YR>
<VL>9</VL>
<NO>1</NO>
<PG>16-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="CAJ"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dube-1976" NAME="Dube 1976" YEAR="1976">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dube KC, Kumar N</AU>
<TI>Loxapine succinate: a comparative study with chlorpromazine</TI>
<SO>Current Therapeutic Research - Clinical and Experimental</SO>
<YR>1976</YR>
<VL>19</VL>
<NO>6</NO>
<PG>653-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dubin-1996" NAME="Dubin 1996" YEAR="1996">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dubin WR, Weiss KJ</AU>
<TI>Rapid tranquilization: a comparison of thiothixene with loxapine</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>1986</YR>
<VL>47</VL>
<NO>6</NO>
<PG>294-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fruensgaard-1977" NAME="Fruensgaard 1977" YEAR="1977">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fruensgaard K, Korsgaard S, Jorgensen H, Jensen K</AU>
<TI>Loxapine versus haloperidol parenterally in acute psychosis with agitation. A double-blind study</TI>
<SO>Acta Psychiatrica Scandinavica</SO>
<YR>1977</YR>
<VL>56</VL>
<NO>4</NO>
<PG>256-64</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fruensgaard-1978" NAME="Fruensgaard 1978" YEAR="1978">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fruensgaard K, Wollenberg J, Hansen KM, Fensbo C, Sihm F</AU>
<TI>Loxapine versus perphenazine in psychotic patients. A double-blind, randomized, multicentre trial</TI>
<SO>Current Medical Research and Opinion</SO>
<YR>1978</YR>
<VL>5</VL>
<NO>8</NO>
<PG>601-7</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="79044730"/>
<IDENTIFIER TYPE="OTHER" VALUE="PMID 361345"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gallant-1971" NAME="Gallant 1971" YEAR="1971">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gallant, Bishop</AU>
<TI>Oxilapine versus Trifluoperazine</TI>
<SO>Psychopharmacology Bulletin</SO>
<YR>1971</YR>
<VL>7</VL>
<NO>1</NO>
<PG>40-3</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="08024"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Huang-1997" NAME="Huang 1997" YEAR="1997">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Huang S, Qin Y, Wang L</AU>
<TI>Study on the efficacy of loxapine in treatment of schizo phrenia in comparison with chlorpromazine</TI>
<SO>Chinese New Drugs Journal</SO>
<YR>1997</YR>
<VL>6</VL>
<NO>3</NO>
<PG>161-4</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="MEDI9706"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kiloh-1976" NAME="Kiloh 1976" YEAR="1976">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kiloh LG, Williams SE, Grant DA, Whetton PS</AU>
<TI>A double-blind comparative trial of loxapine and trifluoperazine in acute and chronic schizophrenic patients</TI>
<SO>Journal of International Medical Research</SO>
<YR>1976</YR>
<VL>4</VL>
<NO>6</NO>
<PG>441-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="77205174"/>
<IDENTIFIER TYPE="OTHER" VALUE="PMID 800384"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kramer-1978" NAME="Kramer 1978" YEAR="1978">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kramer MR, Thomas SPJ, Zorick FJ, Blackwell B</AU>
<TI>Relative efficacy and safety of loxapine succinate (Loxitane) and thioridazine hydrochloride (Mellaril) in the treatment of acute schizophrenia</TI>
<SO>Current Therapeutic Research</SO>
<YR>1978</YR>
<VL>23</VL>
<NO>5</NO>
<PG>619-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Li-2004" NAME="Li 2004" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Li Y, Shang J, Li C</AU>
<TI>Control study of loxapine succinate and clozapine on curative effects in treatment of schizophrenics</TI>
<SO>Heath Psychology Journal</SO>
<YR>2004</YR>
<VL>12</VL>
<NO>3</NO>
<PG>202</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="115139"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Li-2005a" NAME="Li 2005a" YEAR="2005">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Li L-X, Li C-Y</AU>
<TI>A comparative study of loxapine succinate and risperidone in the treatment of schizophrenia</TI>
<SO>Shandong Archives of Psychiatry</SO>
<YR>2005</YR>
<VL>18</VL>
<NO>4</NO>
<PG>246-7</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="CAJ MEDI0510"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Li-2005b" NAME="Li 2005b" YEAR="2005">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Li Zhong-yi, HE Rui-fang</AU>
<TI>Comparative study between loxapine and risperedone in treatment of schizophrenia</TI>
<SO>Journal of clinical psychological medicine</SO>
<YR>2005</YR>
<VL>15</VL>
<NO>1</NO>
<PG>11-12</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="MED10504"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Liu-2005" NAME="Liu 2005" YEAR="2005">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Liu</AU>
<TI>Control study of loxapine and chlorpromazine in the treatment of schizophrenia</TI>
<SO>Medical Journal of Chinese People's Health</SO>
<YR>2005</YR>
<VL>17</VL>
<NO>9</NO>
<PG>503-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lu-2003" NAME="Lu 2003" YEAR="2003">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lu X-Q, Zhu G-L</AU>
<TI>Control studies of loxapine succinate and clozapine in treatment of schizophrenia</TI>
<SO>Journal of Clinical Psychosomatic Diseases</SO>
<YR>2003</YR>
<VL>9</VL>
<NO>3</NO>
<PG>157-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="115139"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Malik-1980" NAME="Malik 1980" YEAR="1980">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Malik SC, Kumar K</AU>
<TI>Loxapine in adolescent schizophrenia - a comparative study with trifluoperazine</TI>
<SO>Current Therapeutic Research - Clinical and Experimental</SO>
<YR>1980</YR>
<VL>28</VL>
<NO>3</NO>
<PG>432-46</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Moore-1975" NAME="Moore 1975" YEAR="1974">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Moore DF</AU>
<TI>Treatment of acute schizophrenia with loxapine succinate (Loxitane) in a controlled study with chlorpromazine</TI>
<SO>Current Therapeutic Research</SO>
<YR>1975</YR>
<VL>18</VL>
<NO>1</NO>
<PG>172-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Moyano-1975" NAME="Moyano 1975" YEAR="1975">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Moyano CZ</AU>
<TI>A double-blind comparison of loxitane--loxapine succinate and trifluoperazine hydrochloride in chronic schizophrenic patients</TI>
<SO>Diseases of the Nervous System</SO>
<YR>1975</YR>
<VL>36</VL>
<NO>6</NO>
<PG>301-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pool-1976" NAME="Pool 1976" YEAR="1976">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pool D, et al</AU>
<TI>A controlled evaluation of loxitane in seventy-five adolescent schizophrenic patients</TI>
<SO>Current Therapeutic Research</SO>
<YR>1976</YR>
<VL>19</VL>
<NO>1</NO>
<PG>99-104</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="PsycINFO 1976-10411-001"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rifkin-1984" NAME="Rifkin 1984" YEAR="1984">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rifkin A, Rieder E, Sarantakos S, Saraf K, Kane J</AU>
<TI>Is loxapine more effective than chlorpromazine in paranoid schizophrenia?</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1984</YR>
<VL>141</VL>
<NO>11</NO>
<PG>1411-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schiele-1975" NAME="Schiele 1975" YEAR="1975">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schiele BC</AU>
<TI>Loxapine succinate: a controlled double-blind study in chronic schizophrenia</TI>
<SO>Diseases of the Nervous System</SO>
<YR>1975</YR>
<VL>36</VL>
<NO>7</NO>
<PG>361-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Selman-1976" NAME="Selman 1976" YEAR="1976">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Selman FB, McClure RF, Helwig DH</AU>
<TI>Loxapine succinate - A double-blind comparison with haloperidol and placebo in acute schizophrenics</TI>
<TO>Loxapine succinate - essai comparatif en double aveugle avec l'haloperidol et un placebo dans les psychoses aigues</TO>
<SO>Psychologie Medicale</SO>
<YR>1979</YR>
<VL>11</VL>
<NO>7</NO>
<PG>1533-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Selman FB, McClure RF, Helwig H</AU>
<TI>Loxapine succinate: A double-blind comparison with haloperidol and placebo in acute schizophrenics</TI>
<SO>Current Therapeutic Research</SO>
<YR>1976</YR>
<VL>19</VL>
<NO>6</NO>
<PG>645-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Seth-1979" NAME="Seth 1979" YEAR="1979">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Seth S, Mahal AS, Kumar KA</AU>
<TI>A double-blind comparative trial of loxapine and trifluperazine in chronic schizophrenic patients</TI>
<SO>Current Therapeutic Research</SO>
<YR>1979</YR>
<VL>25</VL>
<NO>2</NO>
<PG>320-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Shopsin-1972" NAME="Shopsin 1972" YEAR="1972">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gershon S</AU>
<TI>Loxapine vs chlorpromazine</TI>
<SO>Early clinical drug evaluation units report</SO>
<YR>1972</YR>
<VL>9</VL>
<PG>67-70</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Shopsin B, Pearson E, Gershon S, Collins P</AU>
<TI>A controlled double-blind comparison between loxapine succinate and chlorpromazine in acute newly hospitalized schizophrenic patients</TI>
<SO>Current Therapeutic Research - Clinical and Experimental</SO>
<YR>1972</YR>
<VL>14</VL>
<NO>11</NO>
<PG>739-48</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Simpson-1976" NAME="Simpson 1976" YEAR="1976">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Simpson GM, Cuculic Z</AU>
<TI>A double-blind comparison of loxapine succinate and trifluoperazine in newly admitted schizophrenic patients</TI>
<SO>Journal of Clinical Pharmacology</SO>
<YR>1976</YR>
<VL>16</VL>
<NO>1</NO>
<PG>60-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Steinbook-1973" NAME="Steinbook 1973" YEAR="1973">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Steinbook R, Goldstein BJ, Brauzer B, Moreno SS, Jacobson AF</AU>
<TI>Loxapine: A double blind comparison with chlorpromazine in acute schizophrenic patients</TI>
<SO>Current Therapeutic Research - Clinical and Experimental</SO>
<YR>1973</YR>
<VL>15</VL>
<NO>1</NO>
<PG>1-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tu-2004" NAME="Tu 2004" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tu Z-M,Gao S-R,Ye S-N</AU>
<TI>Controlled study of loxapine and chlorpromazine in the treatment of schizophrenia</TI>
<SO>Medical Journal of Chinese People Health</SO>
<YR>2004</YR>
<VL>16</VL>
<NO>7</NO>
<PG>415-7</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="MED10505"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tuason-1984" NAME="Tuason 1984" YEAR="1984">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tuason VB, Escobar JI, Garvey M, Schiele B</AU>
<TI>Loxapine versus chlorpromazine in paranoid schizophrenia: A double blind study</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>1984</YR>
<VL>45</VL>
<NO>4</NO>
<PG>158-63</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tuason-1986" NAME="Tuason 1986" YEAR="1986">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tuason VB</AU>
<TI>A comparison of parenteral loxapine and haloperidol in hostile and aggressive acutely schizophrenic patients</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>1986</YR>
<VL>47</VL>
<NO>3</NO>
<PG>126-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Van-Der-Velde-1975" NAME="Van Der Velde 1975" YEAR="1975">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Van Der Velde CD, Kiltie H</AU>
<TI>Effectiveness of loxapine succinate in acute schizophrenia: A comparative study with thiothixene</TI>
<SO>Current Therapeutic Research</SO>
<YR>1975</YR>
<VL>17</VL>
<NO>1</NO>
<PG>1-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vyas-1980" NAME="Vyas 1980" YEAR="1980">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Vyas BK, Kalla V</AU>
<TI>A six-month double-blind comparison of loxapine succinate and chlorpromazine in chronic schizophrenic patients</TI>
<SO>Current Therapeutic Research - Clinical and Experimental</SO>
<YR>1980</YR>
<VL>28</VL>
<NO>1</NO>
<PG>16-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wang-1996" NAME="Wang 1996" YEAR="1996">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wang L, Wang Z, Wang Y</AU>
<TI>Using loxapine succinate and chlorpromazine for treating schizophrenia</TI>
<SO>Tianjing Medical Journal</SO>
<YR>1996</YR>
<VL>24</VL>
<NO>11</NO>
<PG>672-5</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="115139"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wang-2005a" NAME="Wang 2005a" YEAR="2005">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wang</AU>
<TI>Control study of Loxapine and Quetiapine treating first onset schizophrenia</TI>
<SO>Chinese journal of behavioural medical science</SO>
<YR>2005</YR>
<VL>14</VL>
<NO>8</NO>
<PG>752</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wang-2005b" NAME="Wang 2005b" YEAR="2005">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wang H-Y, Wang G-P, Pei G-X</AU>
<TI>A comparative study of loxapine and risperidone in the treatment of schizophrenic patients</TI>
<SO>Shandong Archives of Psychiatry</SO>
<YR>2005</YR>
<VL>18</VL>
<NO>1</NO>
<PG>28-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="CAJ"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Xue-2004" NAME="Xue 2004" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Xue S-J, Huang J-M, Yang M-Z</AU>
<TI>A comparison study on loxapine and chlorpromazine in the treatment of schizophrenia</TI>
<SO>Medical Journal of Chinese People Health</SO>
<YR>2004</YR>
<VL>16</VL>
<NO>10</NO>
<PG>593-4</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="115139"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhang-2005" NAME="Zhang 2005" YEAR="2005">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhang</AU>
<TI>Control study of Loxapine treatment in schizophrenia</TI>
<SO>Sichuan Mental Health</SO>
<YR>2005</YR>
<VL>18</VL>
<NO>4</NO>
<PG>222-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2015-10-14 14:24:02 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Ananth-1980" NAME="Ananth 1980" YEAR="1980">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ananth, JV, Van den Steen N</AU>
<TI>The place of loxapine - a new neuroleptic drug</TI>
<SO>Psychiatric Journal of the University of Ottawa</SO>
<YR>1980</YR>
<VL>5</VL>
<NO>4</NO>
<PG>279-82</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bishop-1977" NAME="Bishop 1977" YEAR="1977">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bishop MP, Simpson GM, Dunnett CW, Kiltie H</AU>
<TI>Efficacy of loxapine in the treatment of paranoid schizophrenia</TI>
<SO>Psychopharmacology</SO>
<YR>1977</YR>
<VL>51</VL>
<PG>107-15</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Branchey-1981" MODIFIED="2015-10-14 14:24:02 +0100" MODIFIED_BY="[Empty name]" NAME="Branchey 1981" YEAR="1981">
<REFERENCE MODIFIED="2015-10-14 14:24:02 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Branchey MH, Branchey LB, Richardson MA</AU>
<TI>Effects of neuroleptic adjustment on clinical condition and tardive dyskinesia in schizophrenic patients</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1981</YR>
<VL>138</VL>
<NO>5</NO>
<PG>608-12</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="81204752"/>
<IDENTIFIER TYPE="OTHER" VALUE="PMID 7015884"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Branchey MH, Branehey LB, Richardson MA</AU>
<TI>Effects of gradual decrease and discontinuation of neuroleptics on clinical condition and tardive dyskinesia</TI>
<SO>Psychopharmacology Bulletin</SO>
<YR>1981</YR>
<VL>17</VL>
<NO>1</NO>
<PG>118-20</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="81200010"/>
<IDENTIFIER TYPE="OTHER" VALUE="PMID 7232639"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Brown-2003" NAME="Brown 2003" YEAR="2003">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Brown ES, Nejtek VA, Perantie DC, Thomas NR, Rush AJ</AU>
<TI>Cocaine and amphetamine use in patients with psychiatric: Illness a randomized trial of typical antipsychotic continuation or discontinuation</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>2003</YR>
<VL>23</VL>
<NO>4</NO>
<PG>384-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="EMBASE 2003319642"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bueno-1979" NAME="Bueno 1979" YEAR="1979">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bueno JR</AU>
<TI>A double-blind comparative clinical trial with loxapine succinate and haloperidol in the treatment of Schizophrenia</TI>
<TO>Ensaio clinico comparativo e duplo-cego com succina de loxapina e haloperidol no tratamento da esquizofrenia</TO>
<SO>Folha Medica</SO>
<YR>1979</YR>
<VL>78</VL>
<NO>1</NO>
<PG>47-52</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="CENTRAL 79169917; CENTRAL CN-00316048"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Burdock-1974" NAME="Burdock 1974" YEAR="1974">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Burdock EI, Gershon S, Hardesty AS, Linden KJ</AU>
<TI>Problems and profits of cross-national collaborative studies</TI>
<SO>Diseases of the Nervous System</SO>
<YR>1974</YR>
<VL>35</VL>
<NO>7, Sect 2</NO>
<PG>31-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cottereau-1979" NAME="Cottereau 1979" YEAR="1979">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cottereau MJ, Poirier MF, Loo H, Deniker P</AU>
<TI>The loxapine succinate: A new major tranquillizer</TI>
<TO>Le succinate de loxapine: un nouveau neuroleptique</TO>
<SO>Encephale</SO>
<YR>1979</YR>
<VL>5</VL>
<PG>251-67</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Delteil-1980" NAME="Delteil 1980" YEAR="1980">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Delteil P</AU>
<TI>Clinical trial of a new neuroleptic, loxapine</TI>
<TO>Essai clinique d'un nouveau neuroleptique la loxapine</TO>
<SO>Psychiatrique</SO>
<YR>1980</YR>
<VL>56</VL>
<PG>915-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jones-2006" NAME="Jones 2006" YEAR="2006">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jones PB, Barnes TRE, Davies L, Dunn G, Lloyd H, Hayhurst KP, Murray RM, Markwick A, Lewis SW</AU>
<TI>Randomized controlled trial of the effect on quality of life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1)</TI>
<SO>Archives of General Psychiatry</SO>
<YR>2006</YR>
<VL>63</VL>
<NO>10</NO>
<PG>1079-87</PG>
<CY>United States</CY>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="17015810"/>
<IDENTIFIER TYPE="OTHER" VALUE="EMBASE 2006486244"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Leone-1982" NAME="Leone 1982" YEAR="1982">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Leone NF</AU>
<TI>Response of borderline patients to loxapine and chlorpromazine</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>1982</YR>
<VL>43</VL>
<NO>4</NO>
<PG>148-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lewis-2006" NAME="Lewis 2006" YEAR="2006">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lewis SW, Davies L, Jones PB, Barnes TRE, Murray RM, Kerwin R, Taylor D, Hayhurst KP, Markwick A, Lloyd H, Dunn G</AU>
<TI>Randomised controlled trials of conventional antipsychotic versus new atypical drugs, and new atypical drugs versus clozapine, in people with schizophrenia responding poorly to, or intolerant of, current drug treatment</TI>
<SO>Health Technology Assessment</SO>
<YR>2006</YR>
<VL>10</VL>
<NO>17</NO>
<PG>iii-xi, 1-182</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="16707074"/>
<IDENTIFIER TYPE="OTHER" VALUE="EMBASE 2006300640; CINAHL 2009206784"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lourido-1979" NAME="Lourido 1979" YEAR="1979">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lourido E, Santa Cruz A</AU>
<TI>Comparative treatment of chronic psychoses with loxapine and thioridazine: a double-blind clinical study</TI>
<SO>Current Therapeutic Research</SO>
<YR>1979</YR>
<VL>25</VL>
<NO>5</NO>
<PG>681-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Maes-1996" NAME="Maes 1996" YEAR="1996">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Maes M, Bosmans E, Ranjan R, Vandoolaeghe E, et al</AU>
<TI>Lower plasma CC16, a natural anti-inflammatory protein, and increased plasma interleukin-l receptor antagonist in schizophrenia: Effects of antipsychotic drugs</TI>
<SO>Schizophrenia Research</SO>
<YR>1996</YR>
<VL>21</VL>
<NO>1</NO>
<PG>39-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mahmoud-2004" NAME="Mahmoud 2004" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mahmoud RA, Engelhart LM, Janagap CC, Oster G, Ollendorf D</AU>
<TI>Risperidone versus conventional antipsychotics for schizophrenia and schizoaffective disorder</TI>
<SO>Clinical Drug Investigation</SO>
<YR>2004</YR>
<VL>24</VL>
<NO>5</NO>
<PG>275-86</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Martin-1982" NAME="Martin 1982" YEAR="1982">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Martin A</AU>
<TI>A multi-center study of the effect of loxapine on 403 hospitalized, chronically psychotic patients</TI>
<TO>Efficacite et tolerance de la loxapine a propos d'un essai multicentrique sur 403 psychotiques hospitalises</TO>
<SO>Psychologie Medicale</SO>
<YR>1982</YR>
<VL>14</VL>
<NO>9</NO>
<PG>1439-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mattke-1975" NAME="Mattke 1975" YEAR="1975">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mattke DJ, Mombour W, Glotzner FL</AU>
<TI>The assesment of neuroleptogenic extrapyramidial syndroms in psychopharmalogical research</TI>
<TO>Erfassung neuroleptisch bedingter extrapymidaler syndrome in einem psychopharmakologischen forschungsprojekt</TO>
<SO>Pharmakopsychiat</SO>
<YR>1975</YR>
<VL>1</VL>
<PG>36-44</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nair-1976" NAME="Nair 1976" YEAR="1976">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nair NP, Decker BL, Schwartz G</AU>
<TI>Loxapine succinate in the treatment of chronic schizophrenia</TI>
<SO>Current Therapeutic Research</SO>
<YR>1976</YR>
<VL>20</VL>
<NO>6</NO>
<PG>802-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Paprocki-1976" NAME="Paprocki 1976" YEAR="1976">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Paprocki J, Barcala Peixoto MP, Andrade NM</AU>
<TI>A controlled double-blind comparison between loxapine and haloperidol in acute newly hospitalized schizophrenic patients</TI>
<SO>Psychopharmacoly Bulletin</SO>
<YR>1976</YR>
<VL>12</VL>
<NO>2</NO>
<PG>32-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Paprocki-1977" NAME="Paprocki 1977" YEAR="1977">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Paprocki J, Versiani M</AU>
<TI>A double-blind comparison between loxapine and haloperidol by parenteral route in acute schizophrenia</TI>
<SO>Current Therapeutic Research</SO>
<YR>1977</YR>
<VL>21</VL>
<NO>1</NO>
<PG>80-100</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rainaut-1975" NAME="Rainaut 1975" YEAR="1975">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rainaut J</AU>
<TI>Statistical analysis of the activity of loxapine and thioridazine in a double-blind study</TI>
<TO>Analyse statistique de l'etude comparative double insu de l'activite de la loxapine et de la thioridazine</TO>
<SO>Encephale</SO>
<YR>1975</YR>
<VL>1</VL>
<NO>2</NO>
<PG>147-60</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="76022124"/>
<IDENTIFIER TYPE="OTHER" VALUE="PMID 1100361"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Serafetinides-1971" NAME="Serafetinides 1971" YEAR="1971">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Serafetinides EA, Willis D, Clark ML</AU>
<TI>The EEG effects of dibenzoxazepines (loxapine succinate) as compared to CPZ: EEG changes as drug side effects</TI>
<SO>International Pharmacopsychiatry</SO>
<YR>1971</YR>
<VL>6</VL>
<NO>1</NO>
<PG>38-44</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Serafetinides-1973" NAME="Serafetinides 1973" YEAR="1973">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Serafetinides EA</AU>
<TI>Consistency and similarity of drug EEG responses in chronic schizophrenic patients</TI>
<SO>International Pharmacopsychiatry</SO>
<YR>1973</YR>
<VL>8</VL>
<NO>4</NO>
<PG>214-6</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="74083340"/>
<IDENTIFIER TYPE="OTHER" VALUE="PsycINFO 52-05954; PMID 4589640"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Simpson-1976b" NAME="Simpson 1976b" YEAR="1976">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Branchey MH, Branchey LB, Richardson MA</AU>
<TI>Effects of neuroleptic adjustment on clinical condition and tardive dyskinesia in schizophrenic patients</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1981</YR>
<VL>138</VL>
<NO>5</NO>
<PG>608-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Simpson GM, Branchey MH, Lee JH, Varga E</AU>
<TI>Two year trial of loxapine succinate in chronic psychotic patients</TI>
<SO>Diseases of the Nervour System</SO>
<YR>1976</YR>
<VL>37</VL>
<NO>5</NO>
<PG>305-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Simpson-1978" NAME="Simpson 1978" YEAR="1978">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Simpson GM, Cooper TB, Lee JH, Young MA</AU>
<TI>Clinical and plasma level characteristics of intramuscular and oral loxapine</TI>
<SO>Psychopharmacology</SO>
<YR>1978</YR>
<VL>56</VL>
<NO>2</NO>
<PG>225-32</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="78158740"/>
<IDENTIFIER TYPE="OTHER" VALUE="PMID 417377"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ucer-1979" NAME="Ucer 1979" YEAR="1979">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ucer E, Casey P</AU>
<TI>Effect of loxapine succinate in acutely ill schizophrenic outpatients</TI>
<SO>Current Therapeutic Research</SO>
<YR>1979</YR>
<VL>25</VL>
<NO>1</NO>
<PG>144-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Versiani-1978" NAME="Versiani 1978" YEAR="1978">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Versiani M, da Silva JA, Frota LH, Mundim FD</AU>
<TI>Double-blind comparison between loxapine and haloperidol in the treatment of adolescent schizophrenic patients</TI>
<SO>Current Therapeutic Research</SO>
<YR>1978</YR>
<VL>24</VL>
<NO>5</NO>
<PG>559-66</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Versiani-1980" NAME="Versiani 1980" YEAR="1980">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Versiani M, Da Silva JAR, Mundim FD</AU>
<TI>Loxapine versus thioridazine in the treatment of organic psychosis</TI>
<SO>Journal of International Medical Research</SO>
<YR>1980</YR>
<VL>8</VL>
<NO>1</NO>
<PG>22-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vianna-Filho-1975" NAME="Vianna Filho 1975" YEAR="1975">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Vianna Filho U, Versiani Caldeira MV, Bueno J</AU>
<TI>Preliminary report on a double blind study comparing loxapine succinate with thiothixene in chronic schizophrenic patients</TI>
<SO>Jornal Brasileiro de Psiquiatria</SO>
<YR>1975</YR>
<VL>24</VL>
<NO>1</NO>
<PG>5-27</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Vianna-Filho U, Versiani Caldeira V, Romildo Bueno J</AU>
<TI>The efficacy and safety of loxapine succinate in the treatment of schizophrenia: a comparative study with thiothixene</TI>
<SO>Current Therapeutic Research - Clinical and Experimental</SO>
<YR>1975</YR>
<VL>18</VL>
<NO>3</NO>
<PG>476-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yu-2004" NAME="Yu 2004" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yu H, Luo J-Y, Xia S-Y</AU>
<TI>Treatment of 44 cases of refractory schizophrenia with loxapine</TI>
<SO>Herald of Medicine</SO>
<YR>2004</YR>
<VL>23</VL>
<NO>10</NO>
<PG>723-5</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="MED10411"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2015-10-14 14:24:02 +0100" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2015-10-14 14:24:02 +0100" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Adams-1999" NAME="Adams 1999" TYPE="CONFERENCE_PROC">
<AU>Adams CE, Gray R, Daniels J, Thornley B, Philpott H, Wahlbeck K</AU>
<TI>A survey of UK consultant psychiatrists first and second choice drug treatments for schizophrenia</TI>
<SO>Schizophrenia Trials Meeting, Stratford-upon-Avon</SO>
<YR>5-9th May, 1999</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Altman-1996" NAME="Altman 1996" TYPE="JOURNAL_ARTICLE">
<AU>Altman DG, Bland JM</AU>
<TI>Detecting skewness from summary information</TI>
<SO>BMJ</SO>
<YR>1996</YR>
<VL>313</VL>
<PG>1200</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="LOX020600"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-APA-1994" NAME="APA 1994" TYPE="BOOK">
<AU>American Psychiatric Association</AU>
<SO>Diagnostic and Statistical Manual of Mental Disorders (DSM-IV)</SO>
<YR>1994</YR>
<EN>4th</EN>
<PB>American Psychiatric Association</PB>
<CY>Washington DC</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Begg-1996" NAME="Begg 1996" TYPE="JOURNAL_ARTICLE">
<AU>Begg C, Cho M, Eastwood S, Horton R, Moher D, Olkin I, Pitkin R, Rennie D, Schulz KF, Simel D, Stroup DF</AU>
<TI>Improving the quality of randomized controlled trials. The CONSORT statement</TI>
<SO>JAMA</SO>
<YR>1996</YR>
<VL>276</VL>
<PG>637-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bland-1997" NAME="Bland 1997" TYPE="JOURNAL_ARTICLE">
<AU>Bland JM</AU>
<TI>Statistics notes. Trials randomised in clusters</TI>
<SO>BMJ</SO>
<YR>1997</YR>
<VL>315</VL>
<PG>600</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Boissel-1999" NAME="Boissel 1999" TYPE="JOURNAL_ARTICLE">
<AU>Boissel JP, Cucherat M, Li W, Chatellier G, Gueyffier F, Buyse M, Boutitie F, Nony P, Haugh M, Mignot G</AU>
<TI>The problem of therapeutic efficacy indices. 3. Comparison of the indices and their use</TI>
<SO>Therapie</SO>
<YR>1999</YR>
<VL>54</VL>
<NO>4</NO>
<PG>405-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Buckley-1997" NAME="Buckley 1997" TYPE="JOURNAL_ARTICLE">
<AU>Buckley PF</AU>
<TI>New dimensions in the pharmacologic treatment of schizophrenia and related psychoses</TI>
<SO>Journal of Clinical Pharmacology</SO>
<YR>1997</YR>
<VL>37</VL>
<PG>363-78</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Carpenter-1994" NAME="Carpenter 1994" TYPE="JOURNAL_ARTICLE">
<AU>Carpenter WT Jr, Buchanan RW</AU>
<TI>Schizophrenia</TI>
<SO>New England Journal of Medicine</SO>
<YR>1994</YR>
<VL>330</VL>
<PG>681-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Casey-1997" NAME="Casey 1997" TYPE="JOURNAL_ARTICLE">
<AU>Casey DE</AU>
<TI>The relationship of pharmacology to side effects</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>1997</YR>
<VL>58</VL>
<NO>10</NO>
<PG>55-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Chalmers-1983" NAME="Chalmers 1983" TYPE="JOURNAL_ARTICLE">
<AU>Chalmers TC, Celano P, Sacks HS, Smith H Jr</AU>
<TI>Bias in treatment assignment in controlled clinical trials</TI>
<SO>New England Journal of Medicine</SO>
<YR>1983</YR>
<VL>309</VL>
<PG>1358-61</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-CWG-1998" NAME="CWG 1998" TYPE="JOURNAL_ARTICLE">
<AU>Collaborative Working Group on Clinical Trial Evaluations</AU>
<TI>Adverse effects of the atypical antipsychotics</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>1998</YR>
<VL>59</VL>
<PG>17-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Deeks-2000" NAME="Deeks 2000" TYPE="CONFERENCE_PROC">
<AU>Deeks J</AU>
<TI>Issues in the selection for meta-analyses of binary data</TI>
<SO>Abstracts of 8th International Cochrane Colloquium; 2000 Oct 25-28th; Cape Town, South Africa</SO>
<YR>2000</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Divine-1992" NAME="Divine 1992" TYPE="JOURNAL_ARTICLE">
<AU>Divine GW, Brown JT, Frazier LM</AU>
<TI>The unit of analysis error in studies about physicians' patient care behavior</TI>
<SO>Journal of General Internal Medicine</SO>
<YR>1992</YR>
<VL>7</VL>
<NO>6</NO>
<PG>623-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Donner-2002" NAME="Donner 2002" TYPE="JOURNAL_ARTICLE">
<AU>Donner A, Klar N</AU>
<TI>Issues in the meta-analysis of cluster randomized trials</TI>
<SO>Statistics in Medicine</SO>
<YR>2002</YR>
<VL>21</VL>
<PG>2971-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Egger-1997" NAME="Egger 1997" TYPE="JOURNAL_ARTICLE">
<AU>Egger M, Davey-Smith G, Schneider M, Minder C</AU>
<TI>Bias in meta-analysis detected by a simple graphical test</TI>
<SO>BMJ</SO>
<YR>1997</YR>
<VL>315</VL>
<PG>629-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Elwood-1982" NAME="Elwood 1982" TYPE="JOURNAL_ARTICLE">
<AU>Elwood PC</AU>
<TI>Randomised controlled trials: sampling</TI>
<SO>British Journal of Clinical Pharmacology</SO>
<YR>1982</YR>
<VL>13</VL>
<PG>631-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Glazer-1997" NAME="Glazer 1997" TYPE="JOURNAL_ARTICLE">
<AU>Glazer WM, Johnstone BM</AU>
<TI>Pharmacoeconomic evaluation of antipsychotic therapy for schizophrenia</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>1997</YR>
<VL>58</VL>
<NO>10</NO>
<PG>50-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gulliford-1999" NAME="Gulliford 1999" TYPE="JOURNAL_ARTICLE">
<AU>Gulliford MC</AU>
<TI>Components of variance and intraclass correlations for the design of community-based surveys and intervention studies: data from the Health Survey for England 1994</TI>
<SO>American Journal of Epidemiology</SO>
<YR>1999</YR>
<VL>149</VL>
<PG>876-83 876-83</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Guy-1976" MODIFIED="2015-10-14 14:24:02 +0100" MODIFIED_BY="[Empty name]" NAME="Guy 1976" TYPE="OTHER">
<AU>Guy W</AU>
<TI>Early clinical drug evaluation (ECDEU) assessment manual for psychopharmacology: National Institute of Mental Health Publication No.76-338. Washington DC</TI>
<SO>National Institute of Mental Health Publication</SO>
<YR>1976</YR>
<VL>76-338</VL>
<PG>217-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2003" NAME="Higgins 2003" TYPE="JOURNAL_ARTICLE">
<AU>Higgins JP, Thompson SG, Deeks JJ, Altman DG</AU>
<TI>Measuring inconsistency in meta-analyses</TI>
<SO>BMJ</SO>
<YR>2003</YR>
<VL>327</VL>
<PG>557-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2005" NAME="Higgins 2005" TYPE="BOOK">
<AU>Higgins JPT, Green S</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions 4.2.5 [updated May 2005]</TI>
<SO>The Cochrane Library</SO>
<YR>2005</YR>
<NO>3</NO>
<PB>John Wiley &amp; Sons, Ltd.</PB>
<CY>Chichester, UK</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hollis-1999" MODIFIED="2015-10-14 14:24:02 +0100" MODIFIED_BY="[Empty name]" NAME="Hollis 1999" TYPE="JOURNAL_ARTICLE">
<AU>Hollis S, Campbell F</AU>
<TI>What is meant by intention to treat analysis? Survey of published randomised controlled trials</TI>
<SO>BMJ</SO>
<YR>1999</YR>
<VL>319</VL>
<PG>670-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kane-1996" NAME="Kane 1996" TYPE="JOURNAL_ARTICLE">
<AU>Kane JM</AU>
<TI>Factors which can make patients difficult to treat</TI>
<SO>British Journal of Psychiatry</SO>
<YR>1996</YR>
<VL>169</VL>
<NO>31</NO>
<PG>10-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kay-1986" NAME="Kay 1986" TYPE="JOURNAL_ARTICLE">
<AU>Kay SR</AU>
<TI>Positive and negative symptom (PANNS) scale manual</TI>
<SO>Schizophrenia Bulletin</SO>
<YR>1987</YR>
<VL>13</VL>
<PG>261-78</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kerwin-1994" NAME="Kerwin 1994" TYPE="JOURNAL_ARTICLE">
<AU>Kerwin RW</AU>
<TI>The new atypical antipsychotics. A lack of extrapyramidal side-effects and new routes in schizophrenia research</TI>
<SO>British Journal of Psychiatry</SO>
<YR>1994</YR>
<VL>164</VL>
<PG>141-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kerwin-1996" NAME="Kerwin 1996" TYPE="JOURNAL_ARTICLE">
<AU>Kerwin R, Taylor D</AU>
<TI>New antipsychotics. A review of their current status and clinical potential</TI>
<SO>CNS Drugs</SO>
<YR>1996</YR>
<VL>6</VL>
<PG>71-82</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Leucht-2005a" NAME="Leucht 2005a" TYPE="JOURNAL_ARTICLE">
<AU>Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel R</AU>
<TI>Clinical implications of Brief Psychiatric Rating Scale Scores</TI>
<SO>British Journal of Psychiatry</SO>
<YR>2005</YR>
<VL>187</VL>
<PG>366-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Leucht-2005b" NAME="Leucht 2005b" TYPE="JOURNAL_ARTICLE">
<AU>Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel R</AU>
<TI>What does the PANSS mean?</TI>
<SO>Schizophrenia Research</SO>
<YR>2005</YR>
<VL>79</VL>
<PG>231-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Marshall-2000" NAME="Marshall 2000" TYPE="JOURNAL_ARTICLE">
<AU>Marshall M, Lockwood A, Bradley C, Adams C, Joy C, Fenton M</AU>
<TI>Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia</TI>
<SO>British Journal of Psychiatry</SO>
<YR>2000</YR>
<VL>176</VL>
<PG>249-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Moher-1998" NAME="Moher 1998" TYPE="JOURNAL_ARTICLE">
<AU>Moher D, Pham B, Jones A, Cook DJ, Jadad AR, Moher M, Tugwell P, Klassen TP</AU>
<TI>Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?</TI>
<SO>Lancet</SO>
<YR>1998</YR>
<VL>352</VL>
<PG>609-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Overall-1962" NAME="Overall 1962" TYPE="JOURNAL_ARTICLE">
<AU>Overall JE, Gorham DR</AU>
<TI>The Brief Psychiatric Rating Scale</TI>
<SO>Psychological Reports</SO>
<YR>1962</YR>
<VL>10</VL>
<PG>799-812</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Schulz-1995" NAME="Schulz 1995" TYPE="JOURNAL_ARTICLE">
<AU>Schulz KF, Chalmers I, Hayes RJ, Altman DG</AU>
<TI>Empirical evidence of bias: dimensions of methodological quality associated with estimates of treatment effects in controlled trials</TI>
<SO>JAMA</SO>
<YR>1995</YR>
<VL>273</VL>
<PG>408-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Silverstone-1995" MODIFIED="2015-10-14 14:24:02 +0100" MODIFIED_BY="[Empty name]" NAME="Silverstone 1995" TYPE="BOOK">
<AU>Silverstone T, Turner P</AU>
<SO>Drug treatment in psychiatry.</SO>
<YR>1995</YR>
<PB>TJ Press</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Thomas-1998" NAME="Thomas 1998" TYPE="JOURNAL_ARTICLE">
<AU>Thomas CS, Lewis C</AU>
<TI>Which atypical antipsychotic?</TI>
<SO>British Journal of Psychiatry</SO>
<YR>1998</YR>
<VL>172</VL>
<PG>106-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ukoumunne-1999" NAME="Ukoumunne 1999" TYPE="JOURNAL_ARTICLE">
<AU>Ukoumunne OC, Gulliford MC, Chinn S, Sterne JAC, Burney PGJ</AU>
<TI>Methods for evaluating area-wide and organistation-based intervention in health and health care: a systematic review</TI>
<SO>Health Technology Assessment</SO>
<YR>1999</YR>
<VL>3</VL>
<NO>5</NO>
<PG>1-75</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Vanelle-1994" NAME="Vanelle 1994" TYPE="JOURNAL_ARTICLE">
<AU>Vanelle JM, Olie JP, Levy-Soussan P</AU>
<TI>New antipsychotics in schizophrenia: the French Experience</TI>
<SO>Acta Psychiatrica Scandinavica, Supplementum</SO>
<YR>1994</YR>
<VL>380</VL>
<PG>59-63</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wood-MacKenzie-1998" MODIFIED="2015-10-14 14:24:02 +0100" MODIFIED_BY="[Empty name]" NAME="Wood MacKenzie 1998" TYPE="JOURNAL_ARTICLE">
<AU>Wood MacKenzie</AU>
<TI>Review of the Global Schizophrenia Market</TI>
<SO>PharmaForum</SO>
<YR>1998</YR>
<VL>39</VL>
<PG>9</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2013-12-02 11:33:27 +0000" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Murphy-2000" MODIFIED="2013-12-02 11:33:27 +0000" MODIFIED_BY="[Empty name]" NAME="Murphy 2000" TYPE="COCHRANE_REVIEW">
<AU>Murphy BE, Bagnall A, Chue P, Fenton M, Leitner M, Wood J</AU>
<TI>Loxapine for schizophrenia</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2000</YR>
<NO>2</NO>
<PB>Update Software</PB>
<CY>Oxford, UK</CY>
<IDENTIFIERS MODIFIED="2013-12-02 11:33:27 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-02 11:33:27 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD001943"/>
</IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES MODIFIED="2013-12-02 11:30:40 +0000" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Allen-2011" MODIFIED="2013-12-02 11:11:59 +0000" MODIFIED_BY="[Empty name]" NAME="Allen 2011" TYPE="JOURNAL_ARTICLE">
<AU>Allen MH, Feifel D, Lesem MD, Zimbroff DL, Ross R, Munzar P, et al</AU>
<TI>Efficacy and safety of loxapine for inhalation in the treatment of agitation in patients with schizophrenia: A randomized, double-blind, placebo-controlled trial</TI>
<SO>Journal of clinical psychiatry</SO>
<YR>2011</YR>
<VL>72</VL>
<NO>10</NO>
<PG>1313-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bai-2007" MODIFIED="2013-12-02 11:25:11 +0000" MODIFIED_BY="[Empty name]" NAME="Bai 2007" TYPE="JOURNAL_ARTICLE">
<AU>Bai H</AU>
<TI>The succinate Luosha peace of clozapine treatment of schizophrenia</TI>
<SO>Chinese journal of mental health [&#20013;&#22269;&#27665;&#24247;&#21307;&#23398;]</SO>
<YR>2007</YR>
<VL>19</VL>
<NO>9</NO>
<PG>758-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cai-2007" MODIFIED="2013-12-02 11:11:59 +0000" MODIFIED_BY="[Empty name]" NAME="Cai 2007" TYPE="JOURNAL_ARTICLE">
<AU>Cai J-Y</AU>
<TI>Loxapine with aripiprazole treatment of schizophrenia investigate the efficacy and safety of</TI>
<SO>Chinese journal of clinician [&#20013;&#22269;&#21307;&#24072;&#26434;&#24535;]</SO>
<YR>2007</YR>
<VL>19</VL>
<NO>7</NO>
<PG>982-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cassella-2008" MODIFIED="2013-12-02 11:13:34 +0000" MODIFIED_BY="[Empty name]" NAME="Cassella 2008" TYPE="CONFERENCE_PROC">
<AU>Cassella JV, Allen M, Munzar P, Spyker D</AU>
<TI>Inhaled loxapine rapidly improves acute agitation in schizophrenic patients</TI>
<SO>Proceedings of the 161st Annual Meeting of the American Psychiatric Association; 2008 May 3-8; Washington DC, USA</SO>
<YR>2008</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cassella-2009" MODIFIED="2013-12-02 11:11:59 +0000" MODIFIED_BY="[Empty name]" NAME="Cassella 2009" TYPE="JOURNAL_ARTICLE">
<AU>Cassella J, Spyker D, Fishman R</AU>
<TI>Inhaled loxapine rapidly improves acute agitation in schizophrenic patients</TI>
<SO>Proceedings of the 162nd Annual Meeting of the American Psychiatric Association; 2009 May 16-21; San Francisco, CA</SO>
<YR>2009</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cassella-2010" MODIFIED="2013-12-02 11:23:07 +0000" MODIFIED_BY="[Empty name]" NAME="Cassella 2010" TYPE="JOURNAL_ARTICLE">
<AU>Cassella JV, Fishman RS, Spyker D</AU>
<TI>Inhaled loxapine (az-004) rapidly improves acute agitation in patients with schizophrenia or bipolar disorder</TI>
<SO>European neuropsychopharmacology</SO>
<YR>2010</YR>
<VL>20</VL>
<NO>Suppl. 3</NO>
<PG>512-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Chang-2006" MODIFIED="2013-12-02 11:11:59 +0000" MODIFIED_BY="[Empty name]" NAME="Chang 2006" TYPE="JOURNAL_ARTICLE">
<AU>Chang S-H</AU>
<TI>Comparative study of loxapine and risperidone in the treatment of schizophrenia</TI>
<SO>Chinese journal of mental health [&#20013;&#22269;&#27665;&#24247;&#21307;&#23398;]</SO>
<YR>2006</YR>
<VL>18</VL>
<NO>12</NO>
<PG>1020-1</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Citrome-2012" MODIFIED="2013-12-02 11:11:59 +0000" MODIFIED_BY="[Empty name]" NAME="Citrome 2012" TYPE="JOURNAL_ARTICLE">
<AU>Citrome L</AU>
<TI>Inhaled loxapine for agitation revisited: Focus on effect sizes from 2 phase iii randomised controlled trials in persons with schizophrenia or bipolar disorder</TI>
<SO>International journal of clinical practice</SO>
<YR>2012</YR>
<VL>66</VL>
<NO>3</NO>
<PG>318-25</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Denber-1970" MODIFIED="2013-12-02 11:11:59 +0000" MODIFIED_BY="[Empty name]" NAME="Denber 1970" TYPE="JOURNAL_ARTICLE">
<AU>Denber</AU>
<TI>Oxilapine versus trifluoperazine</TI>
<SO>Psychopharmacology bulletin</SO>
<YR>1970</YR>
<VL>6</VL>
<NO>4</NO>
<PG>93-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Guo-2008" MODIFIED="2013-12-02 11:25:43 +0000" MODIFIED_BY="[Empty name]" NAME="Guo 2008" TYPE="JOURNAL_ARTICLE">
<AU>Guo L, Wang H-H, Wang W, Zhang R-G, Chen Y-C, Feng Z-H, Qiao Y-T, Tan Q-R</AU>
<TI>Comparative study between loxapine and risperdal in the treatment of schizophrenia</TI>
<SO>Journal of clinical psychiatry [linchuang jingshen yixue zazhi] [&#20020;&#24202;&#31934;&#31070;&#21307;&#23398;&#26434;&#24535;]</SO>
<YR>2008</YR>
<VL>18</VL>
<NO>5</NO>
<PG>327-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lesem-2011" MODIFIED="2013-12-02 11:11:59 +0000" MODIFIED_BY="[Empty name]" NAME="Lesem 2011" TYPE="JOURNAL_ARTICLE">
<AU>Lesem MD, Tran-Johnson TK, Riesenberg RA, Feifel D, Allen MH, Fishman R, et al</AU>
<TI>Rapid acute treatment of agitation in individuals with schizophrenia: Multicentre, randomised, placebo-controlled study of inhaled loxapine</TI>
<SO>British journal of psychiatry</SO>
<YR>2011</YR>
<VL>198</VL>
<NO>1</NO>
<PG>51-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Li-2003" MODIFIED="2013-12-02 11:26:01 +0000" MODIFIED_BY="[Empty name]" NAME="Li 2003" TYPE="JOURNAL_ARTICLE">
<AU>Li X, Zou Z, W ang Y</AU>
<TI>Controlled study of loxapine and clozapine in the treatment of schizophrenia</TI>
<SO>International Chinese Neuropsychiatry Medicine Journal</SO>
<YR>2003</YR>
<VL>4</VL>
<NO>1</NO>
<PG>1-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Li-2004" MODIFIED="2013-12-02 11:26:11 +0000" MODIFIED_BY="[Empty name]" NAME="Li 2004" TYPE="JOURNAL_ARTICLE">
<AU>Li AF</AU>
<TI>Loxapine succinate and Risperdal in the treatment of schizophrenia efficacy comparison</TI>
<SO>Chinese Journal of Clinical Medicine Practice</SO>
<YR>2004</YR>
<VL>3</VL>
<NO>8</NO>
<PG>33-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Liu-2005" MODIFIED="2013-12-02 11:26:21 +0000" MODIFIED_BY="[Empty name]" NAME="Liu 2005" TYPE="JOURNAL_ARTICLE">
<AU>Liu X, Liusheng H, Liu B</AU>
<TI>Control study of loxapine and chlorpromazine in the treatment of schizophrenia</TI>
<SO>Chinese journal of mental health [&#20013;&#22269;&#27665;&#24247;&#21307;&#23398;]</SO>
<YR>2005</YR>
<VL>17</VL>
<NO>9</NO>
<PG>503-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Liu-2007" MODIFIED="2013-12-02 11:26:47 +0000" MODIFIED_BY="[Empty name]" NAME="Liu 2007" TYPE="JOURNAL_ARTICLE">
<AU>Liu M, Che L</AU>
<TI>A comparative study of loxapin and aripiprazole in the treatment of first-schizophrenia</TI>
<SO>Chinese journal of health psychology</SO>
<YR>2007</YR>
<VL>15</VL>
<NO>12</NO>
<PG>1109-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lu-2006" MODIFIED="2013-12-02 11:27:07 +0000" MODIFIED_BY="[Empty name]" NAME="Lu 2006" TYPE="JOURNAL_ARTICLE">
<AU>Lu B-H, Su X-R, Xie B-Q</AU>
<TI>A comparative study of loxapine and risperidone in the treatment of schizophrenia</TI>
<SO>Archives of psychiatry [jingshen yixue] [&#31934;&#31070;&#21307;&#23398;&#26434;&#24535;]</SO>
<YR>2006</YR>
<VL>19</VL>
<NO>2</NO>
<PG>122-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-NCT00369577-2006" MODIFIED="2013-12-02 11:11:59 +0000" MODIFIED_BY="[Empty name]" NAME="NCT00369577 2006" TYPE="JOURNAL_ARTICLE">
<AU>NCT00369577</AU>
<TI>A multi-center, randomized, double-blind, placebo-controlled, single dose efficacy and safety study of staccato TM loxapine for inhalation in schizophrenic patients with agitation</TI>
<SO>http://www.clinicaltrials.gov</SO>
<YR>2006</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ren-2006" MODIFIED="2013-12-02 11:27:15 +0000" MODIFIED_BY="[Empty name]" NAME="Ren 2006" TYPE="JOURNAL_ARTICLE">
<AU>Ren L</AU>
<TI>Old age episode schizophrenia efficacy analysis</TI>
<SO>Chinese journal of mental health [&#20013;&#22269;&#27665;&#24247;&#21307;&#23398;]</SO>
<YR>2006</YR>
<VL>18</VL>
<NO>3</NO>
<PG>202-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Song-2006" MODIFIED="2013-12-02 11:27:23 +0000" MODIFIED_BY="[Empty name]" NAME="Song 2006" TYPE="JOURNAL_ARTICLE">
<AU>Song X</AU>
<TI>Comparison of efficacy of loxapine and risperidone in the treatment of schizophrenia</TI>
<SO>Herald of medicine</SO>
<YR>2006</YR>
<VL>25</VL>
<NO>10</NO>
<PG>1003-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wang-2007" MODIFIED="2013-12-02 11:27:39 +0000" MODIFIED_BY="[Empty name]" NAME="Wang 2007" TYPE="JOURNAL_ARTICLE">
<AU>Wang K-Q, Xu S-W, Li S-F</AU>
<TI>A comparative study of loxapine and risperidone in the treatment of schizophrenic patients</TI>
<SO>Chinese journal of mental health [&#20013;&#22269;&#27665;&#24247;&#21307;&#23398;]</SO>
<YR>2007</YR>
<VL>19</VL>
<NO>17</NO>
<PG>761</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ye-2006" MODIFIED="2013-12-02 11:27:49 +0000" MODIFIED_BY="[Empty name]" NAME="Ye 2006" TYPE="JOURNAL_ARTICLE">
<AU>Ye S</AU>
<TI>Clozapine merger Loxapine succinate single randomized controlled study of the treatment of schizophrenia with loxapine succinate</TI>
<SO>Chinese journal of mental health [&#20013;&#22269;&#27665;&#24247;&#21307;&#23398;]</SO>
<YR>2006</YR>
<VL>18</VL>
<NO>6</NO>
<PG>468-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Yi-2005" MODIFIED="2013-12-02 11:27:54 +0000" MODIFIED_BY="[Empty name]" NAME="Yi 2005" TYPE="JOURNAL_ARTICLE">
<AU>Yi Y</AU>
<TI>Loxapine Risperdal controlled study of the treatment of schizophrenia</TI>
<SO>Jinggangshan university: comprehensive edition [&#20117;&#20872;&#23665;&#23398;&#38498;&#23398;&#25253;: &#32508;&#21512;&#29256;]</SO>
<YR>2005</YR>
<VL>26</VL>
<NO>3</NO>
<PG>96-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Yu-2006" MODIFIED="2013-12-02 11:28:04 +0000" MODIFIED_BY="[Empty name]" NAME="Yu 2006" TYPE="JOURNAL_ARTICLE">
<AU>Yu W</AU>
<TI>Quetiapine in the treatment of schizophrenia with loxapine</TI>
<SO>Journal of clinical psychiatry</SO>
<YR>2006</YR>
<VL>16</VL>
<NO>5</NO>
<PG>298</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Zhang-2006" MODIFIED="2013-12-02 11:28:13 +0000" MODIFIED_BY="[Empty name]" NAME="Zhang 2006" TYPE="JOURNAL_ARTICLE">
<AU>Zhang Y</AU>
<TI>Loxapine succinate controlled study of clozapine treatment of schizophrenia</TI>
<SO>Ningxia medical journal</SO>
<YR>2006</YR>
<VL>28</VL>
<NO>5</NO>
<PG>391-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Zhang-2007" MODIFIED="2013-12-02 11:11:59 +0000" MODIFIED_BY="[Empty name]" NAME="Zhang 2007" TYPE="JOURNAL_ARTICLE">
<AU>Zhang L</AU>
<TI>Loxapine succinate women and clozapine in the treatment of schizophrenia</TI>
<SO>Chinese journal of mental health [&#20013;&#22269;&#27665;&#24247;&#21307;&#23398;]</SO>
<YR>2007</YR>
<VL>19</VL>
<NO>17</NO>
<PG>768</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Zhao-2003" MODIFIED="2013-12-02 11:28:19 +0000" MODIFIED_BY="[Empty name]" NAME="Zhao 2003" TYPE="JOURNAL_ARTICLE">
<AU>Zhao S</AU>
<TI>Loxapine and chlorpromazine in the treatment of schizophrenia</TI>
<SO>Hebei Mental Health</SO>
<YR>2003</YR>
<VL>16</VL>
<NO>1</NO>
<PG>35-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-_x5434__x5ef6__x6d77_-2010" MODIFIED="2013-12-02 11:28:39 +0000" MODIFIED_BY="[Empty name]" NAME="&#21556;&#24310;&#28023; 2010" TYPE="JOURNAL_ARTICLE">
<AU>&#21556;&#24310;&#28023;, &#20309;&#38663;, &#37045;&#24314;&#23792;, &#26472;&#31062;&#25104;</AU>
<TI>succinate loxapine and risperidone in the treatment of schizophrenia clinical observation] Google Translate</TI>
<SO>Journal of Huaihai Medicine</SO>
<YR>2010</YR>
<VL>28</VL>
<NO>3</NO>
<PG>203-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-_x5b8b__x5efa__x94f8_-2008" MODIFIED="2013-12-02 11:29:02 +0000" MODIFIED_BY="[Empty name]" NAME="&#23435;&#24314;&#38136; 2008" TYPE="JOURNAL_ARTICLE">
<AU>&#23435;&#24314;&#38136;, &#39532;&#26690;&#33805;, &#24352;&#38470;, &#24352;&#20122;&#19996;, &#21016;&#27946;&#23721;</AU>
<TI>Bezoar Ning Gong tablets and small doses of loxapine treatment 34 patients with schizophrenia</TI>
<SO>Journal of chinese rural physician</SO>
<YR>2008</YR>
<VL>10</VL>
<NO>13</NO>
<PG>104</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-_x5eb7__x7ea2__x82f1_-2008" MODIFIED="2013-12-02 11:29:25 +0000" MODIFIED_BY="[Empty name]" NAME="&#24247;&#32418;&#33521; 2008" TYPE="JOURNAL_ARTICLE">
<AU>&#24247;&#32418;&#33521;, &#24352;&#36726;&#26480;, &#38472;&#34527;, &#21608;&#21033;&#22269;</AU>
<TI>Loxapine succinate and risperidone in the treatment of 120 female patients with schizophrenia</TI>
<SO>Chinese journal of mental health [&#20013;&#22269;&#27665;&#24247;&#21307;&#23398;]</SO>
<YR>2008</YR>
<VL>20</VL>
<NO>23</NO>
<PG>2776-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-_x5f20__x6587__x654f_-2008" MODIFIED="2013-12-02 11:29:49 +0000" MODIFIED_BY="[Empty name]" NAME="&#24352;&#25991;&#25935; 2008" TYPE="JOURNAL_ARTICLE">
<AU>&#24352;&#25991;&#25935;, &#21513;&#20210;&#23439;, &#36158;&#21465;&#38155;</AU>
<TI>Comparison of loxapine succinate and risperidone in the treatment of schizophrenia</TI>
<SO>Nei Mongol Journal of Traditional Chinese Medicine</SO>
<YR>2008</YR>
<NO>4</NO>
<PG>18</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-_x738b__x521a__x5e73_-2010" MODIFIED="2013-12-02 11:30:08 +0000" MODIFIED_BY="[Empty name]" NAME="&#29579;&#21018;&#24179; 2010" TYPE="JOURNAL_ARTICLE">
<AU>&#29579;&#21018;&#24179;, &#39049;&#29790;, &#35060;&#26681;&#31077;, &#24352;&#27704;&#24405;</AU>
<TI>Ziprasidone, and loxapine treatment of schizophrenia</TI>
<SO>Journal of clinical psychiatry [linchuang jingshen yixue zazhi] [&#20020;&#24202;&#31934;&#31070;&#21307;&#23398;&#26434;&#24535;]</SO>
<YR>2010</YR>
<VL>20</VL>
<NO>05</NO>
<PG>327-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-_x9ad8__x6d77__x6c5f_-2011" MODIFIED="2013-12-02 11:30:40 +0000" MODIFIED_BY="[Empty name]" NAME="&#39640;&#28023;&#27743; 2011" TYPE="JOURNAL_ARTICLE">
<AU>&#39640;&#28023;&#27743;, &#39640;&#28023;&#33521;, &#24352;&#28113;&#33395;, &#31398;&#24314;&#20891;, &#21016;&#28851;&#20070;, &#33503;&#27741;&#32418;, &#24352;&#32487;&#38738;, &#24378;&#29790;&#39321;</AU>
<TI>Clinical analysis of loxapine treatment of schizophrenia</TI>
<SO>Hebei medical journal</SO>
<YR>2011</YR>
<VL>33</VL>
<NO>13</NO>
<PG>1969-70</PG>
<IDENTIFIERS/>
</REFERENCE>
</PENDING_REFERENCES>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES>
<CHARACTERISTICS_OF_INCLUDED_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR STUDY_ID="STD-Bagadia-1980">
<CHAR_METHODS>
<P>Allocation: randomised - no further details.<BR/>Blinding: double blind - identical capsules.<BR/>Duration: 4 weeks.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Diagnosis: schizophrenia with onset between 13-19 yrs (ICD-10).<BR/>N=55.<BR/>Age: mean ~17 years, range 14-24.<BR/>Sex: male and female.<BR/>History: outpatients.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Loxapine: dose 10 mg/day increased to 120 mg/day. N=25.<BR/>2. Trifluperazine: dose 2.5 mg/day increased up to 25 mg/day max. N=30.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Leaving the study early.<BR/>Drug preference.<BR/>Patients self evaluation.<BR/>Adverse effects.</P>
<P>Unable to use - <BR/>Global effect: CGI (no SD).<BR/>Mental state: BPRS (no SD).<BR/>Behaviour: NOSIE (no SD).<BR/>Laboratory tests: Blood tests, ECG, opthmalogical, physiological (no data).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Bishop-1970">
<CHAR_METHODS>
<P>Allocation: randomised - no further details.<BR/>Blinding: double - no further information.<BR/>Duration: 8 weeks - preceded by 4 weeks washout + 2 week assessment period.<BR/>Setting: single centre.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Diagnosis: schizophrenia, chronic - no further details.<BR/>N=24.<BR/>Age: mean ~ 44 years, range 30-55.<BR/>Sex: 12 M, 12 F.<BR/>History: inpatients ~ 17 years, range 5-29 years.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Loxapine: dose 20 mg/day, increased to 120 mg/day maximum. N=12.<BR/>2. Trifluoperazine: dose 10 mg/day, increased to 60 mg/day maximum. N=12.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Global effect: CGI.<BR/>Adverse effects.</P>
<P>Unable to use - <BR/>Mental state: BPRS (no usable data).<BR/>Behaviour: NOSIE (no usable data).<BR/>Laboratory tests: ECG (no data).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Charalampous-1974">
<CHAR_METHODS>
<P>Allocation: randomised - no further details.<BR/>Blinding: double - identical capsules.<BR/>Duration: 4 weeks - preceded by 1 week washout.<BR/>Setting: single centre.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Diagnosis: schizophrenia (by 2 psychiatrists).<BR/>N=60*.<BR/>Age: mean ~ 26 years, range 18-53.<BR/>Sex: 58 M, 2 F.<BR/>History: inpatients, ill &lt; 6 years, healthy, mean length ill ~ 2.5 years.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Loxapine: dose range 50 mg-150 mg/day, mean 147.5 mg. N=20.<BR/>2. Thiothixene: dose range 20 mg-60 mg/day, mean 51.9 mg. N=20.<BR/>3. Placebo. N=19.</P>
<P>Chloral hydrate and trihexyphenidyl as required.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Excluded from analysis.<BR/>Adverse effects (TESS, use of anticholinergic drugs).</P>
<P>Unable to use - <BR/>Global effect: CGI (no data).<BR/>Mental state: BPRS (no SD).<BR/>Behaviour: NOSIE (no data).<BR/>Leaving the study early (not reported).<BR/>Laboratory tests: (no data).<BR/>Physiological measures: BP, ECG, weight (no data).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>*One participant not accounted for.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Clark-1972">
<CHAR_METHODS>
<P>Allocation: random, stratified age and sex.<BR/>Blinding: double blind-identical capsules.<BR/>Duration: 12 weeks, with 12 weeks washout.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Diagnosis: schizophrenia, confirmed by project psychiatrist.<BR/>N=55.<BR/>Age: 21-60 years.<BR/>Sex: 31 M, 24 F.<BR/>History: inpatients, ill for at least 2 years.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Loxapine: dose 10 mg/day increased to 100 mg/day in 25 days. N=18<BR/>2. Chlorpromazine: dose 100 mg/day increased to 1gm/day . N=19.<BR/>3. Placebo. N=18.</P>
<P>Antiparkinsonian medication allowed as required.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Global effect: CGI (improvement).<BR/>Adverse effects(physical examination, lab results, ECG and eye examination).</P>
<P>Unable to use -<BR/>Global effect: CGI (severity) (no SD).<BR/>Mental state: BPRS (no SD).<BR/>Behaviour: NOSIE (no SD).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Weight increase or decrease - 10 lbs.<BR/>All blood test abnormalities combined.<BR/>For CGI (improvement) reading by psychiatrist 2 used (randomly chosen by lots).</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Clark-1975">
<CHAR_METHODS>
<P>Allocation: random - pre-randomised list, blocks of 3, provided by drug company.<BR/>Blinding: double - identical capsules.<BR/>Duration: 4 weeks.<BR/>Setting: single centre.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Diagnosis: schizophrenia, confirmed by research psychiatrists.<BR/>N=42.<BR/>Age: range 21-57 years.<BR/>Sex: 21 M, 16 F, 6 unreported.<BR/>History: ill &gt; 2 years, healthy, not able to bear children.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Loxapine: dose 100mg/day, mean 71mg/day. N=15.<BR/>2. Trifluoperazine: dose 50 mg/day, mean 36 mg/day. N=14.<BR/>3. Placebo. N=13.<BR/>Short acting sedatives and antiparkinsonian medication as required.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Global effect (CGI-I, CGI-S, use of additional sedation).<BR/>Adverse effects.<BR/>Leaving the study early.<BR/>Laboratory tests.<BR/>Physiological measures (ECG, weight).</P>
<P>Unable to use - <BR/>Efficacy: (analysis of covariance - no usable data).<BR/>Mental state: BPRS (no SD).<BR/>Behaviour: NOSIE (no usable data).<BR/>Physiological measures: BP, pulse (no data).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>6 people removed from analysis but original group of allocation reported so ITT analysis possible.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Clark-1977">
<CHAR_METHODS>
<P>Allocation: random - pre-randomised list, blocks of 3, provided by drug company.<BR/>Blinding: double - identical capsules.<BR/>Duration: 12 weeks - "..effects of previous treatment allowed to dissipate over a period of 12 weeks" before trial.<BR/>Setting: single centre.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Diagnosis: schizophrenia (DSM-II).<BR/>N=38.<BR/>Age: range 21-57 years.<BR/>Sex: 11 M, 27 F.<BR/>History: &gt; 2 years ill &amp; institutionalizations without remission, healthy, not pregnant, inpatients.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Loxapine: dose 100 mg/day. N=12.<BR/>2. Loxapine: dose 50 mg/day. N=13.<BR/>3. Placebo. N=13.</P>
<P>Short acting sedatives and antiparkinsonian medication as required.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Global effect (CGI-I, CGI-S, use of additional sedation).<BR/>Adverse effects.<BR/>Leaving the study early.<BR/>Laboratory tests.<BR/>Physiological measures (ECG, weight).</P>
<P>Unable to use - <BR/>Efficacy: (analysis of covariance - no usable data).<BR/>Mental state: BPRS (no SD).<BR/>Behaviour: NOSIE (no usable data).<BR/>Physiological measures: BP, pulse (no data).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Du-2003">
<CHAR_METHODS>
<P>Allocation: randomised.<BR/>Blinding: none.<BR/>Duration: 8 weeks.<BR/>Setting: single centre.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Diagnosis: schizophrenia (CCMD-3).<BR/>N=60. <BR/>Loxapine grp: 18 M, 12 F; average age 29.<BR/>Risperidone grp: 17 M, 13 F; average age 26.<BR/>History: hospitalised patients.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Loxapine: dose range: 68-305 mg. N=30.<BR/>2. Risperidone: dose range: 1-6 mgs. N=30.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Adverse effects: TESS.<BR/>Laboratory tests.<BR/>Physiological measures: ECG, EEG.</P>
<P>Unable to use - <BR/>Global effect: CGI (no data).<BR/>Mental State: BPRS (no data).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Dube-1976">
<CHAR_METHODS>
<P>Allocation: randomised - no further information.<BR/>Blinding: double - identical capsules.<BR/>Duration: 12 weeks.<BR/>Setting: single centre.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Diagnosis: schizophrenia, no further information.<BR/>N=52.<BR/>Age: mean ~ 32 years, range 18-55.<BR/>Sex: 52 M.<BR/>History: &lt; 2 years ill, healthy, no co-existing mental illnesses.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Loxapine: dose 20-80 mg/day, mean 34.3 mg/day. N=26.<BR/>2. Chlorpromazine: dose 200-800 mg/day, mean 320 mg/day. N=26.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Global effect: CGI.<BR/>Adverse effects.<BR/>Leaving the study early.</P>
<P>Unable to use - <BR/>Efficacy (analysis of covariance - no usable data).<BR/>Mental state: BPRS (no SD).<BR/>Laboratory tests: (no data).<BR/>Physiological measures: BP, ECG, pulse, ophthalmic change (no data).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Dubin-1996">
<CHAR_METHODS>
<P>Allocation: randomised - randomisation table.<BR/>Blinding: double - identical ampules, staff administering medication not blinded, assessors blind.<BR/>Duration: 6 days - preceded by 24h washout (only data from first 72 hours used).<BR/>Setting: single centre.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Diagnosis: schizophrenia (52), bipolar manic (9) (DSM-III).<BR/>N=61.<BR/>Age: mean ~ 35 years, range 18-65.<BR/>Sex: ~27 M, ~31 F.<BR/>Inclusion : BPRS score of 6/7 in &gt;2 prespecified symptom categories.<BR/>History: admitted as psychiatric emergency, healthy, drug sensitivity, not pregnant or lactating, no co-existing mental illness.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Loxapine: dose mean 75.5 mg/day IM, range 25-175 mg/day IM. N=30.<BR/>2. Thiothixene: dose mean 31 mg/day IM, range 20-60 mg/day IM, N=31.</P>
<P>IM for first 24 hours, then oral. IM injections every 30 minutes as needed, until BPRS reduced or sedation occurred. Chloral hydrate, trihexyphenidyl/benztropine as required.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Global effect (sedation, requiring further injections).<BR/>Dropped from study.</P>
<P>Unable to use - <BR/>Global effect: CGI (no data).<BR/>Mental state: BPRS (no SD).<BR/>Side effects: (only data for 5 day oral phase available).<BR/>Physiological measures: BP, pulse (no data).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Fruensgaard-1977">
<CHAR_METHODS>
<P>Allocation: randomised - no further details.<BR/>Blinding: double - identical ampules.<BR/>Duration: 72 hours - preceded by 12 h washout (study continued for 4 weeks but not reported).<BR/>Setting: single centre.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Diagnosis: acute schizophrenia (12), psychogenic psychosis (18).<BR/>N=30.<BR/>Age: mean ~ 40 years, range 19-65.<BR/>Sex: 7 M, 23 F.<BR/>Inclusion: healthy, not pregnant, no coexisting mental illness, mania or treatment with ECT in last 8 weeks.<BR/>History: duration of present episode: &lt;1week (14), 1 week-1 month (13), &gt;1month (3).</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Loxapine: dose 25-50 mg/6-12 hours IM, mean 130 mg/day IM. N=15.<BR/>2. Thiothixene: dose 2.5-5 mg/6-12 hours IM, mean 12 mg/day IM. N=15.</P>
<P>Both given with biperiden. IM for first 24 hours, then oral. IM injections every 30 minutes as needed, until BPRS reduced or sedation occurred.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Global effect: CGI, sedation.<BR/>Adverse effects: pain at injection site.</P>
<P>Unable to use - <BR/>Mental state: BPRS (no SD), continued aggression (no usable data).<BR/>Physiological measures: BP, pulse (no data).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Fruensgaard-1978">
<CHAR_METHODS>
<P>Allocation: randomised - no further details.<BR/>Blinding: double blind.<BR/>Duration: group one -3 weeks, group two - 12 weeks.<BR/>Setting: multicenter.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Diagnosis: acute schizophrenia (7, acute schizophreniform psychotic episodes or acute exacerbations of a chronic schizophrenic process), psychogenic (reactive) psychosis (15), chronic schizophrenia (25).<BR/>N=47.<BR/>Age: range 16-67 years.<BR/>Sex: 32 M, 15F.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Loxapine: dose 10 mg bid increased to 150 mg/day. N=23.<BR/>2. Perphenazine: dose 8 mg bid increased to 120 mg/day. N=24.</P>
<P>Chloralodolol used for insomnia and antiparkinsonian medications used as required.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Global effect: CGI.<BR/>Adverse effects. <BR/>Physiological effects, laboratory tests, ECG.</P>
<P>Unable to use -<BR/>Mental state: BPRS (no data).<BR/>Behaviour: NOSIE (no data).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Data of adverse effects and CGI were extracted after clubbing both acute and chronic patients.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Gallant-1971">
<CHAR_METHODS>
<P>Allocation: randomised by random numbers.<BR/>Blinding: double blind.<BR/>Duration: 8 weeks, with 4 weeks washout.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Diagnosis: chronic schizophrenia.<BR/>N=24.<BR/>Age: range 30-55.<BR/>Sex: 11 M, 13F.<BR/>Design: phase 2 trial.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Loxapine: dose 20 mg/day increased to 120 mg/day. N=12.<BR/>2. Trifluperazine: dose 10 mg/day increased up to 60 mg/day. N=12.</P>
<P>Antiparkinsonian medication given as required.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Adverse events.</P>
<P>Unable to use -<BR/>Global effect: CGI (no data).<BR/>Mental state: BPRS (no data).<BR/>Behaviour: NOSIE (no data).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Huang-1997">
<CHAR_METHODS>
<P>Allocation: randomised - no further details<BR/>Blinding: double blind.<BR/>Duration: 8 weeks.<BR/>Setting: multicenter.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Diagnosis: schizophrenia.<BR/>N=205.<BR/>Age: mean ~35 years, range 18-60.<BR/>Sex: 123 M, 82 F.<BR/>History: hospitalised.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Loxapine: dose range: 50-300 mg. N=104.<BR/>2. Chlorpromazine: dose range: 75-600 mg. N=101.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Mental state: BPRS.<BR/>Global effect: CGI.<BR/>Adverse effects: TESS.<BR/>Physiological effects: EEG.</P>
<P>Unable to use -<BR/>Laboratory tests (no data).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Kiloh-1976">
<CHAR_METHODS>
<P>Allocation: randomised - by a prearranged system.<BR/>Blinding: double blind, no more details.<BR/>Duration: 12 weeks with a 2 weeks washout.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Diagnosis: schizophrenia (Slater and Roth criteria).<BR/>N=57<BR/>Age: less than 69.<BR/>Sex: no details available.<BR/>History: inpatients, duration ill - acute &lt; 2 years, chronic &gt; 2 years.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Loxapine: dose 10 mg /day increased progressively - acute group mean ~37 mg/day (SD ~22), chronic group 56 mg/day (SD 20). N=30.<BR/>2. Trifluperazine: dose 5mg/day increased progressively - acute group mean ~24 mg/day (SD 14.5), chronic group 31 mg/day (SD 11.7). N=27.</P>
<P>Diazepam, barbiturates and benztropine for adverse effects as required.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Global effect: CGI.<BR/>Adverse effects - physical examination, ophthalmic examination, laboratory tests, ECG.</P>
<P>Unable to use -<BR/>Mental state: BPRS (no data).<BR/>Behaviour: NOSIE (no data).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Data extracted clubbing both acute and chronic patients.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Kramer-1978">
<CHAR_METHODS>
<P>Allocation: randomised - no further details.<BR/>Blinding: double - identical ampules.<BR/>Duration: 4 weeks - preceded by 2 week drug free period. <BR/>Setting: single centre.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Diagnosis: schizophrenia, acute (DSM-II).<BR/>N=69.<BR/>Age: mean ~31 years, range &gt;18-57.<BR/>Sex: 21 M, 35 F, 13 not reported.<BR/>Exclusion: ill health, &lt; 1 week of study medications.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Loxapine: dose mean 74 mg/day. N=34.<BR/>2. Thioridazine: dose mean 442 mg/day. N=35.</P>
<P>Doses individually titrated, antiparkinsonian medication as required.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Leaving the study early.<BR/>Dropped from analysis.</P>
<P>Unable to use - <BR/>Global effect: CGI (&gt;50% attrition).<BR/>Mental state: BPRS (&gt;50% attrition).<BR/>Behaviour: NOSIE (&gt;50% attrition).<BR/>Side effects: DOTES (&gt;50% attrition).<BR/>Efficacy: (analysis of covariance).<BR/>Laboratory tests (no data).<BR/>Physiological measures: ECG, hand writing (&gt;50% attrition).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Loss to follow up 60%. <BR/>Only data from the outcome of 'leaving the study early' used.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Li-2004">
<CHAR_METHODS>
<P>Allocation: randomised - no further details.<BR/>Blinding: non blind.<BR/>Duration: 8 weeks.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Diagnosis: schizophrenia (CCMD-3).<BR/>N=60.<BR/>Age: mean ~30, range 18-60.<BR/>Sex: 38M 22F.<BR/>History: hospitalised.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Loxapine: mean dose 208 mg/day (max 306 mg/day). N=30.<BR/>2. Clozapine: mean dose 415 mgs/day (max 600 mg/day). N=30.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Mental state: PANSS.</P>
<P>Unable to use - <BR/>Physiological measures: EEG (no data).<BR/>Laboratory tests: bloods, urine (no data).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Li-2005a">
<CHAR_METHODS>
<P>Allocation: randomised - no further details.<BR/>Blinding: not mentioned.<BR/>Duration: 8 weeks.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Diagnosis: schizophrenia (CCMD3).<BR/>N=87.<BR/>Age: mean ~33.<BR/>Sex: not reported.<BR/>History: duration ill ~ 5 years.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Loxapine: dose, no average dose, max dose 272 mgs/day. N=44<BR/>2. Risperidone: dose, no average dose, max dose 6 mgs/day. N=43.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Mental state: PANSS<BR/>Adverse effects: EPSE, abnormal ECG, agitation, insomnia.</P>
<P>Unable to use - <BR/>Adverse effects: TESS (no data)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>1 dropout from the loxapine group after 1 week due to difficulty swallowing and hypermyotonia. <BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Li-2005b">
<CHAR_METHODS>
<P>Allocation: randomised - no further details.<BR/>Blinding: not mentioned.<BR/>Duration: 8 weeks.<BR/>Setting: single centre.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Diagnosis: schizophrenia (CCMD-3).<BR/>N=68.<BR/>Age: mean ~25, range 16-50.<BR/>Sex: 40 M, 28 F.<BR/>History: hospitalised.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Loxapine: dose range 34-340 mg. N=34.<BR/>2. Risperidone: dose range 1-7mg. N=34.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Mental state: PANSS.<BR/>Adverse effects: TESS.<BR/>Physiological measures: EEG, ECG.</P>
<P>Unable to use -<BR/>Haematological tests (no data).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Liu-2005">
<CHAR_METHODS>
<P>Allocation: randomised - no further details. <BR/>Blinding: not mentioned. <BR/>Duration 8 weeks.<BR/>Setting: single centre.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Diagnosis: schizophrenia (CCMD-3).<BR/>N=80.<BR/>Age: mean ~28 years. <BR/>Sex: 43 M, 37 F.<BR/>History: mean duration ill ~ 22 months.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Loxapine: dose 68-204 mgs/day. N=40.<BR/>2. Chlorpromazine: dose 250-600 mgs/day. N=40.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Mental state: PANSS. <BR/>Adverse effects: TESS.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Lu-2003">
<CHAR_METHODS>
<P>Allocation: randomised - no further details.<BR/>Blinding: non-blind.<BR/>Duration: 6 weeks.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Diagnosis: schizophrenia (CCMD-3).<BR/>N=122.<BR/>Age: mean ~34 years, range 16-56.<BR/>Sex: 81M, 41F.<BR/>History: hospitalised.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Loxapine: dose range 34-272 mgs. N=62.<BR/>2. Clozapine: dose range 25mgs-600 mg. N=60.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Mental state: PANSS.<BR/>Adverse effects: TESS.<BR/>Laboratory tests: Bloods, Urine, EEG.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Malik-1980">
<CHAR_METHODS>
<P>Allocation: randomised - no further details.<BR/>Blinding: double - identical capsules.<BR/>Duration: 28 days.<BR/>Setting: single centre.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Diagnosis: schizophrenia, no further details.<BR/>N=54.<BR/>Age: mean ~17 years, range: &gt;14-19.<BR/>Sex: 25 M, 27 F, 2 not reported.<BR/>Exclusion: sensitivity to study drugs, ECT in last 8 weeks, co-existing mental illness, ill health.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Loxapine: dose mean 91.5 mg/day. N=27.<BR/>2. Trifluoperazine: dose mean 23.57 mg/day. N=27.</P>
<P>Antiparkinsonian medication as required.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Global effect: CGI.<BR/>Adverse effects.<BR/>Drug preference.<BR/>Dropped from analysis.</P>
<P>Unable to use - <BR/>Efficacy: analysis of covariance (no usable data).<BR/>Mental state: BPRS (no SD).<BR/>Behaviour: NOSIE (no usable data).<BR/>Adverse effects: Use of antiparkinsonian drugs (no data).<BR/>Physiological measures: BP, pulse (no data).<BR/>Laboratory tests: (no data).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Moore-1975">
<CHAR_METHODS>
<P>Allocation: no details.<BR/>Blinding: double - identical capsules.<BR/>Duration: 6 weeks - preceded by 2 week washout.<BR/>Setting: single centre.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Diagnosis: schizophrenia, acute or exacerbations of chronic.<BR/>N=54*.<BR/>Age: mean ~ 37 years.<BR/>Sex: 25 M, 27 F, 2 not reported.<BR/>History: hospitalised.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Loxapine: dose 20 mg-120 mg/day. N=29.<BR/>2. Chlorpromazine: dose 200 mg-1200 mg/day. N=29.</P>
<P>Antiparkinsonian or sedative medication as required.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Global effect: CGI, use of additional sedation.<BR/>Adverse effects: TESS, use of antiparkinsonian drugs.<BR/>Dropped from analysis.<BR/>Laboratory tests.</P>
<P>Unable to use - <BR/>Mental state: BPRS (no usable data).<BR/>Behaviour: NOSIE (no usable data).<BR/>Physiological tests: BP, ECG, ophthalmic tests, pulse (no data).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>*Four participants not accounted for.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Moyano-1975">
<CHAR_METHODS>
<P>Allocation: no details.<BR/>Blinding: double - identical capsules.<BR/>Duration: 12 weeks - preceded by 4 week washout.<BR/>Setting: single centre.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Diagnosis: schizophrenia, chronic (no further details).<BR/>N=49.<BR/>Age: mean ~ 47 years, all &gt;21.<BR/>Sex: 30 M, 19 F.<BR/>History: prolonged drug treatment, hospitalised patients.<BR/>Exclusion: co-existing mental illness, ill health, &lt; 4 weeks of study medication.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Loxapine: dose 20 mg-120 mg/day. N=25.<BR/>2. Trifluoperazine: dose 20 mg-40 mg/day. N=24.</P>
<P>Antiparkinsonian or sedative medication as required.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Global effect.<BR/>Adverse effects: TESS.<BR/>Dropped from analysis.<BR/>Physiological measures. (ophthalmic tests).<BR/>Laboratory tests.</P>
<P>Unable to use - <BR/>Global effect: CGI, use of sedation (no data).<BR/>Mental state: BPRS (no usable data).<BR/>Behaviour: NOSIE (no usable data).<BR/>Side effects: use of antiparkinsonian drugs (no data).<BR/>Physiological measures: BP, ECG, EEG, pulse (no usable data).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Pool-1976">
<CHAR_METHODS>
<P>Allocation: random (pre arranged procedure).<BR/>Blinding: double blind, identical capsules in bottles which were numbered only with the person's study number.<BR/>Duration: 4 weeks, with 5 day washout.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Diagnosis: schizophrenia confirmed by two psychiatrists (no other details).<BR/>N=75.<BR/>Age range: 13-18 years.<BR/>Sex: 43 M, 32 F.<BR/>History: inpatients.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Loxapine: dose 10 mg/day increased to 200 mg/day, mean 87.5 mg/day. N=25.<BR/>2. Haloperidol: dose 2mg/day increased to 16 mg/day, mean 9.8 mg/day. N=25.<BR/>3. Placebo. N=25.</P>
<P>Antiparkinsonian medications, sodium amobarbital used as required.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Global effect: CGI.</P>
<P>Unable to use -<BR/>Behaviour: NOSIE (no data).<BR/>Physical examinations (no data).<BR/>Laboratory tests including ECG (no data).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Values of CGI are given in percentages. These were rounded to the nearest whole number.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Rifkin-1984">
<CHAR_METHODS>
<P>Allocation: randomised - no further details.<BR/>Blinding: double - identical capsules, evaluation by psychiatrist blind to drug taken.<BR/>Duration: 4 weeks.<BR/>Setting: single centre.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Diagnosis: schizophrenia, paranoid (RDC).<BR/>N=64.<BR/>Age: 18-60 years.<BR/>Sex: 41 M, 23 F.<BR/>History: hospitalised.<BR/>Exclusion: pregnant or risk of, co-existing mental illnesses, ill health, recent amphetamine abuse, hospitalised patients.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Loxapine: dose mean 128.6 mg/day (SD 38). N=31.<BR/>2. Chlorpromazine: dose mean 1288 mg/day (SD 358). N=33.</P>
<P>Antiparkinsonian or benzodiazepine as required.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Global effect: CGI.<BR/>Leaving the study early.</P>
<P>Unable to use -<BR/>Mental state: BPRS, use of additional sedation (no data).<BR/>Behaviour: IMPS, NOSIE, Prerbid Asociality Adjustment Scale (no data).<BR/>Side effects: use of antiparkinsonian drugs (no data).<BR/>Laboratory tests: (no data).<BR/>Physiological measures: BP, pulse (no usable data).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Schiele-1975">
<CHAR_METHODS>
<P>Allocation: random - no further details.<BR/>Blinding: double - identical opaque capsules.<BR/>Duration: 12 weeks - preceded by 1 week placebo period.<BR/>Setting: single centre.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Diagnosis: schizophrenia, chronic, no further details.<BR/>N=64*.<BR/>Age: mean ~45 years, range 25-74.<BR/>Sex: 50 M, 14 F.<BR/>History: long term hospitalisation.<BR/>Exclusion: ill health.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Loxapine: dose mean 110 mg/day. N=26.<BR/>2. Chlorpromazine: dose mean 1100 mg/day. N=24.</P>
<P>Antiparkinsonian or benzodiazepine as required.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Global effect: CGI.<BR/>Adverse effects (use of antiparkinsonian drugs).<BR/>Leaving the study early.<BR/>Laboratory tests.</P>
<P>Unable to use - <BR/>Mental state: BPRS (no usable data).<BR/>Behaviour: NOSIE (no usable data).<BR/>Physiological measures: BP, ECG, ophthalmic tests, pulse (no usable data).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>*3 people withdrawn from analysis - original group uncertain.<BR/>4 people not included in BPRS and CGI analyses - original group clear.<BR/>Other data is reported for original total.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Selman-1976">
<CHAR_METHODS>
<P>Allocation: random - no further details.<BR/>Blinding: double - identical capsules.<BR/>Duration: 12 weeks - preceded by 2 week placebo period.<BR/>Setting: single centre.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Diagnosis: schizophrenia, acute or exacerbations of chronic (by 2 psychiatrists).<BR/>N=87.<BR/>Age: mean ~ 32 years.<BR/>Sex: 69 M, 18 F.<BR/>History: long term hospitalisation.<BR/>Exclusion: ill health, &lt; 4 weeks of study medication.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Loxapine: dose 50-150 mg/day. N=29.<BR/>2. Haloperidol: dose 4-12 mg/day. N=29.<BR/>3. Placebo. N=29.</P>
<P>Antiparkinsonian, chloral hydrate or paraldehyde as required.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Global effect: CGI.<BR/>Adverse effects.<BR/>Leaving the study early.<BR/>Dropped from analysis.</P>
<P>Unable to use - <BR/>Global effect: BPRS, CGI, NOSIE (analysis of covariance - no usable data).<BR/>Mental state: BPRS (no usable data).<BR/>Behaviour: NOSIE (no usable data).<BR/>Adverse effects: Use of antiparkinsonian drugs (no data).<BR/>Physiological measures: ECG, ophthalmic tests (no data).<BR/>Laboratory tests: (no data).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>5 categories of "muscle spasms" - impossible to combine data for these outcomes.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Seth-1979">
<CHAR_METHODS>
<P>Allocation: random - no further details.<BR/>Blinding: double - identical capsules.<BR/>Duration: 12 weeks - preceded by 4 week washout period.<BR/>Setting: single centre.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Diagnosis: schizophrenia, chronic (by 2 psychiatrists).<BR/>N=72.<BR/>Age: mean ~ 30 years, range &lt;20-49.<BR/>Sex: 28 M, 36 F, 8 not reported.<BR/>History: hospitalised patients.<BR/>Exclusion: ill health, pregnant or risk of, substance abuse.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Loxapine: dose 20-90 mg/day. N=36.<BR/>2. Trifluoperazine: dose 5-45 mg/day. N=36.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Leaving the study early.<BR/>Dropped from analysis.<BR/>Adverse effects.</P>
<P>Unable to use - <BR/>Global effect: CGI (no usable data).<BR/>Mental state: BPRS (no usable data).<BR/>Behaviour: NOSIE (no usable data).<BR/>Physiological measures: BP, ECG, ophthalmic tests, pulse, temperature, weight (no data).<BR/>Laboratory tests: (no data).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Shopsin-1972">
<CHAR_METHODS>
<P>Allocation: random - no further details.<BR/>Blinding: double - identical capsules, rated by independant psychologists.<BR/>Duration: 3 weeks - preceded by 7 day placebo washout period.<BR/>Setting: single centre.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Diagnosis: schizophrenia, acute (SPS), undertaken by 2 psychiatrists.<BR/>N=30.<BR/>Age range: 21-62 years.<BR/>Sex: male and female (some participants not reported on)**.<BR/>History: newly hospitalised.<BR/>Exclusion: ill health, pregnant or risk of, substance abuse, unmanageable behaviour, refusal to take oral medication, spontaneous remission during placebo phase.<BR/>Inclusion: demonstrating disturbance of affect and association.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Loxapine: dose 30-120 mg/day. N=15.<BR/>2. Chlorpromazine: dose 300-1200 mg/day. N=15.</P>
<P>Antiparkinsonian drugs, chlorayl hydrate and paraldehyde as required.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Global effect (discharge).<BR/>Leaving the study early.<BR/>Adverse effects: TESS.</P>
<P>Unable to use - <BR/>Global effect: CGI (no usable data).<BR/>Mental state: BPRS (no usable data), SSRS (no data).<BR/>Behaviour: NOSIE, IMPS (no usable data).<BR/>Physiological measures: ECG (no data).<BR/>Laboratory tests: (no data).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Simpson-1976">
<CHAR_METHODS>
<P>Allocation: randomised - no further details.<BR/>Blinding: double - identical capsules.<BR/>Duration: 4 weeks - preceded by 3 day drug free period, evaluation carried out by the same physician, study lasted over 3 years.<BR/>Setting: single centre.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Diagnosis: schizophrenia, acute (no further details).<BR/>N=43.<BR/>Age: mean 32 years, range 16-61.<BR/>Sex: 27 M, 16 F.<BR/>Exclusion: ill health.<BR/>History: newly hospitalised.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Loxapine: dose mean 74 mg/day, range 30-120 mg/day. N=24.<BR/>2. Trifluoperazine: dose mean 35 mg/day, range 20-50 mg/day. N=19.</P>
<P>Antiparkinsonian drugs and chlorayl hydrate as required.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Global effect (discharge).<BR/>Leaving the study early.<BR/>Adverse effects (Neurological Rating Scale, Unwanted Effects Checklist).</P>
<P>Unable to use - <BR/>Global effect: CGI (no usable data).<BR/>Mental state: BPRS (no usable data).<BR/>Physiological measures: BP, ECG, ophthalmic tests, pulse (no data).<BR/>Laboratory tests (no data).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Steinbook-1973">
<CHAR_METHODS>
<P>Allocation: randomised - no further details.<BR/>Blinding: double - identical capsules.<BR/>Duration: 6 weeks - preceded by 3 day drug free period.<BR/>Setting: single centre.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Diagnosis: schizophrenia, acute (no further details).<BR/>N=54.<BR/>Age: mean ~34 years, range 21-65.<BR/>Sex: 16 M, 38 F.<BR/>Exclusion: ill health, hospitalisation in last 6 months.<BR/>History: newly admitted.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Loxapine: dose range 30-150 mg/day. N=26.<BR/>2. Chlorpromazine: dose range 10-1200 mg/day. N=28.</P>
<P>Antiparkinsonian medication as required.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Adverse effects (use of antiparkinsonian drugs).</P>
<P>Unable to use - <BR/>Global effect: CGI (no usable data).<BR/>Mental state: BPRS (no usable data).<BR/>Behaviour: NOSIE (no usable data).<BR/>Physiological measures: BP, ECG, ophthalmic tests, pulse (no data).<BR/>Laboratory tests (no data).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Tu-2004">
<CHAR_METHODS>
<P>Allocation: randomised. <BR/>Blinding: not mentioned. <BR/>Duration: 8 weeks.<BR/>Setting: multicenter.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Diagnosis: schizophrenia (CCMD-3).<BR/>N=238.<BR/>Age: adults, mean ~32 years, range 21-43.<BR/>Sex: 130 M, 108 F.<BR/>History: hospitalised.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Loxapine. dose mean 113 mgs/day. N=126.<BR/>2. Chlorpromazine. dose mean 428 mgs/day. N=112.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Global effect: CGI.<BR/>Mental state: BPRS.<BR/>Laboratory tests: ECG, bloods.</P>
<P>Unable to use -<BR/>Laboratory tests: ECG &amp; haematology (no data)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Tuason-1984">
<CHAR_METHODS>
<P>Allocation: randomised - no further details.<BR/>Blinding: double - identical capsules.<BR/>Duration: 4 weeks - preceded by 8 hr drug free period.<BR/>Setting: single centre.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Diagnosis: schizophrenia, paranoid (RDC).<BR/>N=68.<BR/>Age: mean ~ 35 years, range 19-61 years.<BR/>Sex: 32 M, 36 F.<BR/>Exclusion: pregnancy or the risk of, ill health, recent amphetamine abuse.<BR/>History: mainly people with acute exacerbation of chronic illness, ill &lt;1 week - &gt;6 months - 20 years.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Loxapine: dose range 30-150 mg/day. N=34.<BR/>2. Chlorpromazine: dose range 300-1500 mg/day. N=34.</P>
<P>Doses individually titrated, antiparkinsonian and sedative medication as required.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Leaving the study early.</P>
<P>Unable to use - <BR/>Global effect: CGI, use of additional sedative medication (&gt;50% attrition).<BR/>Mental state: BPRS (&gt;50% attrition).<BR/>Behaviour: NOSIE, IMPS (&gt;50% attrition).<BR/>Side effects: use of antiparkinsonian medication (&gt;50% attrition).<BR/>Physiological measures: BP, ECG, pulse (&gt;50% attrition).<BR/>Laboratory tests (&gt;50% attrition).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Loss to follow up 70%.<BR/>Only data from the outcome 'leaving the study early' included. <BR/>People who had improved were discharged and not followed up - adds to dropout over the 50% cut off point.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Tuason-1986">
<CHAR_METHODS>
<P>Allocation: randomised - no further details.<BR/>Blinding: "modified double" - staff administering drugs not blinded, assessments blind.<BR/>Duration: 24-72 hours (IM phase) - oral phase data not included.<BR/>Setting: single centre.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Diagnosis: schizophrenia, acutely psychotic (DSM-III used beyond 3 days).<BR/>N=54.<BR/>Age: mean ~35 years (SD ~ 10), range 18-65 years.<BR/>Sex: 33 M, 19 F, 2 not reported.<BR/>History: newly admitted.<BR/>Inclusion criteria: &gt; 7 on BPRS hostility &amp; uncooperativeness, behaviour = hostile/aggressive/uncooperative/unmanageable.<BR/>Exclusion: ill health, co-existing mental illness condition.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Loxapine: dose 25 mg IM, then 12.5-25 mg/hour IM, max. 250 mg/day. N=25.<BR/>2. Haloperidol: dose 5mg IM, then 2.5-5mg/hour IM, max. 100 mg/day. N=29.</P>
<P>Antiparkinsonian drugs and chlorayl hydrate as required.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>General effect (requiring extended period of medication &gt; 24 hours).<BR/>Mental state: BPRS.*<BR/>Side effects (sedation - ESBE, use of antiparkinsonian drugs).<BR/>Dropped from analysis.<BR/>Leaving the study early.</P>
<P>Unable to use - <BR/>Global effect: CGI (no data).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>2 people withdrawn from analysis - original group unclear.</P>
<P>* BPRS scores reported with SD. Data thought not to be SD but standard error and reviewers have converted to SD.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Van-Der-Velde-1975">
<CHAR_METHODS>
<P>Allocation: randomised - no further details.<BR/>Blinding: double - identical capsules.<BR/>Duration: 6 weeks - preceded by 14 day drug free period.<BR/>Setting: single centre.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Diagnosis: schizophrenia, acute or acute exacerbation (by 2 psychiatrists &amp; principal investigator).<BR/>N=82.<BR/>Age: mean ~ 27 years. <BR/>Sex: 43 M, 33 F, 6 not reported.<BR/>Exclusion: not completing 2 weeks of study medication.<BR/>History: 18/82 first episode, rest onset in last 6 years.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Loxapine: dose range 50-150 mg/day. N=26.<BR/>2. Thiothixene: dose range 20-60 mg/day. N=28.<BR/>3. Placebo. N=28.</P>
<P>Antiparkinsonian drugs and chlorayl hydrate as required.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Dropped from analysis.<BR/>Leaving the study early.<BR/>Adverse effects.<BR/>Laboratory tests.</P>
<P>Unable to use - <BR/>Efficacy: (variance analyses - no usable data).<BR/>Global effect: CGI (no usable data).<BR/>Mental state: BPRS (no usable data).<BR/>Behaviour: NOSIE (no usable data).<BR/>Adverse effects: Use of antiparkinsonian drugs (no data).<BR/>Physiological measures: BP, EEG, pulse, temperature, weight (no data).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>6 people withdrawn from analyses - original group clear so ITT analysis possible.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Vyas-1980">
<CHAR_METHODS>
<P>Allocation: randomised - no further details.<BR/>Blinding: double - identical capsules.<BR/>Duration: 6 months - preceded by 15 day antipsychotic free period.<BR/>Setting: single centre.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Diagnosis: schizophrenia, chronic - no further details. <BR/>N=30.<BR/>Age: mean ~ 32 years (SD ~ 9), all &gt;21.<BR/>Sex: 17 M, 13 F.<BR/>Exclusion: pregnant women, ill health, substance abuse.<BR/>History: inpatients, hospitalisation duration &lt;2 weeks-&gt;2 years.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Loxapine: dose mean 44 mg/day, range 30-90 mg/day. N=15.<BR/>2. Chlorpromazine: dose mean 453 mg/day, range 300-900 mg/day. N=15.</P>
<P>Antiparkinsonian drugs as required.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Global effect: CGI.<BR/>Leaving the study early.<BR/>Adverse effects.</P>
<P>Unable to use - <BR/>Efficacy: (analyses of covariance - no usable data).<BR/>Mental state: BPRS (no usable data).<BR/>Behaviour: NOSIE (no usable data).<BR/>Adverse effects: Use of antiparkinsonian drugs (no usable data).<BR/>Physiological measures: BP, ECG. pulse, ophthalmic tests, temperature, weight (no data).<BR/>Laboratory tests: (no data).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Wang-1996">
<CHAR_METHODS>
<P>Allocation: randomised - no further details. <BR/>Blinding: double blind.<BR/>Duration: 8 weeks.<BR/>Setting: single centre.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Diagnosis: schizophrenia (CCMD-2).<BR/>N=60.<BR/>Age: mean ~36 years, range 18-60. <BR/>Sex: M &amp; F - no further details.<BR/>History: hospitalised.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Loxapine: dose range 50-300 mg/day. N=30.<BR/>2. Chlorpromazine: dose range 75 mg-600 mg/day. N=30.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Global effect: CGI.<BR/>Mental state: BPRS.<BR/>Adverse effects: TESS.<BR/>Physiological measures: Temperature, BP, Weight.</P>
<P>Unable to use -<BR/>Physiological measures: temperature, BP, weight (no data).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Wang-2005a">
<CHAR_METHODS>
<P>Allocation: randomised - no further details. <BR/>Blinding: not mentioned. <BR/>Duration: 8 weeks<BR/>Setting: single centre.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Diagnosis: schizophrenia. <BR/>N=68.<BR/>Age: mean ~33 years.<BR/>Sex: 32 M, 36 F.<BR/>History: duration ill 3-12 months.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Loxapine: dose mean 267 mg/day. N=34.<BR/>2. Quetiapine: dose mean 426 mg/day. N=34.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Mental state: PANSS. </P>
<P>Unable to use - <BR/>Adverse effects: TESS (no data).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Wang-2005b">
<CHAR_METHODS>
<P>Allocation: randomised - no further details.<BR/>Blinding: not mentioned.<BR/>Duration: 8 weeks.<BR/>Setting: single centre.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Diagnosis: schizophrenia (CCMD-3).<BR/>N=63. <BR/>Age: mean ~29 years.<BR/>Sex: 36 M, 30 F. <BR/>History: hospitalised.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Loxapine: dose mean 86 mgs/day. N=32. <BR/>2. Risperidone: dose mean 4 mgs/day. N=31.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Mental state: PANSS.<BR/>Adverse effects: TESS.<BR/>Laboratory tests: ECG.</P>
<P>Unable to use -<BR/>Haematology (no data).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Xue-2004">
<CHAR_METHODS>
<P>Allocation: randomised - no further details.<BR/>Blinding: double blind.<BR/>Duration: 8 weeks.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Diagnosis: schizophrenia (CCMD-3).<BR/>N=200.<BR/>Age: mean ~32 years.<BR/>Sex: 90 M, 110 F.<BR/>History: in community.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Loxapine: dose range 34-136 mg/day. N=100.<BR/>2. Chlorpromazine: dose range 250-500 mg/day. N=100.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Mental state: BPRS.<BR/>Adverse effects: TESS.</P>
<P>Unable to use -<BR/>Laboratory tests: Bloods, ECG, EEG (no data)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Zhang-2005">
<CHAR_METHODS>
<P>Allocation: randomised - no further details.<BR/>Blinding: not mentioned.<BR/>Duration: 8 weeks.<BR/>Setting: single centre.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Diagnosis: schizophrenia (CCMD3).<BR/>N=134.<BR/>Age: mean ~30, range 18-60.<BR/>Sex: not reported.<BR/>History: hospitalised, mean duration ill ~ 4 years.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Loxapine: dose range: 34-68 mgs/day. N=44. <BR/>2. Perphenazine: dose range: 6-12mgs/day. N=46.<BR/>3. Sulpride: dose range 300-400 mgs/day. N=44.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Mental state: PANSS.</P>
<P>Unable to use -<BR/>Adverse effects: TESS (no data).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>General<BR/>BP - blood pressure<BR/>IM - intramuscular<BR/>ECG- electro cardiogram<BR/>ITT - intention-to-treat</P>
<P>Diagnostic tools<BR/>RDC - Research Diagnostic Criteria<BR/>ICD- International classification of diseases</P>
<P>Global state scale<BR/>CGI - Clinical Global Impression ( CGI-I - Improvement , CGI-S - Severity)</P>
<P>Mental state scales<BR/>BPRS - Brief Psychiatric Rating Scale<BR/>PANSS - Postive and Negative Symptom Score<BR/>SPS - Symptom profile for schizophrenia<BR/>SSRS - Self rating Symptom Scale</P>
<P>Behaviour scale<BR/>NOSIE - Nurse's Observation Scale for In-patient Evaluation<BR/>IMPS - Inpatient Multidimensional Psychiatric Scale</P>
<P>Side effect scales<BR/>ESBE - Evaluation of Sedative and Behavioral Effects of Parental Treatment<BR/>TESS - Treatment Emergent Symptom Scale</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES SORT_BY="STUDY">
<EXCLUDED_CHAR STUDY_ID="STD-Ananth-1980">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised, review article.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Bishop-1977">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised, review article.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Branchey-1981">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised. <BR/>Participants: people with chronic schizophrenia.<BR/>Intervention: continuing or discontinuing loxapine, not initiation of loxapine as per protocol.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Brown-2003">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Participants: people with any mental illness and with cocaine and amphetamine dependence.<BR/>Intervention: continuing typical antipsychotic versus discontinuing typical antipsychotic and starting quetiapine, not starting loxapine as per protocol.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Bueno-1979">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Participants: people with schizophrenia.<BR/>Intervention: loxapine versus haloperidol.<BR/>Outcomes no usable data.<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Burdock-1974">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised, methodology paper.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Cottereau-1979">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised, case series.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Delteil-1980">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised, case series.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Jones-2006">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: random.<BR/>Participants: people with schizophrenia.<BR/>Interventions: 1st generation antipsychotics vs 2nd generation antipsychotics (rather than loxapine vs another treatment).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Leone-1982">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: random.<BR/>Participants: people with borderline personality disorder, not schizophrenia.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Lewis-2006">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: random.<BR/>Participants: people with schizophrenia.<BR/>Interventions: 1st generation antipsychotics vs 2nd generation antipsychotics (rather than loxapine vs another treatment).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Lourido-1979">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: random.<BR/>Participants: people with chronic psychoses associated with either organic brain syndrome or mental retardation, not clearly schizophrenia.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Maes-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not clear.<BR/>Participants: either healthy people or those with schizophrenia.<BR/>Interventions: loxapine versus placebo.<BR/>Outcomes: plasma levels, no clinical outcomes.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Mahmoud-2004">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: random but open label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Martin-1982">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised, case series.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Mattke-1975">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised, patients matched.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Nair-1976">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised, case series.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Paprocki-1976">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised, review article.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Paprocki-1977">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised by consecutive admission, quality rating 'C'.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Rainaut-1975">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Participants: people with schizophrenia.<BR/>Interventions: loxapine versus thioridazine.<BR/>Outcomes no usable data.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Serafetinides-1971">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: random.<BR/>Participants: people with schizophrenia.<BR/>Interventions: loxapine versus chlorpromazine.<BR/>Outcomes: EEG readings, no clinical outcomes.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Serafetinides-1973">
<CHAR_REASON_FOR_EXCLUSION>
<P>Pooled data from 4 randomised control trials: <BR/>Study 1<BR/>Allocation: no details, double blind.<BR/>Participants: people with chronic schizophrenia.<BR/>Intervention: chlorpromazine.<BR/>Study 2.<BR/>Allocation: no details, double blind.<BR/>Participants: people with chronic schizophrenia.<BR/>Intervention: haloperidol versus clopenthixol versus chlorpromazine.<BR/>Study 3.<BR/>Allocation: no details, double blind.<BR/>Participants: people with chronic schizophrenia.<BR/>Intervention: chlorpromazine versus molindone.<BR/>Study 4.<BR/>Allocation: no details, double blind.<BR/>Participants: people with chronic schizophrenia.<BR/>Intervention: chlorpromazine versus loxapine.<BR/>Outcomes: EEG readings, no clinical outcomes available.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Simpson-1976b">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised, case series.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Simpson-1978">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised.<BR/>Participants: people with chronic schizophrenia.<BR/>Intervention: oral loxapine versus parenteral loxapine, not loxapine versus placebo or any other intervention.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Ucer-1979">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised, case series.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Versiani-1978">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: by consecutive admission, quality 'C'.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Versiani-1980">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: random.<BR/>Participants: chronic psychosis associated with organic brain syndrome or mental retardation, not clearly schizophrenia (two studies).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Vianna-Filho-1975">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: by consecutive admission, quality rating 'C'.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Yu-2004">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Bagadia-1980">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Bishop-1970">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Charalampous-1974">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Clark-1972">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Clark-1975">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Clark-1977">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Du-2003">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Dube-1976">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Dubin-1996">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Fruensgaard-1977">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Fruensgaard-1978">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Gallant-1971">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Huang-1997">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Kiloh-1976">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Kramer-1978">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Li-2004">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Li-2005a">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Li-2005b">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Liu-2005">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Lu-2003">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Malik-1980">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Moore-1975">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Moyano-1975">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Pool-1976">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Rifkin-1984">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Schiele-1975">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Selman-1976">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Seth-1979">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Shopsin-1972">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Simpson-1976">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Steinbook-1973">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Tu-2004">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Tuason-1984">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Tuason-1986">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Van-Der-Velde-1975">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Vyas-1980">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Wang-1996">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Wang-2005a">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Wang-2005b">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Xue-2004">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Zhang-2005">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES>
<ADDITIONAL_TABLE ID="TBL-01" NO="1">
<TITLE>Suggested design for future study</TITLE>
<TABLE COLS="5" ROWS="2">
<TR>
<TH>
<P>Methods</P>
</TH>
<TH>
<P>Participants</P>
</TH>
<TH>
<P>Interventions</P>
</TH>
<TH>
<P>Outcomes</P>
</TH>
<TH>
<P>Notes</P>
</TH>
</TR>
<TR>
<TD>
<P>Allocation: randomised, block, fully explicit description..<BR/>Duration: 2 weeks.</P>
</TD>
<TD>
<P>Diagnosis: not prestipulated, acute agression thought to be due to serious mental illness. <BR/>N=300.*<BR/>Age: adults.<BR/>Sex: both.</P>
</TD>
<TD>
<P>1. Loxapine: dose 25-50 mg/6-12 hours IM. N=150.<BR/>2. Haloperidol + promethazine: dose 5-10mg, 25-50 mg IM stat. N=150.<BR/>
</P>
</TD>
<TD>
<P>Tranquil by 20, 40, 60, 90, 180 mins.<BR/>Need for further medication. <BR/>Need to call doctor again. <BR/>Time in restraints. <BR/>General functioning.<BR/>Behaviour.<BR/>Symptoms.<BR/>Adverse events.<BR/>Satisfaction with care.<BR/>Economic outcomes.</P>
</TD>
<TD>
<P>* powered to be able to identify a difference of ~20% between groups for primary outcome with adequate degree of certainty.</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2009-03-03 15:36:50 +0000" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" MODIFIED="2009-03-03 15:36:50 +0000" MODIFIED_BY="[Empty name]" NO="1">
<NAME>LOXAPINE versus PLACEBO</NAME>
<DICH_OUTCOME CHI2="3.2669034343086194" CI_END="0.8267766999587624" CI_START="0.2851262860750653" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="0.48552628134081527" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="30" I2="8.169921140173054" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="-0.08261177106497569" LOG_CI_START="-0.5449627428058885" LOG_EFFECT_SIZE="-0.31378725693543214" METHOD="MH" MODIFIED="2009-03-03 15:36:50 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.352275757985996" P_Q="0.7285155387700524" P_Z="0.007805545923826862" Q="0.12047906933686374" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="95" TOTAL_2="83" WEIGHT="200.0" Z="2.660367383182215">
<NAME>Leaving the study early - any reason</NAME>
<GROUP_LABEL_1>Loxapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Loxapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.8469408834597" CI_END="1.1252179649420067" CI_START="0.16124056854108892" DF="1" EFFECT_SIZE="0.4259469267407575" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="12" I2="45.85641538635529" ID="CMP-001.01.01" LOG_CI_END="0.05123665738304771" LOG_CI_START="-0.7925256791755088" LOG_EFFECT_SIZE="-0.3706445108962305" MODIFIED="2009-03-03 15:36:50 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.17413978751216574" P_Z="0.08508217724177264" STUDIES="2" TAU2="0.0" TOTAL_1="41" TOTAL_2="41" WEIGHT="100.0" Z="1.7219301240371503">
<NAME>short term - up to 6 weeks</NAME>
<DICH_DATA CI_END="16.991596952010106" CI_START="0.1768194274458128" EFFECT_SIZE="1.7333333333333334" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.2302341978715983" LOG_CI_START="-0.7524700200413248" LOG_EFFECT_SIZE="0.23888208891513674" ORDER="962" O_E="0.0" SE="1.1646502721462166" STUDY_ID="STD-Clark-1975" TOTAL_1="15" TOTAL_2="13" VAR="1.3564102564102565" WEIGHT="9.185756407348604"/>
<DICH_DATA CI_END="0.9365668604952618" CI_START="0.09210595698108631" EFFECT_SIZE="0.2937062937062937" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="11" LOG_CI_END="-0.02846121336865871" LOG_CI_START="-1.035712280765664" LOG_EFFECT_SIZE="-0.5320867470671614" ORDER="963" O_E="0.0" SE="0.5916642629621972" STUDY_ID="STD-Van-Der-Velde-1975" TOTAL_1="26" TOTAL_2="28" VAR="0.35006660006660006" WEIGHT="90.8142435926514"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.40918108115495" CI_END="0.9797235235326519" CI_START="0.2789639111636037" DF="1" EFFECT_SIZE="0.5227882037533512" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="18" I2="29.036799218138064" ID="CMP-001.01.02" LOG_CI_END="-0.00889646425102284" LOG_CI_START="-0.5544519766413163" LOG_EFFECT_SIZE="-0.2816742204461696" NO="2" P_CHI2="0.23519261405544734" P_Z="0.042981790091799345" STUDIES="2" TAU2="0.0" TOTAL_1="54" TOTAL_2="42" WEIGHT="100.0" Z="2.023886900268119">
<NAME>medium term - by 12 weeks</NAME>
<DICH_DATA CI_END="52.27057388717676" CI_START="0.13867306537909294" EFFECT_SIZE="2.6923076923076925" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.7182572683140485" LOG_CI_START="-0.8580078842271709" LOG_EFFECT_SIZE="0.4301246920434389" ORDER="964" O_E="0.0" SE="1.5133109033208907" STUDY_ID="STD-Clark-1977" TOTAL_1="25" TOTAL_2="13" VAR="2.29010989010989" WEIGHT="3.485254691689008"/>
<DICH_DATA CI_END="0.8553860581671379" CI_START="0.2309259805108191" EFFECT_SIZE="0.4444444444444444" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="18" LOG_CI_END="-0.06783783253422655" LOG_CI_START="-0.6365272036884985" LOG_EFFECT_SIZE="-0.35218251811136253" ORDER="965" O_E="0.0" SE="0.33405095167380716" STUDY_ID="STD-Selman-1976" TOTAL_1="29" TOTAL_2="29" VAR="0.11159003831417626" WEIGHT="96.51474530831099"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.505875593684597" CI_END="2.170559656441673" CI_START="0.25564017345456336" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7449041865006713" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="7" I2="20.187578144722107" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="0.33657172664437385" LOG_CI_START="-0.5923708964499793" LOG_EFFECT_SIZE="-0.1278995849028027" METHOD="MH" NO="2" P_CHI2="0.2856644344867022" P_Q="1.0" P_Z="0.589398873659569" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="75" TOTAL_2="76" WEIGHT="100.0" Z="0.5397073485811074">
<NAME>Removed from analysis</NAME>
<GROUP_LABEL_1>Loxapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Loxapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="93.18795082934068" CI_START="0.24333335758158653" EFFECT_SIZE="4.761904761904762" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.9693597618537708" LOG_CI_START="-0.6137983513216091" LOG_EFFECT_SIZE="0.6777807052660807" ORDER="966" O_E="0.0" SE="1.5173598625181017" STUDY_ID="STD-Charalampous-1974" TOTAL_1="20" TOTAL_2="19" VAR="2.3023809523809526" WEIGHT="6.92054192603442"/>
<DICH_DATA CI_END="2.103714397333878" CI_START="0.02970935602247566" EFFECT_SIZE="0.25" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" LOG_CI_END="0.3229867791693706" LOG_CI_START="-1.5271067618252954" LOG_EFFECT_SIZE="-0.6020599913279624" ORDER="967" O_E="0.0" SE="1.0867541040909947" STUDY_ID="STD-Selman-1976" TOTAL_1="29" TOTAL_2="29" VAR="1.1810344827586206" WEIGHT="54.04613694617356"/>
<DICH_DATA CI_END="3.9604297097740644" CI_START="0.13015010980553757" EFFECT_SIZE="0.717948717948718" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.5977423097788176" LOG_CI_START="-0.8855554611473776" LOG_EFFECT_SIZE="-0.14390657568427997" ORDER="968" O_E="0.0" SE="0.8712964530844305" STUDY_ID="STD-Van-Der-Velde-1975" TOTAL_1="26" TOTAL_2="28" VAR="0.7591575091575091" WEIGHT="39.033321127792014"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="4.1004853766377" CI_END="0.6291447291618218" CI_START="0.2954272901219019" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="0.4311223984331537" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="43" I2="26.837929551161366" I2_Q="47.33465031090035" ID="CMP-001.03" LOG_CI_END="-0.20124943747020163" LOG_CI_START="-0.5295493891800505" LOG_EFFECT_SIZE="-0.36539941332512604" METHOD="MH" NO="3" P_CHI2="0.25081607005028284" P_Q="0.1682149827003504" P_Z="1.2835047734198088E-5" Q="1.8987816579654724" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="83" TOTAL_2="66" WEIGHT="200.0" Z="4.36289854055332">
<NAME>Global effect: 1. Not improved</NAME>
<GROUP_LABEL_1>Loxapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Loxapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.313793580477764" CI_END="0.6294876269983944" CI_START="0.14235596008791349" DF="1" EFFECT_SIZE="0.2993514915693904" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="21" I2="56.78093290441601" ID="CMP-001.03.01" LOG_CI_END="-0.20101280182161765" LOG_CI_START="-0.8466243453129086" LOG_EFFECT_SIZE="-0.5238185735672631" NO="1" P_CHI2="0.1282308907399703" P_Z="0.0014704977955957894" STUDIES="2" TAU2="0.0" TOTAL_1="41" TOTAL_2="37" WEIGHT="99.99999999999999" Z="3.1804435623100966">
<NAME>short term - up to 4 weeks</NAME>
<DICH_DATA CI_END="1.6090561638297667" CI_START="0.2074676869571005" EFFECT_SIZE="0.5777777777777777" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="6" LOG_CI_END="0.20657120333809248" LOG_CI_START="-0.683049534947144" LOG_EFFECT_SIZE="-0.23823916580452575" ORDER="969" O_E="0.0" SE="0.5225676253624243" STUDY_ID="STD-Clark-1975" TOTAL_1="15" TOTAL_2="13" VAR="0.27307692307692305" WEIGHT="29.182879377431906"/>
<DICH_DATA CI_END="0.5593501123395324" CI_START="0.06093292820507686" EFFECT_SIZE="0.18461538461538463" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="15" LOG_CI_END="-0.25231627035956633" LOG_CI_START="-1.215147950830895" LOG_EFFECT_SIZE="-0.7337321105952307" ORDER="970" O_E="0.0" SE="0.5655720952025434" STUDY_ID="STD-Pool-1976" TOTAL_1="26" TOTAL_2="24" VAR="0.3198717948717948" WEIGHT="70.81712062256808"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.055728230622675665" CI_END="0.8186128296343003" CI_START="0.3609783693807458" DF="1" EFFECT_SIZE="0.5436005191273716" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="22" I2="0.0" ID="CMP-001.03.02" LOG_CI_END="-0.08692145319707818" LOG_CI_START="-0.4425188211969265" LOG_EFFECT_SIZE="-0.2647201371970024" NO="2" P_CHI2="0.8133796927543266" P_Z="0.003521231451390754" STUDIES="2" TAU2="0.0" TOTAL_1="42" TOTAL_2="29" WEIGHT="100.0" Z="2.9181427174615524">
<NAME>medium term - up to 12 weeks</NAME>
<DICH_DATA CI_END="1.0583472847901376" CI_START="0.24901817907675478" EFFECT_SIZE="0.5133689839572193" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="11" LOG_CI_END="0.02462819994842814" LOG_CI_START="-0.6037689469422892" LOG_EFFECT_SIZE="-0.2895703734969305" ORDER="971" O_E="0.0" SE="0.36912359469965184" STUDY_ID="STD-Clark-1972" TOTAL_1="17" TOTAL_2="16" VAR="0.13625222816399285" WEIGHT="43.915703602991165"/>
<DICH_DATA CI_END="0.9069471397783833" CI_START="0.35481488721169674" EFFECT_SIZE="0.5672727272727273" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="11" LOG_CI_END="-0.042418024485168" LOG_CI_START="-0.4499981664664341" LOG_EFFECT_SIZE="-0.24620809547580105" ORDER="972" O_E="0.0" SE="0.2394145929540372" STUDY_ID="STD-Clark-1977" TOTAL_1="25" TOTAL_2="13" VAR="0.05731934731934732" WEIGHT="56.08429639700883"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.3552120724472303" CI_END="1.3914966899413101" CI_START="0.5433318739676161" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8695081967213114" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="14" I2="57.54097850895737" I2_Q="56.21317161790775" ID="CMP-001.04" LOG_CI_END="0.14348217758207502" LOG_CI_START="-0.26493481681017567" LOG_EFFECT_SIZE="-0.060726319614050346" METHOD="MH" NO="4" P_CHI2="0.12486506375067752" P_Q="0.13073202935540196" P_Z="0.5599993070947422" Q="2.2837918089746267" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="40" TOTAL_2="26" WEIGHT="200.0" Z="0.5828425407924959">
<NAME>Global effect: 2. Needing additional antipsychotic/sedative drugs</NAME>
<GROUP_LABEL_1>Loxapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Loxapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.1953486035710474" CI_START="0.6017635892044825" DF="0" EFFECT_SIZE="1.3866666666666667" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="5" I2="0.0" ID="CMP-001.04.01" LOG_CI_END="0.5045182453890996" LOG_CI_START="-0.22057409357493898" LOG_EFFECT_SIZE="0.14197207590708033" NO="1" P_CHI2="1.0" P_Z="0.44277451206710905" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="13" WEIGHT="100.0" Z="0.7675164682771932">
<NAME>short term - up to 6 weeks</NAME>
<DICH_DATA CI_END="3.1953486035710474" CI_START="0.6017635892044825" EFFECT_SIZE="1.3866666666666667" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="5" LOG_CI_END="0.5045182453890996" LOG_CI_START="-0.22057409357493898" LOG_EFFECT_SIZE="0.14197207590708033" ORDER="973" O_E="0.0" SE="0.42592282917244106" STUDY_ID="STD-Clark-1975" TOTAL_1="15" TOTAL_2="13" VAR="0.18141025641025643" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.1257994302155445" CI_START="0.3587946958901859" DF="0" EFFECT_SIZE="0.6355555555555555" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="9" I2="0.0" ID="CMP-001.04.02" LOG_CI_END="0.05146102452110336" LOG_CI_START="-0.4451539858137047" LOG_EFFECT_SIZE="-0.1968464806463007" NO="2" P_CHI2="1.0" P_Z="0.12023999981190046" STUDIES="1" TAU2="0.0" TOTAL_1="25" TOTAL_2="13" WEIGHT="100.00000000000001" Z="1.553767020815997">
<NAME>medium term- 7 - 26 weeks</NAME>
<DICH_DATA CI_END="1.1257994302155443" CI_START="0.3587946958901859" EFFECT_SIZE="0.6355555555555555" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="9" LOG_CI_END="0.05146102452110328" LOG_CI_START="-0.4451539858137047" LOG_EFFECT_SIZE="-0.1968464806463007" ORDER="974" O_E="0.0" SE="0.29171411535461406" STUDY_ID="STD-Clark-1977" TOTAL_1="25" TOTAL_2="13" VAR="0.08509712509712508" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.0776195529261314" CI_START="0.1423110150160979" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.3916083916083916" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="11" I2="0.0" I2_Q="0.0" ID="CMP-001.05" LOG_CI_END="0.03246546286608377" LOG_CI_START="-0.8467614837838066" LOG_EFFECT_SIZE="-0.4071480104588614" METHOD="MH" NO="5" P_CHI2="1.0" P_Q="1.0" P_Z="0.06949001376241794" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="26" TOTAL_2="28" WEIGHT="100.0" Z="1.8152206092342817">
<NAME>Mental state: Specific symptoms - anxiety/tension</NAME>
<GROUP_LABEL_1>Loxapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Loxapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.0776195529261314" CI_START="0.1423110150160979" DF="0" EFFECT_SIZE="0.3916083916083916" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="11" I2="0.0" ID="CMP-001.05.01" LOG_CI_END="0.03246546286608377" LOG_CI_START="-0.8467614837838066" LOG_EFFECT_SIZE="-0.4071480104588614" NO="1" P_CHI2="1.0" P_Z="0.06949001376241794" STUDIES="1" TAU2="0.0" TOTAL_1="26" TOTAL_2="28" WEIGHT="100.0" Z="1.8152206092342817">
<NAME>short term - up to 6 weeks</NAME>
<DICH_DATA CI_END="1.0776195529261314" CI_START="0.1423110150160979" EFFECT_SIZE="0.3916083916083916" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="11" LOG_CI_END="0.03246546286608377" LOG_CI_START="-0.8467614837838066" LOG_EFFECT_SIZE="-0.4071480104588614" ORDER="975" O_E="0.0" SE="0.5164622607057235" STUDY_ID="STD-Van-Der-Velde-1975" TOTAL_1="26" TOTAL_2="28" VAR="0.2667332667332668" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.526893361324702" CI_END="2.4914311803031883" CI_START="1.2373166390460917" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="1.7557588827704613" ESTIMABLE="YES" EVENTS_1="48" EVENTS_2="21" I2="0.0" I2_Q="27.045796824125215" ID="CMP-001.06" LOG_CI_END="0.39644889534919514" LOG_CI_START="0.09248085322123036" LOG_EFFECT_SIZE="0.24446487428521277" METHOD="MH" NO="6" P_CHI2="0.4660574272745651" P_Q="0.2416878945030554" P_Z="0.001618324129876116" Q="1.3707229418834772" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="60" TOTAL_2="45" WEIGHT="200.0" Z="3.152583710641655">
<NAME>Adverse effects: 1. Any adverse event</NAME>
<GROUP_LABEL_1>Loxapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Loxapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0036534949665896835" CI_END="2.1690467757136322" CI_START="1.0449684176133687" DF="1" EFFECT_SIZE="1.5055183084063952" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="17" I2="0.0" ID="CMP-001.06.01" LOG_CI_END="0.33626891771971407" LOG_CI_START="0.019103164836059002" LOG_EFFECT_SIZE="0.17768604127788654" NO="1" P_CHI2="0.9518019411540737" P_Z="0.028087319767697468" STUDIES="2" TAU2="0.0" TOTAL_1="35" TOTAL_2="32" WEIGHT="100.0" Z="2.1960646021445163">
<NAME>up to 6 weeks</NAME>
<DICH_DATA CI_END="2.455363456684147" CI_START="0.940960489458488" EFFECT_SIZE="1.52" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="10" LOG_CI_END="0.39011578792499246" LOG_CI_START="-0.026428612035447347" LOG_EFFECT_SIZE="0.18184358794477254" ORDER="976" O_E="0.0" SE="0.24468024246479647" STUDY_ID="STD-Charalampous-1974" TOTAL_1="20" TOTAL_2="19" VAR="0.059868421052631585" WEIGHT="57.76173285198556"/>
<DICH_DATA CI_END="2.6095975979571877" CI_START="0.8458572082161012" EFFECT_SIZE="1.4857142857142858" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="7" LOG_CI_END="0.41657354394358764" LOG_CI_START="-0.07270294537454051" LOG_EFFECT_SIZE="0.17193529928452353" ORDER="977" O_E="0.0" SE="0.2874034317831514" STUDY_ID="STD-Clark-1975" TOTAL_1="15" TOTAL_2="13" VAR="0.08260073260073258" WEIGHT="42.238267148014444"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="6.014245005601762" CI_START="1.1239981067787612" DF="0" EFFECT_SIZE="2.6" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="4" I2="0.0" ID="CMP-001.06.02" LOG_CI_END="0.7791811162176946" LOG_CI_START="0.05076557972394132" LOG_EFFECT_SIZE="0.414973347970818" NO="2" P_CHI2="1.0" P_Z="0.025538649045492138" STUDIES="1" TAU2="0.0" TOTAL_1="25" TOTAL_2="13" WEIGHT="100.0" Z="2.2331561473326307">
<NAME>by 12 weeks</NAME>
<DICH_DATA CI_END="6.014245005601762" CI_START="1.123998106778761" EFFECT_SIZE="2.6" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="4" LOG_CI_END="0.7791811162176946" LOG_CI_START="0.05076557972394124" LOG_EFFECT_SIZE="0.414973347970818" ORDER="978" O_E="0.0" SE="0.42787489185148864" STUDY_ID="STD-Clark-1977" TOTAL_1="25" TOTAL_2="13" VAR="0.18307692307692308" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.825549848665103" CI_END="0.8497655740050002" CI_START="0.21343907002884252" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.42587929493948495" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="23" I2="29.217316730586944" I2_Q="27.694240203585448" ID="CMP-001.07" LOG_CI_END="-0.07070086717743965" LOG_CI_START="-0.6707260800153343" LOG_EFFECT_SIZE="-0.37071347359638696" METHOD="MH" NO="7" P_CHI2="0.24346705209254005" P_Q="0.2508212650715289" P_Z="0.015441790126189594" Q="2.766031372370939" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="95" TOTAL_2="87" WEIGHT="300.0" Z="2.4218484199894985">
<NAME>Adverse effects: 2. Anticholinergic effects - specific symptoms</NAME>
<GROUP_LABEL_1>Loxapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Loxapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="67.8941684273104" CI_START="0.20925362105180706" DF="0" EFFECT_SIZE="3.769230769230769" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" I2="0.0" ID="CMP-001.07.01" LOG_CI_END="1.8318324734174263" LOG_CI_START="-0.6793270179740727" LOG_EFFECT_SIZE="0.5762527277216769" NO="1" P_CHI2="1.0" P_Z="0.3683691855542349" STUDIES="1" TAU2="0.0" TOTAL_1="25" TOTAL_2="13" WEIGHT="100.0" Z="0.8995323444801219">
<NAME>blurred vision - 12 weeks</NAME>
<DICH_DATA CI_END="67.89416842731046" CI_START="0.20925362105180695" EFFECT_SIZE="3.769230769230769" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="1.8318324734174267" LOG_CI_START="-0.6793270179740729" LOG_EFFECT_SIZE="0.5762527277216769" ORDER="979" O_E="0.0" SE="1.4750675156833248" STUDY_ID="STD-Clark-1977" TOTAL_1="25" TOTAL_2="13" VAR="2.1758241758241756" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.8477561786854991" CI_START="0.08550242265763813" DF="0" EFFECT_SIZE="0.2692307692307692" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="12" I2="0.0" ID="CMP-001.07.02" LOG_CI_END="-0.07172903627799276" LOG_CI_START="-1.0680215796351293" LOG_EFFECT_SIZE="-0.5698753079565612" NO="2" P_CHI2="1.0" P_Z="0.024949550334189496" STUDIES="1" TAU2="0.0" TOTAL_1="26" TOTAL_2="28" WEIGHT="99.99999999999999" Z="2.242182954636747">
<NAME>constipation - 6 weeks</NAME>
<DICH_DATA CI_END="0.8477561786854991" CI_START="0.08550242265763813" EFFECT_SIZE="0.2692307692307692" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="12" LOG_CI_END="-0.07172903627799276" LOG_CI_START="-1.0680215796351293" LOG_EFFECT_SIZE="-0.5698753079565612" ORDER="980" O_E="0.0" SE="0.5852271716956096" STUDY_ID="STD-Van-Der-Velde-1975" TOTAL_1="26" TOTAL_2="28" VAR="0.3424908424908425" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-001.07.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="18" TOTAL_2="18" WEIGHT="0.0" Z="0.0">
<NAME>constipation - 12 weeks</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="981" O_E="0.0" SE="0.0" STUDY_ID="STD-Clark-1972" TOTAL_1="18" TOTAL_2="18" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.0776195529261314" CI_START="0.1423110150160979" DF="0" EFFECT_SIZE="0.3916083916083916" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="11" I2="0.0" ID="CMP-001.07.04" LOG_CI_END="0.03246546286608377" LOG_CI_START="-0.8467614837838066" LOG_EFFECT_SIZE="-0.4071480104588614" NO="4" P_CHI2="1.0" P_Z="0.06949001376241794" STUDIES="1" TAU2="0.0" TOTAL_1="26" TOTAL_2="28" WEIGHT="100.0" Z="1.8152206092342817">
<NAME>dry mouth - 6 weeks</NAME>
<DICH_DATA CI_END="1.0776195529261314" CI_START="0.1423110150160979" EFFECT_SIZE="0.3916083916083916" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="11" LOG_CI_END="0.03246546286608377" LOG_CI_START="-0.8467614837838066" LOG_EFFECT_SIZE="-0.4071480104588614" ORDER="982" O_E="0.0" SE="0.5164622607057235" STUDY_ID="STD-Van-Der-Velde-1975" TOTAL_1="26" TOTAL_2="28" VAR="0.2667332667332668" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="5.249281447865761" CI_END="3.6736817069250605" CI_START="1.1293282125658242" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="RR" EFFECT_SIZE="2.0368584623427926" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="10" I2="4.748868018252544" I2_Q="13.18618128608193" ID="CMP-001.08" LOG_CI_END="0.5651015257002601" LOG_CI_START="0.052820177701007144" LOG_EFFECT_SIZE="0.30896085170063364" METHOD="MH" NO="8" P_CHI2="0.386221247725403" P_Q="0.32998346408238866" P_Z="0.018072033439058884" Q="4.6075613989305095" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="137" TOTAL_2="111" WEIGHT="500.0" Z="2.3641389417400602">
<NAME>Adverse effects: 3. Cardiovascular problems</NAME>
<GROUP_LABEL_1>Loxapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Loxapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="5.585348881148442" CI_START="0.5379152687462345" DF="0" EFFECT_SIZE="1.7333333333333334" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="3" I2="0.0" ID="CMP-001.08.01" LOG_CI_END="0.7470503059073762" LOG_CI_START="-0.2692861280771027" LOG_EFFECT_SIZE="0.23888208891513674" NO="1" P_CHI2="1.0" P_Z="0.3568682443739931" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="13" WEIGHT="100.0" Z="0.9213490241411794">
<NAME>ECG abnormalites - 6 weeks</NAME>
<DICH_DATA CI_END="5.585348881148442" CI_START="0.5379152687462345" EFFECT_SIZE="1.7333333333333334" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="3" LOG_CI_END="0.7470503059073762" LOG_CI_START="-0.2692861280771027" LOG_EFFECT_SIZE="0.23888208891513674" ORDER="983" O_E="0.0" SE="0.5970010522689692" STUDY_ID="STD-Clark-1975" TOTAL_1="15" TOTAL_2="13" VAR="0.3564102564102564" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="7.581849412378474E-4" CI_END="2.3239865230910466" CI_START="0.4606954758655239" DF="1" EFFECT_SIZE="1.0347222222222223" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="6" I2="0.0" ID="CMP-001.08.02" LOG_CI_END="0.3662336052311321" LOG_CI_START="-0.3365860525970832" LOG_EFFECT_SIZE="0.014823776317024424" NO="2" P_CHI2="0.9780328990640782" P_Z="0.934107112610575" STUDIES="2" TAU2="0.0" TOTAL_1="43" TOTAL_2="31" WEIGHT="100.0" Z="0.08267858581538749">
<NAME>ECG abnormalities - 12 weeks</NAME>
<DICH_DATA CI_END="14.786473993825217" CI_START="0.06762937536140103" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.169864623787869" LOG_CI_START="-1.169864623787869" LOG_EFFECT_SIZE="0.0" ORDER="984" O_E="0.0" SE="1.3743685418725535" STUDY_ID="STD-Clark-1972" TOTAL_1="18" TOTAL_2="18" VAR="1.8888888888888888" WEIGHT="13.194444444444445"/>
<DICH_DATA CI_END="2.4056980022407055" CI_START="0.4495992427115044" EFFECT_SIZE="1.04" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="5" LOG_CI_END="0.38124110754565715" LOG_CI_START="-0.34717442894809636" LOG_EFFECT_SIZE="0.01703333929878037" ORDER="985" O_E="0.0" SE="0.4278748918514887" STUDY_ID="STD-Clark-1977" TOTAL_1="25" TOTAL_2="13" VAR="0.18307692307692314" WEIGHT="86.80555555555556"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="69.09028858730679" CI_START="0.1302643277951726" DF="0" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-001.08.03" LOG_CI_END="1.8394170067179525" LOG_CI_START="-0.8851744972786274" LOG_EFFECT_SIZE="0.47712125471966244" NO="3" P_CHI2="1.0" P_Z="0.49243283298336993" STUDIES="1" TAU2="0.0" TOTAL_1="18" TOTAL_2="18" WEIGHT="100.0" Z="0.6864445360982625">
<NAME>blood pressure - hypertension - 12 weeks</NAME>
<DICH_DATA CI_END="69.09028858730679" CI_START="0.1302643277951726" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8394170067179525" LOG_CI_START="-0.8851744972786274" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="986" O_E="0.0" SE="1.6004385363930504" STUDY_ID="STD-Clark-1972" TOTAL_1="18" TOTAL_2="18" VAR="2.5614035087719293" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="67.8941684273104" CI_START="0.20925362105180706" DF="0" EFFECT_SIZE="3.769230769230769" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" I2="0.0" ID="CMP-001.08.04" LOG_CI_END="1.8318324734174263" LOG_CI_START="-0.6793270179740727" LOG_EFFECT_SIZE="0.5762527277216769" NO="4" P_CHI2="1.0" P_Z="0.3683691855542349" STUDIES="2" TAU2="0.0" TOTAL_1="43" TOTAL_2="31" WEIGHT="100.0" Z="0.8995323444801219">
<NAME>blood pressure - hypotension, 12 weeks</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="987" O_E="0.0" SE="0.0" STUDY_ID="STD-Clark-1972" TOTAL_1="18" TOTAL_2="18" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="67.89416842731046" CI_START="0.20925362105180695" EFFECT_SIZE="3.769230769230769" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="1.8318324734174267" LOG_CI_START="-0.6793270179740729" LOG_EFFECT_SIZE="0.5762527277216769" ORDER="988" O_E="0.0" SE="1.4750675156833248" STUDY_ID="STD-Clark-1977" TOTAL_1="25" TOTAL_2="13" VAR="2.1758241758241756" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="63.89164245808205" CI_START="1.2677714468389574" DF="0" EFFECT_SIZE="9.0" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="1" I2="0.0" ID="CMP-001.08.05" LOG_CI_END="1.805444052654181" LOG_CI_START="0.103040966224469" LOG_EFFECT_SIZE="0.9542425094393249" NO="5" P_CHI2="1.0" P_Z="0.028004411148107238" STUDIES="1" TAU2="0.0" TOTAL_1="18" TOTAL_2="18" WEIGHT="100.0" Z="2.1972245773362196">
<NAME>tachycardia - 12 weeks</NAME>
<DICH_DATA CI_END="63.89164245808205" CI_START="1.2677714468389574" EFFECT_SIZE="9.0" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="1" LOG_CI_END="1.805444052654181" LOG_CI_START="0.103040966224469" LOG_EFFECT_SIZE="0.9542425094393249" ORDER="989" O_E="0.0" SE="1.0" STUDY_ID="STD-Clark-1972" TOTAL_1="18" TOTAL_2="18" VAR="1.0" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.9340791371232647" CI_END="0.7148777750196665" CI_START="0.19699833045749374" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.3752728716015083" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="27" I2="0.0" I2_Q="0.0" ID="CMP-001.09" LOG_CI_END="-0.14576820459335418" LOG_CI_START="-0.7055374544281037" LOG_EFFECT_SIZE="-0.4256528295107289" METHOD="MH" NO="9" P_CHI2="0.6268553232696632" P_Q="0.737440268608389" P_Z="0.0028754973450407307" Q="0.11238925758844283" RANDOM="NO" SCALE="5.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="87" TOTAL_2="86" WEIGHT="200.0" Z="2.9807432830755936">
<NAME>Adverse effects: 4. Gastrointestinal problems</NAME>
<GROUP_LABEL_1>Loxapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Loxapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.8876344932885878" CI_START="0.12369965099183801" DF="0" EFFECT_SIZE="0.33136094674556216" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="13" I2="0.0" ID="CMP-001.09.01" LOG_CI_END="-0.051765829520439344" LOG_CI_START="-0.9076315256945068" LOG_EFFECT_SIZE="-0.4796986776074731" NO="1" P_CHI2="1.0" P_Z="0.028016497060582783" STUDIES="1" TAU2="0.0" TOTAL_1="26" TOTAL_2="28" WEIGHT="100.0" Z="2.197055299084963">
<NAME>abdominal pain - 6 weeks</NAME>
<DICH_DATA CI_END="0.8876344932885878" CI_START="0.12369965099183801" EFFECT_SIZE="0.33136094674556216" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="13" LOG_CI_END="-0.051765829520439344" LOG_CI_START="-0.9076315256945068" LOG_EFFECT_SIZE="-0.4796986776074731" ORDER="990" O_E="0.0" SE="0.5027397465361703" STUDY_ID="STD-Van-Der-Velde-1975" TOTAL_1="26" TOTAL_2="28" VAR="0.25274725274725274" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.8204883766105491" CI_END="0.9725370387595802" CI_START="0.17635637931672637" DF="1" EFFECT_SIZE="0.4141414141414142" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="14" I2="0.0" ID="CMP-001.09.02" LOG_CI_END="-0.012093849721958065" LOG_CI_START="-0.7536088260336706" LOG_EFFECT_SIZE="-0.38285133787781434" NO="2" P_CHI2="0.36503747689635047" P_Z="0.04298078797445049" STUDIES="3" TAU2="0.0" TOTAL_1="61" TOTAL_2="58" WEIGHT="100.0" Z="2.023896637680463">
<NAME>nausea or vomiting - short term, up to 6 weeks</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="991" O_E="0.0" SE="0.0" STUDY_ID="STD-Charalampous-1974" TOTAL_1="20" TOTAL_2="19" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="5.315874769603765" CI_START="0.14129586261248542" EFFECT_SIZE="0.8666666666666667" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.7255747413619915" LOG_CI_START="-0.8498705548596804" LOG_EFFECT_SIZE="-0.06214790674884446" ORDER="992" O_E="0.0" SE="0.9254243655806003" STUDY_ID="STD-Clark-1975" TOTAL_1="15" TOTAL_2="13" VAR="0.8564102564102565" WEIGHT="15.151515151515152"/>
<DICH_DATA CI_END="0.8992933901679381" CI_START="0.12355379493044168" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="12" LOG_CI_END="-0.04609859865163574" LOG_CI_START="-0.9081439107876892" LOG_EFFECT_SIZE="-0.47712125471966244" ORDER="993" O_E="0.0" SE="0.5063696835418333" STUDY_ID="STD-Van-Der-Velde-1975" TOTAL_1="26" TOTAL_2="26" VAR="0.2564102564102564" WEIGHT="84.84848484848484"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="57.80870883010068" CI_END="1.9255414634887862" CI_START="1.185614793475624" CI_STUDY="95" CI_TOTAL="95" DF="23" EFFECT_MEASURE="RR" EFFECT_SIZE="1.5109435610117965" ESTIMABLE="YES" EVENTS_1="145" EVENTS_2="86" I2="60.21360714421626" I2_Q="66.00598400731573" ID="CMP-001.10" LOG_CI_END="0.28455287490395836" LOG_CI_START="0.07394360956638432" LOG_EFFECT_SIZE="0.17924824223517136" METHOD="MH" NO="10" P_CHI2="7.872378025264304E-5" P_Q="2.6703345949674606E-5" P_Z="8.492396354696664E-4" Q="52.950495769236895" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="550" TOTAL_2="460" WEIGHT="1900.0" Z="3.3362264334376324">
<NAME>Adverse effects: 5. Movement disorders</NAME>
<GROUP_LABEL_1>Loxapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Loxapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.4994589171440795" CI_START="0.313217129551298" DF="0" EFFECT_SIZE="0.6853146853146853" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="11" I2="0.0" ID="CMP-001.10.01" LOG_CI_END="0.17593457126123635" LOG_CI_START="-0.5041544948063702" LOG_EFFECT_SIZE="-0.16410996177256695" NO="1" P_CHI2="1.0" P_Z="0.34419736870294515" STUDIES="1" TAU2="0.0" TOTAL_1="26" TOTAL_2="28" WEIGHT="100.0" Z="0.9459043840781338">
<NAME>akathisia - 6 weeks</NAME>
<DICH_DATA CI_END="1.4994589171440795" CI_START="0.313217129551298" EFFECT_SIZE="0.6853146853146853" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="11" LOG_CI_END="0.17593457126123635" LOG_CI_START="-0.5041544948063702" LOG_EFFECT_SIZE="-0.16410996177256695" ORDER="994" O_E="0.0" SE="0.3994876839032833" STUDY_ID="STD-Van-Der-Velde-1975" TOTAL_1="26" TOTAL_2="28" VAR="0.1595904095904096" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.10329902133380377" CI_END="38.2335533319933" CI_START="0.5660661966015057" DF="1" EFFECT_SIZE="4.6521739130434785" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="0" I2="0.0" ID="CMP-001.10.02" LOG_CI_END="1.5824446621509818" LOG_CI_START="-0.24713277881574822" LOG_EFFECT_SIZE="0.6676559416676168" NO="2" P_CHI2="0.7479060616631403" P_Z="0.15258098536665157" STUDIES="2" TAU2="0.0" TOTAL_1="43" TOTAL_2="31" WEIGHT="100.0" Z="1.4304741307274351">
<NAME>akathisia - 12 weeks</NAME>
<DICH_DATA CI_END="69.09028858730679" CI_START="0.1302643277951726" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8394170067179525" LOG_CI_START="-0.8851744972786274" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="995" O_E="0.0" SE="1.6004385363930504" STUDY_ID="STD-Clark-1972" TOTAL_1="18" TOTAL_2="18" VAR="2.5614035087719293" WEIGHT="43.47826086956522"/>
<DICH_DATA CI_END="99.49089711060313" CI_START="0.352623619401935" EFFECT_SIZE="5.923076923076923" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="0" LOG_CI_END="1.9977833469217707" LOG_CI_START="-0.4526886011904805" LOG_EFFECT_SIZE="0.7725473728656451" ORDER="996" O_E="0.0" SE="1.4394193523529102" STUDY_ID="STD-Clark-1977" TOTAL_1="25" TOTAL_2="13" VAR="2.0719280719280717" WEIGHT="56.52173913043479"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="67.8941684273104" CI_START="0.20925362105180706" DF="0" EFFECT_SIZE="3.769230769230769" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" I2="0.0" ID="CMP-001.10.03" LOG_CI_END="1.8318324734174263" LOG_CI_START="-0.6793270179740727" LOG_EFFECT_SIZE="0.5762527277216769" NO="3" P_CHI2="1.0" P_Z="0.3683691855542349" STUDIES="1" TAU2="0.0" TOTAL_1="25" TOTAL_2="13" WEIGHT="100.0" Z="0.8995323444801219">
<NAME>akinesia - 12 weeks</NAME>
<DICH_DATA CI_END="67.89416842731046" CI_START="0.20925362105180695" EFFECT_SIZE="3.769230769230769" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="1.8318324734174267" LOG_CI_START="-0.6793270179740729" LOG_EFFECT_SIZE="0.5762527277216769" ORDER="997" O_E="0.0" SE="1.4750675156833248" STUDY_ID="STD-Clark-1977" TOTAL_1="25" TOTAL_2="13" VAR="2.1758241758241756" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="83.66079139373137" CI_START="0.28071939924717754" DF="0" EFFECT_SIZE="4.846153846153846" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" I2="0.0" ID="CMP-001.10.04" LOG_CI_END="1.9225219684959254" LOG_CI_START="-0.5517275742024357" LOG_EFFECT_SIZE="0.6853971971467449" NO="4" P_CHI2="1.0" P_Z="0.2775375487889178" STUDIES="1" TAU2="0.0" TOTAL_1="25" TOTAL_2="13" WEIGHT="100.0" Z="1.0858676930761701">
<NAME>bradykinesia - 12 weeks</NAME>
<DICH_DATA CI_END="83.66079139373137" CI_START="0.28071939924717754" EFFECT_SIZE="4.846153846153846" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="1.9225219684959254" LOG_CI_START="-0.5517275742024357" LOG_EFFECT_SIZE="0.6853971971467449" ORDER="998" O_E="0.0" SE="1.4533864291137826" STUDY_ID="STD-Clark-1977" TOTAL_1="25" TOTAL_2="13" VAR="2.1123321123321124" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.011119246374366901" CI_END="29.025001730842384" CI_START="0.406467902341645" DF="1" EFFECT_SIZE="3.4347826086956528" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" I2="0.0" ID="CMP-001.10.05" LOG_CI_END="1.4627722543088122" LOG_CI_START="-0.39097374376311467" LOG_EFFECT_SIZE="0.5358992552728487" NO="5" P_CHI2="0.9160204601012052" P_Z="0.2571254202868908" STUDIES="2" TAU2="0.0" TOTAL_1="43" TOTAL_2="31" WEIGHT="100.0" Z="1.1332116058716541">
<NAME>drooling - 12 weeks</NAME>
<DICH_DATA CI_END="69.09028858730679" CI_START="0.1302643277951726" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8394170067179525" LOG_CI_START="-0.8851744972786274" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="999" O_E="0.0" SE="1.6004385363930504" STUDY_ID="STD-Clark-1972" TOTAL_1="18" TOTAL_2="18" VAR="2.5614035087719293" WEIGHT="43.47826086956522"/>
<DICH_DATA CI_END="67.89416842731046" CI_START="0.20925362105180695" EFFECT_SIZE="3.769230769230769" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="1.8318324734174267" LOG_CI_START="-0.6793270179740729" LOG_EFFECT_SIZE="0.5762527277216769" ORDER="1000" O_E="0.0" SE="1.4750675156833248" STUDY_ID="STD-Clark-1977" TOTAL_1="25" TOTAL_2="13" VAR="2.1758241758241756" WEIGHT="56.52173913043479"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="27.24314627466482" CI_START="0.4411303179381265" DF="0" EFFECT_SIZE="3.466666666666667" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" I2="0.0" ID="CMP-001.10.06" LOG_CI_END="1.4352572622282669" LOG_CI_START="-0.355433093070031" LOG_EFFECT_SIZE="0.5399120845791179" NO="6" P_CHI2="1.0" P_Z="0.23724550263455546" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="13" WEIGHT="100.00000000000001" Z="1.1818997488448926">
<NAME>dyskinesia - 4 weeks</NAME>
<DICH_DATA CI_END="27.24314627466482" CI_START="0.4411303179381265" EFFECT_SIZE="3.466666666666667" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" LOG_CI_END="1.4352572622282669" LOG_CI_START="-0.355433093070031" LOG_EFFECT_SIZE="0.5399120845791179" ORDER="1001" O_E="0.0" SE="1.0518603787624365" STUDY_ID="STD-Clark-1975" TOTAL_1="15" TOTAL_2="13" VAR="1.1064102564102565" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="67.8941684273104" CI_START="0.20925362105180706" DF="0" EFFECT_SIZE="3.769230769230769" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" I2="0.0" ID="CMP-001.10.07" LOG_CI_END="1.8318324734174263" LOG_CI_START="-0.6793270179740727" LOG_EFFECT_SIZE="0.5762527277216769" NO="7" P_CHI2="1.0" P_Z="0.3683691855542349" STUDIES="1" TAU2="0.0" TOTAL_1="25" TOTAL_2="13" WEIGHT="100.0" Z="0.8995323444801219">
<NAME>dyskinesia - 12 weeks</NAME>
<DICH_DATA CI_END="67.89416842731046" CI_START="0.20925362105180695" EFFECT_SIZE="3.769230769230769" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="1.8318324734174267" LOG_CI_START="-0.6793270179740729" LOG_EFFECT_SIZE="0.5762527277216769" ORDER="1002" O_E="0.0" SE="1.4750675156833248" STUDY_ID="STD-Clark-1977" TOTAL_1="25" TOTAL_2="13" VAR="2.1758241758241756" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.2190896625507133" CI_START="0.1965569282569739" DF="0" EFFECT_SIZE="0.48951048951048953" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="11" I2="0.0" ID="CMP-001.10.08" LOG_CI_END="0.08603564862000637" LOG_CI_START="-0.7065116435216163" LOG_EFFECT_SIZE="-0.31023799745080494" NO="8" P_CHI2="1.0" P_Z="0.12492320029184972" STUDIES="1" TAU2="0.0" TOTAL_1="26" TOTAL_2="28" WEIGHT="100.0" Z="1.5344328538334133">
<NAME>dystonia - 6 weeks</NAME>
<DICH_DATA CI_END="1.2190896625507133" CI_START="0.19655692825697388" EFFECT_SIZE="0.48951048951048953" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="11" LOG_CI_END="0.08603564862000637" LOG_CI_START="-0.7065116435216163" LOG_EFFECT_SIZE="-0.31023799745080494" ORDER="1003" O_E="0.0" SE="0.46554620257635737" STUDY_ID="STD-Van-Der-Velde-1975" TOTAL_1="26" TOTAL_2="28" VAR="0.21673326673326676" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="67.8941684273104" CI_START="0.20925362105180706" DF="0" EFFECT_SIZE="3.769230769230769" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" I2="0.0" ID="CMP-001.10.09" LOG_CI_END="1.8318324734174263" LOG_CI_START="-0.6793270179740727" LOG_EFFECT_SIZE="0.5762527277216769" NO="9" P_CHI2="1.0" P_Z="0.3683691855542349" STUDIES="1" TAU2="0.0" TOTAL_1="25" TOTAL_2="13" WEIGHT="100.0" Z="0.8995323444801219">
<NAME>dystonia - 12 weeks</NAME>
<DICH_DATA CI_END="67.89416842731046" CI_START="0.20925362105180695" EFFECT_SIZE="3.769230769230769" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="1.8318324734174267" LOG_CI_START="-0.6793270179740729" LOG_EFFECT_SIZE="0.5762527277216769" ORDER="1004" O_E="0.0" SE="1.4750675156833248" STUDY_ID="STD-Clark-1977" TOTAL_1="25" TOTAL_2="13" VAR="2.1758241758241756" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.9469689711683922" CI_END="29.545827538960182" CI_START="3.173269655938763" DF="1" EFFECT_SIZE="9.682813536828137" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="3" I2="0.0" ID="CMP-001.10.10" LOG_CI_END="1.4704961584913774" LOG_CI_START="0.501506978848041" LOG_EFFECT_SIZE="0.9860015686697092" NO="10" P_CHI2="0.33049219394783125" P_Z="6.642251138849993E-5" STUDIES="2" TAU2="0.0" TOTAL_1="46" TOTAL_2="43" WEIGHT="100.0" Z="3.9887495214424327">
<NAME>extrapyramidal symptoms - 4 weeks, unspecified</NAME>
<DICH_DATA CI_END="22.18377824871314" CI_START="1.464583698761266" EFFECT_SIZE="5.7" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="2" LOG_CI_END="1.3460355153400192" LOG_CI_START="0.16571419600496382" LOG_EFFECT_SIZE="0.7558748556724915" ORDER="1005" O_E="0.0" SE="0.6933265856621719" STUDY_ID="STD-Charalampous-1974" TOTAL_1="20" TOTAL_2="19" VAR="0.4807017543859649" WEIGHT="66.35700066357"/>
<DICH_DATA CI_END="121.17384304497362" CI_START="2.5384821130244273" EFFECT_SIZE="17.53846153846154" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="1" LOG_CI_END="2.083408881816852" LOG_CI_START="0.4045741075703824" LOG_EFFECT_SIZE="1.243991494693617" ORDER="1006" O_E="0.0" SE="0.9861558567585366" STUDY_ID="STD-Pool-1976" TOTAL_1="26" TOTAL_2="24" VAR="0.9725033738191632" WEIGHT="33.642999336429995"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.0776195529261314" CI_START="0.1423110150160979" DF="0" EFFECT_SIZE="0.3916083916083916" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="11" I2="0.0" ID="CMP-001.10.11" LOG_CI_END="0.03246546286608377" LOG_CI_START="-0.8467614837838066" LOG_EFFECT_SIZE="-0.4071480104588614" NO="11" P_CHI2="1.0" P_Z="0.06949001376241794" STUDIES="1" TAU2="0.0" TOTAL_1="26" TOTAL_2="28" WEIGHT="100.0" Z="1.8152206092342817">
<NAME>muscle cramp - 6 weeks</NAME>
<DICH_DATA CI_END="1.0776195529261314" CI_START="0.1423110150160979" EFFECT_SIZE="0.3916083916083916" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="11" LOG_CI_END="0.03246546286608377" LOG_CI_START="-0.8467614837838066" LOG_EFFECT_SIZE="-0.4071480104588614" ORDER="1007" O_E="0.0" SE="0.5164622607057235" STUDY_ID="STD-Van-Der-Velde-1975" TOTAL_1="26" TOTAL_2="28" VAR="0.2667332667332668" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.30254378814623123" CI_END="10.829816443800867" CI_START="1.5561664391266659" DF="1" EFFECT_SIZE="4.105240174672489" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="4" I2="0.0" ID="CMP-001.10.12" LOG_CI_END="1.0346210957647506" LOG_CI_START="0.19205604492141773" LOG_EFFECT_SIZE="0.6133385703430841" NO="12" P_CHI2="0.5822921656310358" P_Z="0.0043243169805632885" STUDIES="2" TAU2="0.0" TOTAL_1="35" TOTAL_2="32" WEIGHT="100.0" Z="2.853480587637749">
<NAME>needing additional anticholinergic medication - 4 weeks</NAME>
<DICH_DATA CI_END="20.553187227238563" CI_START="1.3282915539162334" EFFECT_SIZE="5.225" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="2" LOG_CI_END="1.3128791784199545" LOG_CI_START="0.12329341114622851" LOG_EFFECT_SIZE="0.7180862947830916" ORDER="1008" O_E="0.0" SE="0.698768568241104" STUDY_ID="STD-Charalampous-1974" TOTAL_1="20" TOTAL_2="19" VAR="0.4882775119617225" WEIGHT="48.90829694323144"/>
<DICH_DATA CI_END="12.11628315059001" CI_START="0.7594004693314765" EFFECT_SIZE="3.033333333333333" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="2" LOG_CI_END="1.0833694139924375" LOG_CI_START="-0.11952913878957498" LOG_EFFECT_SIZE="0.48192013760143115" ORDER="1009" O_E="0.0" SE="0.7065885643480223" STUDY_ID="STD-Clark-1975" TOTAL_1="15" TOTAL_2="13" VAR="0.4992673992673992" WEIGHT="51.091703056768566"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="147.13518280900317" CI_START="0.5694960091024313" DF="0" EFFECT_SIZE="9.153846153846153" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="0" I2="0.0" ID="CMP-001.10.13" LOG_CI_END="2.1677165331818435" LOG_CI_START="-0.2445093150104558" LOG_EFFECT_SIZE="0.961603609085694" NO="13" P_CHI2="1.0" P_Z="0.11813960820654436" STUDIES="1" TAU2="0.0" TOTAL_1="25" TOTAL_2="13" WEIGHT="100.0" Z="1.5626301680036112">
<NAME>needing additional anticholinergic medication - 12 weeks</NAME>
<DICH_DATA CI_END="147.13518280900317" CI_START="0.5694960091024313" EFFECT_SIZE="9.153846153846153" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="0" LOG_CI_END="2.1677165331818435" LOG_CI_START="-0.2445093150104558" LOG_EFFECT_SIZE="0.961603609085694" ORDER="1010" O_E="0.0" SE="1.4169534039386826" STUDY_ID="STD-Clark-1977" TOTAL_1="25" TOTAL_2="13" VAR="2.0077569489334195" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.2190896625507133" CI_START="0.1965569282569739" DF="0" EFFECT_SIZE="0.48951048951048953" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="11" I2="0.0" ID="CMP-001.10.14" LOG_CI_END="0.08603564862000637" LOG_CI_START="-0.7065116435216163" LOG_EFFECT_SIZE="-0.31023799745080494" NO="14" P_CHI2="1.0" P_Z="0.12492320029184972" STUDIES="1" TAU2="0.0" TOTAL_1="26" TOTAL_2="28" WEIGHT="100.0" Z="1.5344328538334133">
<NAME>oculogyric crisis - 6 weeks</NAME>
<DICH_DATA CI_END="1.2190896625507133" CI_START="0.19655692825697388" EFFECT_SIZE="0.48951048951048953" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="11" LOG_CI_END="0.08603564862000637" LOG_CI_START="-0.7065116435216163" LOG_EFFECT_SIZE="-0.31023799745080494" ORDER="1011" O_E="0.0" SE="0.46554620257635737" STUDY_ID="STD-Van-Der-Velde-1975" TOTAL_1="26" TOTAL_2="28" VAR="0.21673326673326676" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.8350981816617054" CI_START="0.5310469759310164" DF="0" EFFECT_SIZE="0.9871794871794872" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="12" I2="0.0" ID="CMP-001.10.15" LOG_CI_END="0.2636593048895924" LOG_CI_START="-0.27486705992558935" LOG_EFFECT_SIZE="-0.005603877517998511" NO="15" P_CHI2="1.0" P_Z="0.9674628588723061" STUDIES="1" TAU2="0.0" TOTAL_1="26" TOTAL_2="28" WEIGHT="99.99999999999999" Z="0.040790567840890066">
<NAME>rigidity - 6 weeks</NAME>
<DICH_DATA CI_END="1.8350981816617054" CI_START="0.5310469759310164" EFFECT_SIZE="0.9871794871794872" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="12" LOG_CI_END="0.2636593048895924" LOG_CI_START="-0.27486705992558935" LOG_EFFECT_SIZE="-0.005603877517998511" ORDER="1012" O_E="0.0" SE="0.3163330524409362" STUDY_ID="STD-Van-Der-Velde-1975" TOTAL_1="26" TOTAL_2="28" VAR="0.10006660006660008" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.24803146012957722" CI_END="75.55064328347066" CI_START="1.266692495696951" DF="1" EFFECT_SIZE="9.782608695652174" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="0" I2="0.0" ID="CMP-001.10.16" LOG_CI_END="1.8782381665343721" LOG_CI_START="0.10267119765316718" LOG_EFFECT_SIZE="0.9904546820937696" NO="16" P_CHI2="0.6184646426142932" P_Z="0.028769421641947006" STUDIES="2" TAU2="0.0" TOTAL_1="43" TOTAL_2="31" WEIGHT="100.0" Z="2.1866316948282205">
<NAME>rigidity - 12 weeks</NAME>
<DICH_DATA CI_END="97.36507426675908" CI_START="0.25676558240489245" EFFECT_SIZE="5.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.9884031994519553" LOG_CI_START="-0.5904631907799176" LOG_EFFECT_SIZE="0.6989700043360189" ORDER="1013" O_E="0.0" SE="1.5148388832167146" STUDY_ID="STD-Clark-1972" TOTAL_1="18" TOTAL_2="18" VAR="2.2947368421052627" WEIGHT="43.47826086956522"/>
<DICH_DATA CI_END="210.7882100608914" CI_START="0.8596923789007527" EFFECT_SIZE="13.461538461538462" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="0" LOG_CI_END="2.32384631598695" LOG_CI_START="-0.06565692322803458" LOG_EFFECT_SIZE="1.1290946963794577" ORDER="1014" O_E="0.0" SE="1.4036060309466794" STUDY_ID="STD-Clark-1977" TOTAL_1="25" TOTAL_2="13" VAR="1.9701098901098903" WEIGHT="56.52173913043479"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.359791020044241" CI_START="0.2537548364156164" DF="0" EFFECT_SIZE="0.5874125874125874" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="11" I2="0.0" ID="CMP-001.10.17" LOG_CI_END="0.13347216880006355" LOG_CI_START="-0.5955856716064241" LOG_EFFECT_SIZE="-0.23105675140318016" NO="17" P_CHI2="1.0" P_Z="0.21411718418110304" STUDIES="1" TAU2="0.0" TOTAL_1="26" TOTAL_2="28" WEIGHT="100.0" Z="1.242323684174532">
<NAME>thick speech - 6 weeks</NAME>
<DICH_DATA CI_END="1.359791020044241" CI_START="0.2537548364156164" EFFECT_SIZE="0.5874125874125874" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="11" LOG_CI_END="0.13347216880006355" LOG_CI_START="-0.5955856716064241" LOG_EFFECT_SIZE="-0.23105675140318016" ORDER="1015" O_E="0.0" SE="0.4282521843492843" STUDY_ID="STD-Van-Der-Velde-1975" TOTAL_1="26" TOTAL_2="28" VAR="0.18339993339993338" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.359791020044241" CI_START="0.2537548364156164" DF="0" EFFECT_SIZE="0.5874125874125874" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="11" I2="0.0" ID="CMP-001.10.18" LOG_CI_END="0.13347216880006355" LOG_CI_START="-0.5955856716064241" LOG_EFFECT_SIZE="-0.23105675140318016" NO="18" P_CHI2="1.0" P_Z="0.21411718418110304" STUDIES="1" TAU2="0.0" TOTAL_1="26" TOTAL_2="28" WEIGHT="100.0" Z="1.242323684174532">
<NAME>tremor - 6 weeks</NAME>
<DICH_DATA CI_END="1.359791020044241" CI_START="0.2537548364156164" EFFECT_SIZE="0.5874125874125874" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="11" LOG_CI_END="0.13347216880006355" LOG_CI_START="-0.5955856716064241" LOG_EFFECT_SIZE="-0.23105675140318016" ORDER="1016" O_E="0.0" SE="0.4282521843492843" STUDY_ID="STD-Van-Der-Velde-1975" TOTAL_1="26" TOTAL_2="28" VAR="0.18339993339993338" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="126.47715552794979" CI_START="0.38742174264957774" DF="0" EFFECT_SIZE="7.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" I2="0.0" ID="CMP-001.10.19" LOG_CI_END="2.1020120897482624" LOG_CI_START="-0.41181600971974874" LOG_EFFECT_SIZE="0.8450980400142568" NO="19" P_CHI2="1.0" P_Z="0.18757050481968676" STUDIES="1" TAU2="0.0" TOTAL_1="18" TOTAL_2="18" WEIGHT="100.0" Z="1.3178003079716234">
<NAME>tremor - 12 weeks</NAME>
<DICH_DATA CI_END="126.47715552794979" CI_START="0.3874217426495779" EFFECT_SIZE="7.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="2.1020120897482624" LOG_CI_START="-0.4118160097197486" LOG_EFFECT_SIZE="0.8450980400142568" ORDER="1017" O_E="0.0" SE="1.4766350692772905" STUDY_ID="STD-Clark-1972" TOTAL_1="18" TOTAL_2="18" VAR="2.1804511278195484" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.400090824701129" CI_END="0.6558812765815417" CI_START="0.23478402371537044" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="RR" EFFECT_SIZE="0.39241616326979717" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="42" I2="0.0" I2_Q="0.0" ID="CMP-001.11" LOG_CI_END="-0.1831747667094639" LOG_CI_START="-0.6293314587375352" LOG_EFFECT_SIZE="-0.40625311272349957" METHOD="MH" NO="11" P_CHI2="0.7914606147346428" P_Q="0.9643848899711032" P_Z="3.578877981987956E-4" Q="0.27650529278567904" RANDOM="NO" SCALE="2.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="136" TOTAL_2="140" WEIGHT="400.0" Z="3.5693355440928896">
<NAME>Adverse effects: 6. Neurological</NAME>
<GROUP_LABEL_1>Loxapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Loxapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.9298810452226682" CI_END="1.0256786011801111" CI_START="0.140096794806976" DF="1" EFFECT_SIZE="0.3790702896923422" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="12" I2="48.183334797994206" ID="CMP-001.11.01" LOG_CI_END="0.011011294888061018" LOG_CI_START="-0.8535718005712346" LOG_EFFECT_SIZE="-0.42128025284158677" NO="1" P_CHI2="0.1647717232683067" P_Z="0.056128070708409424" STUDIES="2" TAU2="0.0" TOTAL_1="46" TOTAL_2="47" WEIGHT="100.0" Z="1.9100399424969128">
<NAME>ataxia - up to 6 weeks</NAME>
<DICH_DATA CI_END="66.10875420857639" CI_START="0.1234823648372944" EFFECT_SIZE="2.857142857142857" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.820258973142833" LOG_CI_START="-0.908395061843384" LOG_EFFECT_SIZE="0.4559319556497244" ORDER="1018" O_E="0.0" SE="1.602824887206216" STUDY_ID="STD-Charalampous-1974" TOTAL_1="20" TOTAL_2="19" VAR="2.5690476190476192" WEIGHT="4.244329665394116"/>
<DICH_DATA CI_END="0.8477561786854991" CI_START="0.08550242265763813" EFFECT_SIZE="0.2692307692307692" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="12" LOG_CI_END="-0.07172903627799276" LOG_CI_START="-1.0680215796351293" LOG_EFFECT_SIZE="-0.5698753079565612" ORDER="1019" O_E="0.0" SE="0.5852271716956096" STUDY_ID="STD-Van-Der-Velde-1975" TOTAL_1="26" TOTAL_2="28" VAR="0.3424908424908425" WEIGHT="95.75567033460588"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.1934928546641024" CI_END="0.9961442267351577" CI_START="0.210056846171945" DF="1" EFFECT_SIZE="0.4574351479722324" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="16" I2="0.0" ID="CMP-001.11.02" LOG_CI_END="-0.001677777700233731" LOG_CI_START="-0.6776631593711918" LOG_EFFECT_SIZE="-0.33967046853571276" NO="2" P_CHI2="0.66002531456208" P_Z="0.04887354952822813" STUDIES="2" TAU2="0.0" TOTAL_1="46" TOTAL_2="47" WEIGHT="100.0" Z="1.9696931412812668">
<NAME>dizziness - up to 6 weeks</NAME>
<DICH_DATA CI_END="3.382585190420412" CI_START="0.11858122960127374" EFFECT_SIZE="0.6333333333333333" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.5292487431155136" LOG_CI_START="-0.9259840506491807" LOG_EFFECT_SIZE="-0.1983676537668335" ORDER="1020" O_E="0.0" SE="0.8548109465758875" STUDY_ID="STD-Charalampous-1974" TOTAL_1="20" TOTAL_2="19" VAR="0.7307017543859649" WEIGHT="19.729630982827913"/>
<DICH_DATA CI_END="1.001119233425927" CI_START="0.17137081641047508" EFFECT_SIZE="0.41420118343195267" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="13" LOG_CI_END="4.858050868808376E-4" LOG_CI_START="-0.7660631342857144" LOG_EFFECT_SIZE="-0.3827886645994167" ORDER="1021" O_E="0.0" SE="0.45027464146590884" STUDY_ID="STD-Van-Der-Velde-1975" TOTAL_1="26" TOTAL_2="28" VAR="0.20274725274725275" WEIGHT="80.27036901717209"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.8876344932885878" CI_START="0.12369965099183801" DF="0" EFFECT_SIZE="0.33136094674556216" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="13" I2="0.0" ID="CMP-001.11.03" LOG_CI_END="-0.051765829520439344" LOG_CI_START="-0.9076315256945068" LOG_EFFECT_SIZE="-0.4796986776074731" NO="3" P_CHI2="1.0" P_Z="0.028016497060582783" STUDIES="1" TAU2="0.0" TOTAL_1="26" TOTAL_2="28" WEIGHT="100.0" Z="2.197055299084963">
<NAME>weakness - 6 weeks</NAME>
<DICH_DATA CI_END="0.8876344932885878" CI_START="0.12369965099183801" EFFECT_SIZE="0.33136094674556216" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="13" LOG_CI_END="-0.051765829520439344" LOG_CI_START="-0.9076315256945068" LOG_EFFECT_SIZE="-0.4796986776074731" ORDER="1022" O_E="0.0" SE="0.5027397465361703" STUDY_ID="STD-Van-Der-Velde-1975" TOTAL_1="26" TOTAL_2="28" VAR="0.25274725274725274" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="7.676698731922972" CI_START="0.014473814199463616" DF="0" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-001.11.04" LOG_CI_END="0.8851744972786274" LOG_CI_START="-1.8394170067179525" LOG_EFFECT_SIZE="-0.47712125471966244" NO="4" P_CHI2="1.0" P_Z="0.49243283298336993" STUDIES="1" TAU2="0.0" TOTAL_1="18" TOTAL_2="18" WEIGHT="100.0" Z="0.6864445360982625">
<NAME>seizures - 12 weeks</NAME>
<DICH_DATA CI_END="7.676698731922972" CI_START="0.014473814199463616" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8851744972786274" LOG_CI_START="-1.8394170067179525" LOG_EFFECT_SIZE="-0.47712125471966244" ORDER="1023" O_E="0.0" SE="1.6004385363930504" STUDY_ID="STD-Clark-1972" TOTAL_1="18" TOTAL_2="18" VAR="2.5614035087719293" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="13.762275418843195" CI_END="3.105015539117457" CI_START="1.1321338234015181" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="RR" EFFECT_SIZE="1.8749114949837427" ESTIMABLE="YES" EVENTS_1="44" EVENTS_2="20" I2="63.66879859740315" I2_Q="80.4383689503794" ID="CMP-001.12" LOG_CI_END="0.4920637779541702" LOG_CI_START="0.05389776548276627" LOG_EFFECT_SIZE="0.27298077171846824" METHOD="MH" NO="12" P_CHI2="0.017192157270019326" P_Q="0.006023759381705185" P_Z="0.014600278790717257" Q="10.224096318587863" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="119" TOTAL_2="104" WEIGHT="300.0" Z="2.4421450583188067">
<NAME>Adverse effects: 7. Sleep problems</NAME>
<GROUP_LABEL_1>Loxapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Loxapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.4517534938118908" CI_END="5.559517080026074" CI_START="1.0911015887188038" DF="1" EFFECT_SIZE="2.462924667651403" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="6" I2="31.11778244292114" ID="CMP-001.12.01" LOG_CI_END="0.7450370688143331" LOG_CI_START="0.03786518813740933" LOG_EFFECT_SIZE="0.3914511284758712" NO="1" P_CHI2="0.22824708611409628" P_Z="0.03001785519853445" STUDIES="2" TAU2="0.0" TOTAL_1="35" TOTAL_2="32" WEIGHT="100.0" Z="2.169854697236706">
<NAME>drowsiness - 4 weeks</NAME>
<DICH_DATA CI_END="4.184571382077925" CI_START="0.6987812449618162" EFFECT_SIZE="1.71" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="5" LOG_CI_END="0.6216509806252424" LOG_CI_START="-0.15565875984093466" LOG_EFFECT_SIZE="0.23299611039215382" ORDER="1024" O_E="0.0" SE="0.45659558929510335" STUDY_ID="STD-Charalampous-1974" TOTAL_1="20" TOTAL_2="19" VAR="0.2084795321637427" WEIGHT="82.7178729689808"/>
<DICH_DATA CI_END="43.036785334951176" CI_START="0.8551857244447738" EFFECT_SIZE="6.066666666666666" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="1" LOG_CI_END="1.6338398239168745" LOG_CI_START="-0.06793955738604981" LOG_EFFECT_SIZE="0.7829501332654123" ORDER="1025" O_E="0.0" SE="0.9996336325211348" STUDY_ID="STD-Clark-1975" TOTAL_1="15" TOTAL_2="13" VAR="0.9992673992673993" WEIGHT="17.2821270310192"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.3176499933379071" CI_END="27.894062582993843" CI_START="1.633412123617234" DF="1" EFFECT_SIZE="6.75" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="2" I2="0.0" ID="CMP-001.12.02" LOG_CI_END="1.4455117709489778" LOG_CI_START="0.2130957747130722" LOG_EFFECT_SIZE="0.829303772831025" NO="2" P_CHI2="0.5730234695611609" P_Z="0.008345693329649878" STUDIES="2" TAU2="0.0" TOTAL_1="43" TOTAL_2="31" WEIGHT="100.0" Z="2.6377546736757305">
<NAME>drowsiness - 12 weeks</NAME>
<DICH_DATA CI_END="32.393026779206984" CI_START="0.49393346626905393" EFFECT_SIZE="4.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" LOG_CI_END="1.5104515300445103" LOG_CI_START="-0.30633154738858576" LOG_EFFECT_SIZE="0.6020599913279624" ORDER="1026" O_E="0.0" SE="1.0671873729054748" STUDY_ID="STD-Clark-1972" TOTAL_1="18" TOTAL_2="18" VAR="1.1388888888888888" WEIGHT="43.18181818181818"/>
<DICH_DATA CI_END="59.232028702860184" CI_START="1.319313245069158" EFFECT_SIZE="8.84" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="1" LOG_CI_END="1.7725566075247747" LOG_CI_START="0.12034792250137129" LOG_EFFECT_SIZE="0.9464522650130731" ORDER="1027" O_E="0.0" SE="0.9705155601476402" STUDY_ID="STD-Clark-1977" TOTAL_1="25" TOTAL_2="13" VAR="0.9419004524886878" WEIGHT="56.81818181818182"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.4833220590876444" CI_END="1.3931685245819312" CI_START="0.2536589498990312" DF="1" EFFECT_SIZE="0.5944658652755727" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="12" I2="59.73136080596033" ID="CMP-001.12.03" LOG_CI_END="0.14400365401847098" LOG_CI_START="-0.5957498097779153" LOG_EFFECT_SIZE="-0.22587307787972213" NO="3" P_CHI2="0.11505926242870002" P_Z="0.2313480459364603" STUDIES="2" TAU2="0.0" TOTAL_1="41" TOTAL_2="41" WEIGHT="100.0" Z="1.1968936122300284">
<NAME>insomnia - up to 6 weeks</NAME>
<DICH_DATA CI_END="22.050810822496313" CI_START="0.3065646907234551" EFFECT_SIZE="2.6" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.3434245633848887" LOG_CI_START="-0.513477867443253" LOG_EFFECT_SIZE="0.414973347970818" ORDER="1028" O_E="0.0" SE="1.0907536796837267" STUDY_ID="STD-Clark-1975" TOTAL_1="15" TOTAL_2="13" VAR="1.1897435897435897" WEIGHT="9.185756407348604"/>
<DICH_DATA CI_END="1.0776195529261314" CI_START="0.1423110150160979" EFFECT_SIZE="0.3916083916083916" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="11" LOG_CI_END="0.03246546286608377" LOG_CI_START="-0.8467614837838066" LOG_EFFECT_SIZE="-0.4071480104588614" ORDER="1029" O_E="0.0" SE="0.5164622607057235" STUDY_ID="STD-Van-Der-Velde-1975" TOTAL_1="26" TOTAL_2="28" VAR="0.2667332667332668" WEIGHT="90.8142435926514"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="7.570610369952579" CI_END="1.4935524770973279" CI_START="0.3990890123213016" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7720494692277212" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="15" I2="33.95512705494948" I2_Q="60.22874050797526" ID="CMP-001.13" LOG_CI_END="0.17422048647373273" LOG_CI_START="-0.39893022900354025" LOG_EFFECT_SIZE="-0.11235487126490377" METHOD="MH" NO="13" P_CHI2="0.18154197911714565" P_Q="0.056460460936078705" P_Z="0.4422350873462726" Q="7.543135516242789" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="116" TOTAL_2="88" WEIGHT="400.0" Z="0.7684244134057184">
<NAME>Adverse effects: 8. Weight changes</NAME>
<GROUP_LABEL_1>Loxapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Loxapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.9423243908144285" CI_START="0.11345695312726019" DF="0" EFFECT_SIZE="0.5777777777777777" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" I2="0.0" ID="CMP-001.13.01" LOG_CI_END="0.46869055193139536" LOG_CI_START="-0.945168883540447" LOG_EFFECT_SIZE="-0.23823916580452575" NO="1" P_CHI2="1.0" P_Z="0.5089211293585906" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="13" WEIGHT="100.0" Z="0.6605185394938595">
<NAME>weight increase - 4 weeks</NAME>
<DICH_DATA CI_END="2.9423243908144285" CI_START="0.11345695312726019" EFFECT_SIZE="0.5777777777777777" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.46869055193139536" LOG_CI_START="-0.945168883540447" LOG_EFFECT_SIZE="-0.23823916580452575" ORDER="1030" O_E="0.0" SE="0.8305080311132396" STUDY_ID="STD-Clark-1975" TOTAL_1="15" TOTAL_2="13" VAR="0.6897435897435897" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.09066275908090704" CI_END="48.76544246786415" CI_START="0.9074339435869437" DF="1" EFFECT_SIZE="6.652173913043479" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="0" I2="0.0" ID="CMP-001.13.02" LOG_CI_END="1.6881121690927705" LOG_CI_START="-0.04218497949275858" LOG_EFFECT_SIZE="0.822963594800006" NO="2" P_CHI2="0.7633362960944007" P_Z="0.06226620096729774" STUDIES="2" TAU2="0.0" TOTAL_1="43" TOTAL_2="31" WEIGHT="100.0" Z="1.8643953816998344">
<NAME>weight increase - 12 weeks</NAME>
<DICH_DATA CI_END="155.8552614005574" CI_START="0.5197129649144481" EFFECT_SIZE="9.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="2.192721467881129" LOG_CI_START="-0.2842364490024794" LOG_EFFECT_SIZE="0.9542425094393249" ORDER="1031" O_E="0.0" SE="1.4549773415168654" STUDY_ID="STD-Clark-1972" TOTAL_1="18" TOTAL_2="18" VAR="2.116959064327485" WEIGHT="43.47826086956522"/>
<DICH_DATA CI_END="83.66079139373137" CI_START="0.28071939924717754" EFFECT_SIZE="4.846153846153846" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="1.9225219684959254" LOG_CI_START="-0.5517275742024357" LOG_EFFECT_SIZE="0.6853971971467449" ORDER="1032" O_E="0.0" SE="1.4533864291137826" STUDY_ID="STD-Clark-1977" TOTAL_1="25" TOTAL_2="13" VAR="2.1123321123321124" WEIGHT="56.52173913043479"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.9423243908144285" CI_START="0.11345695312726019" DF="0" EFFECT_SIZE="0.5777777777777777" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" I2="0.0" ID="CMP-001.13.03" LOG_CI_END="0.46869055193139536" LOG_CI_START="-0.945168883540447" LOG_EFFECT_SIZE="-0.23823916580452575" NO="3" P_CHI2="1.0" P_Z="0.5089211293585906" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="13" WEIGHT="100.0" Z="0.6605185394938595">
<NAME>weight loss - 4 weeks</NAME>
<DICH_DATA CI_END="2.9423243908144285" CI_START="0.11345695312726019" EFFECT_SIZE="0.5777777777777777" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.46869055193139536" LOG_CI_START="-0.945168883540447" LOG_EFFECT_SIZE="-0.23823916580452575" ORDER="1033" O_E="0.0" SE="0.8305080311132396" STUDY_ID="STD-Clark-1975" TOTAL_1="15" TOTAL_2="13" VAR="0.6897435897435897" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.6897242017569307" CI_END="0.8658435948532321" CI_START="0.06894821170229239" DF="1" EFFECT_SIZE="0.2443324937027708" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="9" I2="40.8187443276112" ID="CMP-001.13.04" LOG_CI_END="-0.06256055143166814" LOG_CI_START="-1.1614769935620723" LOG_EFFECT_SIZE="-0.6120187724968702" NO="4" P_CHI2="0.19363741248976074" P_Z="0.029026770378503864" STUDIES="2" TAU2="0.0" TOTAL_1="43" TOTAL_2="31" WEIGHT="100.0" Z="2.183122767061">
<NAME>weight loss - 12 weeks</NAME>
<DICH_DATA CI_END="1.2716585200924873" CI_START="0.004653104327790181" EFFECT_SIZE="0.07692307692307693" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="6" LOG_CI_END="0.10437050537709905" LOG_CI_START="-2.3322572099907726" LOG_EFFECT_SIZE="-1.1139433523068367" ORDER="1034" O_E="0.0" SE="1.4312871815088042" STUDY_ID="STD-Clark-1972" TOTAL_1="18" TOTAL_2="18" VAR="2.0485829959514166" WEIGHT="62.216624685138534"/>
<DICH_DATA CI_END="2.2239454859223513" CI_START="0.12158571408860558" EFFECT_SIZE="0.52" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.347124137472397" LOG_CI_START="-0.9151174502027987" LOG_EFFECT_SIZE="-0.28399665636520083" ORDER="1035" O_E="0.0" SE="0.7414469567970385" STUDY_ID="STD-Clark-1977" TOTAL_1="25" TOTAL_2="13" VAR="0.5497435897435896" WEIGHT="37.78337531486146"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="16.23932140147148" CI_END="0.8016267195419984" CI_START="0.3959793460655112" CI_STUDY="95" CI_TOTAL="95" DF="7" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5634071566752427" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="64" I2="56.89475054440565" I2_Q="57.99780701874408" ID="CMP-001.14" LOG_CI_END="-0.09602781548349867" LOG_CI_START="-0.402327465902025" LOG_EFFECT_SIZE="-0.24917764069276188" METHOD="MH" NO="14" P_CHI2="0.023017617897670206" P_Q="0.03612519499032307" P_Z="0.0014281616322365522" Q="11.904140343889477" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="256" TOTAL_2="246" WEIGHT="600.0" Z="3.188898197194522">
<NAME>Adverse effects: 9.Others</NAME>
<GROUP_LABEL_1>Loxapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Loxapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="3.8162518293290693" CI_END="1.1437340707771586" CI_START="0.3199610134930314" DF="1" EFFECT_SIZE="0.6049382716049383" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="17" I2="73.79627852872045" ID="CMP-001.14.01" LOG_CI_END="0.058325058530893384" LOG_CI_START="-0.49490293623116544" LOG_EFFECT_SIZE="-0.21828893885013606" NO="1" P_CHI2="0.05075770856342887" P_Z="0.12193596189407621" STUDIES="2" TAU2="0.0" TOTAL_1="41" TOTAL_2="39" WEIGHT="99.99999999999999" Z="1.5466985128030066">
<NAME>abnormal blood results - up to 6 weeks</NAME>
<DICH_DATA CI_END="2.910390044514067" CI_START="0.5058352163321738" EFFECT_SIZE="1.2133333333333334" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="5" LOG_CI_END="0.46395119614354247" LOG_CI_START="-0.29599093828475526" LOG_EFFECT_SIZE="0.08398012892939356" ORDER="1036" O_E="0.0" SE="0.4463937715374166" STUDY_ID="STD-Clark-1975" TOTAL_1="15" TOTAL_2="13" VAR="0.19926739926739928" WEIGHT="30.864197530864192"/>
<DICH_DATA CI_END="0.8992933901679381" CI_START="0.12355379493044168" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="12" LOG_CI_END="-0.04609859865163574" LOG_CI_START="-0.9081439107876892" LOG_EFFECT_SIZE="-0.47712125471966244" ORDER="1037" O_E="0.0" SE="0.5063696835418333" STUDY_ID="STD-Van-Der-Velde-1975" TOTAL_1="26" TOTAL_2="26" VAR="0.2564102564102564" WEIGHT="69.1358024691358"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.11949285095929889" CI_END="3.067736010443019" CI_START="0.7647131770632922" DF="1" EFFECT_SIZE="1.5316455696202531" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="8" I2="0.0" ID="CMP-001.14.02" LOG_CI_END="0.4868179843053916" LOG_CI_START="-0.11650142625337423" LOG_EFFECT_SIZE="0.18515827902600865" NO="2" P_CHI2="0.7295852423727347" P_Z="0.22896744901598398" STUDIES="2" TAU2="0.0" TOTAL_1="43" TOTAL_2="31" WEIGHT="100.0" Z="1.2030229824506757">
<NAME>abnormal blood results - 12 weeks</NAME>
<DICH_DATA CI_END="2.909786936500758" CI_START="0.7013628045855654" EFFECT_SIZE="1.4285714285714286" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="7" LOG_CI_END="0.46386118977983093" LOG_CI_START="-0.15405726980834458" LOG_EFFECT_SIZE="0.1549019599857432" ORDER="1038" O_E="0.0" SE="0.3629683619078001" STUDY_ID="STD-Clark-1972" TOTAL_1="18" TOTAL_2="18" VAR="0.13174603174603175" WEIGHT="84.17721518987342"/>
<DICH_DATA CI_END="16.754599922745168" CI_START="0.2582216239091872" EFFECT_SIZE="2.08" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" LOG_CI_END="1.2241340619284633" LOG_CI_START="-0.5880073920029403" LOG_EFFECT_SIZE="0.31806333496276157" ORDER="1039" O_E="0.0" SE="1.0644608602841736" STUDY_ID="STD-Clark-1977" TOTAL_1="25" TOTAL_2="13" VAR="1.133076923076923" WEIGHT="15.822784810126583"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="14.786473993825217" CI_START="0.06762937536140103" DF="0" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" I2="0.0" ID="CMP-001.14.03" LOG_CI_END="1.169864623787869" LOG_CI_START="-1.169864623787869" LOG_EFFECT_SIZE="0.0" NO="3" P_CHI2="1.0" P_Z="1.0" STUDIES="1" TAU2="0.0" TOTAL_1="18" TOTAL_2="18" WEIGHT="100.0" Z="0.0">
<NAME>eye pigments - 12 weeks</NAME>
<DICH_DATA CI_END="14.786473993825217" CI_START="0.06762937536140103" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.169864623787869" LOG_CI_START="-1.169864623787869" LOG_EFFECT_SIZE="0.0" ORDER="1040" O_E="0.0" SE="1.3743685418725535" STUDY_ID="STD-Clark-1972" TOTAL_1="18" TOTAL_2="18" VAR="1.8888888888888888" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.7538998363702472" CI_START="0.10939391929536171" DF="0" EFFECT_SIZE="0.28717948717948716" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="15" I2="0.0" ID="CMP-001.14.04" LOG_CI_END="-0.12268635094894535" LOG_CI_START="-0.9610068177636899" LOG_EFFECT_SIZE="-0.5418465843563176" NO="4" P_CHI2="1.0" P_Z="0.01128856695642486" STUDIES="1" TAU2="0.0" TOTAL_1="26" TOTAL_2="28" WEIGHT="100.0" Z="2.5336367952927765">
<NAME>headache - 6 weeks</NAME>
<DICH_DATA CI_END="0.7538998363702472" CI_START="0.10939391929536171" EFFECT_SIZE="0.28717948717948716" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="15" LOG_CI_END="-0.12268635094894535" LOG_CI_START="-0.9610068177636899" LOG_EFFECT_SIZE="-0.5418465843563176" ORDER="1041" O_E="0.0" SE="0.492433591960218" STUDY_ID="STD-Van-Der-Velde-1975" TOTAL_1="26" TOTAL_2="28" VAR="0.24249084249084252" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-001.14.05" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="5" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="18" TOTAL_2="18" WEIGHT="0.0" Z="0.0">
<NAME>lactation - 12 weeks</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="1042" O_E="0.0" SE="0.0" STUDY_ID="STD-Clark-1972" TOTAL_1="18" TOTAL_2="18" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-001.14.06" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="6" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="19" WEIGHT="0.0" Z="0.0">
<NAME>libido - decrease - 4 weeks</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="1043" O_E="0.0" SE="0.0" STUDY_ID="STD-Charalampous-1974" TOTAL_1="20" TOTAL_2="19" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.0776195529261314" CI_START="0.1423110150160979" DF="0" EFFECT_SIZE="0.3916083916083916" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="11" I2="0.0" ID="CMP-001.14.07" LOG_CI_END="0.03246546286608377" LOG_CI_START="-0.8467614837838066" LOG_EFFECT_SIZE="-0.4071480104588614" NO="7" P_CHI2="1.0" P_Z="0.06949001376241794" STUDIES="1" TAU2="0.0" TOTAL_1="26" TOTAL_2="28" WEIGHT="100.0" Z="1.8152206092342817">
<NAME>ringing in ears - 6 weeks</NAME>
<DICH_DATA CI_END="1.0776195529261314" CI_START="0.1423110150160979" EFFECT_SIZE="0.3916083916083916" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="11" LOG_CI_END="0.03246546286608377" LOG_CI_START="-0.8467614837838066" LOG_EFFECT_SIZE="-0.4071480104588614" ORDER="1044" O_E="0.0" SE="0.5164622607057235" STUDY_ID="STD-Van-Der-Velde-1975" TOTAL_1="26" TOTAL_2="28" VAR="0.2667332667332668" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.8477561786854991" CI_START="0.08550242265763813" DF="0" EFFECT_SIZE="0.2692307692307692" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="12" I2="0.0" ID="CMP-001.14.08" LOG_CI_END="-0.07172903627799276" LOG_CI_START="-1.0680215796351293" LOG_EFFECT_SIZE="-0.5698753079565612" NO="8" P_CHI2="1.0" P_Z="0.024949550334189496" STUDIES="2" TAU2="0.0" TOTAL_1="46" TOTAL_2="47" WEIGHT="99.99999999999999" Z="2.242182954636747">
<NAME>skin problems - rash, up to 6 weeks</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="1045" O_E="0.0" SE="0.0" STUDY_ID="STD-Charalampous-1974" TOTAL_1="20" TOTAL_2="19" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.8477561786854991" CI_START="0.08550242265763813" EFFECT_SIZE="0.2692307692307692" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="12" LOG_CI_END="-0.07172903627799276" LOG_CI_START="-1.0680215796351293" LOG_EFFECT_SIZE="-0.5698753079565612" ORDER="1046" O_E="0.0" SE="0.5852271716956096" STUDY_ID="STD-Van-Der-Velde-1975" TOTAL_1="26" TOTAL_2="28" VAR="0.3424908424908425" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-001.14.09" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="9" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="18" TOTAL_2="18" WEIGHT="0.0" Z="0.0">
<NAME>skin problems - rash, 12 weeks</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="1047" O_E="0.0" SE="0.0" STUDY_ID="STD-Clark-1972" TOTAL_1="18" TOTAL_2="18" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" NO="2">
<NAME>LOXAPINE versus TYPICAL ANTIPSYCHOTICS</NAME>
<DICH_OUTCOME CHI2="8.09504160017796" CI_END="1.3750544098372004" CI_START="0.8889422120899142" CI_STUDY="95" CI_TOTAL="95" DF="13" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1055966302520428" ESTIMABLE="YES" EVENTS_1="100" EVENTS_2="91" I2="0.0" I2_Q="0.0" ID="CMP-002.01" LOG_CI_END="0.1383198832023127" LOG_CI_START="-0.05112647051032506" LOG_EFFECT_SIZE="0.043596706345993795" METHOD="MH" NO="1" P_CHI2="0.837353819693885" P_Q="0.594657104701086" P_Z="0.3670138726142598" Q="0.2831299469046434" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="16" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="638" TOTAL_2="667" WEIGHT="99.99999999999997" Z="0.9020809596824299">
<NAME>Leaving the study early - any reason</NAME>
<GROUP_LABEL_1>Loxapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Typicals</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Loxapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Typicals</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.388465060513497" CI_END="1.3395890824077805" CI_START="0.8368369683493933" DF="6" EFFECT_SIZE="1.058781217511943" ESTIMABLE="YES" EVENTS_1="69" EVENTS_2="66" I2="0.0" ID="CMP-002.01.01" LOG_CI_END="0.1269715994012886" LOG_CI_START="-0.07735914253570049" LOG_EFFECT_SIZE="0.02480622843279405" NO="1" P_CHI2="0.966556349327437" P_Z="0.6341538925808745" STUDIES="7" TAU2="0.0" TOTAL_1="188" TOTAL_2="192" WEIGHT="71.58463461850899" Z="0.47588839407770456">
<NAME>short term - up to 6 weeks</NAME>
<DICH_DATA CI_END="3.653484112546019" CI_START="0.12164948053783173" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.5627072231227036" LOG_CI_START="-0.9148897412340662" LOG_EFFECT_SIZE="-0.17609125905568127" ORDER="1048" O_E="0.0" SE="0.8679477710861024" STUDY_ID="STD-Bagadia-1980" TOTAL_1="25" TOTAL_2="25" VAR="0.7533333333333332" WEIGHT="3.2734528189712515"/>
<DICH_DATA CI_END="3.1892264350131265" CI_START="0.12139636420189365" EFFECT_SIZE="0.6222222222222222" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.5036853552371823" LOG_CI_START="-0.9157943201034313" LOG_EFFECT_SIZE="-0.20605448243312446" ORDER="1049" O_E="0.0" SE="0.8338093878327919" STUDY_ID="STD-Clark-1975" TOTAL_1="15" TOTAL_2="14" VAR="0.6952380952380952" WEIGHT="3.386330502384053"/>
<DICH_DATA CI_END="3.1340734779695767" CI_START="0.34742225686833184" EFFECT_SIZE="1.0434782608695652" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="5" LOG_CI_END="0.4961091742329702" LOG_CI_START="-0.4591423628449439" LOG_EFFECT_SIZE="0.018483405694013133" ORDER="1050" O_E="0.0" SE="0.5611194814509367" STUDY_ID="STD-Fruensgaard-1978" TOTAL_1="23" TOTAL_2="24" VAR="0.31485507246376815" WEIGHT="5.339674811087856"/>
<DICH_DATA CI_END="1.7674143983202644" CI_START="0.8291060447462211" EFFECT_SIZE="1.2105263157894737" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="19" LOG_CI_END="0.24733838867124405" LOG_CI_START="-0.08138991854171623" LOG_EFFECT_SIZE="0.08297423506476391" ORDER="1051" O_E="0.0" SE="0.19309663488825723" STUDY_ID="STD-Kramer-1978" TOTAL_1="34" TOTAL_2="34" VAR="0.03728631040516892" WEIGHT="20.73186785348459"/>
<DICH_DATA CI_END="2.5175692499743505" CI_START="0.5556969943961211" EFFECT_SIZE="1.1827956989247312" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="9" LOG_CI_END="0.40098142538974635" LOG_CI_START="-0.2551619521811665" LOG_EFFECT_SIZE="0.07290973660428994" ORDER="1052" O_E="0.0" SE="0.38542186794725564" STUDY_ID="STD-Rifkin-1984" TOTAL_1="31" TOTAL_2="33" VAR="0.14855001629195178" WEIGHT="9.513472255135198"/>
<DICH_DATA CI_END="1.3591292864926254" CI_START="0.735765176969002" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="24" LOG_CI_END="0.13326077074257706" LOG_CI_START="-0.13326077074257708" LOG_EFFECT_SIZE="0.0" ORDER="1053" O_E="0.0" SE="0.15655607277128736" STUDY_ID="STD-Tuason-1984" TOTAL_1="34" TOTAL_2="34" VAR="0.024509803921568624" WEIGHT="26.187622551770012"/>
<DICH_DATA CI_END="4.868371145122238" CI_START="0.23822409570631606" EFFECT_SIZE="1.0769230769230769" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.6873836796924396" LOG_CI_START="-0.623014312949637" LOG_EFFECT_SIZE="0.032184683371401235" ORDER="1054" O_E="0.0" SE="0.7697342674526336" STUDY_ID="STD-Van-Der-Velde-1975" TOTAL_1="26" TOTAL_2="28" VAR="0.5924908424908425" WEIGHT="3.1522138256760197"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="6.786851385295442" CI_END="1.9733096681100357" CI_START="0.75864326948008" DF="6" EFFECT_SIZE="1.2235350825831064" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="25" I2="11.593761828942558" ID="CMP-002.01.02" LOG_CI_END="0.2951952436903253" LOG_CI_START="-0.11996239079150939" LOG_EFFECT_SIZE="0.08761642644940794" NO="2" P_CHI2="0.3410098939067526" P_Z="0.408080469534434" STUDIES="9" TAU2="0.0" TOTAL_1="450" TOTAL_2="475" WEIGHT="28.415365381490993" Z="0.8272763212425329">
<NAME>medium term - 7 - 26 weeks</NAME>
<DICH_DATA CI_END="130.00265237546364" CI_START="0.3556850506899904" EFFECT_SIZE="6.8" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="2.1139522130781967" LOG_CI_START="-0.4489343876657242" LOG_EFFECT_SIZE="0.8325089127062363" ORDER="1055" O_E="0.0" SE="1.505452275770258" STUDY_ID="STD-Huang-1997" TOTAL_1="104" TOTAL_2="101" VAR="2.2663865546218487" WEIGHT="0.5534823606956223"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="1056" O_E="0.0" SE="0.0" STUDY_ID="STD-Liu-2005" TOTAL_1="40" TOTAL_2="40" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="7.3944422052041405" CI_START="0.6273702769862677" EFFECT_SIZE="2.1538461538461537" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="3" LOG_CI_END="0.8689054188550851" LOG_CI_START="-0.20247606078432026" LOG_EFFECT_SIZE="0.33321467903538243" ORDER="1057" O_E="0.0" SE="0.6293347845640435" STUDY_ID="STD-Schiele-1975" TOTAL_1="26" TOTAL_2="24" VAR="0.39606227106227104" WEIGHT="3.4043909317301013"/>
<DICH_DATA CI_END="1.5416658771333782" CI_START="0.3430870642465096" EFFECT_SIZE="0.7272727272727273" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="11" LOG_CI_END="0.18799025994022903" LOG_CI_START="-0.4645956562727918" LOG_EFFECT_SIZE="-0.13830269816628143" ORDER="1058" O_E="0.0" SE="0.3833321975359122" STUDY_ID="STD-Selman-1976" TOTAL_1="29" TOTAL_2="29" VAR="0.1469435736677116" WEIGHT="12.00266033622792"/>
<DICH_DATA CI_END="2.3254889474370875" CI_START="0.15480615394743313" EFFECT_SIZE="0.6" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" LOG_CI_END="0.3665142797415406" LOG_CI_START="-0.8102117789742533" LOG_EFFECT_SIZE="-0.2218487496163564" ORDER="1059" O_E="0.0" SE="0.6912147117775906" STUDY_ID="STD-Seth-1979" TOTAL_1="36" TOTAL_2="36" VAR="0.47777777777777775" WEIGHT="5.455754698285419"/>
<DICH_DATA CI_END="5.7447841545307945" CI_START="0.5501501435293921" EFFECT_SIZE="1.7777777777777777" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="4" LOG_CI_END="0.7592737158341862" LOG_CI_START="-0.2595187694009864" LOG_EFFECT_SIZE="0.2498774732165999" ORDER="1060" O_E="0.0" SE="0.5984437489312765" STUDY_ID="STD-Tu-2004" TOTAL_1="126" TOTAL_2="112" VAR="0.35813492063492064" WEIGHT="4.621345156194708"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="1061" O_E="0.0" SE="0.0" STUDY_ID="STD-Vyas-1980" TOTAL_1="15" TOTAL_2="15" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="99.95416281504153" CI_START="0.25011464551267176" EFFECT_SIZE="5.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.9998008859974516" LOG_CI_START="-0.6018608773254143" LOG_EFFECT_SIZE="0.6989700043360189" ORDER="1062" O_E="0.0" SE="1.5282289982092807" STUDY_ID="STD-Wang-1996" TOTAL_1="30" TOTAL_2="30" VAR="2.335483870967742" WEIGHT="0.5455754698285419"/>
<DICH_DATA CI_END="8.066018618224573" CI_START="0.01939794648841313" EFFECT_SIZE="0.39555555555555555" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.9066592201242236" LOG_CI_START="-1.7122442430571228" LOG_EFFECT_SIZE="-0.40279251146644973" ORDER="1063" O_E="0.0" SE="1.5383568580539426" STUDY_ID="STD-Zhang-2005" TOTAL_1="44" TOTAL_2="88" VAR="2.366541822721598" WEIGHT="1.8321564285286855"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="7.463087505961312" CI_END="1.7918234072550736" CI_START="0.5419264958131574" CI_STUDY="95" CI_TOTAL="95" DF="10" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9854118835338521" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="19" I2="0.0" I2_Q="0.0" ID="CMP-002.02" LOG_CI_END="0.2532952056420748" LOG_CI_START="-0.26605961498845043" LOG_EFFECT_SIZE="-0.006382204673187825" METHOD="MH" NO="2" P_CHI2="0.6811219265109975" P_Q="1.0" P_Z="0.9615800517033732" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="11" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="377" TOTAL_2="416" WEIGHT="100.00000000000001" Z="0.0481708874338545">
<NAME>Removed from analysis</NAME>
<GROUP_LABEL_1>Loxapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Typicals</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Loxapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Typicals</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.556675830226646" CI_START="0.107806002130339" EFFECT_SIZE="0.525" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" LOG_CI_END="0.4076756658172201" LOG_CI_START="-0.9673570590053063" LOG_EFFECT_SIZE="-0.2798406965940431" ORDER="1064" O_E="0.0" SE="0.8077010290825141" STUDY_ID="STD-Charalampous-1974" TOTAL_1="20" TOTAL_2="21" VAR="0.6523809523809523" WEIGHT="19.229454056434722"/>
<DICH_DATA CI_END="3.1892264350131265" CI_START="0.12139636420189365" EFFECT_SIZE="0.6222222222222222" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.5036853552371823" LOG_CI_START="-0.9157943201034313" LOG_EFFECT_SIZE="-0.20605448243312446" ORDER="1065" O_E="0.0" SE="0.8338093878327919" STUDY_ID="STD-Clark-1975" TOTAL_1="15" TOTAL_2="14" VAR="0.6952380952380952" WEIGHT="15.292389109535373"/>
<DICH_DATA CI_END="130.00265237546364" CI_START="0.3556850506899904" EFFECT_SIZE="6.8" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="2.1139522130781967" LOG_CI_START="-0.4489343876657242" LOG_EFFECT_SIZE="0.8325089127062363" ORDER="1066" O_E="0.0" SE="1.505452275770258" STUDY_ID="STD-Huang-1997" TOTAL_1="104" TOTAL_2="101" VAR="2.2663865546218487" WEIGHT="2.4994806676615786"/>
<DICH_DATA CI_END="15.180224957567825" CI_START="0.06587517660609293" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1812782074689785" LOG_CI_START="-1.1812782074689785" LOG_EFFECT_SIZE="0.0" ORDER="1067" O_E="0.0" SE="1.387777332977422" STUDY_ID="STD-Malik-1980" TOTAL_1="27" TOTAL_2="27" VAR="1.925925925925926" WEIGHT="4.927547601961398"/>
<DICH_DATA CI_END="70.73632649924677" CI_START="0.127233070268299" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8496425021491938" LOG_CI_START="-0.8953999927098687" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="1068" O_E="0.0" SE="1.61245154965971" STUDY_ID="STD-Moore-1975" TOTAL_1="29" TOTAL_2="29" VAR="2.6" WEIGHT="2.463773800980699"/>
<DICH_DATA CI_END="31.94408505268964" CI_START="0.4616065846205367" EFFECT_SIZE="3.84" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" LOG_CI_END="1.504390453518131" LOG_CI_START="-0.3357280047830692" LOG_EFFECT_SIZE="0.5843312243675308" ORDER="1069" O_E="0.0" SE="1.0808946911393973" STUDY_ID="STD-Moyano-1975" TOTAL_1="25" TOTAL_2="24" VAR="1.1683333333333332" WEIGHT="5.028109797919794"/>
<DICH_DATA CI_END="6.048181889024459" CI_START="0.14088051939433233" EFFECT_SIZE="0.9230769230769231" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.781624843374736" LOG_CI_START="-0.8511490558931599" LOG_EFFECT_SIZE="-0.03476210625921192" ORDER="1070" O_E="0.0" SE="0.959099470791114" STUDY_ID="STD-Schiele-1975" TOTAL_1="26" TOTAL_2="24" VAR="0.9198717948717949" WEIGHT="10.249299012079709"/>
<DICH_DATA CI_END="3.0199847904557613" CI_START="0.03679194394033447" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.48000475572610146" LOG_CI_START="-1.4342472651654263" LOG_EFFECT_SIZE="-0.47712125471966244" ORDER="1071" O_E="0.0" SE="1.124441112772009" STUDY_ID="STD-Selman-1976" TOTAL_1="29" TOTAL_2="29" VAR="1.2643678160919538" WEIGHT="14.782642805884194"/>
<DICH_DATA CI_END="22.36744584945718" CI_START="0.2074020111934439" EFFECT_SIZE="2.1538461538461537" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3496163946099329" LOG_CI_START="-0.683187036539168" LOG_EFFECT_SIZE="0.33321467903538243" ORDER="1072" O_E="0.0" SE="1.1940787979962526" STUDY_ID="STD-Van-Der-Velde-1975" TOTAL_1="26" TOTAL_2="28" VAR="1.4258241758241756" WEIGHT="4.74504583892579"/>
<DICH_DATA CI_END="3.8843813103531986" CI_START="0.009683006254130959" EFFECT_SIZE="0.19393939393939394" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.5893218558533486" LOG_CI_START="-2.013989787641349" LOG_EFFECT_SIZE="-0.7123339658940003" ORDER="1073" O_E="0.0" SE="1.5291981459892532" STUDY_ID="STD-Wang-2005b" TOTAL_1="32" TOTAL_2="31" VAR="2.3384469696969696" WEIGHT="12.508390066517393"/>
<DICH_DATA CI_END="8.066018618224573" CI_START="0.01939794648841313" EFFECT_SIZE="0.39555555555555555" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.9066592201242236" LOG_CI_START="-1.7122442430571228" LOG_EFFECT_SIZE="-0.40279251146644973" ORDER="1074" O_E="0.0" SE="1.5383568580539426" STUDY_ID="STD-Zhang-2005" TOTAL_1="44" TOTAL_2="88" VAR="2.366541822721598" WEIGHT="8.273867242099362"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="9.34041910052205" CI_END="1.0894609616208606" CI_START="0.677163995046417" CI_STUDY="95" CI_TOTAL="95" DF="11" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8589200994378308" ESTIMABLE="YES" EVENTS_1="76" EVENTS_2="88" I2="0.0" I2_Q="0.0" ID="CMP-002.03" LOG_CI_END="0.03721167289673427" LOG_CI_START="-0.169306141479168" LOG_EFFECT_SIZE="-0.06604723429121688" METHOD="MH" NO="3" P_CHI2="0.5905016802863448" P_Q="0.86035052103548" P_Z="0.20997043033454366" Q="0.030950672705482386" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="13" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="292" TOTAL_2="288" WEIGHT="100.00000000000001" Z="1.2536468186094551">
<NAME>Global effect: 1. Not improved (CGI)</NAME>
<GROUP_LABEL_1>Loxapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Typicals</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Loxapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Typicals</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="5.2132002559623585" CI_END="1.2091071166600469" CI_START="0.584505076174049" DF="5" EFFECT_SIZE="0.8406719023055103" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="45" I2="4.089623369417287" ID="CMP-002.03.01" LOG_CI_END="0.08246477738159115" LOG_CI_START="-0.23321171282582656" LOG_EFFECT_SIZE="-0.07537346772211773" NO="1" P_CHI2="0.3904193320863325" P_Z="0.34929706200184674" STUDIES="6" TAU2="0.0" TOTAL_1="146" TOTAL_2="148" WEIGHT="50.26954209705765" Z="0.9359536532364279">
<NAME>short term - up to 6 weeks</NAME>
<DICH_DATA CI_END="3.03463899113354" CI_START="0.2870559277911742" EFFECT_SIZE="0.9333333333333333" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" LOG_CI_END="0.48210703363731067" LOG_CI_START="-0.5420334803921971" LOG_EFFECT_SIZE="-0.02996322337744321" ORDER="1075" O_E="0.0" SE="0.6015852075182384" STUDY_ID="STD-Clark-1975" TOTAL_1="15" TOTAL_2="14" VAR="0.36190476190476195" WEIGHT="4.661277273197564"/>
<DICH_DATA CI_END="2.5530005934144993" CI_START="0.48357525040109794" EFFECT_SIZE="1.1111111111111112" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="7" LOG_CI_END="0.4070509157508279" LOG_CI_START="-0.31553593462947754" LOG_EFFECT_SIZE="0.04575749056067514" ORDER="1076" O_E="0.0" SE="0.4244510927759877" STUDY_ID="STD-Fruensgaard-1978" TOTAL_1="18" TOTAL_2="20" VAR="0.18015873015873013" WEIGHT="7.470310156256096"/>
<DICH_DATA CI_END="5.39978681433592" CI_START="0.32923110465360345" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.732376614047939" LOG_CI_START="-0.48249914083133916" LOG_EFFECT_SIZE="0.12493873660829993" ORDER="1077" O_E="0.0" SE="0.7136240321480628" STUDY_ID="STD-Malik-1980" TOTAL_1="27" TOTAL_2="27" VAR="0.5092592592592593" WEIGHT="3.379426023068234"/>
<DICH_DATA CI_END="1.059653229050268" CI_START="0.26843163088304134" EFFECT_SIZE="0.5333333333333333" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="15" LOG_CI_END="0.025163765878670193" LOG_CI_START="-0.5711663100061456" LOG_EFFECT_SIZE="-0.27300127206373764" ORDER="1078" O_E="0.0" SE="0.3502872384562237" STUDY_ID="STD-Moore-1975" TOTAL_1="29" TOTAL_2="29" VAR="0.12270114942528733" WEIGHT="16.89713011534117"/>
<DICH_DATA CI_END="1.4184255645972876" CI_START="0.1197217897981049" EFFECT_SIZE="0.41208791208791207" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="7" LOG_CI_END="0.15180655004878463" LOG_CI_START="-0.9218267992355342" LOG_EFFECT_SIZE="-0.38501012459337475" ORDER="1079" O_E="0.0" SE="0.6306575439404002" STUDY_ID="STD-Pool-1976" TOTAL_1="26" TOTAL_2="25" VAR="0.39772893772893775" WEIGHT="8.03994164965253"/>
<DICH_DATA CI_END="2.7050608155369376" CI_START="0.6257888345448348" EFFECT_SIZE="1.3010752688172043" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="9" LOG_CI_END="0.43217703341863495" LOG_CI_START="-0.203572189893605" LOG_EFFECT_SIZE="0.11430242176251496" ORDER="1080" O_E="0.0" SE="0.37344224078301946" STUDY_ID="STD-Rifkin-1984" TOTAL_1="31" TOTAL_2="33" VAR="0.13945910720104268" WEIGHT="9.821456879542055"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="4.113256484709383" CI_END="1.1930410812088503" CI_START="0.6452177563431192" DF="5" EFFECT_SIZE="0.8773661092398904" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="43" I2="0.0" ID="CMP-002.03.02" LOG_CI_END="0.07665539843575299" LOG_CI_START="-0.1902936893678176" LOG_EFFECT_SIZE="-0.05681914546603233" NO="2" P_CHI2="0.533227923908437" P_Z="0.4040880420956541" STUDIES="7" TAU2="0.0" TOTAL_1="146" TOTAL_2="140" WEIGHT="49.73045790294236" Z="0.8343424557997394">
<NAME>medium term - 7 - 26 weeks</NAME>
<DICH_DATA CI_END="3.303025227094486" CI_START="0.13455678170384458" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.5189118906596525" LOG_CI_START="-0.871094408771015" LOG_EFFECT_SIZE="-0.17609125905568127" ORDER="1081" O_E="0.0" SE="0.8164965809277259" STUDY_ID="STD-Bishop-1970" TOTAL_1="12" TOTAL_2="12" VAR="0.6666666666666665" WEIGHT="3.379426023068234"/>
<DICH_DATA CI_END="1.6988130306654883" CI_START="0.3311135421298528" EFFECT_SIZE="0.75" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="8" LOG_CI_END="0.23014558356682463" LOG_CI_START="-0.4800230567834245" LOG_EFFECT_SIZE="-0.12493873660829995" ORDER="1082" O_E="0.0" SE="0.41715657473320156" STUDY_ID="STD-Clark-1972" TOTAL_1="17" TOTAL_2="17" VAR="0.1740196078431372" WEIGHT="9.011802728181957"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="1083" O_E="0.0" SE="0.0" STUDY_ID="STD-Dube-1976" TOTAL_1="26" TOTAL_2="26" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="12.629792597014145" CI_START="0.05586790080518132" EFFECT_SIZE="0.84" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1013962187491655" LOG_CI_START="-1.2528376466254023" LOG_EFFECT_SIZE="-0.07572071393811836" ORDER="1084" O_E="0.0" SE="1.3828886261666022" STUDY_ID="STD-Kiloh-1976" TOTAL_1="25" TOTAL_2="21" VAR="1.9123809523809523" WEIGHT="1.224429718502983"/>
<DICH_DATA CI_END="1.0857254047276859" CI_START="0.3856270833160418" EFFECT_SIZE="0.6470588235294118" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="17" LOG_CI_END="0.03571999993891077" LOG_CI_START="-0.4138324723790085" LOG_EFFECT_SIZE="-0.18905623622004886" ORDER="1085" O_E="0.0" SE="0.26406934756017325" STUDY_ID="STD-Moyano-1975" TOTAL_1="25" TOTAL_2="25" VAR="0.06973262032085559" WEIGHT="19.150080797386657"/>
<DICH_DATA CI_END="1.7383166945039312" CI_START="0.7227509277193503" EFFECT_SIZE="1.120879120879121" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="14" LOG_CI_END="0.24012890108044532" LOG_CI_START="-0.1410113421987974" LOG_EFFECT_SIZE="0.049558779440823965" ORDER="1086" O_E="0.0" SE="0.22388366557685932" STUDY_ID="STD-Schiele-1975" TOTAL_1="26" TOTAL_2="24" VAR="0.05012389571213099" WEIGHT="16.401480965291164"/>
<DICH_DATA CI_END="96.12715085961011" CI_START="0.260072204121721" EFFECT_SIZE="5.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.982846070323241" LOG_CI_START="-0.5849060616512035" LOG_EFFECT_SIZE="0.6989700043360189" ORDER="1087" O_E="0.0" SE="1.5083103128998356" STUDY_ID="STD-Vyas-1980" TOTAL_1="15" TOTAL_2="15" VAR="2.275" WEIGHT="0.5632376705113723"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="4.786920352026763" CI_END="1.5950213417214418" CI_START="0.8732852226190044" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1802154750244858" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="22" I2="79.1097422463567" I2_Q="0.0" ID="CMP-002.04" LOG_CI_END="0.20276649838370048" LOG_CI_START="-0.058843888735746655" LOG_EFFECT_SIZE="0.07196130482397693" METHOD="MH" NO="4" P_CHI2="0.028676756001199122" P_Q="1.0" P_Z="0.2809192673636861" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="39" TOTAL_2="34" WEIGHT="100.0" Z="1.078256618848287">
<NAME>Global effect: 2. Not ready for discharge - up to 4 weeks</NAME>
<GROUP_LABEL_1>Loxapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Typicals</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Loxapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Typicals</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.3045651993521403" CI_START="1.0437014807614955" EFFECT_SIZE="1.8571428571428572" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="7" LOG_CI_END="0.519114324958006" LOG_CI_START="0.018576299627153958" LOG_EFFECT_SIZE="0.26884531229257996" ORDER="1088" O_E="0.0" SE="0.29401851378252775" STUDY_ID="STD-Shopsin-1972" TOTAL_1="15" TOTAL_2="15" VAR="0.08644688644688646" WEIGHT="29.48090107737512"/>
<DICH_DATA CI_END="1.2683315466805036" CI_START="0.6346981734833144" EFFECT_SIZE="0.8972222222222223" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="15" LOG_CI_END="0.10323279461241287" LOG_CI_START="-0.19743275148478162" LOG_EFFECT_SIZE="-0.04709997843618436" ORDER="1089" O_E="0.0" SE="0.17661243009594849" STUDY_ID="STD-Simpson-1976" TOTAL_1="24" TOTAL_2="19" VAR="0.031191950464396295" WEIGHT="70.51909892262488"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.532368119472444" CI_END="2.1216450619265235" CI_START="0.6169709466856245" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1441124780316345" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="9" I2="60.511270367424885" I2_Q="0.0" ID="CMP-002.05" LOG_CI_END="0.3266727308659899" LOG_CI_START="-0.20973528651974827" LOG_EFFECT_SIZE="0.0584687221731208" METHOD="MH" NO="5" P_CHI2="0.11153303419573035" P_Q="1.0" P_Z="0.669179796072318" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="44" TOTAL_2="43" WEIGHT="100.0" Z="0.4272739629802637">
<NAME>Global effect: 3. Needing additional antipsychotic/sedative drugs - up to 6 weeks</NAME>
<GROUP_LABEL_1>Loxapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Typicals</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Loxapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Typicals</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.5324067807171424" CI_START="0.449153143290902" EFFECT_SIZE="0.8296296296296296" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="9" LOG_CI_END="0.1853740650165498" LOG_CI_START="-0.34760555666619875" LOG_EFFECT_SIZE="-0.08111574582482452" ORDER="1090" O_E="0.0" SE="0.3130748680681236" STUDY_ID="STD-Clark-1975" TOTAL_1="15" TOTAL_2="14" VAR="0.09801587301587303" WEIGHT="94.90333919156414"/>
<DICH_DATA CI_END="129.74412565322564" CI_START="0.3776664242276759" EFFECT_SIZE="7.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="2.1130877036754665" LOG_CI_START="-0.4228916236469528" LOG_EFFECT_SIZE="0.8450980400142568" ORDER="1091" O_E="0.0" SE="1.4896468101693163" STUDY_ID="STD-Moore-1975" TOTAL_1="29" TOTAL_2="29" VAR="2.219047619047619" WEIGHT="5.0966608084358525"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.411395097283723" CI_END="1.3839896839170844" CI_START="0.9013274529965933" CI_STUDY="95" CI_TOTAL="95" DF="7" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1168831168831168" ESTIMABLE="YES" EVENTS_1="86" EVENTS_2="77" I2="0.0" I2_Q="0.0" ID="CMP-002.06" LOG_CI_END="0.1411328529570233" LOG_CI_START="-0.045117400814851646" LOG_EFFECT_SIZE="0.048007726071085825" METHOD="MH" NO="6" P_CHI2="0.9336200506485621" P_Q="0.7527882381730797" P_Z="0.3123048028327433" Q="1.9073853389764304" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="233" TOTAL_2="233" WEIGHT="500.0" Z="1.010397700657539">
<NAME>Global effect: 4. Participant rating of illness</NAME>
<GROUP_LABEL_1>Loxapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Typicals</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Loxapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Typicals</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.497084228310096" CI_END="2.2110351205386047" CI_START="0.6851057612505417" DF="1" EFFECT_SIZE="1.2307692307692308" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="13" I2="0.0" ID="CMP-002.06.01" LOG_CI_END="0.3445956410567685" LOG_CI_START="-0.16424238035859248" LOG_EFFECT_SIZE="0.09017663034908803" NO="1" P_CHI2="0.48078414695246763" P_Z="0.4872481100831345" STUDIES="2" TAU2="0.0" TOTAL_1="52" TOTAL_2="52" WEIGHT="100.0" Z="0.6946923786857511">
<NAME>did not feel better - 4 weeks</NAME>
<DICH_DATA CI_END="9.948749291495155" CI_START="0.4020605890048373" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" LOG_CI_END="0.9977684867815639" LOG_CI_START="-0.3957084954536016" LOG_EFFECT_SIZE="0.3010299956639812" ORDER="1092" O_E="0.0" SE="0.818535277187245" STUDY_ID="STD-Bagadia-1980" TOTAL_1="25" TOTAL_2="25" VAR="0.6699999999999999" WEIGHT="15.384615384615385"/>
<DICH_DATA CI_END="2.028563491478506" CI_START="0.5866627540263551" EFFECT_SIZE="1.0909090909090908" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="11" LOG_CI_END="0.3071886051225451" LOG_CI_START="-0.23161148334374557" LOG_EFFECT_SIZE="0.037788560889399754" ORDER="1093" O_E="0.0" SE="0.3164938390685515" STUDY_ID="STD-Malik-1980" TOTAL_1="27" TOTAL_2="27" VAR="0.10016835016835018" WEIGHT="84.61538461538461"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.3655049485987585" CI_START="0.7323298249678047" DF="0" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="19" I2="0.0" ID="CMP-002.06.02" LOG_CI_END="0.1352932783646131" LOG_CI_START="-0.1352932783646131" LOG_EFFECT_SIZE="0.0" NO="2" P_CHI2="1.0" P_Z="1.0" STUDIES="1" TAU2="0.0" TOTAL_1="25" TOTAL_2="25" WEIGHT="100.0" Z="0.0">
<NAME>much, or very much better - 4 weeks</NAME>
<DICH_DATA CI_END="1.3655049485987583" CI_START="0.7323298249678047" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="19" LOG_CI_END="0.13529327836461305" LOG_CI_START="-0.1352932783646131" LOG_EFFECT_SIZE="0.0" ORDER="1094" O_E="0.0" SE="0.15894388284780522" STUDY_ID="STD-Bagadia-1980" TOTAL_1="25" TOTAL_2="25" VAR="0.025263157894736828" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.0065554000778807" CI_START="0.03695628263102449" DF="0" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" I2="0.0" ID="CMP-002.06.03" LOG_CI_END="0.47806921075143305" LOG_CI_START="-1.432311720190758" LOG_EFFECT_SIZE="-0.47712125471966244" NO="3" P_CHI2="1.0" P_Z="0.3275753315601371" STUDIES="2" TAU2="0.0" TOTAL_1="52" TOTAL_2="52" WEIGHT="100.0" Z="0.9790094324778388">
<NAME>worse - 4 weeks</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="1095" O_E="0.0" SE="0.0" STUDY_ID="STD-Bagadia-1980" TOTAL_1="25" TOTAL_2="25" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="3.0065554000778807" CI_START="0.03695628263102449" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.47806921075143305" LOG_CI_START="-1.432311720190758" LOG_EFFECT_SIZE="-0.47712125471966244" ORDER="1096" O_E="0.0" SE="1.1221672153735642" STUDY_ID="STD-Malik-1980" TOTAL_1="27" TOTAL_2="27" VAR="1.2592592592592593" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.015851139219241632" CI_END="1.808419231511" CI_START="0.7836864015798775" DF="1" EFFECT_SIZE="1.1904761904761905" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="21" I2="0.0" ID="CMP-002.06.04" LOG_CI_END="0.2572991168618671" LOG_CI_START="-0.10585768898563049" LOG_EFFECT_SIZE="0.07572071393811834" NO="4" P_CHI2="0.8998100514993101" P_Z="0.4137386282113399" STUDIES="2" TAU2="0.0" TOTAL_1="52" TOTAL_2="52" WEIGHT="100.0" Z="0.8173321816510006">
<NAME>would not prefer to stay on medication - 4 weeks</NAME>
<DICH_DATA CI_END="2.672538003920275" CI_START="0.4887198786560473" EFFECT_SIZE="1.1428571428571428" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="7" LOG_CI_END="0.426923889662112" LOG_CI_START="-0.31093999570673847" LOG_EFFECT_SIZE="0.05799194697768673" ORDER="1097" O_E="0.0" SE="0.43342489875080187" STUDY_ID="STD-Bagadia-1980" TOTAL_1="25" TOTAL_2="25" VAR="0.18785714285714283" WEIGHT="33.333333333333336"/>
<DICH_DATA CI_END="1.9322880182732507" CI_START="0.7630797179170082" EFFECT_SIZE="1.2142857142857142" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="14" LOG_CI_END="0.286071860911777" LOG_CI_START="-0.11743008951170529" LOG_EFFECT_SIZE="0.08432088570003587" ORDER="1098" O_E="0.0" SE="0.2370190430456212" STUDY_ID="STD-Malik-1980" TOTAL_1="27" TOTAL_2="27" VAR="0.056178026766262046" WEIGHT="66.66666666666667"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.015851139219241632" CI_END="1.808419231511" CI_START="0.7836864015798775" DF="1" EFFECT_SIZE="1.1904761904761905" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="21" I2="0.0" ID="CMP-002.06.05" LOG_CI_END="0.2572991168618671" LOG_CI_START="-0.10585768898563049" LOG_EFFECT_SIZE="0.07572071393811834" NO="5" P_CHI2="0.8998100514993101" P_Z="0.4137386282113399" STUDIES="2" TAU2="0.0" TOTAL_1="52" TOTAL_2="52" WEIGHT="100.0" Z="0.8173321816510006">
<NAME>prefer another medication - 4 weeks</NAME>
<DICH_DATA CI_END="2.672538003920275" CI_START="0.4887198786560473" EFFECT_SIZE="1.1428571428571428" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="7" LOG_CI_END="0.426923889662112" LOG_CI_START="-0.31093999570673847" LOG_EFFECT_SIZE="0.05799194697768673" ORDER="1099" O_E="0.0" SE="0.43342489875080187" STUDY_ID="STD-Bagadia-1980" TOTAL_1="25" TOTAL_2="25" VAR="0.18785714285714283" WEIGHT="33.333333333333336"/>
<DICH_DATA CI_END="1.9322880182732507" CI_START="0.7630797179170082" EFFECT_SIZE="1.2142857142857142" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="14" LOG_CI_END="0.286071860911777" LOG_CI_START="-0.11743008951170529" LOG_EFFECT_SIZE="0.08432088570003587" ORDER="1100" O_E="0.0" SE="0.2370190430456212" STUDY_ID="STD-Malik-1980" TOTAL_1="27" TOTAL_2="27" VAR="0.056178026766262046" WEIGHT="66.66666666666667"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.044093749008121" CI_END="1.0520389551147462" CI_START="0.7593557629890377" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8937963098241949" ESTIMABLE="YES" EVENTS_1="162" EVENTS_2="193" I2="0.0" I2_Q="100.0" ID="CMP-002.07" LOG_CI_END="0.02203182126082947" LOG_CI_START="-0.11955470670813843" LOG_EFFECT_SIZE="-0.048761442723654465" METHOD="MH" NO="7" P_CHI2="0.8430108497646137" P_Q="0.0" P_Z="0.1770170468001193" Q="2.78433455764245E-32" RANDOM="NO" SCALE="5.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="444" TOTAL_2="471" WEIGHT="99.99999999999999" Z="1.3499966832087587">
<NAME>Mental state: 1a. General - not improved, by 8 weeks (BPRS/PANSS)</NAME>
<GROUP_LABEL_1>Loxapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Typicals</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Loxapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Typicals</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.0828354006237952" CI_START="0.5907066391325929" EFFECT_SIZE="0.7997737556561086" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="51" LOG_CI_END="0.03456244551392429" LOG_CI_START="-0.22862814794627165" LOG_EFFECT_SIZE="-0.09703285121617365" ORDER="1101" O_E="0.0" SE="0.15459945741296827" STUDY_ID="STD-Huang-1997" TOTAL_1="104" TOTAL_2="101" VAR="0.02390099223238419" WEIGHT="28.128816636623174"/>
<DICH_DATA CI_END="1.486837648556294" CI_START="0.4304437681016716" EFFECT_SIZE="0.8" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="15" LOG_CI_END="0.17226354943286248" LOG_CI_START="-0.36608357544897524" LOG_EFFECT_SIZE="-0.09691001300805639" ORDER="1102" O_E="0.0" SE="0.31622776601683794" STUDY_ID="STD-Liu-2005" TOTAL_1="40" TOTAL_2="40" VAR="0.1" WEIGHT="8.153856632505304"/>
<DICH_DATA CI_END="1.353194222816237" CI_START="0.7626384793685905" EFFECT_SIZE="1.0158730158730158" ESTIMABLE="YES" EVENTS_1="56" EVENTS_2="49" LOG_CI_END="0.1313601349891435" LOG_CI_START="-0.11768128592853262" LOG_EFFECT_SIZE="0.006839424530305442" ORDER="1103" O_E="0.0" SE="0.14628816342195844" STUDY_ID="STD-Tu-2004" TOTAL_1="126" TOTAL_2="112" VAR="0.021400226757369616" WEIGHT="28.20275117595952"/>
<DICH_DATA CI_END="1.5936403131049317" CI_START="0.3074721415934314" EFFECT_SIZE="0.7" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="10" LOG_CI_END="0.2023903072352323" LOG_CI_START="-0.5121942272067187" LOG_EFFECT_SIZE="-0.1549019599857432" ORDER="1104" O_E="0.0" SE="0.4197504927816955" STUDY_ID="STD-Wang-1996" TOTAL_1="30" TOTAL_2="30" VAR="0.1761904761904762" WEIGHT="5.435904421670203"/>
<DICH_DATA CI_END="1.353856652944612" CI_START="0.5547936773641868" EFFECT_SIZE="0.8666666666666667" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="30" LOG_CI_END="0.13157268345486917" LOG_CI_START="-0.2558684969525582" LOG_EFFECT_SIZE="-0.06214790674884446" ORDER="1105" O_E="0.0" SE="0.22758486723609675" STUDY_ID="STD-Xue-2004" TOTAL_1="100" TOTAL_2="100" VAR="0.051794871794871786" WEIGHT="16.30771326501061"/>
<DICH_DATA CI_END="1.5145335530585005" CI_START="0.6602692941206657" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="38" LOG_CI_END="0.18027889915896575" LOG_CI_START="-0.18027889915896578" LOG_EFFECT_SIZE="0.0" ORDER="1106" O_E="0.0" SE="0.21179343552183938" STUDY_ID="STD-Zhang-2005" TOTAL_1="44" TOTAL_2="88" VAR="0.04485645933014354" WEIGHT="13.770957868231179"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.19312801332769725" CI_END="-0.6717586563081044" CI_START="-2.9192118270357894" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.795485241671947" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.08" NO="8" P_CHI2="0.9079518453390318" P_Q="1.0" P_Z="0.0017384379834300408" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="234" TOTAL_2="231" UNITS="" WEIGHT="100.00000000000001" Z="3.1316215654992217">
<NAME>Mental state: 1b. General - average endpoint score, by 8 weeks (BPRS, high score=worse)</NAME>
<GROUP_LABEL_1>Loxapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Typicals</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Loxapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Typicals</GRAPH_LABEL_2>
<CONT_DATA CI_END="1.0516297588747867" CI_START="-4.451629758874793" EFFECT_SIZE="-1.7000000000000028" ESTIMABLE="YES" MEAN_1="26.9" MEAN_2="28.6" ORDER="1107" SD_1="10.3" SD_2="9.8" SE="1.4039185314522582" STUDY_ID="STD-Huang-1997" TOTAL_1="104" TOTAL_2="101" WEIGHT="16.677898093036024"/>
<CONT_DATA CI_END="3.086087144970546" CI_START="-9.426087144970541" EFFECT_SIZE="-3.169999999999998" ESTIMABLE="YES" MEAN_1="27.1" MEAN_2="30.27" ORDER="1108" SD_1="12.6" SD_2="12.12" SE="3.1919398490573094" STUDY_ID="STD-Wang-1996" TOTAL_1="30" TOTAL_2="30" WEIGHT="3.2263815977141452"/>
<CONT_DATA CI_END="-0.5043864321840736" CI_START="-3.0156135678159224" EFFECT_SIZE="-1.759999999999998" ESTIMABLE="YES" MEAN_1="20.12" MEAN_2="21.88" ORDER="1109" SD_1="4.22" SD_2="4.82" SE="0.6406309389968611" STUDY_ID="STD-Xue-2004" TOTAL_1="100" TOTAL_2="100" WEIGHT="80.09572030924984"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="5.097885290011344" CI_START="-8.597885290011344" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.75" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.09" NO="9" P_CHI2="1.0" P_Q="1.0" P_Z="0.6164588502577162" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="40" TOTAL_2="40" UNITS="" WEIGHT="99.99999999999999" Z="0.5008753546073803">
<NAME>Mental state: 1c. General - average endpoint score, by 8 weeks (PANSS, high score=worse)</NAME>
<GROUP_LABEL_1>Loxapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Typicals</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Loxapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Typicals</GRAPH_LABEL_2>
<CONT_DATA CI_END="5.0978852900113445" CI_START="-8.597885290011344" EFFECT_SIZE="-1.75" ESTIMABLE="YES" MEAN_1="40.37" MEAN_2="42.12" ORDER="1110" SD_1="15.22" SD_2="16.02" SE="3.493883226440174" STUDY_ID="STD-Liu-2005" TOTAL_1="40" TOTAL_2="40" WEIGHT="99.99999999999999"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="7.068390941478536" CI_END="-0.16022205243595544" CI_START="-2.603574499361665" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.3818982758988103" ESTIMABLE="YES" I2="71.70501721595993" I2_Q="0.0" ID="CMP-002.10" NO="10" P_CHI2="0.0291822668358388" P_Q="1.0" P_Z="0.026622271326891392" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="234" TOTAL_2="231" UNITS="" WEIGHT="100.0" Z="2.2170120028876985">
<NAME>Mental state: 1d. General - average change score (BPRS, high score=worse)</NAME>
<GROUP_LABEL_1>Loxapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Typicals</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="10.335741473474943" CI_START="-2.1557414734749507" EFFECT_SIZE="4.089999999999996" ESTIMABLE="YES" MEAN_1="41.58" MEAN_2="37.49" ORDER="1111" SD_1="25.3" SD_2="20.1" SE="3.1866613482393342" STUDY_ID="STD-Huang-1997" TOTAL_1="104" TOTAL_2="101" WEIGHT="3.8259935693213243"/>
<CONT_DATA CI_END="18.43290219097926" CI_START="-1.4729021909792657" EFFECT_SIZE="8.479999999999997" ESTIMABLE="YES" MEAN_1="57.5" MEAN_2="49.02" ORDER="1112" SD_1="20.2" SD_2="19.12" SE="5.078104633292491" STUDY_ID="STD-Wang-1996" TOTAL_1="30" TOTAL_2="30" WEIGHT="1.5066513700770587"/>
<CONT_DATA CI_END="-0.5043864321840736" CI_START="-3.0156135678159224" EFFECT_SIZE="-1.759999999999998" ESTIMABLE="YES" MEAN_1="21.12" MEAN_2="22.88" ORDER="1113" SD_1="4.22" SD_2="4.82" SE="0.6406309389968611" STUDY_ID="STD-Xue-2004" TOTAL_1="100" TOTAL_2="100" WEIGHT="94.66735506060162"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="5.88273908907354" CI_END="1.4897292199810703" CI_START="0.675145817383332" CI_STUDY="95" CI_TOTAL="95" DF="8" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0028880555196344" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="33" I2="0.0" I2_Q="0.0" ID="CMP-002.11" LOG_CI_END="0.1731073362277212" LOG_CI_START="-0.17060241850863997" LOG_EFFECT_SIZE="0.0012524588595406165" METHOD="MH" NO="11" P_CHI2="0.6603651246279721" P_Q="0.9337247978120008" P_Z="0.9886034082471951" Q="2.4099381268742346" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="226" TOTAL_2="226" WEIGHT="800.0" Z="0.01428399527793808">
<NAME>Mental state: 2. Specific</NAME>
<GROUP_LABEL_1>Loxapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Typicals</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Loxapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Typicals</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="5.81434250695042" CI_START="0.3546061216641725" DF="0" EFFECT_SIZE="1.435897435897436" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" I2="0.0" ID="CMP-002.11.01" LOG_CI_END="0.764500611283274" LOG_CI_START="-0.4502537713238717" LOG_EFFECT_SIZE="0.15712341997970122" NO="1" P_CHI2="1.0" P_Z="0.612136327556394" STUDIES="1" TAU2="0.0" TOTAL_1="26" TOTAL_2="28" WEIGHT="99.99999999999999" Z="0.5070263564343432">
<NAME>anxiety - 6 weeks</NAME>
<DICH_DATA CI_END="5.81434250695042" CI_START="0.3546061216641727" EFFECT_SIZE="1.435897435897436" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.764500611283274" LOG_CI_START="-0.4502537713238714" LOG_EFFECT_SIZE="0.15712341997970122" ORDER="1114" O_E="0.0" SE="0.7135527374746096" STUDY_ID="STD-Van-Der-Velde-1975" TOTAL_1="26" TOTAL_2="28" VAR="0.5091575091575091" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="7.584304769707433" CI_START="0.014650137947370117" DF="0" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-002.11.02" LOG_CI_END="0.87991577648491" LOG_CI_START="-1.8341582859242351" LOG_EFFECT_SIZE="-0.47712125471966244" NO="2" P_CHI2="1.0" P_Z="0.4907574432545426" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="15" WEIGHT="100.0" Z="0.6891046110061">
<NAME>anxiety - 7 - 26 weeks</NAME>
<DICH_DATA CI_END="7.584304769707433" CI_START="0.014650137947370117" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.87991577648491" LOG_CI_START="-1.8341582859242351" LOG_EFFECT_SIZE="-0.47712125471966244" ORDER="1115" O_E="0.0" SE="1.5942605391424158" STUDY_ID="STD-Vyas-1980" TOTAL_1="15" TOTAL_2="15" VAR="2.5416666666666665" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.83229496233342" CI_END="1.5022945920393687" CI_START="0.5923784290485348" DF="1" EFFECT_SIZE="0.943359375" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="20" I2="73.90597514469196" ID="CMP-002.11.03" LOG_CI_END="0.1767551038746348" LOG_CI_START="-0.227400764323272" LOG_EFFECT_SIZE="-0.02532283022431861" NO="3" P_CHI2="0.050274099620358226" P_Z="0.8059861634621549" STUDIES="2" TAU2="0.0" TOTAL_1="62" TOTAL_2="60" WEIGHT="100.0" Z="0.24560739621369607">
<NAME>behaviour changes (not specified), by 12 weeks</NAME>
<DICH_DATA CI_END="2.1306004851053206" CI_START="0.8026184090130352" EFFECT_SIZE="1.3076923076923077" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="12" LOG_CI_END="0.32850202156751757" LOG_CI_START="-0.09549088342464321" LOG_EFFECT_SIZE="0.11650556907143717" ORDER="1116" O_E="0.0" SE="0.24905553119112392" STUDY_ID="STD-Schiele-1975" TOTAL_1="26" TOTAL_2="24" VAR="0.062028657616892906" WEIGHT="60.9375"/>
<DICH_DATA CI_END="1.3009015149289371" CI_START="0.10809811379740128" EFFECT_SIZE="0.375" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="8" LOG_CI_END="0.1142444194348484" LOG_CI_START="-0.9661818839794107" LOG_EFFECT_SIZE="-0.42596873227228116" ORDER="1117" O_E="0.0" SE="0.6346477588219923" STUDY_ID="STD-Seth-1979" TOTAL_1="36" TOTAL_2="36" VAR="0.40277777777777773" WEIGHT="39.0625"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="5.1928763992528335" CI_START="0.048142875119456086" DF="0" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" I2="0.0" ID="CMP-002.11.04" LOG_CI_END="0.7154079856489205" LOG_CI_START="-1.317467976976883" LOG_EFFECT_SIZE="-0.3010299956639812" NO="4" P_CHI2="1.0" P_Z="0.5616002386525207" STUDIES="1" TAU2="0.0" TOTAL_1="27" TOTAL_2="27" WEIGHT="100.0" Z="0.5804662562939223">
<NAME>depression - 4 weeks</NAME>
<DICH_DATA CI_END="5.1928763992528335" CI_START="0.048142875119456086" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7154079856489205" LOG_CI_START="-1.317467976976883" LOG_EFFECT_SIZE="-0.3010299956639812" ORDER="1118" O_E="0.0" SE="1.1941214033447043" STUDY_ID="STD-Malik-1980" TOTAL_1="27" TOTAL_2="27" VAR="1.425925925925926" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="20.771505597011338" CI_START="0.1925715004778244" DF="0" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" I2="0.0" ID="CMP-002.11.05" LOG_CI_END="1.317467976976883" LOG_CI_START="-0.7154079856489205" LOG_EFFECT_SIZE="0.3010299956639812" NO="5" P_CHI2="1.0" P_Z="0.5616002386525207" STUDIES="1" TAU2="0.0" TOTAL_1="27" TOTAL_2="27" WEIGHT="100.0" Z="0.5804662562939223">
<NAME>excitement - 4 weeks</NAME>
<DICH_DATA CI_END="20.771505597011338" CI_START="0.1925715004778244" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.317467976976883" LOG_CI_START="-0.7154079856489205" LOG_EFFECT_SIZE="0.3010299956639812" ORDER="1119" O_E="0.0" SE="1.1941214033447043" STUDY_ID="STD-Malik-1980" TOTAL_1="27" TOTAL_2="27" VAR="1.425925925925926" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.157243854505122" CI_START="0.3758499752923442" DF="0" EFFECT_SIZE="1.25" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" I2="0.0" ID="CMP-002.11.06" LOG_CI_END="0.6188054999836834" LOG_CI_START="-0.4249854739675706" LOG_EFFECT_SIZE="0.09691001300805642" NO="6" P_CHI2="1.0" P_Z="0.7159006805416286" STUDIES="1" TAU2="0.0" TOTAL_1="27" TOTAL_2="27" WEIGHT="100.0" Z="0.363942858248876">
<NAME>restlessness - 4 weeks</NAME>
<DICH_DATA CI_END="4.157243854505122" CI_START="0.3758499752923442" EFFECT_SIZE="1.25" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" LOG_CI_END="0.6188054999836834" LOG_CI_START="-0.4249854739675706" LOG_EFFECT_SIZE="0.09691001300805642" ORDER="1120" O_E="0.0" SE="0.6131279849476176" STUDY_ID="STD-Malik-1980" TOTAL_1="27" TOTAL_2="27" VAR="0.37592592592592594" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="7.584304769707433" CI_START="0.014650137947370117" DF="0" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-002.11.07" LOG_CI_END="0.87991577648491" LOG_CI_START="-1.8341582859242351" LOG_EFFECT_SIZE="-0.47712125471966244" NO="7" P_CHI2="1.0" P_Z="0.4907574432545426" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="15" WEIGHT="100.0" Z="0.6891046110061">
<NAME>restlessness - 7 - 26 weeks</NAME>
<DICH_DATA CI_END="7.584304769707433" CI_START="0.014650137947370117" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.87991577648491" LOG_CI_START="-1.8341582859242351" LOG_EFFECT_SIZE="-0.47712125471966244" ORDER="1121" O_E="0.0" SE="1.5942605391424158" STUDY_ID="STD-Vyas-1980" TOTAL_1="15" TOTAL_2="15" VAR="2.5416666666666665" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="20.771505597011338" CI_START="0.1925715004778244" DF="0" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" I2="0.0" ID="CMP-002.11.08" LOG_CI_END="1.317467976976883" LOG_CI_START="-0.7154079856489205" LOG_EFFECT_SIZE="0.3010299956639812" NO="8" P_CHI2="1.0" P_Z="0.5616002386525207" STUDIES="1" TAU2="0.0" TOTAL_1="27" TOTAL_2="27" WEIGHT="100.0" Z="0.5804662562939223">
<NAME>violence or aggression - 4 weeks</NAME>
<DICH_DATA CI_END="20.771505597011338" CI_START="0.1925715004778244" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.317467976976883" LOG_CI_START="-0.7154079856489205" LOG_EFFECT_SIZE="0.3010299956639812" ORDER="1122" O_E="0.0" SE="1.1941214033447043" STUDY_ID="STD-Malik-1980" TOTAL_1="27" TOTAL_2="27" VAR="1.425925925925926" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="8.624239111430512" CI_END="-0.02911383460410623" CI_START="-0.1095338701521016" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.06932385237810391" ESTIMABLE="YES" I2="76.80954836526723" I2_Q="0.0" ID="CMP-002.12" NO="12" P_CHI2="0.013405140751899358" P_Q="1.0" P_Z="7.273287376024266E-4" Q="0.0" RANDOM="NO" SCALE="0.5" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="170" TOTAL_2="170" UNITS="" WEIGHT="100.0" Z="3.3790647568059162">
<NAME>Adverse effects: 1. Average change score, by 8 weeks (TESS, high score=worse)</NAME>
<GROUP_LABEL_1>Loxapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Typicals</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Typicals</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Loxapine</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.07527396970620313" CI_START="-0.13527396970620298" EFFECT_SIZE="-0.029999999999999916" ESTIMABLE="YES" MEAN_1="0.68" MEAN_2="0.71" ORDER="1123" SD_1="0.23" SD_2="0.25" SE="0.053712196007983146" STUDY_ID="STD-Liu-2005" TOTAL_1="40" TOTAL_2="40" WEIGHT="14.58903380501366"/>
<CONT_DATA CI_END="0.13144165006372946" CI_START="-0.05144165006372939" EFFECT_SIZE="0.040000000000000036" ESTIMABLE="YES" MEAN_1="0.9" MEAN_2="0.86" ORDER="1124" SD_1="0.13" SD_2="0.22" SE="0.04665476038590989" STUDY_ID="STD-Wang-1996" TOTAL_1="30" TOTAL_2="30" WEIGHT="19.33661371859008"/>
<CONT_DATA CI_END="-0.06053274548974686" CI_START="-0.15946725451025312" EFFECT_SIZE="-0.10999999999999999" ESTIMABLE="YES" MEAN_1="0.8" MEAN_2="0.91" ORDER="1125" SD_1="0.21" SD_2="0.14" SE="0.025238858928247926" STUDY_ID="STD-Xue-2004" TOTAL_1="100" TOTAL_2="100" WEIGHT="66.07435247639626"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="13.017715417566817" CI_END="1.0585118258724635" CI_START="0.8806300533201002" CI_STUDY="95" CI_TOTAL="95" DF="12" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9654829494393073" ESTIMABLE="YES" EVENTS_1="208" EVENTS_2="214" I2="7.8179264557700865" I2_Q="41.10863742417242" ID="CMP-002.13" LOG_CI_END="0.02469571439365928" LOG_CI_START="-0.05520649742706448" LOG_EFFECT_SIZE="-0.015255391516702625" METHOD="MH" NO="13" P_CHI2="0.3677544736359366" P_Q="0.19254434246458074" P_Z="0.4542097173837947" Q="1.6980418795921322" RANDOM="NO" SCALE="5.0" SORT_BY="STUDY" STUDIES="14" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="315" TOTAL_2="312" WEIGHT="100.0" Z="0.7484152756592413">
<NAME>Adverse effects: 2. Any adverse event</NAME>
<GROUP_LABEL_1>Loxapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Typicals</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Loxapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Typicals</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="7.190634988064637" CI_END="1.1329727930307216" CI_START="0.9129999427665786" DF="6" EFFECT_SIZE="1.01705658406656" ESTIMABLE="YES" EVENTS_1="128" EVENTS_2="125" I2="16.558134157009928" ID="CMP-002.13.01" LOG_CI_END="0.054219480932684735" LOG_CI_START="-0.03952924969041067" LOG_EFFECT_SIZE="0.007345115621137037" NO="1" P_CHI2="0.3035768345287636" P_Z="0.7587502980139843" STUDIES="7" TAU2="0.0" TOTAL_1="160" TOTAL_2="158" WEIGHT="58.494243975332154" Z="0.3071222828091196">
<NAME>up to 6 weeks</NAME>
<DICH_DATA CI_END="1.4438393046033107" CI_START="0.9159606583527324" EFFECT_SIZE="1.15" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="20" LOG_CI_END="0.1595188601258811" LOG_CI_START="-0.03812317941865779" LOG_EFFECT_SIZE="0.06069784035361165" ORDER="1126" O_E="0.0" SE="0.11609591237233642" STUDY_ID="STD-Bagadia-1980" TOTAL_1="25" TOTAL_2="25" VAR="0.013478260869565217" WEIGHT="9.297289349525599"/>
<DICH_DATA CI_END="1.235154862371491" CI_START="0.7052646899989385" EFFECT_SIZE="0.9333333333333333" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="18" LOG_CI_END="0.09172141237866646" LOG_CI_START="-0.15164785913355286" LOG_EFFECT_SIZE="-0.02996322337744321" ORDER="1127" O_E="0.0" SE="0.1429563147836007" STUDY_ID="STD-Charalampous-1974" TOTAL_1="20" TOTAL_2="21" VAR="0.020436507936507933" WEIGHT="8.163473575193208"/>
<DICH_DATA CI_END="1.6992692491250958" CI_START="0.7381996706206824" EFFECT_SIZE="1.12" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="10" LOG_CI_END="0.230262198259717" LOG_CI_START="-0.1318261529193538" LOG_EFFECT_SIZE="0.04921802267018165" ORDER="1128" O_E="0.0" SE="0.21269248984883143" STUDY_ID="STD-Clark-1975" TOTAL_1="15" TOTAL_2="14" VAR="0.04523809523809526" WEIGHT="4.808942766995999"/>
<DICH_DATA CI_END="1.1543680662234828" CI_START="0.49199897911327556" EFFECT_SIZE="0.7536231884057971" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="18" LOG_CI_END="0.062344304177993776" LOG_CI_START="-0.30803579838290607" LOG_EFFECT_SIZE="-0.12284574710245615" ORDER="1129" O_E="0.0" SE="0.21756310565534911" STUDY_ID="STD-Fruensgaard-1978" TOTAL_1="23" TOTAL_2="24" VAR="0.0473337049424006" WEIGHT="8.189527214262974"/>
<DICH_DATA CI_END="1.0731864344072939" CI_START="0.9318045475968827" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="27" LOG_CI_END="0.030675174343461484" LOG_CI_START="-0.03067517434346144" LOG_EFFECT_SIZE="0.0" ORDER="1130" O_E="0.0" SE="0.03603749850782236" STUDY_ID="STD-Malik-1980" TOTAL_1="27" TOTAL_2="27" VAR="0.0012987012987012991" WEIGHT="12.783772855597697"/>
<DICH_DATA CI_END="1.3447024288377185" CI_START="0.5405400729507072" EFFECT_SIZE="0.8525641025641025" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="13" LOG_CI_END="0.1286261893110408" LOG_CI_START="-0.2671721040857925" LOG_EFFECT_SIZE="-0.06927295738737582" ORDER="1131" O_E="0.0" SE="0.2324938767744503" STUDY_ID="STD-Simpson-1976" TOTAL_1="24" TOTAL_2="19" VAR="0.054053402737613276" WEIGHT="6.745940179190666"/>
<DICH_DATA CI_END="1.742701611072734" CI_START="0.975202496022286" EFFECT_SIZE="1.3036437246963564" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="19" LOG_CI_END="0.24122303268764242" LOG_CI_START="-0.010905195815312024" LOG_EFFECT_SIZE="0.1151589184361652" ORDER="1132" O_E="0.0" SE="0.1481013694774949" STUDY_ID="STD-Steinbook-1973" TOTAL_1="26" TOTAL_2="28" VAR="0.02193401564110946" WEIGHT="8.50529803456601"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="7.056089096647016" CI_END="1.0514832912462275" CI_START="0.7580642000076672" DF="5" EFFECT_SIZE="0.8928000000000001" ESTIMABLE="YES" EVENTS_1="80" EVENTS_2="89" I2="29.13921675994779" ID="CMP-002.13.02" LOG_CI_END="0.021802375855228182" LOG_CI_START="-0.12029401266822091" LOG_EFFECT_SIZE="-0.049245818406496396" NO="2" P_CHI2="0.21650229538826804" P_Z="0.17430035816984457" STUDIES="7" TAU2="0.0" TOTAL_1="155" TOTAL_2="154" WEIGHT="41.505756024667846" Z="1.3585148992017437">
<NAME>7 - 26 weeks</NAME>
<DICH_DATA CI_END="1.7979481080542332" CI_START="0.4086290779249003" EFFECT_SIZE="0.8571428571428571" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="7" LOG_CI_END="0.25477715307523086" LOG_CI_START="-0.3886707323364573" LOG_EFFECT_SIZE="-0.06694678963061322" ORDER="1133" O_E="0.0" SE="0.3779644730092273" STUDY_ID="STD-Bishop-1970" TOTAL_1="12" TOTAL_2="12" VAR="0.1428571428571429" WEIGHT="3.2540512723339594"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="1134" O_E="0.0" SE="0.0" STUDY_ID="STD-Dube-1976" TOTAL_1="26" TOTAL_2="26" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.2843242747808734" CI_START="0.49831651753930634" EFFECT_SIZE="0.8" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="10" LOG_CI_END="0.10867469115301573" LOG_CI_START="-0.30249471716912857" LOG_EFFECT_SIZE="-0.09691001300805639" ORDER="1135" O_E="0.0" SE="0.24152294576982397" STUDY_ID="STD-Gallant-1971" TOTAL_1="12" TOTAL_2="12" VAR="0.058333333333333334" WEIGHT="4.648644674762799"/>
<DICH_DATA CI_END="1.55894387499218" CI_START="0.5911694543875885" EFFECT_SIZE="0.96" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="14" LOG_CI_END="0.19283048002530256" LOG_CI_START="-0.22828801394616574" LOG_EFFECT_SIZE="-0.017728766960431602" ORDER="1136" O_E="0.0" SE="0.24736708792900516" STUDY_ID="STD-Moyano-1975" TOTAL_1="25" TOTAL_2="24" VAR="0.06119047619047618" WEIGHT="6.640920963946856"/>
<DICH_DATA CI_END="1.1021594363088758" CI_START="0.907309747625074" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="28" LOG_CI_END="0.04224442328227009" LOG_CI_START="-0.04224442328227013" LOG_EFFECT_SIZE="0.0" ORDER="1137" O_E="0.0" SE="0.04962916669854648" STUDY_ID="STD-Selman-1976" TOTAL_1="29" TOTAL_2="29" VAR="0.0024630541871921152" WEIGHT="13.016205089335838"/>
<DICH_DATA CI_END="1.0655474769455096" CI_START="0.4865104664186729" EFFECT_SIZE="0.72" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="25" LOG_CI_END="0.02757280507423962" LOG_CI_START="-0.3129078122117027" LOG_EFFECT_SIZE="-0.14266750356873156" ORDER="1138" O_E="0.0" SE="0.2" STUDY_ID="STD-Seth-1979" TOTAL_1="36" TOTAL_2="36" VAR="0.04000000000000001" WEIGHT="11.621611686906999"/>
<DICH_DATA CI_END="3.0927915802339063" CI_START="0.4655987843484408" EFFECT_SIZE="1.2" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" LOG_CI_END="0.49035065436976916" LOG_CI_START="-0.3319881622745195" LOG_EFFECT_SIZE="0.07918124604762482" ORDER="1139" O_E="0.0" SE="0.483045891539648" STUDY_ID="STD-Vyas-1980" TOTAL_1="15" TOTAL_2="15" VAR="0.2333333333333334" WEIGHT="2.3243223373813997"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="10.271124367249374" CI_END="1.3798654475880656" CI_START="0.9056776608042338" CI_STUDY="95" CI_TOTAL="95" DF="15" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1179057700880457" ESTIMABLE="YES" EVENTS_1="101" EVENTS_2="88" I2="0.0" I2_Q="0.0" ID="CMP-002.14" LOG_CI_END="0.13983673986573622" LOG_CI_START="-0.04302634431322001" LOG_EFFECT_SIZE="0.04840519777625812" METHOD="MH" NO="14" P_CHI2="0.8023477693128023" P_Q="0.905737658366319" P_Z="0.299440662622968" Q="2.1465626094493606" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="9" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="395" TOTAL_2="382" WEIGHT="700.0" Z="1.0376336452157697">
<NAME>Adverse effects: 3. Anticholinergic effects - specific symptoms</NAME>
<GROUP_LABEL_1>Loxapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Typicals</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Loxapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Typicals</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.689232752777765" CI_END="1.3869622794224838" CI_START="0.6259463286407589" DF="3" EFFECT_SIZE="0.931753157637645" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="27" I2="0.0" ID="CMP-002.14.01" LOG_CI_END="0.14206464992589327" LOG_CI_START="-0.20346290348995544" LOG_EFFECT_SIZE="-0.0306991267820311" NO="1" P_CHI2="0.4420602417127295" P_Z="0.7276341957654553" STUDIES="4" TAU2="0.0" TOTAL_1="93" TOTAL_2="94" WEIGHT="100.00000000000001" Z="0.3482742968239945">
<NAME>blurred vision - up to 6 weeks</NAME>
<DICH_DATA CI_END="128.87064248425733" CI_START="0.3802262412557286" EFFECT_SIZE="7.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="2.1101539936976934" LOG_CI_START="-0.4199579136691801" LOG_EFFECT_SIZE="0.8450980400142568" ORDER="1140" O_E="0.0" SE="1.4862002586432317" STUDY_ID="STD-Bagadia-1980" TOTAL_1="25" TOTAL_2="25" VAR="2.208791208791209" WEIGHT="1.8213114372775696"/>
<DICH_DATA CI_END="2.1619895170852463" CI_START="0.10073026536751283" EFFECT_SIZE="0.4666666666666667" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" LOG_CI_END="0.33485358384343905" LOG_CI_START="-0.9968400219262878" LOG_EFFECT_SIZE="-0.3309932190414244" ORDER="1141" O_E="0.0" SE="0.7822434160188003" STUDY_ID="STD-Clark-1975" TOTAL_1="15" TOTAL_2="14" VAR="0.611904761904762" WEIGHT="15.072922239538508"/>
<DICH_DATA CI_END="1.3407859243516331" CI_START="0.5892987407159761" EFFECT_SIZE="0.8888888888888888" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="18" LOG_CI_END="0.1273594420614832" LOG_CI_START="-0.2296644869562458" LOG_EFFECT_SIZE="-0.05115252244738131" ORDER="1142" O_E="0.0" SE="0.20971762320196527" STUDY_ID="STD-Malik-1980" TOTAL_1="27" TOTAL_2="27" VAR="0.04398148148148148" WEIGHT="65.56721174199251"/>
<DICH_DATA CI_END="2.8648344010485234" CI_START="0.2590895028481918" EFFECT_SIZE="0.8615384615384616" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" LOG_CI_END="0.45709952306103857" LOG_CI_START="-0.5865501823343489" LOG_EFFECT_SIZE="-0.06472532963665513" ORDER="1143" O_E="0.0" SE="0.6130450030986109" STUDY_ID="STD-Van-Der-Velde-1975" TOTAL_1="26" TOTAL_2="28" VAR="0.3758241758241758" WEIGHT="17.538554581191413"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.793582426620492" CI_START="0.517488754594934" DF="0" EFFECT_SIZE="1.575" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="4" I2="0.0" ID="CMP-002.14.02" LOG_CI_END="0.6806601995530678" LOG_CI_START="-0.28609908330182915" LOG_EFFECT_SIZE="0.19728055812561932" NO="2" P_CHI2="1.0" P_Z="0.42375985834617824" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="27" WEIGHT="100.0" Z="0.799915337009926">
<NAME>blurred vision - 12 weeks</NAME>
<DICH_DATA CI_END="4.793582426620492" CI_START="0.517488754594934" EFFECT_SIZE="1.575" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="4" LOG_CI_END="0.6806601995530678" LOG_CI_START="-0.28609908330182915" LOG_EFFECT_SIZE="0.19728055812561932" ORDER="1144" O_E="0.0" SE="0.5678791882845967" STUDY_ID="STD-Kiloh-1976" TOTAL_1="30" TOTAL_2="27" VAR="0.3224867724867725" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.4006283286032029" CI_START="0.9219593004643689" DF="0" EFFECT_SIZE="1.1363636363636365" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="22" I2="0.0" ID="CMP-002.14.03" LOG_CI_END="0.14632290598429357" LOG_CI_START="-0.0352882502846307" LOG_EFFECT_SIZE="0.05551732784983141" NO="3" P_CHI2="1.0" P_Z="0.2308018162394888" STUDIES="1" TAU2="0.0" TOTAL_1="27" TOTAL_2="27" WEIGHT="100.00000000000001" Z="1.198296022546618">
<NAME>constipation - 4 weeks</NAME>
<DICH_DATA CI_END="1.4006283286032029" CI_START="0.9219593004643689" EFFECT_SIZE="1.1363636363636365" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="22" LOG_CI_END="0.14632290598429357" LOG_CI_START="-0.0352882502846307" LOG_EFFECT_SIZE="0.05551732784983141" ORDER="1145" O_E="0.0" SE="0.10667929218208837" STUDY_ID="STD-Malik-1980" TOTAL_1="27" TOTAL_2="27" VAR="0.01138047138047138" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.9291554295340103" CI_END="2.960014939089996" CI_START="0.4836559713910267" DF="2" EFFECT_SIZE="1.1965069580648173" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="6" I2="0.0" ID="CMP-002.14.04" LOG_CI_END="0.47129390293325535" LOG_CI_START="-0.3154634459012575" LOG_EFFECT_SIZE="0.07791522851599889" NO="4" P_CHI2="0.6284004490340245" P_Z="0.6978653246963539" STUDIES="3" TAU2="0.0" TOTAL_1="63" TOTAL_2="61" WEIGHT="100.0" Z="0.3882036614333231">
<NAME>constipation - 7 - 26 weeks</NAME>
<DICH_DATA CI_END="8.093763717196325" CI_START="0.015211069763955837" EFFECT_SIZE="0.3508771929824561" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9081505217981177" LOG_CI_START="-1.817840241815138" LOG_EFFECT_SIZE="-0.4548448600085102" ORDER="1146" O_E="0.0" SE="1.6012604684183327" STUDY_ID="STD-Clark-1972" TOTAL_1="18" TOTAL_2="19" VAR="2.564035087719298" WEIGHT="20.22975623423928"/>
<DICH_DATA CI_END="3.5050967580860473" CI_START="0.4529404206424551" EFFECT_SIZE="1.26" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="5" LOG_CI_END="0.5447000111537027" LOG_CI_START="-0.3439589209185769" LOG_EFFECT_SIZE="0.10037054511756291" ORDER="1147" O_E="0.0" SE="0.5220026556319158" STUDY_ID="STD-Kiloh-1976" TOTAL_1="30" TOTAL_2="27" VAR="0.2724867724867725" WEIGHT="72.84953768562623"/>
<DICH_DATA CI_END="68.25874292736694" CI_START="0.13185124152633113" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8341582859242351" LOG_CI_START="-0.87991577648491" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="1148" O_E="0.0" SE="1.5942605391424158" STUDY_ID="STD-Vyas-1980" TOTAL_1="15" TOTAL_2="15" VAR="2.5416666666666665" WEIGHT="6.920706080134491"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.0872475146190204" CI_END="2.387796143605438" CI_START="0.7609264491884359" DF="2" EFFECT_SIZE="1.347938144329897" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="14" I2="0.0" ID="CMP-002.14.05" LOG_CI_END="0.3779972464580004" LOG_CI_START="-0.11865731991186633" LOG_EFFECT_SIZE="0.12966996327306704" NO="5" P_CHI2="0.5806404525883333" P_Z="0.30609914003724115" STUDIES="3" TAU2="0.0" TOTAL_1="77" TOTAL_2="74" WEIGHT="100.0" Z="1.0234415430807675">
<NAME>dry mouth - up to 6 weeks</NAME>
<DICH_DATA CI_END="2.7992989435518267" CI_START="0.7453365271660174" EFFECT_SIZE="1.4444444444444444" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="9" LOG_CI_END="0.44704928024619645" LOG_CI_START="-0.1276475945111726" LOG_EFFECT_SIZE="0.15970084286751188" ORDER="1149" O_E="0.0" SE="0.3375797890278889" STUDY_ID="STD-Malik-1980" TOTAL_1="27" TOTAL_2="27" VAR="0.11396011396011396" WEIGHT="62.628865979381445"/>
<DICH_DATA CI_END="78.66369313090676" CI_START="0.2033975187685873" EFFECT_SIZE="4.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.895774331963415" LOG_CI_START="-0.6916543493074901" LOG_EFFECT_SIZE="0.6020599913279624" ORDER="1150" O_E="0.0" SE="1.5198684153570663" STUDY_ID="STD-Simpson-1976" TOTAL_1="24" TOTAL_2="19" VAR="2.31" WEIGHT="3.865979381443299"/>
<DICH_DATA CI_END="2.8648344010485234" CI_START="0.2590895028481918" EFFECT_SIZE="0.8615384615384616" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" LOG_CI_END="0.45709952306103857" LOG_CI_START="-0.5865501823343489" LOG_EFFECT_SIZE="-0.06472532963665513" ORDER="1151" O_E="0.0" SE="0.6130450030986109" STUDY_ID="STD-Van-Der-Velde-1975" TOTAL_1="26" TOTAL_2="28" VAR="0.3758241758241758" WEIGHT="33.50515463917526"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.7269013551913885" CI_END="2.261156147266658" CI_START="0.5968415029807447" DF="2" EFFECT_SIZE="1.1617021276595745" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="12" I2="26.656679524088272" ID="CMP-002.14.06" LOG_CI_END="0.35433055418734505" LOG_CI_START="-0.22414098464930549" LOG_EFFECT_SIZE="0.06509478476901977" NO="6" P_CHI2="0.2557768682274263" P_Z="0.6591367608083212" STUDIES="3" TAU2="0.0" TOTAL_1="75" TOTAL_2="72" WEIGHT="100.0" Z="0.44110530998722963">
<NAME>dry mouth - 7 - 26 weeks</NAME>
<DICH_DATA CI_END="3.3444867915282375" CI_START="0.7117409371431833" EFFECT_SIZE="1.542857142857143" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="7" LOG_CI_END="0.5243294851211449" LOG_CI_START="-0.14767805417575908" LOG_EFFECT_SIZE="0.1883257154726929" ORDER="1152" O_E="0.0" SE="0.3947405550739698" STUDY_ID="STD-Kiloh-1976" TOTAL_1="30" TOTAL_2="27" VAR="0.1558201058201058" WEIGHT="59.57446808510639"/>
<DICH_DATA CI_END="19.775299481351468" CI_START="0.20227253720086952" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.296123069267743" LOG_CI_START="-0.6940630779397805" LOG_EFFECT_SIZE="0.3010299956639812" ORDER="1153" O_E="0.0" SE="1.1690451944500122" STUDY_ID="STD-Vyas-1980" TOTAL_1="15" TOTAL_2="15" VAR="1.3666666666666667" WEIGHT="8.085106382978724"/>
<DICH_DATA CI_END="2.1080777784770572" CI_START="0.029647862445166522" EFFECT_SIZE="0.25" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" LOG_CI_END="0.3238866303262053" LOG_CI_START="-1.52800661298213" LOG_EFFECT_SIZE="-0.6020599913279624" ORDER="1154" O_E="0.0" SE="1.0878112581387145" STUDY_ID="STD-Wang-1996" TOTAL_1="30" TOTAL_2="30" VAR="1.1833333333333331" WEIGHT="32.340425531914896"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.323966636969886" CI_START="0.10830433614946702" DF="0" EFFECT_SIZE="0.6" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" I2="0.0" ID="CMP-002.14.07" LOG_CI_END="0.5216566560709802" LOG_CI_START="-0.9653541553036931" LOG_EFFECT_SIZE="-0.2218487496163564" NO="7" P_CHI2="1.0" P_Z="0.5586699083880828" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="27" WEIGHT="100.0" Z="0.584818289063192">
<NAME>nasal congestion - 12 weeks</NAME>
<DICH_DATA CI_END="3.3239666369698853" CI_START="0.10830433614946702" EFFECT_SIZE="0.6" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.5216566560709801" LOG_CI_START="-0.9653541553036931" LOG_EFFECT_SIZE="-0.2218487496163564" ORDER="1155" O_E="0.0" SE="0.8734775114237131" STUDY_ID="STD-Kiloh-1976" TOTAL_1="30" TOTAL_2="27" VAR="0.7629629629629628" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="10.820231540101682" CI_END="1.163752059599549" CI_START="0.7206822016523171" CI_STUDY="95" CI_TOTAL="95" DF="20" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9158031428694823" ESTIMABLE="YES" EVENTS_1="82" EVENTS_2="103" I2="0.0" I2_Q="0.0" ID="CMP-002.15" LOG_CI_END="0.06586046260115203" LOG_CI_START="-0.14225620337365555" LOG_EFFECT_SIZE="-0.038197870386251796" METHOD="MH" NO="15" P_CHI2="0.9507518429420488" P_Q="0.6980556965709603" P_Z="0.47185374481194764" Q="3.8419443888429172" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="12" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="642" TOTAL_2="751" WEIGHT="700.0" Z="0.7194661695401671">
<NAME>Adverse effects: 4. Cardiovascular problems</NAME>
<GROUP_LABEL_1>Loxapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Typicals</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Loxapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Typicals</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="5.329140029409427" CI_START="0.05226910555527625" DF="0" EFFECT_SIZE="0.5277777777777778" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" I2="0.0" ID="CMP-002.15.01" LOG_CI_END="0.7266571319881123" LOG_CI_START="-1.2817549316170291" LOG_EFFECT_SIZE="-0.2775488998144583" NO="1" P_CHI2="1.0" P_Z="0.588020087298718" STUDIES="1" TAU2="0.0" TOTAL_1="18" TOTAL_2="19" WEIGHT="100.0" Z="0.5417074089951324">
<NAME>hypertension - 12 weeks</NAME>
<DICH_DATA CI_END="5.329140029409427" CI_START="0.05226910555527625" EFFECT_SIZE="0.5277777777777778" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7266571319881123" LOG_CI_START="-1.2817549316170291" LOG_EFFECT_SIZE="-0.2775488998144583" ORDER="1156" O_E="0.0" SE="1.1797511879617142" STUDY_ID="STD-Clark-1972" TOTAL_1="18" TOTAL_2="19" VAR="1.391812865497076" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.2199883493085374" CI_END="1.9038823864166747" CI_START="0.36590644863621463" DF="1" EFFECT_SIZE="0.8346513299784328" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="8" I2="0.0" ID="CMP-002.15.02" LOG_CI_END="0.2796401160505985" LOG_CI_START="-0.4366299365575436" LOG_EFFECT_SIZE="-0.07849491025347255" NO="2" P_CHI2="0.6390488126583789" P_Z="0.6675020985664868" STUDIES="2" TAU2="0.0" TOTAL_1="38" TOTAL_2="38" WEIGHT="100.0" Z="0.4295787503786003">
<NAME>ECG abnormalites - up to 4 weeks</NAME>
<DICH_DATA CI_END="2.218945347844558" CI_START="0.3925788942739361" EFFECT_SIZE="0.9333333333333333" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="6" LOG_CI_END="0.34614660578233475" LOG_CI_START="-0.40607305253722115" LOG_EFFECT_SIZE="-0.02996322337744321" ORDER="1157" O_E="0.0" SE="0.4418575508442684" STUDY_ID="STD-Clark-1975" TOTAL_1="15" TOTAL_2="14" VAR="0.19523809523809524" WEIGHT="76.02444284687276"/>
<DICH_DATA CI_END="5.369550152012239" CI_START="0.050695442359325354" EFFECT_SIZE="0.5217391304347826" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7299379030771684" LOG_CI_START="-1.2950310830171046" LOG_EFFECT_SIZE="-0.28254658996996806" ORDER="1158" O_E="0.0" SE="1.1894768061899181" STUDY_ID="STD-Fruensgaard-1978" TOTAL_1="23" TOTAL_2="24" VAR="1.414855072463768" WEIGHT="23.975557153127248"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.8659261118701567" CI_END="1.4656115167332748" CI_START="0.11173620591739113" DF="3" EFFECT_SIZE="0.40467501804362616" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="7" I2="0.0" ID="CMP-002.15.03" LOG_CI_END="0.1660188690107698" LOG_CI_START="-0.9518060795045447" LOG_EFFECT_SIZE="-0.3928936052468874" NO="3" P_CHI2="0.6006950054893005" P_Z="0.16827183764160236" STUDIES="4" TAU2="0.0" TOTAL_1="213" TOTAL_2="243" WEIGHT="100.00000000000001" Z="1.3777780090930698">
<NAME>ECG abnormalities - up to 12 weeks</NAME>
<DICH_DATA CI_END="15.640507378231115" CI_START="0.07123794029949233" EFFECT_SIZE="1.0555555555555556" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1942508374701124" LOG_CI_START="-1.1472886457710665" LOG_EFFECT_SIZE="0.0234810958495229" ORDER="1159" O_E="0.0" SE="1.3754318832632446" STUDY_ID="STD-Clark-1972" TOTAL_1="18" TOTAL_2="19" VAR="1.891812865497076" WEIGHT="12.532911013354672"/>
<DICH_DATA CI_END="14.495014695564524" CI_START="0.06358048055529116" EFFECT_SIZE="0.96" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.161218659994524" LOG_CI_START="-1.1966761939153874" LOG_EFFECT_SIZE="-0.017728766960431602" ORDER="1160" O_E="0.0" SE="1.3850391089544487" STUDY_ID="STD-Moyano-1975" TOTAL_1="25" TOTAL_2="24" VAR="1.9183333333333332" WEIGHT="13.1439259493799"/>
<DICH_DATA CI_END="1.8161216265702638" CI_START="0.005381700142648293" EFFECT_SIZE="0.09886264216972879" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="4" LOG_CI_END="0.2591449300768777" LOG_CI_START="-2.2690805039006015" LOG_EFFECT_SIZE="-1.004967786911862" ORDER="1161" O_E="0.0" SE="1.4850921348361075" STUDY_ID="STD-Tu-2004" TOTAL_1="126" TOTAL_2="112" VAR="2.205498648952067" WEIGHT="61.34598838724334"/>
<DICH_DATA CI_END="15.860429190816676" CI_START="0.027402964049088756" EFFECT_SIZE="0.6592592592592592" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="1.2003149353574596" LOG_CI_START="-1.5622024590576462" LOG_EFFECT_SIZE="-0.18094376185009337" ORDER="1162" O_E="0.0" SE="1.6227163921610779" STUDY_ID="STD-Zhang-2005" TOTAL_1="44" TOTAL_2="88" VAR="2.633208489388265" WEIGHT="12.977174650022095"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.317431275514169" CI_END="1.516492981247579" CI_START="0.46043258221785105" DF="4" EFFECT_SIZE="0.8356092264157152" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="24" I2="0.0" ID="CMP-002.15.04" LOG_CI_END="0.18084040461536" LOG_CI_START="-0.33683395138294653" LOG_EFFECT_SIZE="-0.07799677338379322" NO="4" P_CHI2="0.506175372047438" P_Z="0.5547842489797628" STUDIES="5" TAU2="0.0" TOTAL_1="119" TOTAL_2="161" WEIGHT="100.0" Z="0.5906062951399784">
<NAME>hypotension - 7 - 26 weeks</NAME>
<DICH_DATA CI_END="24.91862084290609" CI_START="0.3611756869185699" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.3965240019963447" LOG_CI_START="-0.4422814925570198" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="1163" O_E="0.0" SE="1.0801234497346435" STUDY_ID="STD-Bishop-1970" TOTAL_1="12" TOTAL_2="12" VAR="1.1666666666666667" WEIGHT="4.87644368398539"/>
<DICH_DATA CI_END="2.721765208572215" CI_START="0.008308182944817652" EFFECT_SIZE="0.15037593984962405" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.43485065833260267" LOG_CI_START="-2.080493948938812" LOG_EFFECT_SIZE="-0.8228216453031046" ORDER="1164" O_E="0.0" SE="1.4775258734678447" STUDY_ID="STD-Clark-1972" TOTAL_1="18" TOTAL_2="19" VAR="2.183082706766917" WEIGHT="16.62992333256556"/>
<DICH_DATA CI_END="2.40875481521069" CI_START="0.21521493043892737" EFFECT_SIZE="0.72" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" LOG_CI_END="0.38179259583884584" LOG_CI_START="-0.6671276029763089" LOG_EFFECT_SIZE="-0.14266750356873156" ORDER="1165" O_E="0.0" SE="0.6161409170227454" STUDY_ID="STD-Kiloh-1976" TOTAL_1="30" TOTAL_2="27" VAR="0.37962962962962965" WEIGHT="25.66549307360732"/>
<DICH_DATA CI_END="7.584304769707433" CI_START="0.014650137947370117" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.87991577648491" LOG_CI_START="-1.8341582859242351" LOG_EFFECT_SIZE="-0.47712125471966244" ORDER="1166" O_E="0.0" SE="1.5942605391424158" STUDY_ID="STD-Vyas-1980" TOTAL_1="15" TOTAL_2="15" VAR="2.5416666666666665" WEIGHT="7.314665525978086"/>
<DICH_DATA CI_END="2.2978919098579835" CI_START="0.4351814790373682" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="14" LOG_CI_END="0.3613295961293424" LOG_CI_START="-0.3613295961293424" LOG_EFFECT_SIZE="0.0" ORDER="1167" O_E="0.0" SE="0.4244935867534458" STUDY_ID="STD-Zhang-2005" TOTAL_1="44" TOTAL_2="88" VAR="0.18019480519480519" WEIGHT="45.513474383863645"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="24.43193645431481" CI_START="0.298379950915129" DF="0" EFFECT_SIZE="2.7" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" I2="0.0" ID="CMP-002.15.05" LOG_CI_END="1.3879578901455354" LOG_CI_START="-0.5252303618275606" LOG_EFFECT_SIZE="0.43136376415898736" NO="5" P_CHI2="1.0" P_Z="0.3767931597931501" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="27" WEIGHT="100.0" Z="0.8838204406861834">
<NAME>syncope - 8 weeks</NAME>
<DICH_DATA CI_END="24.431936454314783" CI_START="0.29837995091512914" EFFECT_SIZE="2.7" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.387957890145535" LOG_CI_START="-0.5252303618275603" LOG_EFFECT_SIZE="0.43136376415898736" ORDER="1168" O_E="0.0" SE="1.1238162496435806" STUDY_ID="STD-Kiloh-1976" TOTAL_1="30" TOTAL_2="27" VAR="1.2629629629629628" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.4962598878079838" CI_END="1.474146940849678" CI_START="0.7845469684130569" DF="5" EFFECT_SIZE="1.0754243411040112" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="45" I2="0.0" ID="CMP-002.15.06" LOG_CI_END="0.1685407755308698" LOG_CI_START="-0.10538105142437941" LOG_EFFECT_SIZE="0.031579862053245165" NO="6" P_CHI2="0.9135010470797847" P_Z="0.6513265317411814" STUDIES="6" TAU2="0.0" TOTAL_1="162" TOTAL_2="203" WEIGHT="100.0" Z="0.4519201185907361">
<NAME>tachycardia - 7 to 26 weeks</NAME>
<DICH_DATA CI_END="2.046086736866081" CI_START="0.5445504879088238" EFFECT_SIZE="1.0555555555555556" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="9" LOG_CI_END="0.310924040199149" LOG_CI_START="-0.26396184850010324" LOG_EFFECT_SIZE="0.0234810958495229" ORDER="1169" O_E="0.0" SE="0.33769081675298523" STUDY_ID="STD-Clark-1972" TOTAL_1="18" TOTAL_2="19" VAR="0.11403508771929824" WEIGHT="21.510638047524015"/>
<DICH_DATA CI_END="10.656244427620182" CI_START="0.47507356220906327" EFFECT_SIZE="2.25" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="2" LOG_CI_END="1.0276041735707089" LOG_CI_START="-0.32323913734798393" LOG_EFFECT_SIZE="0.3521825181113625" ORDER="1170" O_E="0.0" SE="0.7934920476158722" STUDY_ID="STD-Kiloh-1976" TOTAL_1="30" TOTAL_2="27" VAR="0.6296296296296295" WEIGHT="5.171498425980433"/>
<DICH_DATA CI_END="1.4489320513100228" CI_START="0.7130855141296973" EFFECT_SIZE="1.016470588235294" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="17" LOG_CI_END="0.16104801940282476" LOG_CI_START="-0.14685838587362374" LOG_EFFECT_SIZE="0.007094816764600511" ORDER="1171" O_E="0.0" SE="0.1808657466206733" STUDY_ID="STD-Moyano-1975" TOTAL_1="25" TOTAL_2="24" VAR="0.0327124183006536" WEIGHT="42.61209162223673"/>
<DICH_DATA CI_END="14.553341064518706" CI_START="0.06871274407483083" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1629627073641946" LOG_CI_START="-1.1629627073641946" LOG_EFFECT_SIZE="0.0" ORDER="1172" O_E="0.0" SE="1.3662601021279464" STUDY_ID="STD-Vyas-1980" TOTAL_1="15" TOTAL_2="15" VAR="1.8666666666666667" WEIGHT="2.4564617523407057"/>
<DICH_DATA CI_END="7.8698689779204765" CI_START="0.01411854649967386" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8959675020363439" LOG_CI_START="-1.850210011475669" LOG_EFFECT_SIZE="-0.47712125471966244" ORDER="1173" O_E="0.0" SE="1.613118265234886" STUDY_ID="STD-Wang-1996" TOTAL_1="30" TOTAL_2="30" VAR="2.6021505376344085" WEIGHT="3.6846926285110584"/>
<DICH_DATA CI_END="2.322309491025187" CI_START="0.48993374146505514" EFFECT_SIZE="1.0666666666666667" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="15" LOG_CI_END="0.36592009709407275" LOG_CI_START="-0.3098626498935857" LOG_EFFECT_SIZE="0.028028723600243534" ORDER="1174" O_E="0.0" SE="0.3969581307590985" STUDY_ID="STD-Zhang-2005" TOTAL_1="44" TOTAL_2="88" VAR="0.15757575757575756" WEIGHT="24.56461752340706"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.5478538202240513" CI_END="1.5400857358477287" CI_START="0.450912847434557" DF="1" EFFECT_SIZE="0.8333333333333333" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="16" I2="35.3944160014251" ID="CMP-002.15.07" LOG_CI_END="0.18754489847875797" LOG_CI_START="-0.3459073905740077" LOG_EFFECT_SIZE="-0.07918124604762487" NO="7" P_CHI2="0.2134530312135815" P_Z="0.5606733231055977" STUDIES="2" TAU2="0.0" TOTAL_1="62" TOTAL_2="60" WEIGHT="100.0" Z="0.5818416892724164">
<NAME>unspecified - 12 weeks</NAME>
<DICH_DATA CI_END="2.4329460209325706" CI_START="0.5472217366479997" EFFECT_SIZE="1.1538461538461537" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="8" LOG_CI_END="0.3861324734720514" LOG_CI_START="-0.2618366599743625" LOG_EFFECT_SIZE="0.062147906748844434" ORDER="1175" O_E="0.0" SE="0.38062027648536395" STUDY_ID="STD-Schiele-1975" TOTAL_1="26" TOTAL_2="24" VAR="0.14487179487179488" WEIGHT="50.98039215686274"/>
<DICH_DATA CI_END="1.5137848344184843" CI_START="0.16514896590045225" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="8" LOG_CI_END="0.1800641500217368" LOG_CI_START="-0.7821241413496992" LOG_EFFECT_SIZE="-0.3010299956639812" ORDER="1176" O_E="0.0" SE="0.565194165260439" STUDY_ID="STD-Seth-1979" TOTAL_1="36" TOTAL_2="36" VAR="0.3194444444444444" WEIGHT="49.01960784313725"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="4.831480356695337" CI_END="1.4912810168202697" CI_START="0.577449748922803" CI_STUDY="95" CI_TOTAL="95" DF="8" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9279762112986556" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="26" I2="0.0" I2_Q="0.0" ID="CMP-002.16" LOG_CI_END="0.17355948956611267" LOG_CI_START="-0.23848580315025497" LOG_EFFECT_SIZE="-0.03246315679207115" METHOD="MH" NO="16" P_CHI2="0.7754266247633064" P_Q="0.8304343737168048" P_Z="0.7574484687407876" Q="3.545019172943955" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="244" TOTAL_2="241" WEIGHT="800.0" Z="0.3088331271423301">
<NAME>Adverse effects: 5. Gastrointestinal problems</NAME>
<GROUP_LABEL_1>Loxapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Typicals</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Loxapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Typicals</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="5.81434250695042" CI_START="0.3546061216641725" DF="0" EFFECT_SIZE="1.435897435897436" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" I2="0.0" ID="CMP-002.16.01" LOG_CI_END="0.764500611283274" LOG_CI_START="-0.4502537713238717" LOG_EFFECT_SIZE="0.15712341997970122" NO="1" P_CHI2="1.0" P_Z="0.612136327556394" STUDIES="1" TAU2="0.0" TOTAL_1="26" TOTAL_2="28" WEIGHT="99.99999999999999" Z="0.5070263564343432">
<NAME>abdominal pain - 6 weeks</NAME>
<DICH_DATA CI_END="5.81434250695042" CI_START="0.3546061216641727" EFFECT_SIZE="1.435897435897436" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.764500611283274" LOG_CI_START="-0.4502537713238714" LOG_EFFECT_SIZE="0.15712341997970122" ORDER="1177" O_E="0.0" SE="0.7135527374746096" STUDY_ID="STD-Van-Der-Velde-1975" TOTAL_1="26" TOTAL_2="28" VAR="0.5091575091575091" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.704556822700689" CI_START="0.4929596752582568" DF="0" EFFECT_SIZE="0.9166666666666666" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="12" I2="0.0" ID="CMP-002.16.02" LOG_CI_END="0.23161148334374548" LOG_CI_START="-0.3071886051225451" LOG_EFFECT_SIZE="-0.0377885608893998" NO="2" P_CHI2="1.0" P_Z="0.7833755392068956" STUDIES="1" TAU2="0.0" TOTAL_1="27" TOTAL_2="27" WEIGHT="100.0" Z="0.2749228144399469">
<NAME>appetite loss - 4 weeks</NAME>
<DICH_DATA CI_END="1.704556822700689" CI_START="0.4929596752582568" EFFECT_SIZE="0.9166666666666666" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="12" LOG_CI_END="0.23161148334374548" LOG_CI_START="-0.3071886051225451" LOG_EFFECT_SIZE="-0.0377885608893998" ORDER="1178" O_E="0.0" SE="0.3164938390685515" STUDY_ID="STD-Malik-1980" TOTAL_1="27" TOTAL_2="27" VAR="0.10016835016835018" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="99.95416281504153" CI_START="0.25011464551267176" DF="0" EFFECT_SIZE="5.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" I2="0.0" ID="CMP-002.16.03" LOG_CI_END="1.9998008859974516" LOG_CI_START="-0.6018608773254143" LOG_EFFECT_SIZE="0.6989700043360189" NO="3" P_CHI2="1.0" P_Z="0.2922772002054833" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="30" WEIGHT="100.0" Z="1.053139231306288">
<NAME>constipation - 8 weeks</NAME>
<DICH_DATA CI_END="99.95416281504153" CI_START="0.25011464551267176" EFFECT_SIZE="5.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.9998008859974516" LOG_CI_START="-0.6018608773254143" LOG_EFFECT_SIZE="0.6989700043360189" ORDER="1179" O_E="0.0" SE="1.5282289982092807" STUDY_ID="STD-Wang-1996" TOTAL_1="30" TOTAL_2="30" VAR="2.335483870967742" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="5.1928763992528335" CI_START="0.048142875119456086" DF="0" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" I2="0.0" ID="CMP-002.16.04" LOG_CI_END="0.7154079856489205" LOG_CI_START="-1.317467976976883" LOG_EFFECT_SIZE="-0.3010299956639812" NO="4" P_CHI2="1.0" P_Z="0.5616002386525207" STUDIES="1" TAU2="0.0" TOTAL_1="27" TOTAL_2="27" WEIGHT="100.0" Z="0.5804662562939223">
<NAME>diarrhoea - 4 weeks</NAME>
<DICH_DATA CI_END="5.1928763992528335" CI_START="0.048142875119456086" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7154079856489205" LOG_CI_START="-1.317467976976883" LOG_EFFECT_SIZE="-0.3010299956639812" ORDER="1180" O_E="0.0" SE="1.1941214033447043" STUDY_ID="STD-Malik-1980" TOTAL_1="27" TOTAL_2="27" VAR="1.425925925925926" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.6032494228942094" CI_START="0.00905645723281498" DF="0" EFFECT_SIZE="0.18064516129032257" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" I2="0.0" ID="CMP-002.16.05" LOG_CI_END="0.5566943257465986" LOG_CI_START="-2.043041659402743" LOG_EFFECT_SIZE="-0.7431736668280723" NO="5" P_CHI2="1.0" P_Z="0.2624707805106986" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="27" WEIGHT="100.0" Z="1.1205704191211687">
<NAME>diarrhoea - 12 weeks</NAME>
<DICH_DATA CI_END="3.6032494228942107" CI_START="0.009056457232814973" EFFECT_SIZE="0.18064516129032257" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.5566943257465988" LOG_CI_START="-2.0430416594027436" LOG_EFFECT_SIZE="-0.7431736668280723" ORDER="1181" O_E="0.0" SE="1.5270977865773971" STUDY_ID="STD-Kiloh-1976" TOTAL_1="30" TOTAL_2="27" VAR="2.3320276497695853" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.3878530352743998" CI_END="3.600844666977097" CI_START="0.1478834905973497" DF="1" EFFECT_SIZE="0.7297297297297297" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" I2="27.94626126949496" ID="CMP-002.16.06" LOG_CI_END="0.5564043872058502" LOG_CI_START="-0.8300803070218656" LOG_EFFECT_SIZE="-0.1368379599080077" NO="6" P_CHI2="0.2387682076329708" P_Z="0.6988494555315896" STUDIES="2" TAU2="0.0" TOTAL_1="47" TOTAL_2="48" WEIGHT="100.0" Z="0.3868740480932886">
<NAME>nausea or vomiting - 4 weeks</NAME>
<DICH_DATA CI_END="4.1123185972915905" CI_START="0.010675298063307328" EFFECT_SIZE="0.20952380952380953" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.6140867537707091" LOG_CI_START="-1.9716199902661726" LOG_EFFECT_SIZE="-0.6787666182477319" ORDER="1182" O_E="0.0" SE="1.5188569409020742" STUDY_ID="STD-Charalampous-1974" TOTAL_1="20" TOTAL_2="21" VAR="2.306926406926407" WEIGHT="70.94594594594595"/>
<DICH_DATA CI_END="20.771505597011338" CI_START="0.1925715004778244" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.317467976976883" LOG_CI_START="-0.7154079856489205" LOG_EFFECT_SIZE="0.3010299956639812" ORDER="1183" O_E="0.0" SE="1.1941214033447043" STUDY_ID="STD-Malik-1980" TOTAL_1="27" TOTAL_2="27" VAR="1.425925925925926" WEIGHT="29.054054054054056"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="18.751226495456805" CI_START="0.17278869735721092" DF="0" EFFECT_SIZE="1.8" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" I2="0.0" ID="CMP-002.16.07" LOG_CI_END="1.2730296796791112" LOG_CI_START="-0.762484669472499" LOG_EFFECT_SIZE="0.25527250510330607" NO="7" P_CHI2="1.0" P_Z="0.6230052790003637" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="27" WEIGHT="100.0" Z="0.4915955679254528">
<NAME>nausea or vomiting - 12 weeks</NAME>
<DICH_DATA CI_END="18.751226495456805" CI_START="0.17278869735721092" EFFECT_SIZE="1.8" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.2730296796791112" LOG_CI_START="-0.762484669472499" LOG_EFFECT_SIZE="0.25527250510330607" ORDER="1184" O_E="0.0" SE="1.1956712046501872" STUDY_ID="STD-Kiloh-1976" TOTAL_1="30" TOTAL_2="27" VAR="1.4296296296296296" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.677962750103403" CI_START="0.12083984385974253" DF="0" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" I2="0.0" ID="CMP-002.16.08" LOG_CI_END="0.5656073264500563" LOG_CI_START="-0.9177898445614188" LOG_EFFECT_SIZE="-0.17609125905568127" NO="8" P_CHI2="1.0" P_Z="0.6416971608956727" STUDIES="1" TAU2="0.0" TOTAL_1="27" TOTAL_2="27" WEIGHT="100.0" Z="0.46532719960105434">
<NAME>stomach trouble - 4 weeks</NAME>
<DICH_DATA CI_END="3.6779627501034033" CI_START="0.12083984385974247" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.5656073264500564" LOG_CI_START="-0.917789844561419" LOG_EFFECT_SIZE="-0.17609125905568127" ORDER="1185" O_E="0.0" SE="0.8713548411865624" STUDY_ID="STD-Malik-1980" TOTAL_1="27" TOTAL_2="27" VAR="0.7592592592592593" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="58.872690767564606" CI_END="1.2108272364580372" CI_START="0.9988009583592962" CI_STUDY="95" CI_TOTAL="95" DF="61" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0997160561626014" ESTIMABLE="YES" EVENTS_1="477" EVENTS_2="445" I2="0.0" I2_Q="0.0" ID="CMP-002.17" LOG_CI_END="0.08308218145400502" LOG_CI_START="-5.210496106835149E-4" LOG_EFFECT_SIZE="0.041280565921660774" METHOD="MH" NO="17" P_CHI2="0.5534183281505851" P_Q="0.9802983624632488" P_Z="0.052924875804858426" Q="11.965096333464432" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="19" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="1543" TOTAL_2="1642" WEIGHT="2500.0" Z="1.935533386389891">
<NAME>Adverse effects: 6. Movement disorders</NAME>
<GROUP_LABEL_1>Loxapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Typicals</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Loxapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Typicals</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.1799124260520544" CI_START="0.010166101831794776" DF="0" EFFECT_SIZE="0.1797979797979798" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="5" I2="0.0" ID="CMP-002.17.01" LOG_CI_END="0.5024151597938495" LOG_CI_START="-1.9928455443711615" LOG_EFFECT_SIZE="-0.745215192288656" NO="1" P_CHI2="1.0" P_Z="0.2417213122093489" STUDIES="1" TAU2="0.0" TOTAL_1="44" TOTAL_2="88" WEIGHT="100.0" Z="1.1706952585594583">
<NAME>agitation - 8 weeks</NAME>
<DICH_DATA CI_END="3.1799124260520544" CI_START="0.010166101831794776" EFFECT_SIZE="0.1797979797979798" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="5" LOG_CI_END="0.5024151597938495" LOG_CI_START="-1.9928455443711615" LOG_EFFECT_SIZE="-0.745215192288656" ORDER="1186" O_E="0.0" SE="1.4657284893662195" STUDY_ID="STD-Zhang-2005" TOTAL_1="44" TOTAL_2="88" VAR="2.14836000453978" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.4295104828614149" CI_END="2.190322884999092" CI_START="0.5198716295358713" DF="2" EFFECT_SIZE="1.0670926517571886" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="12" I2="0.0" ID="CMP-002.17.02" LOG_CI_END="0.34050814079314984" LOG_CI_START="-0.2841038822629177" LOG_EFFECT_SIZE="0.02820212926511603" NO="2" P_CHI2="0.8067389856483667" P_Z="0.8595159510681001" STUDIES="3" TAU2="0.0" TOTAL_1="79" TOTAL_2="83" WEIGHT="100.0" Z="0.17699037356509154">
<NAME>akathisia - up to 6 weeks</NAME>
<DICH_DATA CI_END="20.771505597011338" CI_START="0.1925715004778244" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.317467976976883" LOG_CI_START="-0.7154079856489205" LOG_EFFECT_SIZE="0.3010299956639812" ORDER="1187" O_E="0.0" SE="1.1941214033447043" STUDY_ID="STD-Malik-1980" TOTAL_1="27" TOTAL_2="27" VAR="1.425925925925926" WEIGHT="8.626198083067093"/>
<DICH_DATA CI_END="3.2705676601596108" CI_START="0.19946594343609708" EFFECT_SIZE="0.8076923076923077" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.5146231380666739" LOG_CI_START="-0.7001312445404715" LOG_EFFECT_SIZE="-0.09275405323689868" ORDER="1188" O_E="0.0" SE="0.7135527374746096" STUDY_ID="STD-Steinbook-1973" TOTAL_1="26" TOTAL_2="28" VAR="0.5091575091575091" WEIGHT="33.22683706070288"/>
<DICH_DATA CI_END="2.6526530609153243" CI_START="0.43720881961445784" EFFECT_SIZE="1.0769230769230769" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="7" LOG_CI_END="0.423680452551922" LOG_CI_START="-0.35931108580911947" LOG_EFFECT_SIZE="0.032184683371401235" ORDER="1189" O_E="0.0" SE="0.4599331055038999" STUDY_ID="STD-Van-Der-Velde-1975" TOTAL_1="26" TOTAL_2="28" VAR="0.2115384615384615" WEIGHT="58.146964856230035"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.9475177545361597" CI_END="1.8750590765758515" CI_START="0.7998239795867883" DF="2" EFFECT_SIZE="1.224629418472064" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="22" I2="0.0" ID="CMP-002.17.03" LOG_CI_END="0.2730149553846562" LOG_CI_START="-0.09700557938966345" LOG_EFFECT_SIZE="0.08800468799749636" NO="3" P_CHI2="0.37766087365192225" P_Z="0.3511788751822954" STUDIES="3" TAU2="0.0" TOTAL_1="78" TOTAL_2="79" WEIGHT="100.0" Z="0.9323051168010377">
<NAME>akathisia - up to 12 weeks</NAME>
<DICH_DATA CI_END="72.84387345476691" CI_START="0.13689962787560248" EFFECT_SIZE="3.1578947368421053" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8623930312374426" LOG_CI_START="-0.8635977323758133" LOG_EFFECT_SIZE="0.49939764943081466" ORDER="1190" O_E="0.0" SE="1.6012604684183327" STUDY_ID="STD-Clark-1972" TOTAL_1="18" TOTAL_2="19" VAR="2.564035087719298" WEIGHT="2.1664766248574687"/>
<DICH_DATA CI_END="1.8165256832791987" CI_START="0.33301938815029664" EFFECT_SIZE="0.7777777777777778" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="9" LOG_CI_END="0.25924154259376825" LOG_CI_START="-0.4775304814439043" LOG_EFFECT_SIZE="-0.10914446942506803" ORDER="1191" O_E="0.0" SE="0.4327835340000672" STUDY_ID="STD-Kiloh-1976" TOTAL_1="30" TOTAL_2="30" VAR="0.1873015873015873" WEIGHT="40.022805017103764"/>
<DICH_DATA CI_END="2.389296938114047" CI_START="0.8940264562688908" EFFECT_SIZE="1.4615384615384615" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="13" LOG_CI_END="0.37827012654798553" LOG_CI_START="-0.04864962925600118" LOG_EFFECT_SIZE="0.16481024864599217" ORDER="1192" O_E="0.0" SE="0.25077477784613567" STUDY_ID="STD-Wang-1996" TOTAL_1="30" TOTAL_2="30" VAR="0.0628879892037787" WEIGHT="57.81071835803877"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="158.84873801621674" CI_START="0.5099190652161858" DF="0" EFFECT_SIZE="9.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" I2="0.0" ID="CMP-002.17.04" LOG_CI_END="2.2009837688970637" LOG_CI_START="-0.2924987500184136" LOG_EFFECT_SIZE="0.9542425094393249" NO="4" P_CHI2="1.0" P_Z="0.13357928016203077" STUDIES="1" TAU2="0.0" TOTAL_1="25" TOTAL_2="25" WEIGHT="100.0" Z="1.5001356029812194">
<NAME>akinesia - 4 weeks</NAME>
<DICH_DATA CI_END="158.84873801621674" CI_START="0.5099190652161856" EFFECT_SIZE="9.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="2.2009837688970637" LOG_CI_START="-0.2924987500184138" LOG_EFFECT_SIZE="0.9542425094393249" ORDER="1193" O_E="0.0" SE="1.4646839745484845" STUDY_ID="STD-Bagadia-1980" TOTAL_1="25" TOTAL_2="25" VAR="2.1452991452991457" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.034638991133539" CI_START="0.2870559277911743" DF="0" EFFECT_SIZE="0.9333333333333333" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" I2="0.0" ID="CMP-002.17.05" LOG_CI_END="0.48210703363731056" LOG_CI_START="-0.542033480392197" LOG_EFFECT_SIZE="-0.02996322337744321" NO="5" P_CHI2="1.0" P_Z="0.9086947089353191" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="14" WEIGHT="100.0" Z="0.11468511962182809">
<NAME>dyskinesia - 4 weeks</NAME>
<DICH_DATA CI_END="3.03463899113354" CI_START="0.2870559277911742" EFFECT_SIZE="0.9333333333333333" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" LOG_CI_END="0.48210703363731067" LOG_CI_START="-0.5420334803921971" LOG_EFFECT_SIZE="-0.02996322337744321" ORDER="1194" O_E="0.0" SE="0.6015852075182384" STUDY_ID="STD-Clark-1975" TOTAL_1="15" TOTAL_2="14" VAR="0.36190476190476195" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.848204150362556" CI_END="3.543652900837433" CI_START="0.9124999547036095" DF="3" EFFECT_SIZE="1.7982166475426347" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="10" I2="0.0" ID="CMP-002.17.06" LOG_CI_END="0.5494511763545868" LOG_CI_START="-0.03976714842981421" LOG_EFFECT_SIZE="0.2548420139623863" NO="6" P_CHI2="0.4156261222715092" P_Z="0.08999905424323916" STUDIES="4" TAU2="0.0" TOTAL_1="100" TOTAL_2="105" WEIGHT="99.99999999999999" Z="1.69540269914957">
<NAME>dystonia - up to 6 weeks</NAME>
<DICH_DATA CI_END="3.82415621117103" CI_START="0.5125313642456595" EFFECT_SIZE="1.4" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="5" LOG_CI_END="0.5825356242588624" LOG_CI_START="-0.29027955290238633" LOG_EFFECT_SIZE="0.146128035678238" ORDER="1195" O_E="0.0" SE="0.5126959555693247" STUDY_ID="STD-Bagadia-1980" TOTAL_1="25" TOTAL_2="25" VAR="0.2628571428571429" WEIGHT="46.35314933387055"/>
<DICH_DATA CI_END="102.97802320481233" CI_START="0.26342257568062777" EFFECT_SIZE="5.208333333333333" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.0127445507318265" LOG_CI_START="-0.5793470081389256" LOG_EFFECT_SIZE="0.7166987712964503" ORDER="1196" O_E="0.0" SE="1.5226074127408329" STUDY_ID="STD-Fruensgaard-1978" TOTAL_1="23" TOTAL_2="24" VAR="2.3183333333333334" WEIGHT="4.54071666944038"/>
<DICH_DATA CI_END="171.23284582733305" CI_START="0.545715653985401" EFFECT_SIZE="9.666666666666666" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="2.2335870745546034" LOG_CI_START="-0.2630335881960164" LOG_EFFECT_SIZE="0.9852767431792936" ORDER="1197" O_E="0.0" SE="1.4665273357713096" STUDY_ID="STD-Steinbook-1973" TOTAL_1="26" TOTAL_2="28" VAR="2.1507024265644956" WEIGHT="4.469767971480374"/>
<DICH_DATA CI_END="3.2965458880723855" CI_START="0.35181166984683615" EFFECT_SIZE="1.0769230769230769" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="5" LOG_CI_END="0.5180591255212248" LOG_CI_START="-0.4536897587784223" LOG_EFFECT_SIZE="0.032184683371401235" ORDER="1198" O_E="0.0" SE="0.5708101048721684" STUDY_ID="STD-Van-Der-Velde-1975" TOTAL_1="26" TOTAL_2="28" VAR="0.3258241758241759" WEIGHT="44.63636602520868"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.7641809885825612" CI_END="2.4217089168034693" CI_START="0.5906440324339359" DF="1" EFFECT_SIZE="1.1959798994974875" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="10" I2="43.316473396334786" ID="CMP-002.17.07" LOG_CI_END="0.3841219408618837" LOG_CI_START="-0.22867417956827313" LOG_EFFECT_SIZE="0.07772388064680533" NO="7" P_CHI2="0.18410399113767395" P_Z="0.6190597800609416" STUDIES="2" TAU2="0.0" TOTAL_1="60" TOTAL_2="57" WEIGHT="100.0" Z="0.4971833264854705">
<NAME>dystonia - up to 12 weeks</NAME>
<DICH_DATA CI_END="1.931702316597661" CI_START="0.4193192672806162" EFFECT_SIZE="0.9" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="9" LOG_CI_END="0.2859402006405788" LOG_CI_START="-0.37745518176192894" LOG_EFFECT_SIZE="-0.045757490560675115" ORDER="1199" O_E="0.0" SE="0.38968173148333735" STUDY_ID="STD-Kiloh-1976" TOTAL_1="30" TOTAL_2="27" VAR="0.15185185185185185" WEIGHT="90.45226130653266"/>
<DICH_DATA CI_END="33.72924445563291" CI_START="0.4743657991226642" EFFECT_SIZE="4.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" LOG_CI_END="1.52800661298213" LOG_CI_START="-0.32388663032620535" LOG_EFFECT_SIZE="0.6020599913279624" ORDER="1200" O_E="0.0" SE="1.0878112581387145" STUDY_ID="STD-Wang-1996" TOTAL_1="30" TOTAL_2="30" VAR="1.1833333333333331" WEIGHT="9.547738693467338"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.449450870210969" CI_END="1.2304589684470975" CI_START="0.7672663202901525" DF="3" EFFECT_SIZE="0.9716427970136049" ESTIMABLE="YES" EVENTS_1="50" EVENTS_2="52" I2="0.0" ID="CMP-002.17.08" LOG_CI_END="0.09006713606066596" LOG_CI_START="-0.11505386505114219" LOG_EFFECT_SIZE="-0.012493364495238102" NO="8" P_CHI2="0.48449597612110185" P_Z="0.8112977426166649" STUDIES="4" TAU2="0.0" TOTAL_1="84" TOTAL_2="85" WEIGHT="100.00000000000001" Z="0.23875219332661984">
<NAME>extrapyramidial - up to 4 weeks</NAME>
<DICH_DATA CI_END="1.120879853658162" CI_START="0.49009941499150894" EFFECT_SIZE="0.7411764705882353" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="17" LOG_CI_END="0.04955906336242087" LOG_CI_START="-0.30971581588384284" LOG_EFFECT_SIZE="-0.130078376260711" ORDER="1201" O_E="0.0" SE="0.21103984250858987" STUDY_ID="STD-Charalampous-1974" TOTAL_1="20" TOTAL_2="21" VAR="0.044537815126050415" WEIGHT="32.10378719748332"/>
<DICH_DATA CI_END="1.7441793917727655" CI_START="0.624274593567282" EFFECT_SIZE="1.0434782608695652" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="13" LOG_CI_END="0.24159115080890237" LOG_CI_START="-0.20462433942087613" LOG_EFFECT_SIZE="0.018483405694013133" ORDER="1202" O_E="0.0" SE="0.26210918776327163" STUDY_ID="STD-Fruensgaard-1978" TOTAL_1="23" TOTAL_2="24" VAR="0.06870122630992198" WEIGHT="24.628305835666335"/>
<DICH_DATA CI_END="1.4229982705486997" CI_START="0.7239209428499983" EFFECT_SIZE="1.014957264957265" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="18" LOG_CI_END="0.15320437226164701" LOG_CI_START="-0.140308859160162" LOG_EFFECT_SIZE="0.006447756550742514" ORDER="1203" O_E="0.0" SE="0.17241112505109846" STUDY_ID="STD-Pool-1976" TOTAL_1="26" TOTAL_2="25" VAR="0.029725596041385506" WEIGHT="35.52522887804555"/>
<DICH_DATA CI_END="4.2577276665705055" CI_START="0.5284508959240973" EFFECT_SIZE="1.5" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="4" LOG_CI_END="0.6291778795804434" LOG_CI_START="-0.27699536146908094" LOG_EFFECT_SIZE="0.17609125905568124" ORDER="1204" O_E="0.0" SE="0.5322906474223771" STUDY_ID="STD-Shopsin-1972" TOTAL_1="15" TOTAL_2="15" VAR="0.2833333333333333" WEIGHT="7.742678088804801"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="10.030791490410309" CI_END="1.3785904593737248" CI_START="0.8536775218159462" DF="3" EFFECT_SIZE="1.0848371707114706" ESTIMABLE="YES" EVENTS_1="65" EVENTS_2="71" I2="70.09209090959496" ID="CMP-002.17.09" LOG_CI_END="0.1394352686049381" LOG_CI_START="-0.06870615383640365" LOG_EFFECT_SIZE="0.035364557384267234" NO="9" P_CHI2="0.018306242395712324" P_Z="0.5053978070111983" STUDIES="4" TAU2="0.0" TOTAL_1="136" TOTAL_2="178" WEIGHT="100.0" Z="0.6660208044066541">
<NAME>extrapyramidal - up to 12 weeks</NAME>
<DICH_DATA CI_END="4.00333498190743" CI_START="0.9773278936737377" EFFECT_SIZE="1.978021978021978" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="7" LOG_CI_END="0.6024219315258296" LOG_CI_START="-0.009959705961404513" LOG_EFFECT_SIZE="0.2962311127822125" ORDER="1205" O_E="0.0" SE="0.35971600519799557" STUDY_ID="STD-Schiele-1975" TOTAL_1="26" TOTAL_2="24" VAR="0.12939560439560438" WEIGHT="11.325451151213441"/>
<DICH_DATA CI_END="0.9787887679404295" CI_START="0.33360682400553565" EFFECT_SIZE="0.5714285714285714" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="21" LOG_CI_END="-0.009311023024253915" LOG_CI_START="-0.476765074348335" LOG_EFFECT_SIZE="-0.24303804868629447" ORDER="1206" O_E="0.0" SE="0.274584823682638" STUDY_ID="STD-Seth-1979" TOTAL_1="36" TOTAL_2="36" VAR="0.07539682539682538" WEIGHT="32.66957062850031"/>
<DICH_DATA CI_END="1.35685019229308" CI_START="0.7370010379038217" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="22" LOG_CI_END="0.1325319005322849" LOG_CI_START="-0.1325319005322849" LOG_EFFECT_SIZE="0.0" ORDER="1207" O_E="0.0" SE="0.1556997888323046" STUDY_ID="STD-Wang-1996" TOTAL_1="30" TOTAL_2="30" VAR="0.024242424242424246" WEIGHT="34.225264467952705"/>
<DICH_DATA CI_END="2.6159786286160616" CI_START="0.8876201966837242" EFFECT_SIZE="1.5238095238095237" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="21" LOG_CI_END="0.41763419167362575" LOG_CI_START="-0.05177282450165239" LOG_EFFECT_SIZE="0.1829306835859867" ORDER="1208" O_E="0.0" SE="0.27573200490356303" STUDY_ID="STD-Zhang-2005" TOTAL_1="44" TOTAL_2="88" VAR="0.07602813852813851" WEIGHT="21.779713752333542"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.3093145890680553" CI_START="0.8690649831534495" DF="0" EFFECT_SIZE="1.4166666666666667" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="12" I2="0.0" ID="CMP-002.17.10" LOG_CI_END="0.3634830992186051" LOG_CI_START="-0.06094774855730686" LOG_EFFECT_SIZE="0.15126767533064914" NO="10" P_CHI2="1.0" P_Z="0.16239338162944567" STUDIES="1" TAU2="0.0" TOTAL_1="25" TOTAL_2="25" WEIGHT="100.0" Z="1.3970671416876057">
<NAME>excess salivation - 4 weeks</NAME>
<DICH_DATA CI_END="2.3093145890680553" CI_START="0.8690649831534495" EFFECT_SIZE="1.4166666666666667" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="12" LOG_CI_END="0.3634830992186051" LOG_CI_START="-0.06094774855730686" LOG_EFFECT_SIZE="0.15126767533064914" ORDER="1209" O_E="0.0" SE="0.2493127809501511" STUDY_ID="STD-Bagadia-1980" TOTAL_1="25" TOTAL_2="25" VAR="0.062156862745098025" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.48490599579244914" CI_END="2.194271335461896" CI_START="0.3927228188730417" DF="2" EFFECT_SIZE="0.9282997491300478" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="8" I2="0.0" ID="CMP-002.17.11" LOG_CI_END="0.3412903298055785" LOG_CI_START="-0.40591386363223053" LOG_EFFECT_SIZE="-0.03231176691332603" NO="11" P_CHI2="0.7847006371988877" P_Z="0.865394227405663" STUDIES="3" TAU2="0.0" TOTAL_1="63" TOTAL_2="61" WEIGHT="100.0" Z="0.1695116274323828">
<NAME>excess salivation - 7 - 26 weeks</NAME>
<DICH_DATA CI_END="15.640507378231115" CI_START="0.07123794029949233" EFFECT_SIZE="1.0555555555555556" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1942508374701124" LOG_CI_START="-1.1472886457710665" LOG_EFFECT_SIZE="0.0234810958495229" ORDER="1210" O_E="0.0" SE="1.3754318832632446" STUDY_ID="STD-Clark-1972" TOTAL_1="18" TOTAL_2="19" VAR="1.891812865497076" WEIGHT="11.070648215586308"/>
<DICH_DATA CI_END="2.7381364470473635" CI_START="0.40264611399803246" EFFECT_SIZE="1.05" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="6" LOG_CI_END="0.43745508613662626" LOG_CI_START="-0.39507648799675" LOG_EFFECT_SIZE="0.021189299069938092" ORDER="1211" O_E="0.0" SE="0.48903316774370137" STUDY_ID="STD-Kiloh-1976" TOTAL_1="30" TOTAL_2="27" VAR="0.23915343915343917" WEIGHT="71.86210245205147"/>
<DICH_DATA CI_END="7.584304769707433" CI_START="0.014650137947370117" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.87991577648491" LOG_CI_START="-1.8341582859242351" LOG_EFFECT_SIZE="-0.47712125471966244" ORDER="1212" O_E="0.0" SE="1.5942605391424158" STUDY_ID="STD-Vyas-1980" TOTAL_1="15" TOTAL_2="15" VAR="2.5416666666666665" WEIGHT="17.067249332362223"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.270567660159611" CI_START="0.19946594343609705" DF="0" EFFECT_SIZE="0.8076923076923077" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" I2="0.0" ID="CMP-002.17.12" LOG_CI_END="0.514623138066674" LOG_CI_START="-0.7001312445404715" LOG_EFFECT_SIZE="-0.09275405323689868" NO="12" P_CHI2="1.0" P_Z="0.764702851578327" STUDIES="1" TAU2="0.0" TOTAL_1="26" TOTAL_2="28" WEIGHT="100.0" Z="0.2993108835289958">
<NAME>fixed stare - 6 weeks</NAME>
<DICH_DATA CI_END="3.2705676601596108" CI_START="0.19946594343609708" EFFECT_SIZE="0.8076923076923077" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.5146231380666739" LOG_CI_START="-0.7001312445404715" LOG_EFFECT_SIZE="-0.09275405323689868" ORDER="1213" O_E="0.0" SE="0.7135527374746096" STUDY_ID="STD-Van-Der-Velde-1975" TOTAL_1="26" TOTAL_2="28" VAR="0.5091575091575091" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.11932481772549583" CI_END="2.322431952032201" CI_START="0.21251460676593173" DF="1" EFFECT_SIZE="0.7025316455696202" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="6" I2="0.0" ID="CMP-002.17.13" LOG_CI_END="0.36594299789070867" LOG_CI_START="-0.6726112142262392" LOG_EFFECT_SIZE="-0.15333410816776522" NO="13" P_CHI2="0.7297679921731002" P_Z="0.5627608591755622" STUDIES="2" TAU2="0.0" TOTAL_1="53" TOTAL_2="55" WEIGHT="100.00000000000001" Z="0.578745579391184">
<NAME>heavy muscles - up to 6 weeks</NAME>
<DICH_DATA CI_END="5.1928763992528335" CI_START="0.048142875119456086" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7154079856489205" LOG_CI_START="-1.317467976976883" LOG_EFFECT_SIZE="-0.3010299956639812" ORDER="1214" O_E="0.0" SE="1.1941214033447043" STUDY_ID="STD-Malik-1980" TOTAL_1="27" TOTAL_2="27" VAR="1.425925925925926" WEIGHT="34.17721518987342"/>
<DICH_DATA CI_END="3.2705676601596108" CI_START="0.19946594343609708" EFFECT_SIZE="0.8076923076923077" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.5146231380666739" LOG_CI_START="-0.7001312445404715" LOG_EFFECT_SIZE="-0.09275405323689868" ORDER="1215" O_E="0.0" SE="0.7135527374746096" STUDY_ID="STD-Van-Der-Velde-1975" TOTAL_1="26" TOTAL_2="28" VAR="0.5091575091575091" WEIGHT="65.82278481012659"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="5.81434250695042" CI_START="0.3546061216641725" DF="0" EFFECT_SIZE="1.435897435897436" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" I2="0.0" ID="CMP-002.17.14" LOG_CI_END="0.764500611283274" LOG_CI_START="-0.4502537713238717" LOG_EFFECT_SIZE="0.15712341997970122" NO="14" P_CHI2="1.0" P_Z="0.612136327556394" STUDIES="1" TAU2="0.0" TOTAL_1="26" TOTAL_2="28" WEIGHT="99.99999999999999" Z="0.5070263564343432">
<NAME>muscle cramp - 6 weeks</NAME>
<DICH_DATA CI_END="5.81434250695042" CI_START="0.3546061216641727" EFFECT_SIZE="1.435897435897436" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.764500611283274" LOG_CI_START="-0.4502537713238714" LOG_EFFECT_SIZE="0.15712341997970122" ORDER="1216" O_E="0.0" SE="0.7135527374746096" STUDY_ID="STD-Van-Der-Velde-1975" TOTAL_1="26" TOTAL_2="28" VAR="0.5091575091575091" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.869349809266054" CI_START="0.2997307999478739" DF="0" EFFECT_SIZE="1.0769230769230769" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" I2="0.0" ID="CMP-002.17.15" LOG_CI_END="0.587637993966934" LOG_CI_START="-0.5232686272241314" LOG_EFFECT_SIZE="0.032184683371401235" NO="15" P_CHI2="1.0" P_Z="0.9095815418817758" STUDIES="1" TAU2="0.0" TOTAL_1="26" TOTAL_2="28" WEIGHT="100.0" Z="0.11356637733266743">
<NAME>muscle spasm - 6 weeks</NAME>
<DICH_DATA CI_END="3.869349809266054" CI_START="0.2997307999478739" EFFECT_SIZE="1.0769230769230769" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" LOG_CI_END="0.587637993966934" LOG_CI_START="-0.5232686272241314" LOG_EFFECT_SIZE="0.032184683371401235" ORDER="1217" O_E="0.0" SE="0.6525520483640947" STUDY_ID="STD-Van-Der-Velde-1975" TOTAL_1="26" TOTAL_2="28" VAR="0.42582417582417587" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="19.775299481351468" CI_START="0.20227253720086952" DF="0" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" I2="0.0" ID="CMP-002.17.16" LOG_CI_END="1.296123069267743" LOG_CI_START="-0.6940630779397805" LOG_EFFECT_SIZE="0.3010299956639812" NO="16" P_CHI2="1.0" P_Z="0.5532364681192914" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="15" WEIGHT="100.0" Z="0.5929173515708626">
<NAME>muscle spasm - 26 weeks</NAME>
<DICH_DATA CI_END="19.775299481351468" CI_START="0.20227253720086952" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.296123069267743" LOG_CI_START="-0.6940630779397805" LOG_EFFECT_SIZE="0.3010299956639812" ORDER="1218" O_E="0.0" SE="1.1690451944500122" STUDY_ID="STD-Vyas-1980" TOTAL_1="15" TOTAL_2="15" VAR="1.3666666666666667" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="11.685684280442494" CI_END="1.3306366852215223" CI_START="0.8091709478221158" DF="6" EFFECT_SIZE="1.0376476028920307" ESTIMABLE="YES" EVENTS_1="65" EVENTS_2="61" I2="48.65512488608154" ID="CMP-002.17.17" LOG_CI_END="0.12405949263298992" LOG_CI_START="-0.09195971837162507" LOG_EFFECT_SIZE="0.016049887130682394" NO="17" P_CHI2="0.06935960883933456" P_Z="0.7708643511924199" STUDIES="7" TAU2="0.0" TOTAL_1="152" TOTAL_2="150" WEIGHT="100.0" Z="0.2912444739130018">
<NAME>needing additional anticholinergic medication - up to 6 weeks</NAME>
<DICH_DATA CI_END="1.2442751844119824" CI_START="0.47650231028290724" EFFECT_SIZE="0.77" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="15" LOG_CI_END="0.09491643972384851" LOG_CI_START="-0.3219349893788847" LOG_EFFECT_SIZE="-0.11350927482751812" ORDER="1219" O_E="0.0" SE="0.2448605929027984" STUDY_ID="STD-Charalampous-1974" TOTAL_1="20" TOTAL_2="21" VAR="0.05995670995670997" WEIGHT="23.713914815441328"/>
<DICH_DATA CI_END="2.4514017267297032" CI_START="0.48367389131582106" EFFECT_SIZE="1.0888888888888888" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="6" LOG_CI_END="0.38941448767215076" LOG_CI_START="-0.3154473551658109" LOG_EFFECT_SIZE="0.036983566253169946" ORDER="1220" O_E="0.0" SE="0.41403933560541256" STUDY_ID="STD-Clark-1975" TOTAL_1="15" TOTAL_2="14" VAR="0.17142857142857146" WEIGHT="10.057970766549253"/>
<DICH_DATA CI_END="1.0224215341492535" CI_START="0.14082230082043404" EFFECT_SIZE="0.3794466403162055" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="11" LOG_CI_END="0.009629987981485934" LOG_CI_START="-0.851328564253985" LOG_EFFECT_SIZE="-0.42084928813624956" ORDER="1221" O_E="0.0" SE="0.5057313153966828" STUDY_ID="STD-Fruensgaard-1978" TOTAL_1="23" TOTAL_2="24" VAR="0.25576416337285907" WEIGHT="17.44570484968602"/>
<DICH_DATA CI_END="33.659430357342046" CI_START="0.4753496963596106" EFFECT_SIZE="4.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" LOG_CI_END="1.5271067618252954" LOG_CI_START="-0.3229867791693705" LOG_EFFECT_SIZE="0.6020599913279624" ORDER="1222" O_E="0.0" SE="1.0867541040909947" STUDY_ID="STD-Moore-1975" TOTAL_1="29" TOTAL_2="29" VAR="1.1810344827586206" WEIGHT="1.620450845721824"/>
<DICH_DATA CI_END="4.2577276665705055" CI_START="0.5284508959240973" EFFECT_SIZE="1.5" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="4" LOG_CI_END="0.6291778795804434" LOG_CI_START="-0.27699536146908094" LOG_EFFECT_SIZE="0.17609125905568124" ORDER="1223" O_E="0.0" SE="0.5322906474223771" STUDY_ID="STD-Shopsin-1972" TOTAL_1="15" TOTAL_2="15" VAR="0.2833333333333333" WEIGHT="6.481803382887296"/>
<DICH_DATA CI_END="1.4114691246513118" CI_START="0.5911655931224519" EFFECT_SIZE="0.9134615384615384" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="13" LOG_CI_END="0.14967138256071402" LOG_CI_START="-0.2282908505805792" LOG_EFFECT_SIZE="-0.0393097340099326" ORDER="1224" O_E="0.0" SE="0.22201688669042385" STUDY_ID="STD-Simpson-1976" TOTAL_1="24" TOTAL_2="19" VAR="0.049291497975708504" WEIGHT="23.515379714660888"/>
<DICH_DATA CI_END="2.9848567509609274" CI_START="1.0404123848345472" EFFECT_SIZE="1.7622377622377623" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="11" LOG_CI_END="0.47492349333472567" LOG_CI_START="0.017205513298239015" LOG_EFFECT_SIZE="0.2460645033164823" ORDER="1225" O_E="0.0" SE="0.26886580721397485" STUDY_ID="STD-Steinbook-1973" TOTAL_1="26" TOTAL_2="28" VAR="0.07228882228882229" WEIGHT="17.164775625053398"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.560144696013107" CI_END="1.7194707519921586" CI_START="0.707352075334815" DF="2" EFFECT_SIZE="1.1028468637572346" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="21" I2="21.879415522310744" ID="CMP-002.17.18" LOG_CI_END="0.23539479291962373" LOG_CI_START="-0.15036436793475108" LOG_EFFECT_SIZE="0.042515212492436324" NO="18" P_CHI2="0.2780173035038134" P_Z="0.6657251867622298" STUDIES="3" TAU2="0.0" TOTAL_1="63" TOTAL_2="57" WEIGHT="100.0" Z="0.43202232758744136">
<NAME>needing additional anticholinergic medication - up to 12 weeks</NAME>
<DICH_DATA CI_END="3.303025227094486" CI_START="0.13455678170384458" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.5189118906596525" LOG_CI_START="-0.871094408771015" LOG_EFFECT_SIZE="-0.17609125905568127" ORDER="1226" O_E="0.0" SE="0.8164965809277259" STUDY_ID="STD-Gallant-1971" TOTAL_1="12" TOTAL_2="12" VAR="0.6666666666666665" WEIGHT="13.49131862975129"/>
<DICH_DATA CI_END="1.5329536387211595" CI_START="0.46028789271711745" EFFECT_SIZE="0.84" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="11" LOG_CI_END="0.18552902063908785" LOG_CI_START="-0.3369704485153246" LOG_EFFECT_SIZE="-0.07572071393811836" ORDER="1227" O_E="0.0" SE="0.30691877459538736" STUDY_ID="STD-Kiloh-1976" TOTAL_1="25" TOTAL_2="21" VAR="0.0941991341991342" WEIGHT="53.769748162052245"/>
<DICH_DATA CI_END="3.5659692386526785" CI_START="0.8241168988082554" EFFECT_SIZE="1.7142857142857142" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="7" LOG_CI_END="0.5521775924733741" LOG_CI_START="-0.08401118040663819" LOG_EFFECT_SIZE="0.23408320603336796" ORDER="1228" O_E="0.0" SE="0.3737004343749344" STUDY_ID="STD-Schiele-1975" TOTAL_1="26" TOTAL_2="24" VAR="0.13965201465201466" WEIGHT="32.738933208196464"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.476303751638317" CI_START="0.40482734820029975" DF="0" EFFECT_SIZE="1.3461538461538463" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" I2="0.0" ID="CMP-002.17.19" LOG_CI_END="0.6509195490771513" LOG_CI_START="-0.392730156318236" LOG_EFFECT_SIZE="0.1290946963794577" NO="19" P_CHI2="1.0" P_Z="0.6277634826252488" STUDIES="1" TAU2="0.0" TOTAL_1="26" TOTAL_2="28" WEIGHT="100.0" Z="0.48487716556775773">
<NAME>oculogyric crisis - 6 weeks</NAME>
<DICH_DATA CI_END="4.476303751638317" CI_START="0.40482734820029975" EFFECT_SIZE="1.3461538461538463" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" LOG_CI_END="0.6509195490771513" LOG_CI_START="-0.392730156318236" LOG_EFFECT_SIZE="0.1290946963794577" ORDER="1229" O_E="0.0" SE="0.6130450030986109" STUDY_ID="STD-Van-Der-Velde-1975" TOTAL_1="26" TOTAL_2="28" VAR="0.3758241758241758" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.9100492435203824" CI_END="1.5041774894608693" CI_START="0.958238684346879" DF="3" EFFECT_SIZE="1.2005669737774627" ESTIMABLE="YES" EVENTS_1="62" EVENTS_2="53" I2="0.0" ID="CMP-002.17.20" LOG_CI_END="0.1772990850225669" LOG_CI_START="-0.018526300541886413" LOG_EFFECT_SIZE="0.07938639224034023" NO="20" P_CHI2="0.823002173014315" P_Z="0.11203456820683431" STUDIES="4" TAU2="0.0" TOTAL_1="104" TOTAL_2="108" WEIGHT="100.0" Z="1.589114396023237">
<NAME>rigidity - up to 6 weeks</NAME>
<DICH_DATA CI_END="2.4737328572009405" CI_START="0.8552671616015912" EFFECT_SIZE="1.4545454545454546" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="11" LOG_CI_END="0.39335279759390385" LOG_CI_START="-0.06789820259850445" LOG_EFFECT_SIZE="0.16272729749769976" ORDER="1230" O_E="0.0" SE="0.27094112074229504" STUDY_ID="STD-Bagadia-1980" TOTAL_1="25" TOTAL_2="25" VAR="0.0734090909090909" WEIGHT="21.048901488306164"/>
<DICH_DATA CI_END="1.435475343122633" CI_START="0.9729837726350367" EFFECT_SIZE="1.1818181818181819" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="22" LOG_CI_END="0.1569957371057756" LOG_CI_START="-0.011894402808552095" LOG_EFFECT_SIZE="0.07255066714861175" ORDER="1231" O_E="0.0" SE="0.0992069042053518" STUDY_ID="STD-Malik-1980" TOTAL_1="27" TOTAL_2="27" VAR="0.00984200984200985" WEIGHT="42.09780297661233"/>
<DICH_DATA CI_END="2.6660653029919663" CI_START="0.5505586986709324" EFFECT_SIZE="1.2115384615384615" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="8" LOG_CI_END="0.42587078288043756" LOG_CI_START="-0.2591963712428725" LOG_EFFECT_SIZE="0.08333720581878251" ORDER="1232" O_E="0.0" SE="0.4024118374691367" STUDY_ID="STD-Steinbook-1973" TOTAL_1="26" TOTAL_2="28" VAR="0.16193528693528692" WEIGHT="14.7413182140326"/>
<DICH_DATA CI_END="1.8350981816617054" CI_START="0.5310469759310164" EFFECT_SIZE="0.9871794871794872" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="12" LOG_CI_END="0.2636593048895924" LOG_CI_START="-0.27486705992558935" LOG_EFFECT_SIZE="-0.005603877517998511" ORDER="1233" O_E="0.0" SE="0.3163330524409362" STUDY_ID="STD-Van-Der-Velde-1975" TOTAL_1="26" TOTAL_2="28" VAR="0.10006660006660008" WEIGHT="22.1119773210489"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.40205378063515607" CI_END="2.062210933149766" CI_START="0.5125830674346826" DF="2" EFFECT_SIZE="1.0281315119240564" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="12" I2="0.0" ID="CMP-002.17.21" LOG_CI_END="0.314333085010456" LOG_CI_START="-0.29023574431084836" LOG_EFFECT_SIZE="0.012048670349803791" NO="21" P_CHI2="0.8178905151028746" P_Z="0.9377312784967294" STUDIES="3" TAU2="0.0" TOTAL_1="63" TOTAL_2="61" WEIGHT="100.0" Z="0.07812165894732435">
<NAME>rigidity - 7 - 26 weeks</NAME>
<DICH_DATA CI_END="3.7345210116896546" CI_START="0.13260037928726534" EFFECT_SIZE="0.7037037037037037" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.572234907270582" LOG_CI_START="-0.8774552336828987" LOG_EFFECT_SIZE="-0.15261016320615833" ORDER="1234" O_E="0.0" SE="0.8515551648780068" STUDY_ID="STD-Clark-1972" TOTAL_1="18" TOTAL_2="19" VAR="0.7251461988304093" WEIGHT="23.755498958092154"/>
<DICH_DATA CI_END="2.4575594287354106" CI_START="0.43049180064706083" EFFECT_SIZE="1.0285714285714285" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="7" LOG_CI_END="0.3905040287462034" LOG_CI_START="-0.36603511591218024" LOG_EFFECT_SIZE="0.012234456417011586" ORDER="1235" O_E="0.0" SE="0.444394838501498" STUDY_ID="STD-Kiloh-1976" TOTAL_1="30" TOTAL_2="27" VAR="0.1974867724867725" WEIGHT="59.96758508914101"/>
<DICH_DATA CI_END="7.731389706964666" CI_START="0.29102141856503916" EFFECT_SIZE="1.5" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.8882575647876686" LOG_CI_START="-0.5360750466763062" LOG_EFFECT_SIZE="0.17609125905568124" ORDER="1236" O_E="0.0" SE="0.8366600265340756" STUDY_ID="STD-Vyas-1980" TOTAL_1="15" TOTAL_2="15" VAR="0.7" WEIGHT="16.276915952766846"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.0924436526673404" CI_END="3.388028017847534" CI_START="0.44394378550022695" DF="1" EFFECT_SIZE="1.2264150943396224" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="6" I2="52.20898786329319" ID="CMP-002.17.22" LOG_CI_END="0.5299469931422189" LOG_CI_START="-0.3526720190580861" LOG_EFFECT_SIZE="0.08863748704206643" NO="22" P_CHI2="0.1480291779862425" P_Z="0.6938314385407676" STUDIES="2" TAU2="0.0" TOTAL_1="53" TOTAL_2="55" WEIGHT="99.99999999999999" Z="0.3936608658576229">
<NAME>thick speech - up to 6 weeks</NAME>
<DICH_DATA CI_END="3.0065554000778807" CI_START="0.03695628263102449" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.47806921075143305" LOG_CI_START="-1.432311720190758" LOG_EFFECT_SIZE="-0.47712125471966244" ORDER="1237" O_E="0.0" SE="1.1221672153735642" STUDY_ID="STD-Malik-1980" TOTAL_1="27" TOTAL_2="27" VAR="1.2592592592592593" WEIGHT="50.94339622641509"/>
<DICH_DATA CI_END="7.738699618532107" CI_START="0.5994615998957477" EFFECT_SIZE="2.1538461538461537" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="3" LOG_CI_END="0.8886679896309151" LOG_CI_START="-0.2222386315601503" LOG_EFFECT_SIZE="0.33321467903538243" ORDER="1238" O_E="0.0" SE="0.6525520483640947" STUDY_ID="STD-Van-Der-Velde-1975" TOTAL_1="26" TOTAL_2="28" VAR="0.42582417582417587" WEIGHT="49.0566037735849"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="7.682256269201506" CI_END="1.5113889583404652" CI_START="0.8084241536754291" DF="3" EFFECT_SIZE="1.1053702273540658" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="35" I2="60.94897260812389" ID="CMP-002.17.23" LOG_CI_END="0.1793762450953841" LOG_CI_START="-0.09236071933875926" LOG_EFFECT_SIZE="0.04350776287831245" NO="23" P_CHI2="0.053055936498688894" P_Z="0.5302535271200803" STUDIES="4" TAU2="0.0" TOTAL_1="104" TOTAL_2="108" WEIGHT="100.0" Z="0.6276190540876346">
<NAME>tremor - up to 6 weeks</NAME>
<DICH_DATA CI_END="2.0343042970615515" CI_START="1.106029222496364" EFFECT_SIZE="1.5" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="16" LOG_CI_END="0.3084159164579999" LOG_CI_START="0.0437666016533626" LOG_EFFECT_SIZE="0.17609125905568124" ORDER="1239" O_E="0.0" SE="0.1554563175514802" STUDY_ID="STD-Bagadia-1980" TOTAL_1="25" TOTAL_2="25" VAR="0.02416666666666665" WEIGHT="45.56876189041044"/>
<DICH_DATA CI_END="1.6146789623777693" CI_START="0.27525251446266286" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="9" LOG_CI_END="0.20808618689781244" LOG_CI_START="-0.5602687050091749" LOG_EFFECT_SIZE="-0.17609125905568127" ORDER="1240" O_E="0.0" SE="0.45133546692422005" STUDY_ID="STD-Malik-1980" TOTAL_1="27" TOTAL_2="27" VAR="0.20370370370370372" WEIGHT="25.632428563355873"/>
<DICH_DATA CI_END="106.87673661574209" CI_START="0.26985178279389893" EFFECT_SIZE="5.37037037037037" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.0288831845456468" LOG_CI_START="-0.5688747083936717" LOG_EFFECT_SIZE="0.7300042380759876" ORDER="1241" O_E="0.0" SE="1.5259358454215148" STUDY_ID="STD-Steinbook-1973" TOTAL_1="26" TOTAL_2="28" VAR="2.328480204342273" WEIGHT="1.3731658158940647"/>
<DICH_DATA CI_END="1.5268283383037686" CI_START="0.27345234721229156" EFFECT_SIZE="0.6461538461538462" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="10" LOG_CI_END="0.18379021196263914" LOG_CI_START="-0.5631183444525494" LOG_EFFECT_SIZE="-0.18966406624495508" ORDER="1242" O_E="0.0" SE="0.4387377832952645" STUDY_ID="STD-Van-Der-Velde-1975" TOTAL_1="26" TOTAL_2="28" VAR="0.19249084249084247" WEIGHT="27.42564373033962"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.5195197919329528" CI_END="1.3162611548192489" CI_START="0.5375910157196835" DF="3" EFFECT_SIZE="0.8411956794775182" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="28" I2="0.0" ID="CMP-002.17.24" LOG_CI_END="0.11934206469186681" LOG_CI_START="-0.26954799787084016" LOG_EFFECT_SIZE="-0.07510296658948672" NO="24" P_CHI2="0.6777725885073891" P_Z="0.4490368634678159" STUDIES="4" TAU2="0.0" TOTAL_1="93" TOTAL_2="91" WEIGHT="100.0" Z="0.7570217077674679">
<NAME>tremor - 7 to 26 weeks</NAME>
<DICH_DATA CI_END="8.402672276301722" CI_START="0.2983508533963469" EFFECT_SIZE="1.5833333333333333" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.9244174253819445" LOG_CI_START="-0.5252727155715363" LOG_EFFECT_SIZE="0.1995723549052041" ORDER="1243" O_E="0.0" SE="0.8515551648780068" STUDY_ID="STD-Clark-1972" TOTAL_1="18" TOTAL_2="19" VAR="0.7251461988304093" WEIGHT="6.872645064054258"/>
<DICH_DATA CI_END="1.7883146724928813" CI_START="0.23109205134819139" EFFECT_SIZE="0.6428571428571429" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="7" LOG_CI_END="0.2524439397972266" LOG_CI_START="-0.636214992275053" LOG_EFFECT_SIZE="-0.1918855262389131" ORDER="1244" O_E="0.0" SE="0.5220026556319158" STUDY_ID="STD-Kiloh-1976" TOTAL_1="30" TOTAL_2="27" VAR="0.2724867724867725" WEIGHT="26.02361215774931"/>
<DICH_DATA CI_END="3.766239014647583" CI_START="0.4148701115152691" EFFECT_SIZE="1.25" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" LOG_CI_END="0.5759078779346776" LOG_CI_START="-0.38208785191856476" LOG_EFFECT_SIZE="0.09691001300805642" ORDER="1245" O_E="0.0" SE="0.5627314338711378" STUDY_ID="STD-Vyas-1980" TOTAL_1="15" TOTAL_2="15" VAR="0.3166666666666667" WEIGHT="14.127103742778196"/>
<DICH_DATA CI_END="1.3241840361901684" CI_START="0.4061201185637511" EFFECT_SIZE="0.7333333333333333" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="15" LOG_CI_END="0.1219483479039224" LOG_CI_START="-0.39134549569883487" LOG_EFFECT_SIZE="-0.13469857389745624" ORDER="1246" O_E="0.0" SE="0.3015113445777637" STUDY_ID="STD-Wang-1996" TOTAL_1="30" TOTAL_2="30" VAR="0.09090909090909094" WEIGHT="52.97663903541824"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="20.897996678081558" CI_START="0.19140590658602794" DF="0" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" I2="0.0" ID="CMP-002.17.25" LOG_CI_END="1.320104655806998" LOG_CI_START="-0.7180446644790355" LOG_EFFECT_SIZE="0.3010299956639812" NO="25" P_CHI2="1.0" P_Z="0.5626131970048236" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="30" WEIGHT="100.0" Z="0.5789644005914643">
<NAME>twisting movement - 8 weeks</NAME>
<DICH_DATA CI_END="20.897996678081547" CI_START="0.19140590658602802" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3201046558069978" LOG_CI_START="-0.7180446644790353" LOG_EFFECT_SIZE="0.3010299956639812" ORDER="1247" O_E="0.0" SE="1.1972189997378646" STUDY_ID="STD-Wang-1996" TOTAL_1="30" TOTAL_2="30" VAR="1.4333333333333331" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="10.450153009013224" CI_END="1.8808048999769968" CI_START="0.7826832657734912" CI_STUDY="95" CI_TOTAL="95" DF="13" EFFECT_MEASURE="RR" EFFECT_SIZE="1.2132907818807412" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="30" I2="0.0" I2_Q="3.832054622299406" ID="CMP-002.18" LOG_CI_END="0.2743437475663721" LOG_CI_START="-0.10641395155117046" LOG_EFFECT_SIZE="0.0839648980076008" METHOD="MH" NO="18" P_CHI2="0.6567743308711744" P_Q="0.4029664474158402" P_Z="0.3873546491303962" Q="8.31878020121977" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="9" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="417" TOTAL_2="413" WEIGHT="900.0" Z="0.8644246797471756">
<NAME>Adverse effects: 7. Neurological problems</NAME>
<GROUP_LABEL_1>Loxapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Typicals</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Loxapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Typicals</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.1522153308282594" CI_START="0.032016429310296794" DF="0" EFFECT_SIZE="0.2625" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" I2="0.0" ID="CMP-002.18.01" LOG_CI_END="0.3328857206709857" LOG_CI_START="-1.4946271051870343" LOG_EFFECT_SIZE="-0.5808706922580243" NO="1" P_CHI2="1.0" P_Z="0.21278645915415784" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="21" WEIGHT="100.0" Z="1.2459399686741528">
<NAME>ataxia - 4 weeks</NAME>
<DICH_DATA CI_END="2.1522153308282594" CI_START="0.032016429310296794" EFFECT_SIZE="0.2625" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" LOG_CI_END="0.3328857206709857" LOG_CI_START="-1.4946271051870343" LOG_EFFECT_SIZE="-0.5808706922580243" ORDER="1248" O_E="0.0" SE="1.0734900802433864" STUDY_ID="STD-Charalampous-1974" TOTAL_1="20" TOTAL_2="21" VAR="1.1523809523809523" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="68.25874292736694" CI_START="0.13185124152633113" DF="0" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-002.18.02" LOG_CI_END="1.8341582859242351" LOG_CI_START="-0.87991577648491" LOG_EFFECT_SIZE="0.47712125471966244" NO="2" P_CHI2="1.0" P_Z="0.4907574432545426" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="15" WEIGHT="100.0" Z="0.6891046110061">
<NAME>clumsiness - 26 weeks</NAME>
<DICH_DATA CI_END="68.25874292736694" CI_START="0.13185124152633113" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8341582859242351" LOG_CI_START="-0.87991577648491" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="1249" O_E="0.0" SE="1.5942605391424158" STUDY_ID="STD-Vyas-1980" TOTAL_1="15" TOTAL_2="15" VAR="2.5416666666666665" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.270567660159611" CI_START="0.19946594343609705" DF="0" EFFECT_SIZE="0.8076923076923077" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" I2="0.0" ID="CMP-002.18.03" LOG_CI_END="0.514623138066674" LOG_CI_START="-0.7001312445404715" LOG_EFFECT_SIZE="-0.09275405323689868" NO="3" P_CHI2="1.0" P_Z="0.764702851578327" STUDIES="1" TAU2="0.0" TOTAL_1="26" TOTAL_2="28" WEIGHT="100.0" Z="0.2993108835289958">
<NAME>confusion/cloudiness - 6 weeks</NAME>
<DICH_DATA CI_END="3.2705676601596108" CI_START="0.19946594343609708" EFFECT_SIZE="0.8076923076923077" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.5146231380666739" LOG_CI_START="-0.7001312445404715" LOG_EFFECT_SIZE="-0.09275405323689868" ORDER="1250" O_E="0.0" SE="0.7135527374746096" STUDY_ID="STD-Van-Der-Velde-1975" TOTAL_1="26" TOTAL_2="28" VAR="0.5091575091575091" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.004509896940367585" CI_END="13.241758618824498" CI_START="0.6117459129983327" DF="1" EFFECT_SIZE="2.8461538461538467" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="2" I2="0.0" ID="CMP-002.18.04" LOG_CI_END="1.1219456669565646" LOG_CI_START="-0.21342892343624803" LOG_EFFECT_SIZE="0.4542583717601583" NO="4" P_CHI2="0.9464576990531758" P_Z="0.18238298247901896" STUDIES="2" TAU2="0.0" TOTAL_1="45" TOTAL_2="42" WEIGHT="100.0" Z="1.3334536312598526">
<NAME>confusion/cloudiness - 7 to 26 weeks</NAME>
<DICH_DATA CI_END="24.431936454314783" CI_START="0.29837995091512914" EFFECT_SIZE="2.7" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.387957890145535" LOG_CI_START="-0.5252303618275603" LOG_EFFECT_SIZE="0.43136376415898736" ORDER="1251" O_E="0.0" SE="1.1238162496435806" STUDY_ID="STD-Kiloh-1976" TOTAL_1="30" TOTAL_2="27" VAR="1.2629629629629628" WEIGHT="51.282051282051285"/>
<DICH_DATA CI_END="25.6782739076548" CI_START="0.3504908481140964" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.4095658271236327" LOG_CI_START="-0.45532331768430767" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="1252" O_E="0.0" SE="1.0954451150103321" STUDY_ID="STD-Vyas-1980" TOTAL_1="15" TOTAL_2="15" VAR="1.2" WEIGHT="48.71794871794872"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.17523370482972622" CI_END="2.3628104428446726" CI_START="0.3695367232035477" DF="1" EFFECT_SIZE="0.9344224037339557" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="8" I2="0.0" ID="CMP-002.18.05" LOG_CI_END="0.37342888162868976" LOG_CI_START="-0.43234239653256157" LOG_EFFECT_SIZE="-0.029456757451935926" NO="5" P_CHI2="0.6755020379486774" P_Z="0.8860519393508056" STUDIES="2" TAU2="0.0" TOTAL_1="46" TOTAL_2="49" WEIGHT="100.0" Z="0.14330166704098501">
<NAME>dizziness, fainting, weakness - up to 6 weeks</NAME>
<DICH_DATA CI_END="3.7601559255075196" CI_START="0.13031374488382766" EFFECT_SIZE="0.7" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.5752058545509147" LOG_CI_START="-0.8850097745224011" LOG_EFFECT_SIZE="-0.1549019599857432" ORDER="1253" O_E="0.0" SE="0.8577378887016042" STUDY_ID="STD-Charalampous-1974" TOTAL_1="20" TOTAL_2="21" VAR="0.7357142857142855" WEIGHT="37.80630105017503"/>
<DICH_DATA CI_END="3.2965458880723855" CI_START="0.35181166984683615" EFFECT_SIZE="1.0769230769230769" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="5" LOG_CI_END="0.5180591255212248" LOG_CI_START="-0.4536897587784223" LOG_EFFECT_SIZE="0.032184683371401235" ORDER="1254" O_E="0.0" SE="0.5708101048721684" STUDY_ID="STD-Van-Der-Velde-1975" TOTAL_1="26" TOTAL_2="28" VAR="0.3258241758241759" WEIGHT="62.19369894982497"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.3601629792730296" CI_END="3.75185613671768" CI_START="0.674150595951309" DF="2" EFFECT_SIZE="1.590382359840488" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="6" I2="15.260089342811655" ID="CMP-002.18.06" LOG_CI_END="0.5742461771943642" LOG_CI_START="-0.17124307722574378" LOG_EFFECT_SIZE="0.2015015499843102" NO="6" P_CHI2="0.3072537523050457" P_Z="0.2893564554218411" STUDIES="3" TAU2="0.0" TOTAL_1="71" TOTAL_2="66" WEIGHT="99.99999999999999" Z="1.0595344693612072">
<NAME>dizziness/fainting, weakness - 7 - 26 weeks</NAME>
<DICH_DATA CI_END="144.33719395851924" CI_START="0.45782492814460873" EFFECT_SIZE="8.129032258064516" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="2.1593782579786813" LOG_CI_START="-0.33930056408413817" LOG_EFFECT_SIZE="0.9100388469472714" ORDER="1255" O_E="0.0" SE="1.4677363087393485" STUDY_ID="STD-Kiloh-1976" TOTAL_1="30" TOTAL_2="27" VAR="2.1542498719918077" WEIGHT="7.271874266948158"/>
<DICH_DATA CI_END="3.5291253074271585" CI_START="0.47322184000747713" EFFECT_SIZE="1.2923076923076924" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="5" LOG_CI_END="0.5476670789771421" LOG_CI_START="-0.3249352201390899" LOG_EFFECT_SIZE="0.11136592941902611" ORDER="1256" O_E="0.0" SE="0.5125709099519185" STUDY_ID="STD-Schiele-1975" TOTAL_1="26" TOTAL_2="24" VAR="0.26272893772893774" WEIGHT="71.96809758386112"/>
<DICH_DATA CI_END="7.584304769707433" CI_START="0.014650137947370117" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.87991577648491" LOG_CI_START="-1.8341582859242351" LOG_EFFECT_SIZE="-0.47712125471966244" ORDER="1257" O_E="0.0" SE="1.5942605391424158" STUDY_ID="STD-Vyas-1980" TOTAL_1="15" TOTAL_2="15" VAR="2.5416666666666665" WEIGHT="20.76002814919071"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.885785024226322" CI_START="0.08484530205962525" DF="0" EFFECT_SIZE="0.4" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" I2="0.0" ID="CMP-002.18.07" LOG_CI_END="0.2754921825086075" LOG_CI_START="-1.0713721998526826" LOG_EFFECT_SIZE="-0.3979400086720376" NO="7" P_CHI2="1.0" P_Z="0.24679521887420708" STUDIES="1" TAU2="0.0" TOTAL_1="27" TOTAL_2="27" WEIGHT="100.0" Z="1.1581686994162905">
<NAME>giddiness - 4 weeks</NAME>
<DICH_DATA CI_END="1.885785024226322" CI_START="0.08484530205962525" EFFECT_SIZE="0.4" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" LOG_CI_END="0.2754921825086075" LOG_CI_START="-1.0713721998526826" LOG_EFFECT_SIZE="-0.3979400086720376" ORDER="1258" O_E="0.0" SE="0.79115480528524" STUDY_ID="STD-Malik-1980" TOTAL_1="27" TOTAL_2="27" VAR="0.625925925925926" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.04690692985101278" CI_END="34.71710514656712" CI_START="0.446068491387741" DF="1" EFFECT_SIZE="3.9352517985611506" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" I2="0.0" ID="CMP-002.18.08" LOG_CI_END="1.540543504773856" LOG_CI_START="-0.3505984526151846" LOG_EFFECT_SIZE="0.5949725260793356" NO="8" P_CHI2="0.8285357800851498" P_Z="0.21748280032063516" STUDIES="3" TAU2="0.0" TOTAL_1="152" TOTAL_2="150" WEIGHT="100.0" Z="1.2332492739109844">
<NAME>seizures - up to 12 weeks</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="1259" O_E="0.0" SE="0.0" STUDY_ID="STD-Clark-1972" TOTAL_1="18" TOTAL_2="19" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="99.93925556881227" CI_START="0.23606176172134827" EFFECT_SIZE="4.857142857142857" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.999736110129971" LOG_CI_START="-0.6269743560739742" LOG_EFFECT_SIZE="0.6863808770279982" ORDER="1260" O_E="0.0" SE="1.5429427302747056" STUDY_ID="STD-Huang-1997" TOTAL_1="104" TOTAL_2="101" VAR="2.380672268907563" WEIGHT="50.359712230215834"/>
<DICH_DATA CI_END="70.82882080128432" CI_START="0.12706691849706483" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.850210011475669" LOG_CI_START="-0.8959675020363438" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="1261" O_E="0.0" SE="1.613118265234886" STUDY_ID="STD-Wang-1996" TOTAL_1="30" TOTAL_2="30" VAR="2.6021505376344085" WEIGHT="49.64028776978417"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="25.6782739076548" CI_START="0.3504908481140964" DF="0" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" I2="0.0" ID="CMP-002.18.09" LOG_CI_END="1.4095658271236327" LOG_CI_START="-0.45532331768430767" LOG_EFFECT_SIZE="0.47712125471966244" NO="9" P_CHI2="1.0" P_Z="0.3159133624715845" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="15" WEIGHT="100.0" Z="1.0028912207598348">
<NAME>unsteadiness - 26 weeks</NAME>
<DICH_DATA CI_END="25.6782739076548" CI_START="0.3504908481140964" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.4095658271236327" LOG_CI_START="-0.45532331768430767" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="1262" O_E="0.0" SE="1.0954451150103321" STUDY_ID="STD-Vyas-1980" TOTAL_1="15" TOTAL_2="15" VAR="1.2" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="21.433056222801515" CI_END="1.3029872913147058" CI_START="0.8749467559992158" CI_STUDY="95" CI_TOTAL="95" DF="19" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0677286657405087" ESTIMABLE="YES" EVENTS_1="137" EVENTS_2="141" I2="11.351886532230118" I2_Q="61.97327505541154" ID="CMP-002.19" LOG_CI_END="0.11494017984242988" LOG_CI_START="-0.058018374725460106" LOG_EFFECT_SIZE="0.028460902558484887" METHOD="MH" NO="19" P_CHI2="0.3133728757892712" P_Q="0.022024912824628595" P_Z="0.5189031345019623" Q="13.1486474506702" RANDOM="NO" SCALE="5.0" SORT_BY="STUDY" STUDIES="12" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="542" TOTAL_2="633" WEIGHT="600.0" Z="0.6450371202684686">
<NAME>Adverse effects: 8. Sleep problems</NAME>
<GROUP_LABEL_1>Loxapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Typicals</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Loxapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Typicals</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.0969502881358248" CI_END="1.6476455345572862" CI_START="0.7876731713441042" DF="5" EFFECT_SIZE="1.1392129666816866" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="36" I2="0.0" ID="CMP-002.19.01" LOG_CI_END="0.21686378567191628" LOG_CI_START="-0.10365394662874076" LOG_EFFECT_SIZE="0.056604919521587777" NO="1" P_CHI2="0.9543732961166834" P_Z="0.48876309604749" STUDIES="6" TAU2="0.0" TOTAL_1="137" TOTAL_2="142" WEIGHT="100.0" Z="0.6922774775283335">
<NAME>drowsiness / sedation - up to 6 weeks</NAME>
<DICH_DATA CI_END="2.4496971990214713" CI_START="0.5696016483414241" EFFECT_SIZE="1.18125" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="8" LOG_CI_END="0.389112405621167" LOG_CI_START="-0.24442876258652838" LOG_EFFECT_SIZE="0.07234182151731933" ORDER="1263" O_E="0.0" SE="0.37214521828456093" STUDY_ID="STD-Charalampous-1974" TOTAL_1="20" TOTAL_2="21" VAR="0.1384920634920635" WEIGHT="21.993167400116505"/>
<DICH_DATA CI_END="2.4514017267297032" CI_START="0.48367389131582106" EFFECT_SIZE="1.0888888888888888" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="6" LOG_CI_END="0.38941448767215076" LOG_CI_START="-0.3154473551658109" LOG_EFFECT_SIZE="0.036983566253169946" ORDER="1264" O_E="0.0" SE="0.41403933560541256" STUDY_ID="STD-Clark-1975" TOTAL_1="15" TOTAL_2="14" VAR="0.17142857142857146" WEIGHT="17.49025597121334"/>
<DICH_DATA CI_END="6.802070662385297" CI_START="0.16007579676120917" EFFECT_SIZE="1.0434782608695652" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8326411392292543" LOG_CI_START="-0.795674327841228" LOG_EFFECT_SIZE="0.018483405694013133" ORDER="1265" O_E="0.0" SE="0.956480565648758" STUDY_ID="STD-Fruensgaard-1978" TOTAL_1="23" TOTAL_2="24" VAR="0.9148550724637682" WEIGHT="5.515839589976028"/>
<DICH_DATA CI_END="3.439121839380375" CI_START="0.7180285754420811" EFFECT_SIZE="1.5714285714285714" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="7" LOG_CI_END="0.5364475620486074" LOG_CI_START="-0.14385827176067115" LOG_EFFECT_SIZE="0.1962946451439682" ORDER="1266" O_E="0.0" SE="0.3996150143477591" STUDY_ID="STD-Malik-1980" TOTAL_1="27" TOTAL_2="27" VAR="0.1596921596921597" WEIGHT="19.72512201197949"/>
<DICH_DATA CI_END="2.1065207332282205" CI_START="0.4350093421597492" EFFECT_SIZE="0.9572649572649573" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="9" LOG_CI_END="0.323565737985675" LOG_CI_START="-0.361501416137635" LOG_EFFECT_SIZE="-0.018967839075980014" ORDER="1267" O_E="0.0" SE="0.4024118374691367" STUDY_ID="STD-Steinbook-1973" TOTAL_1="26" TOTAL_2="28" VAR="0.16193528693528692" WEIGHT="24.421579633879368"/>
<DICH_DATA CI_END="3.2705676601596108" CI_START="0.19946594343609708" EFFECT_SIZE="0.8076923076923077" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.5146231380666739" LOG_CI_START="-0.7001312445404715" LOG_EFFECT_SIZE="-0.09275405323689868" ORDER="1268" O_E="0.0" SE="0.7135527374746096" STUDY_ID="STD-Van-Der-Velde-1975" TOTAL_1="26" TOTAL_2="28" VAR="0.5091575091575091" WEIGHT="10.854035392835275"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="8.779359173959161" CI_END="1.8594118571325924" CI_START="1.0186366356308703" DF="5" EFFECT_SIZE="1.3762503545509779" ESTIMABLE="YES" EVENTS_1="58" EVENTS_2="46" I2="43.04823505990372" ID="CMP-002.19.02" LOG_CI_END="0.26937559604899813" LOG_CI_START="0.008019291677395202" LOG_EFFECT_SIZE="0.13869744386319668" NO="2" P_CHI2="0.11819517290370374" P_Z="0.037503472140168935" STUDIES="6" TAU2="0.0" TOTAL_1="184" TOTAL_2="224" WEIGHT="99.99999999999999" Z="2.080240577117434">
<NAME>drowsiness/ sedation - up to 12 weeks</NAME>
<DICH_DATA CI_END="1.7163156722855577" CI_START="0.21197709010624718" EFFECT_SIZE="0.6031746031746031" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="7" LOG_CI_END="0.2345971681999845" LOG_CI_START="-0.6737110738735278" LOG_EFFECT_SIZE="-0.21955695283677157" ORDER="1269" O_E="0.0" SE="0.5335447575922931" STUDY_ID="STD-Clark-1972" TOTAL_1="18" TOTAL_2="19" VAR="0.2846700083542189" WEIGHT="15.386012824676575"/>
<DICH_DATA CI_END="1.617944119733593" CI_START="0.7059740497638921" EFFECT_SIZE="1.06875" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="16" LOG_CI_END="0.20896351794965684" LOG_CI_START="-0.15121126247719863" LOG_EFFECT_SIZE="0.028876127736229093" ORDER="1270" O_E="0.0" SE="0.21156844891665216" STUDY_ID="STD-Kiloh-1976" TOTAL_1="30" TOTAL_2="27" VAR="0.04476120857699806" WEIGHT="38.047283175474234"/>
<DICH_DATA CI_END="3.5659692386526785" CI_START="0.8241168988082554" EFFECT_SIZE="1.7142857142857142" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="7" LOG_CI_END="0.5521775924733741" LOG_CI_START="-0.08401118040663819" LOG_EFFECT_SIZE="0.23408320603336796" ORDER="1271" O_E="0.0" SE="0.3737004343749344" STUDY_ID="STD-Schiele-1975" TOTAL_1="26" TOTAL_2="24" VAR="0.13965201465201466" WEIGHT="16.44593815259874"/>
<DICH_DATA CI_END="2.8196372647467483" CI_START="0.4632235732268575" EFFECT_SIZE="1.1428571428571428" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="7" LOG_CI_END="0.4501932416344305" LOG_CI_START="-0.33420934767905713" LOG_EFFECT_SIZE="0.05799194697768673" ORDER="1272" O_E="0.0" SE="0.4607619638181816" STUDY_ID="STD-Seth-1979" TOTAL_1="36" TOTAL_2="36" VAR="0.21230158730158727" WEIGHT="15.81340206980648"/>
<DICH_DATA CI_END="15.259760455310136" CI_START="0.0655318281652329" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1835477162038213" LOG_CI_START="-1.1835477162038213" LOG_EFFECT_SIZE="0.0" ORDER="1273" O_E="0.0" SE="1.390443574307614" STUDY_ID="STD-Wang-1996" TOTAL_1="30" TOTAL_2="30" VAR="1.9333333333333331" WEIGHT="2.259057438543783"/>
<DICH_DATA CI_END="7.254339215861568" CI_START="1.4560251024524962" EFFECT_SIZE="3.25" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="8" LOG_CI_END="0.8605978595064002" LOG_CI_START="0.16316886245134846" LOG_EFFECT_SIZE="0.5118833609788743" ORDER="1274" O_E="0.0" SE="0.40967324519935133" STUDY_ID="STD-Zhang-2005" TOTAL_1="44" TOTAL_2="88" VAR="0.16783216783216784" WEIGHT="12.048306338900176"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.4384844551908937" CI_START="0.17121896840909887" DF="0" EFFECT_SIZE="0.6461538461538462" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" I2="0.0" ID="CMP-002.19.03" LOG_CI_END="0.387119991403355" LOG_CI_START="-0.7664481238932652" LOG_EFFECT_SIZE="-0.18966406624495508" NO="3" P_CHI2="1.0" P_Z="0.5192541681012257" STUDIES="1" TAU2="0.0" TOTAL_1="26" TOTAL_2="28" WEIGHT="100.0" Z="0.6444955162547047">
<NAME>fatigue - 6 weeks</NAME>
<DICH_DATA CI_END="2.4384844551908937" CI_START="0.17121896840909887" EFFECT_SIZE="0.6461538461538462" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" LOG_CI_END="0.387119991403355" LOG_CI_START="-0.7664481238932652" LOG_EFFECT_SIZE="-0.18966406624495508" ORDER="1275" O_E="0.0" SE="0.6776116211794992" STUDY_ID="STD-Van-Der-Velde-1975" TOTAL_1="26" TOTAL_2="28" VAR="0.4591575091575092" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.348440843305098" CI_END="1.808397661973809" CI_START="0.5566027962102658" DF="2" EFFECT_SIZE="1.0032742373422778" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="16" I2="0.0" ID="CMP-002.19.04" LOG_CI_END="0.2572939368755669" LOG_CI_START="-0.25445461622756277" LOG_EFFECT_SIZE="0.0014196603240021045" NO="4" P_CHI2="0.8401117318980766" P_Z="0.9913236430570167" STUDIES="3" TAU2="0.0" TOTAL_1="68" TOTAL_2="69" WEIGHT="100.0" Z="0.010874415133964636">
<NAME>insomnia - up to 6 weeks</NAME>
<DICH_DATA CI_END="3.880477204887019" CI_START="0.2244855632740339" EFFECT_SIZE="0.9333333333333333" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.5888851366007625" LOG_CI_START="-0.6488115833556488" LOG_EFFECT_SIZE="-0.02996322337744321" ORDER="1276" O_E="0.0" SE="0.7270291799999699" STUDY_ID="STD-Clark-1975" TOTAL_1="15" TOTAL_2="14" VAR="0.5285714285714286" WEIGHT="19.405845711547677"/>
<DICH_DATA CI_END="1.8592794573159173" CI_START="0.4356526378069749" EFFECT_SIZE="0.9" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="10" LOG_CI_END="0.26934467091703684" LOG_CI_START="-0.36085965203838705" LOG_EFFECT_SIZE="-0.045757490560675115" ORDER="1277" O_E="0.0" SE="0.3701851388657263" STUDY_ID="STD-Malik-1980" TOTAL_1="27" TOTAL_2="27" VAR="0.13703703703703704" WEIGHT="62.52994729276474"/>
<DICH_DATA CI_END="5.81434250695042" CI_START="0.3546061216641727" EFFECT_SIZE="1.435897435897436" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.764500611283274" LOG_CI_START="-0.4502537713238714" LOG_EFFECT_SIZE="0.15712341997970122" ORDER="1278" O_E="0.0" SE="0.7135527374746096" STUDY_ID="STD-Van-Der-Velde-1975" TOTAL_1="26" TOTAL_2="28" VAR="0.5091575091575091" WEIGHT="18.06420699568759"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.6309427663730567" CI_END="0.6908611806136489" CI_START="0.12936505138827012" DF="1" EFFECT_SIZE="0.2989536621823617" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="30" I2="72.4589434661098" ID="CMP-002.19.05" LOG_CI_END="-0.16060920957247915" LOG_CI_START="-0.8881830346352048" LOG_EFFECT_SIZE="-0.524396122103842" NO="5" P_CHI2="0.05671487052380608" P_Z="0.0047240278216743835" STUDIES="2" TAU2="0.0" TOTAL_1="74" TOTAL_2="115" WEIGHT="100.0" Z="2.825273470681523">
<NAME>insomnia - up to 12 weeks</NAME>
<DICH_DATA CI_END="1.464891591559686" CI_START="0.2457519737803287" EFFECT_SIZE="0.6" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="9" LOG_CI_END="0.16580548617170854" LOG_CI_START="-0.6095029854044214" LOG_EFFECT_SIZE="-0.2218487496163564" ORDER="1279" O_E="0.0" SE="0.45542003404264886" STUDY_ID="STD-Kiloh-1976" TOTAL_1="30" TOTAL_2="27" VAR="0.20740740740740743" WEIGHT="40.35874439461883"/>
<DICH_DATA CI_END="0.6850945120137958" CI_START="0.013239479554315642" EFFECT_SIZE="0.09523809523809523" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="21" LOG_CI_END="-0.16424951140584126" LOG_CI_START="-1.8781290867340348" LOG_EFFECT_SIZE="-1.021189299069938" ORDER="1280" O_E="0.0" SE="1.0067413463885044" STUDY_ID="STD-Zhang-2005" TOTAL_1="44" TOTAL_2="88" VAR="1.0135281385281385" WEIGHT="59.64125560538117"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.43748019683622297" CI_END="3.746015435082664" CI_START="0.7655042616164771" DF="1" EFFECT_SIZE="1.6933962264150944" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="8" I2="0.0" ID="CMP-002.19.06" LOG_CI_END="0.5735695625099656" LOG_CI_START="-0.11605238721083025" LOG_EFFECT_SIZE="0.22875858764956772" NO="6" P_CHI2="0.5083411937681122" P_Z="0.19349729137956476" STUDIES="2" TAU2="0.0" TOTAL_1="53" TOTAL_2="55" WEIGHT="100.0" Z="1.3003025588989063">
<NAME>lethargy - up to 6 weeks</NAME>
<DICH_DATA CI_END="4.157243854505122" CI_START="0.3758499752923442" EFFECT_SIZE="1.25" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" LOG_CI_END="0.6188054999836834" LOG_CI_START="-0.4249854739675706" LOG_EFFECT_SIZE="0.09691001300805642" ORDER="1281" O_E="0.0" SE="0.6131279849476176" STUDY_ID="STD-Malik-1980" TOTAL_1="27" TOTAL_2="27" VAR="0.37592592592592594" WEIGHT="50.943396226415096"/>
<DICH_DATA CI_END="6.3106913712894555" CI_START="0.7351101458618754" EFFECT_SIZE="2.1538461538461537" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="4" LOG_CI_END="0.8000769412231914" LOG_CI_START="-0.13364758315242645" LOG_EFFECT_SIZE="0.33321467903538243" ORDER="1282" O_E="0.0" SE="0.5484744076291763" STUDY_ID="STD-Van-Der-Velde-1975" TOTAL_1="26" TOTAL_2="28" VAR="0.30082417582417587" WEIGHT="49.056603773584904"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.053135451421503" CI_END="1.1312645245353203" CI_START="0.44725052322829495" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7113077045189587" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="41" I2="0.0" I2_Q="0.0" ID="CMP-002.20" LOG_CI_END="0.053564168244240755" LOG_CI_START="-0.34944914268897764" LOG_EFFECT_SIZE="-0.14794248722236844" METHOD="MH" NO="20" P_CHI2="0.5489731068334958" P_Q="0.3963942782324027" P_Z="0.1501591426697126" Q="2.9692272657518464" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="136" TOTAL_2="178" WEIGHT="400.0" Z="1.4389695767997486">
<NAME>Adverse effects: 9. Weight changes</NAME>
<GROUP_LABEL_1>Loxapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Typicals</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Loxapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Typicals</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.1619895170852463" CI_START="0.10073026536751283" DF="0" EFFECT_SIZE="0.4666666666666667" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" I2="0.0" ID="CMP-002.20.01" LOG_CI_END="0.33485358384343905" LOG_CI_START="-0.9968400219262878" LOG_EFFECT_SIZE="-0.3309932190414244" NO="1" P_CHI2="1.0" P_Z="0.32990743196857875" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="14" WEIGHT="100.0" Z="0.9743003730549514">
<NAME>weight increase - 6 weeks</NAME>
<DICH_DATA CI_END="2.1619895170852463" CI_START="0.10073026536751283" EFFECT_SIZE="0.4666666666666667" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" LOG_CI_END="0.33485358384343905" LOG_CI_START="-0.9968400219262878" LOG_EFFECT_SIZE="-0.3309932190414244" ORDER="1283" O_E="0.0" SE="0.7822434160188003" STUDY_ID="STD-Clark-1975" TOTAL_1="15" TOTAL_2="14" VAR="0.611904761904762" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.037020494180189295" CI_END="1.0968681678179262" CI_START="0.2997290862621301" DF="1" EFFECT_SIZE="0.5733788395904437" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="28" I2="0.0" ID="CMP-002.20.02" LOG_CI_END="0.04015443301706113" LOG_CI_START="-0.5232711102735543" LOG_EFFECT_SIZE="-0.2415583386282466" NO="2" P_CHI2="0.847423400262239" P_Z="0.09284121549140228" STUDIES="2" TAU2="0.0" TOTAL_1="62" TOTAL_2="107" WEIGHT="100.0" Z="1.6805970177056393">
<NAME>weight increase 12 weeks</NAME>
<DICH_DATA CI_END="1.4525468989583414" CI_START="0.19176618869642298" EFFECT_SIZE="0.5277777777777778" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="8" LOG_CI_END="0.16213016352708226" LOG_CI_START="-0.7172279631559989" LOG_EFFECT_SIZE="-0.2775488998144583" ORDER="1284" O_E="0.0" SE="0.5165393165065715" STUDY_ID="STD-Clark-1972" TOTAL_1="18" TOTAL_2="19" VAR="0.266812865497076" WEIGHT="36.86006825938567"/>
<DICH_DATA CI_END="1.3863094227784578" CI_START="0.2596822859924617" EFFECT_SIZE="0.6" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="20" LOG_CI_END="0.14186017515842858" LOG_CI_START="-0.5855576743911414" LOG_EFFECT_SIZE="-0.2218487496163564" ORDER="1285" O_E="0.0" SE="0.42728884560184527" STUDY_ID="STD-Zhang-2005" TOTAL_1="44" TOTAL_2="88" VAR="0.18257575757575759" WEIGHT="63.13993174061434"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.1892264350131265" CI_START="0.12139636420189365" DF="0" EFFECT_SIZE="0.6222222222222222" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" I2="0.0" ID="CMP-002.20.03" LOG_CI_END="0.5036853552371823" LOG_CI_START="-0.9157943201034313" LOG_EFFECT_SIZE="-0.20605448243312446" NO="3" P_CHI2="1.0" P_Z="0.5693395084123012" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="14" WEIGHT="100.0" Z="0.5690245114993372">
<NAME>weight loss - 6 weeks</NAME>
<DICH_DATA CI_END="3.1892264350131265" CI_START="0.12139636420189365" EFFECT_SIZE="0.6222222222222222" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.5036853552371823" LOG_CI_START="-0.9157943201034313" LOG_EFFECT_SIZE="-0.20605448243312446" ORDER="1286" O_E="0.0" SE="0.8338093878327919" STUDY_ID="STD-Clark-1975" TOTAL_1="15" TOTAL_2="14" VAR="0.6952380952380952" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.309440734374002" CI_START="0.5793002253827187" DF="0" EFFECT_SIZE="1.3846153846153846" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="6" I2="0.0" ID="CMP-002.20.04" LOG_CI_END="0.5197546081271077" LOG_CI_START="-0.2370963025341691" LOG_EFFECT_SIZE="0.1413291527964693" NO="4" P_CHI2="1.0" P_Z="0.4641804828724476" STUDIES="2" TAU2="0.0" TOTAL_1="44" TOTAL_2="43" WEIGHT="100.0" Z="0.731980487952686">
<NAME>weight loss - 12 weeks</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="1287" O_E="0.0" SE="0.0" STUDY_ID="STD-Clark-1972" TOTAL_1="18" TOTAL_2="19" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="3.309440734374002" CI_START="0.5793002253827187" EFFECT_SIZE="1.3846153846153846" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="6" LOG_CI_END="0.5197546081271077" LOG_CI_START="-0.2370963025341691" LOG_EFFECT_SIZE="0.1413291527964693" ORDER="1288" O_E="0.0" SE="0.44457797139486416" STUDY_ID="STD-Schiele-1975" TOTAL_1="26" TOTAL_2="24" VAR="0.19764957264957267" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="24.265234068247835" CI_END="1.1742541294992714" CI_START="0.7535519504234733" CI_STUDY="95" CI_TOTAL="95" DF="35" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9406707657714222" ESTIMABLE="YES" EVENTS_1="109" EVENTS_2="121" I2="0.0" I2_Q="2.976073656071508" ID="CMP-002.21" LOG_CI_END="0.06976209614129303" LOG_CI_START="-0.12288680173751629" LOG_EFFECT_SIZE="-0.026562352798111644" METHOD="MH" NO="21" P_CHI2="0.9134348965570749" P_Q="0.42028172332837066" P_Z="0.588867364638759" Q="22.67481932447759" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="16" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="1032" TOTAL_2="1090" WEIGHT="2300.0" Z="0.5404780967051885">
<NAME>Adverse effects: 10. Others</NAME>
<GROUP_LABEL_1>Loxapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Typicals</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Loxapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Typicals</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.7721396166999683" CI_END="2.2197981149653314" CI_START="0.5986490637309352" DF="4" EFFECT_SIZE="1.1527706030237284" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="12" I2="0.0" ID="CMP-002.21.01" LOG_CI_END="0.34631347825989955" LOG_CI_START="-0.22282769238322442" LOG_EFFECT_SIZE="0.06174289293833754" NO="1" P_CHI2="0.942143639155193" P_Z="0.6706539144246363" STUDIES="5" TAU2="0.0" TOTAL_1="119" TOTAL_2="116" WEIGHT="100.0" Z="0.425250720568008">
<NAME>abnormal blood results - up to 6 weeks</NAME>
<DICH_DATA CI_END="7.8107039169243295" CI_START="0.014225492643544472" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8926901751653994" LOG_CI_START="-1.8469326846047245" LOG_EFFECT_SIZE="-0.47712125471966244" ORDER="1289" O_E="0.0" SE="1.6092680291808414" STUDY_ID="STD-Bagadia-1980" TOTAL_1="25" TOTAL_2="25" VAR="2.58974358974359" WEIGHT="11.995040810001033"/>
<DICH_DATA CI_END="2.65606718850822" CI_START="0.5124535693223857" EFFECT_SIZE="1.1666666666666667" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="6" LOG_CI_END="0.4242390568515887" LOG_CI_START="-0.2903454775903623" LOG_EFFECT_SIZE="0.06694678963061322" ORDER="1290" O_E="0.0" SE="0.4197504927816955" STUDY_ID="STD-Clark-1975" TOTAL_1="15" TOTAL_2="15" VAR="0.17619047619047623" WEIGHT="47.98016324000413"/>
<DICH_DATA CI_END="15.235048878454709" CI_START="0.06563812219954164" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1828438519035636" LOG_CI_START="-1.1828438519035636" LOG_EFFECT_SIZE="0.0" ORDER="1291" O_E="0.0" SE="1.3896166675593022" STUDY_ID="STD-Moore-1975" TOTAL_1="29" TOTAL_2="29" VAR="1.9310344827586206" WEIGHT="7.996693873334022"/>
<DICH_DATA CI_END="16.172472844346537" CI_START="0.155013056356487" EFFECT_SIZE="1.5833333333333333" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.2087764305770736" LOG_CI_START="-0.8096317207666652" LOG_EFFECT_SIZE="0.1995723549052041" ORDER="1292" O_E="0.0" SE="1.1856229393807987" STUDY_ID="STD-Simpson-1976" TOTAL_1="24" TOTAL_2="19" VAR="1.405701754385965" WEIGHT="8.926541998140303"/>
<DICH_DATA CI_END="5.81434250695042" CI_START="0.3546061216641727" EFFECT_SIZE="1.435897435897436" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.764500611283274" LOG_CI_START="-0.4502537713238714" LOG_EFFECT_SIZE="0.15712341997970122" ORDER="1293" O_E="0.0" SE="0.7135527374746096" STUDY_ID="STD-Van-Der-Velde-1975" TOTAL_1="26" TOTAL_2="28" VAR="0.5091575091575091" WEIGHT="23.101560078520507"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.3410937341282982" CI_END="1.4713267099000316" CI_START="0.76190860253013" DF="4" EFFECT_SIZE="1.0587806559458797" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="33" I2="0.0" ID="CMP-002.21.02" LOG_CI_END="0.16770911905816538" LOG_CI_START="-0.11809712288285633" LOG_EFFECT_SIZE="0.02480599808765455" NO="2" P_CHI2="0.8543658505549324" P_Z="0.7336889453844072" STUDIES="5" TAU2="0.0" TOTAL_1="239" TOTAL_2="267" WEIGHT="100.00000000000003" Z="0.3402225404328661">
<NAME>abnormal blood results - up to 12 weeks</NAME>
<DICH_DATA CI_END="1.505352077037751" CI_START="0.5139982181742826" EFFECT_SIZE="0.8796296296296297" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="12" LOG_CI_END="0.17763808613073456" LOG_CI_START="-0.2890383865269384" LOG_EFFECT_SIZE="-0.05570015019810193" ORDER="1294" O_E="0.0" SE="0.2741280701249133" STUDY_ID="STD-Clark-1972" TOTAL_1="18" TOTAL_2="19" VAR="0.07514619883040938" WEIGHT="34.62698752286718"/>
<DICH_DATA CI_END="1.5696941221088727" CI_START="0.6680129492943796" EFFECT_SIZE="1.024" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="15" LOG_CI_END="0.19581503201278325" LOG_CI_START="-0.17521511873315931" LOG_EFFECT_SIZE="0.010299956639811961" ORDER="1295" O_E="0.0" SE="0.21794494717703364" STUDY_ID="STD-Moyano-1975" TOTAL_1="25" TOTAL_2="24" VAR="0.04749999999999998" WEIGHT="45.393939142080704"/>
<DICH_DATA CI_END="3.895568935666224" CI_START="0.559944339625678" EFFECT_SIZE="1.476923076923077" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="5" LOG_CI_END="0.590570893992275" LOG_CI_START="-0.2518551411988493" LOG_EFFECT_SIZE="0.16935787639671288" ORDER="1296" O_E="0.0" SE="0.4948452231473947" STUDY_ID="STD-Schiele-1975" TOTAL_1="26" TOTAL_2="24" VAR="0.24487179487179486" WEIGHT="15.421834257869552"/>
<DICH_DATA CI_END="64.86894287134616" CI_START="0.10983863671655117" EFFECT_SIZE="2.6692913385826773" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8120368205619228" LOG_CI_START="-0.959244866067672" LOG_EFFECT_SIZE="0.4263959772471253" ORDER="1297" O_E="0.0" SE="1.6278645807918148" STUDY_ID="STD-Tu-2004" TOTAL_1="126" TOTAL_2="112" VAR="2.6499430933965114" WEIGHT="1.5693693515620457"/>
<DICH_DATA CI_END="15.860429190816676" CI_START="0.027402964049088756" EFFECT_SIZE="0.6592592592592592" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="1.2003149353574596" LOG_CI_START="-1.5622024590576462" LOG_EFFECT_SIZE="-0.18094376185009337" ORDER="1298" O_E="0.0" SE="1.6227163921610779" STUDY_ID="STD-Zhang-2005" TOTAL_1="44" TOTAL_2="88" VAR="2.633208489388265" WEIGHT="2.9878697256205355"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.2019625625408166" CI_START="0.06791613616372712" DF="0" EFFECT_SIZE="0.2857142857142857" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="14" I2="0.0" ID="CMP-002.21.03" LOG_CI_END="0.07989094093199156" LOG_CI_START="-1.168027029632543" LOG_EFFECT_SIZE="-0.5440680443502757" NO="3" P_CHI2="1.0" P_Z="0.08744861425982643" STUDIES="1" TAU2="0.0" TOTAL_1="44" TOTAL_2="88" WEIGHT="100.0" Z="1.7090126069476874">
<NAME>anxiety - 8 weeks</NAME>
<DICH_DATA CI_END="1.2019625625408166" CI_START="0.06791613616372712" EFFECT_SIZE="0.2857142857142857" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="14" LOG_CI_END="0.07989094093199156" LOG_CI_START="-1.168027029632543" LOG_EFFECT_SIZE="-0.5440680443502757" ORDER="1299" O_E="0.0" SE="0.7330331932031879" STUDY_ID="STD-Zhang-2005" TOTAL_1="44" TOTAL_2="88" VAR="0.5373376623376623" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.270567660159611" CI_START="0.19946594343609705" DF="0" EFFECT_SIZE="0.8076923076923077" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" I2="0.0" ID="CMP-002.21.04" LOG_CI_END="0.514623138066674" LOG_CI_START="-0.7001312445404715" LOG_EFFECT_SIZE="-0.09275405323689868" NO="4" P_CHI2="1.0" P_Z="0.764702851578327" STUDIES="1" TAU2="0.0" TOTAL_1="26" TOTAL_2="28" WEIGHT="100.0" Z="0.2993108835289958">
<NAME>difficulty swallowing - 6 weeks</NAME>
<DICH_DATA CI_END="3.2705676601596108" CI_START="0.19946594343609708" EFFECT_SIZE="0.8076923076923077" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.5146231380666739" LOG_CI_START="-0.7001312445404715" LOG_EFFECT_SIZE="-0.09275405323689868" ORDER="1300" O_E="0.0" SE="0.7135527374746096" STUDY_ID="STD-Van-Der-Velde-1975" TOTAL_1="26" TOTAL_2="28" VAR="0.5091575091575091" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="5.81434250695042" CI_START="0.3546061216641725" DF="0" EFFECT_SIZE="1.435897435897436" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" I2="0.0" ID="CMP-002.21.05" LOG_CI_END="0.764500611283274" LOG_CI_START="-0.4502537713238717" LOG_EFFECT_SIZE="0.15712341997970122" NO="5" P_CHI2="1.0" P_Z="0.612136327556394" STUDIES="1" TAU2="0.0" TOTAL_1="26" TOTAL_2="28" WEIGHT="99.99999999999999" Z="0.5070263564343432">
<NAME>headache - 6 weeks</NAME>
<DICH_DATA CI_END="5.81434250695042" CI_START="0.3546061216641727" EFFECT_SIZE="1.435897435897436" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.764500611283274" LOG_CI_START="-0.4502537713238714" LOG_EFFECT_SIZE="0.15712341997970122" ORDER="1301" O_E="0.0" SE="0.7135527374746096" STUDY_ID="STD-Van-Der-Velde-1975" TOTAL_1="26" TOTAL_2="28" VAR="0.5091575091575091" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="7.478924933182244" CI_START="0.24368475633630082" DF="0" EFFECT_SIZE="1.35" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" I2="0.0" ID="CMP-002.21.06" LOG_CI_END="0.8738391741823427" LOG_CI_START="-0.6131716371923305" LOG_EFFECT_SIZE="0.13033376849500614" NO="6" P_CHI2="1.0" P_Z="0.7311663110471671" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="27" WEIGHT="100.0" Z="0.3435744922169623">
<NAME>headache - 12 weeks</NAME>
<DICH_DATA CI_END="7.478924933182244" CI_START="0.24368475633630093" EFFECT_SIZE="1.35" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.8738391741823427" LOG_CI_START="-0.6131716371923303" LOG_EFFECT_SIZE="0.13033376849500614" ORDER="1302" O_E="0.0" SE="0.8734775114237131" STUDY_ID="STD-Kiloh-1976" TOTAL_1="30" TOTAL_2="27" VAR="0.7629629629629628" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.1123185972915905" CI_START="0.010675298063307328" DF="0" EFFECT_SIZE="0.20952380952380953" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" I2="0.0" ID="CMP-002.21.07" LOG_CI_END="0.6140867537707091" LOG_CI_START="-1.9716199902661726" LOG_EFFECT_SIZE="-0.6787666182477319" NO="7" P_CHI2="1.0" P_Z="0.30347532561561286" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="21" WEIGHT="100.0" Z="1.0290092863327633">
<NAME>libido - decrease - 4 weeks</NAME>
<DICH_DATA CI_END="4.1123185972915905" CI_START="0.010675298063307328" EFFECT_SIZE="0.20952380952380953" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.6140867537707091" LOG_CI_START="-1.9716199902661726" LOG_EFFECT_SIZE="-0.6787666182477319" ORDER="1303" O_E="0.0" SE="1.5188569409020742" STUDY_ID="STD-Charalampous-1974" TOTAL_1="20" TOTAL_2="21" VAR="2.306926406926407" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.002363271368105589" CI_END="6.813916512133697" CI_START="0.14871414718884013" DF="1" EFFECT_SIZE="1.0066408411732155" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" I2="0.0" ID="CMP-002.21.09" LOG_CI_END="0.8333968080487402" LOG_CI_START="-0.8276477150436367" LOG_EFFECT_SIZE="0.00287454650255182" NO="9" P_CHI2="0.9612273339846339" P_Z="0.9945874380205247" STUDIES="2" TAU2="0.0" TOTAL_1="43" TOTAL_2="43" WEIGHT="100.0" Z="0.00678369247610326">
<NAME>opthalmic changes - 12 weeks</NAME>
<DICH_DATA CI_END="15.640507378231115" CI_START="0.07123794029949233" EFFECT_SIZE="1.0555555555555556" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1942508374701124" LOG_CI_START="-1.1472886457710665" LOG_EFFECT_SIZE="0.0234810958495229" ORDER="1304" O_E="0.0" SE="1.3754318832632446" STUDY_ID="STD-Clark-1972" TOTAL_1="18" TOTAL_2="19" VAR="1.891812865497076" WEIGHT="48.81018262313226"/>
<DICH_DATA CI_END="14.495014695564524" CI_START="0.06358048055529116" EFFECT_SIZE="0.96" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.161218659994524" LOG_CI_START="-1.1966761939153874" LOG_EFFECT_SIZE="-0.017728766960431602" ORDER="1305" O_E="0.0" SE="1.3850391089544487" STUDY_ID="STD-Moyano-1975" TOTAL_1="25" TOTAL_2="24" VAR="1.9183333333333332" WEIGHT="51.18981737686774"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="5.81434250695042" CI_START="0.3546061216641725" DF="0" EFFECT_SIZE="1.435897435897436" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" I2="0.0" ID="CMP-002.21.10" LOG_CI_END="0.764500611283274" LOG_CI_START="-0.4502537713238717" LOG_EFFECT_SIZE="0.15712341997970122" NO="10" P_CHI2="1.0" P_Z="0.612136327556394" STUDIES="1" TAU2="0.0" TOTAL_1="26" TOTAL_2="28" WEIGHT="99.99999999999999" Z="0.5070263564343432">
<NAME>ringing in ears - 6 weeks</NAME>
<DICH_DATA CI_END="5.81434250695042" CI_START="0.3546061216641727" EFFECT_SIZE="1.435897435897436" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.764500611283274" LOG_CI_START="-0.4502537713238714" LOG_EFFECT_SIZE="0.15712341997970122" ORDER="1306" O_E="0.0" SE="0.7135527374746096" STUDY_ID="STD-Van-Der-Velde-1975" TOTAL_1="26" TOTAL_2="28" VAR="0.5091575091575091" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.14463300796876993" CI_END="1.3290799470166998" CI_START="0.08570308374276356" DF="1" EFFECT_SIZE="0.3375" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="7" I2="0.0" ID="CMP-002.21.11" LOG_CI_END="0.12355110547540214" LOG_CI_START="-1.0670035511413147" LOG_EFFECT_SIZE="-0.47172622283295623" NO="11" P_CHI2="0.7037180688683564" P_Z="0.12038271924879808" STUDIES="2" TAU2="0.0" TOTAL_1="47" TOTAL_2="48" WEIGHT="100.0" Z="1.5531691924890136">
<NAME>skin problems - rash - 4 weeks</NAME>
<DICH_DATA CI_END="4.1123185972915905" CI_START="0.010675298063307328" EFFECT_SIZE="0.20952380952380953" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.6140867537707091" LOG_CI_START="-1.9716199902661726" LOG_EFFECT_SIZE="-0.6787666182477319" ORDER="1307" O_E="0.0" SE="1.5188569409020742" STUDY_ID="STD-Charalampous-1974" TOTAL_1="20" TOTAL_2="21" VAR="2.306926406926407" WEIGHT="32.8125"/>
<DICH_DATA CI_END="1.885785024226322" CI_START="0.08484530205962525" EFFECT_SIZE="0.4" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" LOG_CI_END="0.2754921825086075" LOG_CI_START="-1.0713721998526826" LOG_EFFECT_SIZE="-0.3979400086720376" ORDER="1308" O_E="0.0" SE="0.79115480528524" STUDY_ID="STD-Malik-1980" TOTAL_1="27" TOTAL_2="27" VAR="0.625925925925926" WEIGHT="67.1875"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.226581769562577" CI_END="0.7669407371030112" CI_START="0.052821324149957154" DF="3" EFFECT_SIZE="0.20127301179821708" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="11" I2="0.0" ID="CMP-002.21.12" LOG_CI_END="-0.11523819347411118" LOG_CI_START="-1.277190715892982" LOG_EFFECT_SIZE="-0.6962144546835467" NO="12" P_CHI2="0.526731681520987" P_Z="0.018837658296797788" STUDIES="4" TAU2="0.0" TOTAL_1="93" TOTAL_2="91" WEIGHT="99.99999999999999" Z="2.34872807686722">
<NAME>skin problems - rash - 7 - 26 weeks</NAME>
<DICH_DATA CI_END="1.0002731852816513" CI_START="0.0038329779421950364" EFFECT_SIZE="0.06191950464396285" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="8" LOG_CI_END="1.1862665756758571E-4" LOG_CI_START="-2.4164636799918107" LOG_EFFECT_SIZE="-1.2081725266671217" ORDER="1309" O_E="0.0" SE="1.419512409201188" STUDY_ID="STD-Clark-1972" TOTAL_1="18" TOTAL_2="19" VAR="2.015015479876161" WEIGHT="67.01598297962126"/>
<DICH_DATA CI_END="7.093354363224453" CI_START="0.012779048226225425" EFFECT_SIZE="0.3010752688172043" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8508516564717874" LOG_CI_START="-1.8935014908952192" LOG_EFFECT_SIZE="-0.5213249172117159" ORDER="1310" O_E="0.0" SE="1.6120466235305515" STUDY_ID="STD-Kiloh-1976" TOTAL_1="30" TOTAL_2="27" VAR="2.598694316436252" WEIGHT="12.754734232412567"/>
<DICH_DATA CI_END="14.553341064518706" CI_START="0.06871274407483083" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1629627073641946" LOG_CI_START="-1.1629627073641946" LOG_EFFECT_SIZE="0.0" ORDER="1311" O_E="0.0" SE="1.3662601021279464" STUDY_ID="STD-Vyas-1980" TOTAL_1="15" TOTAL_2="15" VAR="1.8666666666666667" WEIGHT="8.091713115186467"/>
<DICH_DATA CI_END="7.8698689779204765" CI_START="0.01411854649967386" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8959675020363439" LOG_CI_START="-1.850210011475669" LOG_EFFECT_SIZE="-0.47712125471966244" ORDER="1312" O_E="0.0" SE="1.613118265234886" STUDY_ID="STD-Wang-1996" TOTAL_1="30" TOTAL_2="30" VAR="2.6021505376344085" WEIGHT="12.137569672779701"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.614678962377769" CI_START="0.2752525144626629" DF="0" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="9" I2="0.0" ID="CMP-002.21.13" LOG_CI_END="0.20808618689781236" LOG_CI_START="-0.5602687050091749" LOG_EFFECT_SIZE="-0.17609125905568127" NO="13" P_CHI2="1.0" P_Z="0.3689896753955606" STUDIES="1" TAU2="0.0" TOTAL_1="27" TOTAL_2="27" WEIGHT="100.0" Z="0.8983674845483454">
<NAME>swelling of hands/face - 4 weeks</NAME>
<DICH_DATA CI_END="1.6146789623777693" CI_START="0.27525251446266286" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="9" LOG_CI_END="0.20808618689781244" LOG_CI_START="-0.5602687050091749" LOG_EFFECT_SIZE="-0.17609125905568127" ORDER="1313" O_E="0.0" SE="0.45133546692422005" STUDY_ID="STD-Malik-1980" TOTAL_1="27" TOTAL_2="27" VAR="0.20370370370370372" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="96.12715085961011" CI_START="0.260072204121721" DF="0" EFFECT_SIZE="5.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" I2="0.0" ID="CMP-002.21.14" LOG_CI_END="1.982846070323241" LOG_CI_START="-0.5849060616512035" LOG_EFFECT_SIZE="0.6989700043360189" NO="14" P_CHI2="1.0" P_Z="0.28595065344202353" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="15" WEIGHT="100.0" Z="1.067046945624763">
<NAME>swelling of hands/face - 26 weeks</NAME>
<DICH_DATA CI_END="96.12715085961011" CI_START="0.260072204121721" EFFECT_SIZE="5.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.982846070323241" LOG_CI_START="-0.5849060616512035" LOG_EFFECT_SIZE="0.6989700043360189" ORDER="1314" O_E="0.0" SE="1.5083103128998356" STUDY_ID="STD-Vyas-1980" TOTAL_1="15" TOTAL_2="15" VAR="2.275" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.4384844551908937" CI_START="0.17121896840909887" DF="0" EFFECT_SIZE="0.6461538461538462" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" I2="0.0" ID="CMP-002.21.15" LOG_CI_END="0.387119991403355" LOG_CI_START="-0.7664481238932652" LOG_EFFECT_SIZE="-0.18966406624495508" NO="15" P_CHI2="1.0" P_Z="0.5192541681012257" STUDIES="1" TAU2="0.0" TOTAL_1="26" TOTAL_2="28" WEIGHT="100.0" Z="0.6444955162547047">
<NAME>tingling sensation - 6 weeks</NAME>
<DICH_DATA CI_END="2.4384844551908937" CI_START="0.17121896840909887" EFFECT_SIZE="0.6461538461538462" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" LOG_CI_END="0.387119991403355" LOG_CI_START="-0.7664481238932652" LOG_EFFECT_SIZE="-0.18966406624495508" ORDER="1315" O_E="0.0" SE="0.6776116211794992" STUDY_ID="STD-Van-Der-Velde-1975" TOTAL_1="26" TOTAL_2="28" VAR="0.4591575091575092" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="8.093763717196325" CI_START="0.015211069763955837" DF="0" EFFECT_SIZE="0.3508771929824561" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-002.21.16" LOG_CI_END="0.9081505217981177" LOG_CI_START="-1.817840241815138" LOG_EFFECT_SIZE="-0.4548448600085102" NO="16" P_CHI2="1.0" P_Z="0.5130737290994685" STUDIES="1" TAU2="0.0" TOTAL_1="18" TOTAL_2="19" WEIGHT="99.99999999999999" Z="0.6540591083941909">
<NAME>lactation - 12 weeks</NAME>
<DICH_DATA CI_END="8.093763717196325" CI_START="0.015211069763955837" EFFECT_SIZE="0.3508771929824561" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9081505217981177" LOG_CI_START="-1.817840241815138" LOG_EFFECT_SIZE="-0.4548448600085102" ORDER="1316" O_E="0.0" SE="1.6012604684183327" STUDY_ID="STD-Clark-1972" TOTAL_1="18" TOTAL_2="19" VAR="2.564035087719298" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="21.478200608048958" CI_START="0.20278176943730142" DF="0" EFFECT_SIZE="2.0869565217391304" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" I2="0.0" ID="CMP-002.21.17" LOG_CI_END="1.331997894405131" LOG_CI_START="-0.6929710916891421" LOG_EFFECT_SIZE="0.31951340135799433" NO="17" P_CHI2="1.0" P_Z="0.5362372749139819" STUDIES="1" TAU2="0.0" TOTAL_1="23" TOTAL_2="24" WEIGHT="100.0" Z="0.6185129387560958">
<NAME>sweating - 72 hours</NAME>
<DICH_DATA CI_END="21.478200608048958" CI_START="0.20278176943730142" EFFECT_SIZE="2.0869565217391304" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.331997894405131" LOG_CI_START="-0.6929710916891421" LOG_EFFECT_SIZE="0.31951340135799433" ORDER="1317" O_E="0.0" SE="1.1894768061899181" STUDY_ID="STD-Fruensgaard-1978" TOTAL_1="23" TOTAL_2="24" VAR="1.414855072463768" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="7.093354363224453" CI_START="0.012779048226225425" DF="0" EFFECT_SIZE="0.3010752688172043" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-002.21.18" LOG_CI_END="0.8508516564717874" LOG_CI_START="-1.8935014908952192" LOG_EFFECT_SIZE="-0.5213249172117159" NO="18" P_CHI2="1.0" P_Z="0.4564891662549351" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="27" WEIGHT="100.0" Z="0.744640363036809">
<NAME>sweating - 12 weeks</NAME>
<DICH_DATA CI_END="7.093354363224453" CI_START="0.012779048226225425" EFFECT_SIZE="0.3010752688172043" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8508516564717874" LOG_CI_START="-1.8935014908952192" LOG_EFFECT_SIZE="-0.5213249172117159" ORDER="1318" O_E="0.0" SE="1.6120466235305515" STUDY_ID="STD-Kiloh-1976" TOTAL_1="30" TOTAL_2="27" VAR="2.598694316436252" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="17.115387067250275" CI_START="0.9583481773185044" DF="0" EFFECT_SIZE="4.05" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="2" I2="0.0" ID="CMP-002.21.19" LOG_CI_END="1.2333867252249966" LOG_CI_START="-0.018476678795659344" LOG_EFFECT_SIZE="0.6074550232146685" NO="19" P_CHI2="1.0" P_Z="0.05715698045965678" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="27" WEIGHT="100.0" Z="1.9021084311672205">
<NAME>excitement - 12 weeks</NAME>
<DICH_DATA CI_END="17.115387067250275" CI_START="0.9583481773185044" EFFECT_SIZE="4.05" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="2" LOG_CI_END="1.2333867252249966" LOG_CI_START="-0.018476678795659344" LOG_EFFECT_SIZE="0.6074550232146685" ORDER="1319" O_E="0.0" SE="0.7353507603455243" STUDY_ID="STD-Kiloh-1976" TOTAL_1="30" TOTAL_2="27" VAR="0.5407407407407407" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.0172039676699867" CI_START="0.47726306057857576" DF="0" EFFECT_SIZE="1.2" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="6" I2="0.0" ID="CMP-002.21.20" LOG_CI_END="0.47960467014825753" LOG_CI_START="-0.3212421780530079" LOG_EFFECT_SIZE="0.07918124604762482" NO="20" P_CHI2="1.0" P_Z="0.6983337493055792" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="27" WEIGHT="100.0" Z="0.38757070931331644">
<NAME>depression - 12 weeks</NAME>
<DICH_DATA CI_END="3.0172039676699867" CI_START="0.47726306057857576" EFFECT_SIZE="1.2" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="6" LOG_CI_END="0.47960467014825753" LOG_CI_START="-0.3212421780530079" LOG_EFFECT_SIZE="0.07918124604762482" ORDER="1320" O_E="0.0" SE="0.4704214028892566" STUDY_ID="STD-Kiloh-1976" TOTAL_1="30" TOTAL_2="27" VAR="0.22129629629629627" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="63.84018926902006" CI_START="0.1150114340360288" DF="0" EFFECT_SIZE="2.7096774193548385" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-002.21.21" LOG_CI_END="1.8050941659111122" LOG_CI_START="-0.9392589814558945" LOG_EFFECT_SIZE="0.43291759222760895" NO="21" P_CHI2="1.0" P_Z="0.5363362455253173" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="27" WEIGHT="100.0" Z="0.6183627568878906">
<NAME>lacrimation -12 weeks</NAME>
<DICH_DATA CI_END="63.84018926902006" CI_START="0.1150114340360288" EFFECT_SIZE="2.7096774193548385" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8050941659111122" LOG_CI_START="-0.9392589814558945" LOG_EFFECT_SIZE="0.43291759222760895" ORDER="1321" O_E="0.0" SE="1.6120466235305515" STUDY_ID="STD-Kiloh-1976" TOTAL_1="30" TOTAL_2="27" VAR="2.598694316436252" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="63.84018926902006" CI_START="0.1150114340360288" DF="0" EFFECT_SIZE="2.7096774193548385" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-002.21.22" LOG_CI_END="1.8050941659111122" LOG_CI_START="-0.9392589814558945" LOG_EFFECT_SIZE="0.43291759222760895" NO="22" P_CHI2="1.0" P_Z="0.5363362455253173" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="27" WEIGHT="100.0" Z="0.6183627568878906">
<NAME>breathlessness - 12 weeks</NAME>
<DICH_DATA CI_END="63.84018926902006" CI_START="0.1150114340360288" EFFECT_SIZE="2.7096774193548385" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8050941659111122" LOG_CI_START="-0.9392589814558945" LOG_EFFECT_SIZE="0.43291759222760895" ORDER="1322" O_E="0.0" SE="1.6120466235305515" STUDY_ID="STD-Kiloh-1976" TOTAL_1="30" TOTAL_2="27" VAR="2.598694316436252" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="63.84018926902006" CI_START="0.1150114340360288" DF="0" EFFECT_SIZE="2.7096774193548385" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-002.21.23" LOG_CI_END="1.8050941659111122" LOG_CI_START="-0.9392589814558945" LOG_EFFECT_SIZE="0.43291759222760895" NO="23" P_CHI2="1.0" P_Z="0.5363362455253173" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="27" WEIGHT="100.0" Z="0.6183627568878906">
<NAME>bulimia - 12 weeks</NAME>
<DICH_DATA CI_END="63.84018926902006" CI_START="0.1150114340360288" EFFECT_SIZE="2.7096774193548385" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8050941659111122" LOG_CI_START="-0.9392589814558945" LOG_EFFECT_SIZE="0.43291759222760895" ORDER="1323" O_E="0.0" SE="1.6120466235305515" STUDY_ID="STD-Kiloh-1976" TOTAL_1="30" TOTAL_2="27" VAR="2.598694316436252" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="7.267071756978603" CI_START="0.5504280312298803" DF="0" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="3" I2="0.0" ID="CMP-002.21.24" LOG_CI_END="0.861359448552416" LOG_CI_START="-0.25929945722445363" LOG_EFFECT_SIZE="0.3010299956639812" NO="24" P_CHI2="1.0" P_Z="0.29235651929402395" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="30" WEIGHT="100.0" Z="1.0529661554041605">
<NAME>hypersalivation - 8 weeks</NAME>
<DICH_DATA CI_END="7.267071756978603" CI_START="0.5504280312298803" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="3" LOG_CI_END="0.861359448552416" LOG_CI_START="-0.25929945722445363" LOG_EFFECT_SIZE="0.3010299956639812" ORDER="1324" O_E="0.0" SE="0.6582805886043833" STUDY_ID="STD-Wang-1996" TOTAL_1="30" TOTAL_2="30" VAR="0.43333333333333335" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" NO="3">
<NAME>LOXAPINE IM versus TYPICAL ANTIPSYCHOTIC IM FOR RAPID TRANQUILISATION</NAME>
<DICH_OUTCOME CHI2="2.5115051694897907E-4" CI_END="1.081759104471869" CI_START="0.3081635536436731" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5773722627737226" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="21" I2="0.0" I2_Q="0.0" ID="CMP-003.01" LOG_CI_END="0.03413055906397113" LOG_CI_START="-0.5112187263814316" LOG_EFFECT_SIZE="-0.23854408365873028" METHOD="MH" NO="1" P_CHI2="0.9873558709630337" P_Q="1.0" P_Z="0.08641194779779962" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="55" TOTAL_2="60" WEIGHT="100.0" Z="1.7146361980262586">
<NAME>Withdrawn from or leaving the study early - by 72 hours</NAME>
<GROUP_LABEL_1>IM Loxapine</GROUP_LABEL_1>
<GROUP_LABEL_2>IM Typical</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Loxapine IM</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours IM Typical</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.5161348746623333" CI_START="0.21736921169193726" EFFECT_SIZE="0.5740740740740741" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="9" LOG_CI_END="0.18073783765230506" LOG_CI_START="-0.6628019696296967" LOG_EFFECT_SIZE="-0.24103206598869584" ORDER="1325" O_E="0.0" SE="0.49549945838683696" STUDY_ID="STD-Dubin-1996" TOTAL_1="30" TOTAL_2="31" VAR="0.24551971326164876" WEIGHT="44.34306569343066"/>
<DICH_DATA CI_END="1.3183690209673908" CI_START="0.2551637626869879" EFFECT_SIZE="0.58" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="12" LOG_CI_END="0.12003698942207355" LOG_CI_START="-0.5931810022961991" LOG_EFFECT_SIZE="-0.23657200643706275" ORDER="1326" O_E="0.0" SE="0.4189477788213113" STUDY_ID="STD-Tuason-1986" TOTAL_1="25" TOTAL_2="29" VAR="0.17551724137931035" WEIGHT="55.65693430656934"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="11.098547229642518" CI_END="0.934001166127036" CI_START="0.5457894930669074" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7139804079835632" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="69" I2="54.949058678186574" I2_Q="41.19864226850204" ID="CMP-003.02" LOG_CI_END="-0.02965258154054821" LOG_CI_START="-0.2629748291406284" LOG_EFFECT_SIZE="-0.1463137053405883" METHOD="MH" NO="2" P_CHI2="0.0494607677933222" P_Q="0.1825667171011176" P_Z="0.013965799179733519" Q="3.401282006331404" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="150" TOTAL_2="164" WEIGHT="300.0" Z="2.4581418691259027">
<NAME>General effect: Not tranquilised</NAME>
<GROUP_LABEL_1>IM Loxapine</GROUP_LABEL_1>
<GROUP_LABEL_2>IM Typical</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Loxapine IM</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours IM Typical</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="9.023164295477347" CI_END="0.8312391098797546" CI_START="0.4672937861237249" DF="2" EFFECT_SIZE="0.6232438293555946" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="54" I2="77.83482673586633" ID="CMP-003.02.01" LOG_CI_END="-0.08027403137318255" LOG_CI_START="-0.33040999400269333" LOG_EFFECT_SIZE="-0.2053420126879379" NO="1" P_CHI2="0.010981087593713523" P_Z="0.0012910874281991777" STUDIES="3" TAU2="0.0" TOTAL_1="70" TOTAL_2="75" WEIGHT="100.0" Z="3.2179535093674936">
<NAME>not sedated / still hostile - at 1hour</NAME>
<DICH_DATA CI_END="0.7265756854865257" CI_START="0.2902919426406748" EFFECT_SIZE="0.45925925925925926" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="27" LOG_CI_END="-0.13871913969064115" LOG_CI_START="-0.5371650183028633" LOG_EFFECT_SIZE="-0.33794207899675227" ORDER="1327" O_E="0.0" SE="0.23404908143572792" STUDY_ID="STD-Dubin-1996" TOTAL_1="30" TOTAL_2="31" VAR="0.05477897252090799" WEIGHT="50.99744662990125"/>
<DICH_DATA CI_END="1.157517561378007" CI_START="0.07052390027157951" EFFECT_SIZE="0.2857142857142857" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="7" LOG_CI_END="0.06352758867634703" LOG_CI_START="-1.1516636773768982" LOG_EFFECT_SIZE="-0.5440680443502757" ORDER="1328" O_E="0.0" SE="0.7138093649734567" STUDY_ID="STD-Fruensgaard-1977" TOTAL_1="15" TOTAL_2="15" VAR="0.5095238095238095" WEIGHT="13.4419195746715"/>
<DICH_DATA CI_END="1.4178011081763326" CI_START="0.68570689809271" EFFECT_SIZE="0.986" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="20" LOG_CI_END="0.15161531146775348" LOG_CI_START="-0.16386148158533112" LOG_EFFECT_SIZE="-0.0061230850587887945" ORDER="1329" O_E="0.0" SE="0.18531262987469324" STUDY_ID="STD-Tuason-1986" TOTAL_1="25" TOTAL_2="29" VAR="0.034340770791075045" WEIGHT="35.56063379542725"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.486359652984049" CI_START="0.04288459195055834" DF="0" EFFECT_SIZE="0.38666666666666666" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" I2="0.0" ID="CMP-003.02.02" LOG_CI_END="0.5423721869189941" LOG_CI_START="-1.367698717904482" LOG_EFFECT_SIZE="-0.41266326549274396" NO="2" P_CHI2="1.0" P_Z="0.3970592681285414" STUDIES="1" TAU2="0.0" TOTAL_1="25" TOTAL_2="29" WEIGHT="100.0" Z="0.8468849361204385">
<NAME>not sedated / still hostile - at 6-24 hours</NAME>
<DICH_DATA CI_END="3.486359652984049" CI_START="0.04288459195055834" EFFECT_SIZE="0.38666666666666666" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.5423721869189941" LOG_CI_START="-1.367698717904482" LOG_EFFECT_SIZE="-0.41266326549274396" ORDER="1330" O_E="0.0" SE="1.121985104496777" STUDY_ID="STD-Tuason-1986" TOTAL_1="25" TOTAL_2="29" VAR="1.2588505747126435" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.09256067720251357" CI_END="2.3801063652127534" CI_START="0.6159137313556174" DF="1" EFFECT_SIZE="1.21076017130621" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="12" I2="0.0" ID="CMP-003.02.03" LOG_CI_END="0.3765963657929682" LOG_CI_START="-0.21048011351731546" LOG_EFFECT_SIZE="0.08305812613782633" NO="3" P_CHI2="0.7609466989082889" P_Z="0.5791808117678048" STUDIES="2" TAU2="0.0" TOTAL_1="55" TOTAL_2="60" WEIGHT="100.0" Z="0.5545816996271987">
<NAME>requiring further sedation - up to 6 days</NAME>
<DICH_DATA CI_END="3.7606650944560744" CI_START="0.2839332274899679" EFFECT_SIZE="1.0333333333333334" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" LOG_CI_END="0.5752646591054879" LOG_CI_START="-0.5467837808762671" LOG_EFFECT_SIZE="0.014240439114610285" ORDER="1331" O_E="0.0" SE="0.6590968078746382" STUDY_ID="STD-Dubin-1996" TOTAL_1="30" TOTAL_2="31" VAR="0.43440860215053767" WEIGHT="34.68950749464668"/>
<DICH_DATA CI_END="2.8695864519740697" CI_START="0.593474017424511" EFFECT_SIZE="1.305" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="8" LOG_CI_END="0.45781931326130587" LOG_CI_START="-0.22659828991270642" LOG_EFFECT_SIZE="0.11561051167429974" ORDER="1332" O_E="0.0" SE="0.40203028802619023" STUDY_ID="STD-Tuason-1986" TOTAL_1="25" TOTAL_2="29" VAR="0.16162835249042146" WEIGHT="65.31049250535332"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="7.008592387598966" CI_START="-7.008592387598966" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.03" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="1.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="25" TOTAL_2="22" UNITS="" WEIGHT="100.0" Z="0.0">
<NAME>Mental state: Average endpoint score - at 72 hours (BPRS, high score=worse)</NAME>
<GROUP_LABEL_1>IM Loxapine</GROUP_LABEL_1>
<GROUP_LABEL_2>IM Typical</GROUP_LABEL_2>
<GRAPH_LABEL_1>50% loss</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Used LOCF</GRAPH_LABEL_2>
<CONT_DATA CI_END="7.008592387598966" CI_START="-7.008592387598966" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="36.5" MEAN_2="36.5" ORDER="1333" SD_1="14.25" SD_2="10.13" SE="3.5758781502526826" STUDY_ID="STD-Tuason-1986" TOTAL_1="25" TOTAL_2="22" WEIGHT="100.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.448118335255184" CI_START="0.44195283245772915" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="10" I2="0.0" I2_Q="0.0" ID="CMP-003.04" LOG_CI_END="0.16080405236422257" LOG_CI_START="-0.3546240783803354" LOG_EFFECT_SIZE="-0.09691001300805639" METHOD="MH" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="0.4611108657122922" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="15" TOTAL_2="15" WEIGHT="100.0" Z="0.7370188932556788">
<NAME>Adverse effects: 1. Any event - 72 hours</NAME>
<GROUP_LABEL_1>IM Loxapine</GROUP_LABEL_1>
<GROUP_LABEL_2>IM Typical</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Loxapine IM</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours IM Typical</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.448118335255184" CI_START="0.44195283245772915" EFFECT_SIZE="0.8" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="10" LOG_CI_END="0.16080405236422257" LOG_CI_START="-0.3546240783803354" LOG_EFFECT_SIZE="-0.09691001300805639" ORDER="1334" O_E="0.0" SE="0.30276503540974914" STUDY_ID="STD-Fruensgaard-1977" TOTAL_1="15" TOTAL_2="15" VAR="0.09166666666666666" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="5.2576556616195305" CI_END="1.1813793467069946" CI_START="0.46504003913322833" CI_STUDY="95" CI_TOTAL="95" DF="8" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7412075941487706" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="35" I2="0.0" I2_Q="0.0" ID="CMP-003.05" LOG_CI_END="0.07238937409786657" LOG_CI_START="-0.3325096535056843" LOG_EFFECT_SIZE="-0.1300601397039088" METHOD="MH" NO="5" P_CHI2="0.7297160994725372" P_Q="0.8414575363530633" P_Z="0.20797817229385762" Q="3.4407818368158978" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="215" TOTAL_2="247" WEIGHT="800.0" Z="1.2591444891959713">
<NAME>Adverse effects: 2. Movement - specific symptoms</NAME>
<GROUP_LABEL_1>IM Loxapine</GROUP_LABEL_1>
<GROUP_LABEL_2>IM Typical</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Loxapine IM</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours IM Typical</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.6367380419347817" CI_START="0.510327525373976" DF="0" EFFECT_SIZE="1.16" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="8" I2="0.0" ID="CMP-003.05.01" LOG_CI_END="0.4210669850860547" LOG_CI_START="-0.29215100663221777" LOG_EFFECT_SIZE="0.06445798922691845" NO="1" P_CHI2="1.0" P_Z="0.7231376658887723" STUDIES="1" TAU2="0.0" TOTAL_1="25" TOTAL_2="29" WEIGHT="100.0" Z="0.35426850939715093">
<NAME>akathisia - 72 hours</NAME>
<DICH_DATA CI_END="2.636738041934782" CI_START="0.5103275253739759" EFFECT_SIZE="1.16" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="8" LOG_CI_END="0.42106698508605483" LOG_CI_START="-0.2921510066322179" LOG_EFFECT_SIZE="0.06445798922691845" ORDER="1335" O_E="0.0" SE="0.4189477788213113" STUDY_ID="STD-Tuason-1986" TOTAL_1="25" TOTAL_2="29" VAR="0.17551724137931035" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.264475981467618" CI_START="0.1402386710684738" DF="0" EFFECT_SIZE="0.7733333333333333" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" I2="0.0" ID="CMP-003.05.02" LOG_CI_END="0.6298656727042774" LOG_CI_START="-0.8531322123618031" LOG_EFFECT_SIZE="-0.11163326982876277" NO="2" P_CHI2="1.0" P_Z="0.7679372180148645" STUDIES="1" TAU2="0.0" TOTAL_1="25" TOTAL_2="29" WEIGHT="100.0" Z="0.29507417447337436">
<NAME>drooling - 72 hours</NAME>
<DICH_DATA CI_END="4.264475981467618" CI_START="0.1402386710684738" EFFECT_SIZE="0.7733333333333333" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.6298656727042774" LOG_CI_START="-0.8531322123618031" LOG_EFFECT_SIZE="-0.11163326982876277" ORDER="1336" O_E="0.0" SE="0.8711202986457403" STUDY_ID="STD-Tuason-1986" TOTAL_1="25" TOTAL_2="29" VAR="0.7588505747126436" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="6.02171648023104" CI_START="0.05586447005673255" DF="0" EFFECT_SIZE="0.58" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" I2="0.0" ID="CMP-003.05.03" LOG_CI_END="0.7797203038220731" LOG_CI_START="-1.2528643166961988" LOG_EFFECT_SIZE="-0.23657200643706275" NO="3" P_CHI2="1.0" P_Z="0.648217824181001" STUDIES="1" TAU2="0.0" TOTAL_1="25" TOTAL_2="29" WEIGHT="100.0" Z="0.45623941821304625">
<NAME>dyskinesia - 72 hours</NAME>
<DICH_DATA CI_END="6.02171648023104" CI_START="0.05586447005673255" EFFECT_SIZE="0.58" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7797203038220731" LOG_CI_START="-1.2528643166961988" LOG_EFFECT_SIZE="-0.23657200643706275" ORDER="1337" O_E="0.0" SE="1.1939502675485736" STUDY_ID="STD-Tuason-1986" TOTAL_1="25" TOTAL_2="29" VAR="1.4255172413793102" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.333013791566032" CI_END="1.9882539635717584" CI_START="0.4236269327939591" DF="1" EFFECT_SIZE="0.9177570093457942" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="10" I2="24.982021466920127" ID="CMP-003.05.04" LOG_CI_END="0.2984718568889718" LOG_CI_START="-0.373016436685492" LOG_EFFECT_SIZE="-0.03727228989826007" NO="4" P_CHI2="0.2482699151731187" P_Z="0.8277537362930808" STUDIES="2" TAU2="0.0" TOTAL_1="40" TOTAL_2="44" WEIGHT="99.99999999999999" Z="0.21758337865595206">
<NAME>dystonia - 72 hours</NAME>
<DICH_DATA CI_END="3.845086034384406" CI_START="0.010402888164868843" EFFECT_SIZE="0.2" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.5849060616512035" LOG_CI_START="-1.982846070323241" LOG_EFFECT_SIZE="-0.6989700043360187" ORDER="1338" O_E="0.0" SE="1.5083103128998356" STUDY_ID="STD-Fruensgaard-1977" TOTAL_1="15" TOTAL_2="15" VAR="2.275" WEIGHT="25.23364485981308"/>
<DICH_DATA CI_END="2.636738041934782" CI_START="0.5103275253739759" EFFECT_SIZE="1.16" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="8" LOG_CI_END="0.42106698508605483" LOG_CI_START="-0.2921510066322179" LOG_EFFECT_SIZE="0.06445798922691845" ORDER="1339" O_E="0.0" SE="0.4189477788213113" STUDY_ID="STD-Tuason-1986" TOTAL_1="25" TOTAL_2="29" VAR="0.17551724137931035" WEIGHT="74.7663551401869"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.0449034400454082" CI_START="0.008923314680162987" DF="0" EFFECT_SIZE="0.16483516483516483" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" I2="0.0" ID="CMP-003.05.05" LOG_CI_END="0.48357352484397675" LOG_CI_START="-2.0494737913748016" LOG_EFFECT_SIZE="-0.7829501332654124" NO="5" P_CHI2="1.0" P_Z="0.22565527642466865" STUDIES="1" TAU2="0.0" TOTAL_1="25" TOTAL_2="29" WEIGHT="100.0" Z="1.2116268441299856">
<NAME>oculogyric crisis - 72 hours</NAME>
<DICH_DATA CI_END="3.0449034400454082" CI_START="0.008923314680162987" EFFECT_SIZE="0.16483516483516483" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.48357352484397675" LOG_CI_START="-2.0494737913748016" LOG_EFFECT_SIZE="-0.7829501332654124" ORDER="1340" O_E="0.0" SE="1.4879245323333485" STUDY_ID="STD-Tuason-1986" TOTAL_1="25" TOTAL_2="29" VAR="2.213919413919414" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.904218686089864" CI_START="0.11583149767998936" DF="0" EFFECT_SIZE="0.58" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" I2="0.0" ID="CMP-003.05.06" LOG_CI_END="0.4630293153979789" LOG_CI_START="-0.9361733282721045" LOG_EFFECT_SIZE="-0.23657200643706275" NO="6" P_CHI2="1.0" P_Z="0.5074798480169411" STUDIES="1" TAU2="0.0" TOTAL_1="25" TOTAL_2="29" WEIGHT="100.0" Z="0.6627669186656423">
<NAME>rigidity - 72 hours</NAME>
<DICH_DATA CI_END="2.904218686089864" CI_START="0.11583149767998936" EFFECT_SIZE="0.58" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" LOG_CI_END="0.4630293153979789" LOG_CI_START="-0.9361733282721045" LOG_EFFECT_SIZE="-0.23657200643706275" ORDER="1341" O_E="0.0" SE="0.8218985590565969" STUDY_ID="STD-Tuason-1986" TOTAL_1="25" TOTAL_2="29" VAR="0.6755172413793104" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.0449034400454082" CI_START="0.008923314680162987" DF="0" EFFECT_SIZE="0.16483516483516483" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" I2="0.0" ID="CMP-003.05.07" LOG_CI_END="0.48357352484397675" LOG_CI_START="-2.0494737913748016" LOG_EFFECT_SIZE="-0.7829501332654124" NO="7" P_CHI2="1.0" P_Z="0.22565527642466865" STUDIES="1" TAU2="0.0" TOTAL_1="25" TOTAL_2="29" WEIGHT="100.0" Z="1.2116268441299856">
<NAME>tremor - 72 hours</NAME>
<DICH_DATA CI_END="3.0449034400454082" CI_START="0.008923314680162987" EFFECT_SIZE="0.16483516483516483" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.48357352484397675" LOG_CI_START="-2.0494737913748016" LOG_EFFECT_SIZE="-0.7829501332654124" ORDER="1342" O_E="0.0" SE="1.4879245323333485" STUDY_ID="STD-Tuason-1986" TOTAL_1="25" TOTAL_2="29" VAR="2.213919413919414" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="6.02171648023104" CI_START="0.05586447005673255" DF="0" EFFECT_SIZE="0.58" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" I2="0.0" ID="CMP-003.05.08" LOG_CI_END="0.7797203038220731" LOG_CI_START="-1.2528643166961988" LOG_EFFECT_SIZE="-0.23657200643706275" NO="8" P_CHI2="1.0" P_Z="0.648217824181001" STUDIES="1" TAU2="0.0" TOTAL_1="25" TOTAL_2="29" WEIGHT="100.0" Z="0.45623941821304625">
<NAME>thick tongue - 72 hours</NAME>
<DICH_DATA CI_END="6.02171648023104" CI_START="0.05586447005673255" EFFECT_SIZE="0.58" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7797203038220731" LOG_CI_START="-1.2528643166961988" LOG_EFFECT_SIZE="-0.23657200643706275" ORDER="1343" O_E="0.0" SE="1.1939502675485736" STUDY_ID="STD-Tuason-1986" TOTAL_1="25" TOTAL_2="29" VAR="1.4255172413793102" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.6574720459897794" CI_END="2.9167897390761945" CI_START="0.9066459023166245" CI_STUDY="95" CI_TOTAL="95" DF="8" EFFECT_MEASURE="RR" EFFECT_SIZE="1.6261904761904762" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="15" I2="0.0" I2_Q="0.0" ID="CMP-003.06" LOG_CI_END="0.46490512351659696" LOG_CI_START="-0.04256229694933272" LOG_EFFECT_SIZE="0.2111714132836321" METHOD="MH" NO="6" P_CHI2="0.8866307326186912" P_Q="0.8891015289852705" P_Z="0.10284984080958108" Q="3.6271402029268036" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="190" TOTAL_2="206" WEIGHT="900.0" Z="1.6311918673334014">
<NAME>Adverse effects: 3. Other</NAME>
<GROUP_LABEL_1>IM Loxapine</GROUP_LABEL_1>
<GROUP_LABEL_2>IM Typical</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Loxapine IM</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours IM Typical</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="5.7569952946989815" CI_START="0.4825047851499105" DF="0" EFFECT_SIZE="1.6666666666666667" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" I2="0.0" ID="CMP-003.06.01" LOG_CI_END="0.760195874498194" LOG_CI_START="-0.3164983752654813" LOG_EFFECT_SIZE="0.2218487496163564" NO="1" P_CHI2="1.0" P_Z="0.41927124044236896" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="15" WEIGHT="100.0" Z="0.807686229138385">
<NAME>anticholinergic - 72 hours</NAME>
<DICH_DATA CI_END="5.7569952946989815" CI_START="0.4825047851499105" EFFECT_SIZE="1.6666666666666667" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" LOG_CI_END="0.760195874498194" LOG_CI_START="-0.3164983752654813" LOG_EFFECT_SIZE="0.2218487496163564" ORDER="1344" O_E="0.0" SE="0.6324555320336759" STUDY_ID="STD-Fruensgaard-1977" TOTAL_1="15" TOTAL_2="15" VAR="0.4" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="68.25874292736694" CI_START="0.13185124152633113" DF="0" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-003.06.02" LOG_CI_END="1.8341582859242351" LOG_CI_START="-0.87991577648491" LOG_EFFECT_SIZE="0.47712125471966244" NO="2" P_CHI2="1.0" P_Z="0.4907574432545426" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="15" WEIGHT="100.0" Z="0.6891046110061">
<NAME>blood test abnormalities - 72 hours</NAME>
<DICH_DATA CI_END="68.25874292736694" CI_START="0.13185124152633113" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8341582859242351" LOG_CI_START="-0.87991577648491" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="1345" O_E="0.0" SE="1.5942605391424158" STUDY_ID="STD-Fruensgaard-1977" TOTAL_1="15" TOTAL_2="15" VAR="2.5416666666666665" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="43.99701310085553" CI_START="0.818237363465475" DF="0" EFFECT_SIZE="6.0" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="1" I2="0.0" ID="CMP-003.06.03" LOG_CI_END="1.6434231938078276" LOG_CI_START="-0.08712069304054032" LOG_EFFECT_SIZE="0.7781512503836436" NO="3" P_CHI2="1.0" P_Z="0.07796405693794232" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="15" WEIGHT="100.0" Z="1.7626232271454516">
<NAME>dizziness - 72 hours</NAME>
<DICH_DATA CI_END="43.99701310085553" CI_START="0.818237363465475" EFFECT_SIZE="6.0" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="1" LOG_CI_END="1.6434231938078276" LOG_CI_START="-0.08712069304054032" LOG_EFFECT_SIZE="0.7781512503836436" ORDER="1346" O_E="0.0" SE="1.0165300454651272" STUDY_ID="STD-Fruensgaard-1977" TOTAL_1="15" TOTAL_2="15" VAR="1.0333333333333334" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.965261095458803" CI_START="0.35804316099383415" DF="0" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" I2="0.0" ID="CMP-003.06.04" LOG_CI_END="0.6959420905626427" LOG_CI_START="-0.4460646173460429" LOG_EFFECT_SIZE="0.12493873660829993" NO="4" P_CHI2="1.0" P_Z="0.6680315801223178" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="15" WEIGHT="100.0" Z="0.4288511132734677">
<NAME>drowsiness/fatigue - 72 hours</NAME>
<DICH_DATA CI_END="4.965261095458803" CI_START="0.35804316099383415" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.6959420905626427" LOG_CI_START="-0.4460646173460429" LOG_EFFECT_SIZE="0.12493873660829993" ORDER="1347" O_E="0.0" SE="0.6708203932499369" STUDY_ID="STD-Fruensgaard-1977" TOTAL_1="15" TOTAL_2="15" VAR="0.44999999999999996" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="7.6444505569118135" CI_START="0.1760231150665708" DF="0" EFFECT_SIZE="1.16" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" I2="0.0" ID="CMP-003.06.05" LOG_CI_END="0.8833462760561878" LOG_CI_START="-0.7544302976023509" LOG_EFFECT_SIZE="0.06445798922691845" NO="5" P_CHI2="1.0" P_Z="0.8773916115933563" STUDIES="1" TAU2="0.0" TOTAL_1="25" TOTAL_2="29" WEIGHT="100.0" Z="0.1542766448520111">
<NAME>increased blood pressure - 72 hours</NAME>
<DICH_DATA CI_END="7.6444505569118135" CI_START="0.1760231150665708" EFFECT_SIZE="1.16" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8833462760561878" LOG_CI_START="-0.7544302976023509" LOG_EFFECT_SIZE="0.06445798922691845" ORDER="1348" O_E="0.0" SE="0.9620380664918152" STUDY_ID="STD-Tuason-1986" TOTAL_1="25" TOTAL_2="29" VAR="0.9255172413793104" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="6.02171648023104" CI_START="0.05586447005673255" DF="0" EFFECT_SIZE="0.58" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" I2="0.0" ID="CMP-003.06.06" LOG_CI_END="0.7797203038220731" LOG_CI_START="-1.2528643166961988" LOG_EFFECT_SIZE="-0.23657200643706275" NO="6" P_CHI2="1.0" P_Z="0.648217824181001" STUDIES="1" TAU2="0.0" TOTAL_1="25" TOTAL_2="29" WEIGHT="100.0" Z="0.45623941821304625">
<NAME>increased pulse rate - 72 hours</NAME>
<DICH_DATA CI_END="6.02171648023104" CI_START="0.05586447005673255" EFFECT_SIZE="0.58" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7797203038220731" LOG_CI_START="-1.2528643166961988" LOG_EFFECT_SIZE="-0.23657200643706275" ORDER="1349" O_E="0.0" SE="1.1939502675485736" STUDY_ID="STD-Tuason-1986" TOTAL_1="25" TOTAL_2="29" VAR="1.4255172413793102" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="6.02171648023104" CI_START="0.05586447005673255" DF="0" EFFECT_SIZE="0.58" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" I2="0.0" ID="CMP-003.06.07" LOG_CI_END="0.7797203038220731" LOG_CI_START="-1.2528643166961988" LOG_EFFECT_SIZE="-0.23657200643706275" NO="7" P_CHI2="1.0" P_Z="0.648217824181001" STUDIES="1" TAU2="0.0" TOTAL_1="25" TOTAL_2="29" WEIGHT="100.0" Z="0.45623941821304625">
<NAME>nervousness - 72 hours</NAME>
<DICH_DATA CI_END="6.02171648023104" CI_START="0.05586447005673255" EFFECT_SIZE="0.58" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7797203038220731" LOG_CI_START="-1.2528643166961988" LOG_EFFECT_SIZE="-0.23657200643706275" ORDER="1350" O_E="0.0" SE="1.1939502675485736" STUDY_ID="STD-Tuason-1986" TOTAL_1="25" TOTAL_2="29" VAR="1.4255172413793102" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="7.731389706964666" CI_START="0.29102141856503916" DF="0" EFFECT_SIZE="1.5" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" I2="0.0" ID="CMP-003.06.08" LOG_CI_END="0.8882575647876686" LOG_CI_START="-0.5360750466763062" LOG_EFFECT_SIZE="0.17609125905568124" NO="8" P_CHI2="1.0" P_Z="0.6279434444203333" STUDIES="2" TAU2="0.0" TOTAL_1="40" TOTAL_2="44" WEIGHT="100.0" Z="0.4846234972977409">
<NAME>pain at injection site - 72 hours</NAME>
<DICH_DATA CI_END="7.731389706964666" CI_START="0.29102141856503916" EFFECT_SIZE="1.5" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.8882575647876686" LOG_CI_START="-0.5360750466763062" LOG_EFFECT_SIZE="0.17609125905568124" ORDER="1351" O_E="0.0" SE="0.8366600265340756" STUDY_ID="STD-Fruensgaard-1977" TOTAL_1="15" TOTAL_2="15" VAR="0.7" WEIGHT="100.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="1352" O_E="0.0" SE="0.0" STUDY_ID="STD-Tuason-1986" TOTAL_1="25" TOTAL_2="29" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="68.25874292736694" CI_START="0.13185124152633113" DF="0" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-003.06.09" LOG_CI_END="1.8341582859242351" LOG_CI_START="-0.87991577648491" LOG_EFFECT_SIZE="0.47712125471966244" NO="9" P_CHI2="1.0" P_Z="0.4907574432545426" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="15" WEIGHT="100.0" Z="0.6891046110061">
<NAME>palpatations - 72 hours</NAME>
<DICH_DATA CI_END="68.25874292736694" CI_START="0.13185124152633113" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8341582859242351" LOG_CI_START="-0.87991577648491" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="1353" O_E="0.0" SE="1.5942605391424158" STUDY_ID="STD-Fruensgaard-1977" TOTAL_1="15" TOTAL_2="15" VAR="2.5416666666666665" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-004" NO="4">
<NAME>LOXAPINE HIGH DOSE versus LOXAPINE LOW DOSE</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="4.078351010616148" CI_START="0.01137482586065345" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.21538461538461542" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-004.01" LOG_CI_END="0.6104846013865542" LOG_CI_START="-1.9440552433157894" LOG_EFFECT_SIZE="-0.6667853209646175" METHOD="MH" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.30622343692742204" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="12" TOTAL_2="13" WEIGHT="100.0" Z="1.0231785714525887">
<NAME>Leaving the study early - any reason - 12 weeks</NAME>
<GROUP_LABEL_1>High dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Low dose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours high dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours low dose</GRAPH_LABEL_2>
<DICH_DATA CI_END="4.078351010616146" CI_START="0.01137482586065346" EFFECT_SIZE="0.2153846153846154" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.610484601386554" LOG_CI_START="-1.944055243315789" LOG_EFFECT_SIZE="-0.6667853209646175" ORDER="1354" O_E="0.0" SE="1.5005493499543263" STUDY_ID="STD-Clark-1977" TOTAL_1="12" TOTAL_2="13" VAR="2.251648351648351" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.3433296689651153" CI_START="0.21841457428972863" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5416666666666666" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="8" I2="0.0" I2_Q="0.0" ID="CMP-004.02" LOG_CI_END="0.12818260674372942" LOG_CI_START="-0.660718385553268" LOG_EFFECT_SIZE="-0.2662678894047693" METHOD="MH" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.1858206521439335" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="12" TOTAL_2="13" WEIGHT="100.0" Z="1.3230442820291743">
<NAME>Global effect: 1. Not improved - 12 weeks</NAME>
<GROUP_LABEL_1>High dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Low dose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours high dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours low dose</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.3433296689651153" CI_START="0.21841457428972863" EFFECT_SIZE="0.5416666666666666" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="8" LOG_CI_END="0.12818260674372942" LOG_CI_START="-0.660718385553268" LOG_EFFECT_SIZE="-0.2662678894047693" ORDER="1355" O_E="0.0" SE="0.46340434799814917" STUDY_ID="STD-Clark-1977" TOTAL_1="12" TOTAL_2="13" VAR="0.21474358974358976" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="3.1671206229468716" CI_START="0.5336077153978199" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.3" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" I2="0.0" I2_Q="0.0" ID="CMP-004.03" LOG_CI_END="0.5006646042252811" LOG_CI_START="-0.27277789961160753" LOG_EFFECT_SIZE="0.11394335230683679" METHOD="MH" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.563613365296268" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="12" TOTAL_2="13" WEIGHT="100.00000000000001" Z="0.5774827881614739">
<NAME>Global effect: 2. Needing additional antipsychotic/sedative drugs - 12 weeks</NAME>
<GROUP_LABEL_1>High dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Low dose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours high dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours low dose</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.1671206229468716" CI_START="0.5336077153978198" EFFECT_SIZE="1.3" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" LOG_CI_END="0.5006646042252811" LOG_CI_START="-0.27277789961160764" LOG_EFFECT_SIZE="0.11394335230683679" ORDER="1356" O_E="0.0" SE="0.45432395535592934" STUDY_ID="STD-Clark-1977" TOTAL_1="12" TOTAL_2="13" VAR="0.20641025641025645" WEIGHT="100.00000000000001"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.718330831205404" CI_START="0.8811012585584387" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.5476190476190477" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="7" I2="0.0" I2_Q="0.0" ID="CMP-004.04" LOG_CI_END="0.4343023109040192" LOG_CI_START="-0.05497417841410897" LOG_EFFECT_SIZE="0.18966406624495513" METHOD="MH" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="0.12862956709413767" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="12" TOTAL_2="13" WEIGHT="100.0" Z="1.5195283121802676">
<NAME>Adverse effects: 1. Any event - 12 weeks</NAME>
<GROUP_LABEL_1>High dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Low dose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours high dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours low dose</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.718330831205404" CI_START="0.8811012585584388" EFFECT_SIZE="1.5476190476190477" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="7" LOG_CI_END="0.4343023109040192" LOG_CI_START="-0.05497417841410891" LOG_EFFECT_SIZE="0.18966406624495513" ORDER="1357" O_E="0.0" SE="0.2874034317831514" STUDY_ID="STD-Clark-1977" TOTAL_1="12" TOTAL_2="13" VAR="0.08260073260073258" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.7009690888575366" CI_START="0.008763017374355015" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.15384615384615385" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-004.05" LOG_CI_END="0.43151961394849525" LOG_CI_START="-2.0573463272342067" LOG_EFFECT_SIZE="-0.8129133566428556" METHOD="MH" NO="5" P_CHI2="1.0" P_Q="1.0" P_Z="0.20043022082624104" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="12" TOTAL_2="13" WEIGHT="100.0" Z="1.2803268148821538">
<NAME>Adverse effects: 2. Anticholinergic effects - specific symptoms</NAME>
<GROUP_LABEL_1>High dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Low dose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours high dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours low dose</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.7009690888575366" CI_START="0.008763017374355015" DF="0" EFFECT_SIZE="0.15384615384615385" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" I2="0.0" ID="CMP-004.05.01" LOG_CI_END="0.43151961394849525" LOG_CI_START="-2.0573463272342067" LOG_EFFECT_SIZE="-0.8129133566428556" NO="1" P_CHI2="1.0" P_Z="0.20043022082624104" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="13" WEIGHT="100.0" Z="1.2803268148821538">
<NAME>blurred vision - 12 weeks</NAME>
<DICH_DATA CI_END="2.7009690888575344" CI_START="0.008763017374355031" EFFECT_SIZE="0.15384615384615385" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.4315196139484949" LOG_CI_START="-2.057346327234206" LOG_EFFECT_SIZE="-0.8129133566428556" ORDER="1358" O_E="0.0" SE="1.4619721739358231" STUDY_ID="STD-Clark-1977" TOTAL_1="12" TOTAL_2="13" VAR="2.137362637362637" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.708557707314207" CI_END="2.2654307462713126" CI_START="0.3878261410779409" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9373330593794945" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="7" I2="63.079981744542735" I2_Q="56.92259329785639" ID="CMP-004.06" LOG_CI_END="0.35515079042960246" LOG_CI_START="-0.41136292103535577" LOG_EFFECT_SIZE="-0.028106065302876675" METHOD="MH" NO="6" P_CHI2="0.09981126427426201" P_Q="0.12760506681728756" P_Z="0.8857108621873007" Q="2.3214025090099915" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="24" TOTAL_2="26" WEIGHT="200.0" Z="0.14373356905902515">
<NAME>Adverse effects: 3. Cardiovascular problems</NAME>
<GROUP_LABEL_1>High dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Low dose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours high dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours low dose</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.7009690888575366" CI_START="0.008763017374355015" DF="0" EFFECT_SIZE="0.15384615384615385" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" I2="0.0" ID="CMP-004.06.01" LOG_CI_END="0.43151961394849525" LOG_CI_START="-2.0573463272342067" LOG_EFFECT_SIZE="-0.8129133566428556" NO="1" P_CHI2="1.0" P_Z="0.20043022082624104" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="13" WEIGHT="100.0" Z="1.2803268148821538">
<NAME>blood pressure - hypotension - 12 weeks</NAME>
<DICH_DATA CI_END="2.7009690888575344" CI_START="0.008763017374355031" EFFECT_SIZE="0.15384615384615385" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.4315196139484949" LOG_CI_START="-2.057346327234206" LOG_EFFECT_SIZE="-0.8129133566428556" ORDER="1359" O_E="0.0" SE="1.4619721739358231" STUDY_ID="STD-Clark-1977" TOTAL_1="12" TOTAL_2="13" VAR="2.137362637362637" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="4.807121141190541E-32" CI_END="4.384055277068699" CI_START="0.6023247502859033" DF="0" EFFECT_SIZE="1.6250000000000002" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="4" I2="100.0" ID="CMP-004.06.02" LOG_CI_END="0.6418760213829199" LOG_CI_START="-0.2201692907531335" LOG_EFFECT_SIZE="0.21085336531489324" NO="2" P_CHI2="0.0" P_Z="0.3376589607377697" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="13" WEIGHT="100.0" Z="0.9588011122344198">
<NAME>ECG abnormalites - 12 weeks</NAME>
<DICH_DATA CI_END="4.384055277068699" CI_START="0.6023247502859033" EFFECT_SIZE="1.625" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="4" LOG_CI_END="0.6418760213829199" LOG_CI_START="-0.2201692907531335" LOG_EFFECT_SIZE="0.21085336531489318" ORDER="1360" O_E="0.0" SE="0.5063696835418333" STUDY_ID="STD-Clark-1977" TOTAL_1="12" TOTAL_2="13" VAR="0.2564102564102564" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.6930101949071963" CI_END="1.112712637255514" CI_START="0.4549292818747332" CI_STUDY="95" CI_TOTAL="95" DF="8" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7114812443062652" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="33" I2="0.0" I2_Q="0.0" ID="CMP-004.07" LOG_CI_END="0.04638302042822256" LOG_CI_START="-0.34205610857048613" LOG_EFFECT_SIZE="-0.14783654407113178" METHOD="MH" NO="7" P_CHI2="0.9521227619068741" P_Q="0.9595422841343132" P_Z="0.13572788217375942" Q="2.5461885748856554" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="111" TOTAL_2="118" WEIGHT="900.0" Z="1.4918903907811514">
<NAME>Adverse effects: 4. Movement disorders</NAME>
<GROUP_LABEL_1>High dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Low dose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours high dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours low dose</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.034638991133539" CI_START="0.2870559277911743" DF="0" EFFECT_SIZE="0.9333333333333333" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" I2="0.0" ID="CMP-004.07.01" LOG_CI_END="0.48210703363731056" LOG_CI_START="-0.542033480392197" LOG_EFFECT_SIZE="-0.02996322337744321" NO="1" P_CHI2="1.0" P_Z="0.9086947089353191" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="14" WEIGHT="100.0" Z="0.11468511962182809">
<NAME>akathisia - 12 weeks</NAME>
<DICH_DATA CI_END="3.03463899113354" CI_START="0.2870559277911742" EFFECT_SIZE="0.9333333333333333" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" LOG_CI_END="0.48210703363731067" LOG_CI_START="-0.5420334803921971" LOG_EFFECT_SIZE="-0.02996322337744321" ORDER="1361" O_E="0.0" SE="0.6015852075182384" STUDY_ID="STD-Clark-1977" TOTAL_1="15" TOTAL_2="14" VAR="0.36190476190476195" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="5.235701242768925" CI_START="0.05603886932681634" DF="0" EFFECT_SIZE="0.5416666666666666" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" I2="0.0" ID="CMP-004.07.02" LOG_CI_END="0.718974857069199" LOG_CI_START="-1.2515106358787376" LOG_EFFECT_SIZE="-0.2662678894047693" NO="2" P_CHI2="1.0" P_Z="0.5963253058676485" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="13" WEIGHT="100.0" Z="0.5296922766907484">
<NAME>akinesia - 12 weeks</NAME>
<DICH_DATA CI_END="5.235701242768925" CI_START="0.05603886932681634" EFFECT_SIZE="0.5416666666666666" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.718974857069199" LOG_CI_START="-1.2515106358787376" LOG_EFFECT_SIZE="-0.2662678894047693" ORDER="1362" O_E="0.0" SE="1.1574729326181195" STUDY_ID="STD-Clark-1977" TOTAL_1="12" TOTAL_2="13" VAR="1.3397435897435899" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.01693511884425" CI_START="0.043223082178133254" DF="0" EFFECT_SIZE="0.36111111111111116" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" I2="0.0" ID="CMP-004.07.03" LOG_CI_END="0.47956597048956995" LOG_CI_START="-1.364284267410471" LOG_EFFECT_SIZE="-0.44235914846045044" NO="3" P_CHI2="1.0" P_Z="0.34699596142186206" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="13" WEIGHT="100.0" Z="0.9404321255523707">
<NAME>bradykinesia - 12 weeks</NAME>
<DICH_DATA CI_END="3.01693511884425" CI_START="0.043223082178133254" EFFECT_SIZE="0.3611111111111111" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.47956597048956995" LOG_CI_START="-1.364284267410471" LOG_EFFECT_SIZE="-0.4423591484604505" ORDER="1363" O_E="0.0" SE="1.0830867569483633" STUDY_ID="STD-Clark-1977" TOTAL_1="12" TOTAL_2="13" VAR="1.1730769230769231" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.7009690888575366" CI_START="0.008763017374355015" DF="0" EFFECT_SIZE="0.15384615384615385" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" I2="0.0" ID="CMP-004.07.04" LOG_CI_END="0.43151961394849525" LOG_CI_START="-2.0573463272342067" LOG_EFFECT_SIZE="-0.8129133566428556" NO="4" P_CHI2="1.0" P_Z="0.20043022082624104" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="13" WEIGHT="100.0" Z="1.2803268148821538">
<NAME>drooling - 12 weeks</NAME>
<DICH_DATA CI_END="2.7009690888575344" CI_START="0.008763017374355031" EFFECT_SIZE="0.15384615384615385" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.4315196139484949" LOG_CI_START="-2.057346327234206" LOG_EFFECT_SIZE="-0.8129133566428556" ORDER="1364" O_E="0.0" SE="1.4619721739358231" STUDY_ID="STD-Clark-1977" TOTAL_1="12" TOTAL_2="13" VAR="2.137362637362637" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="5.235701242768925" CI_START="0.05603886932681634" DF="0" EFFECT_SIZE="0.5416666666666666" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" I2="0.0" ID="CMP-004.07.05" LOG_CI_END="0.718974857069199" LOG_CI_START="-1.2515106358787376" LOG_EFFECT_SIZE="-0.2662678894047693" NO="5" P_CHI2="1.0" P_Z="0.5963253058676485" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="13" WEIGHT="100.0" Z="0.5296922766907484">
<NAME>dyskinesia - 12 weeks</NAME>
<DICH_DATA CI_END="5.235701242768925" CI_START="0.05603886932681634" EFFECT_SIZE="0.5416666666666666" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.718974857069199" LOG_CI_START="-1.2515106358787376" LOG_EFFECT_SIZE="-0.2662678894047693" ORDER="1365" O_E="0.0" SE="1.1574729326181195" STUDY_ID="STD-Clark-1977" TOTAL_1="12" TOTAL_2="13" VAR="1.3397435897435899" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="5.235701242768925" CI_START="0.05603886932681634" DF="0" EFFECT_SIZE="0.5416666666666666" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" I2="0.0" ID="CMP-004.07.06" LOG_CI_END="0.718974857069199" LOG_CI_START="-1.2515106358787376" LOG_EFFECT_SIZE="-0.2662678894047693" NO="6" P_CHI2="1.0" P_Z="0.5963253058676485" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="13" WEIGHT="100.0" Z="0.5296922766907484">
<NAME>dystonia - 12 weeks</NAME>
<DICH_DATA CI_END="5.235701242768925" CI_START="0.05603886932681634" EFFECT_SIZE="0.5416666666666666" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.718974857069199" LOG_CI_START="-1.2515106358787376" LOG_EFFECT_SIZE="-0.2662678894047693" ORDER="1366" O_E="0.0" SE="1.1574729326181195" STUDY_ID="STD-Clark-1977" TOTAL_1="12" TOTAL_2="13" VAR="1.3397435897435899" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.3955211694053795" CI_START="0.3456350446834742" DF="0" EFFECT_SIZE="1.0833333333333333" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" I2="0.0" ID="CMP-004.07.07" LOG_CI_END="0.5309064424238162" LOG_CI_START="-0.4613822299053924" LOG_EFFECT_SIZE="0.03476210625921191" NO="7" P_CHI2="1.0" P_Z="0.890774778219972" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="13" WEIGHT="100.0" Z="0.13732390219648832">
<NAME>needing additional anticholinergic medication - 12 weeks</NAME>
<DICH_DATA CI_END="3.3955211694053795" CI_START="0.3456350446834742" EFFECT_SIZE="1.0833333333333333" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" LOG_CI_END="0.5309064424238162" LOG_CI_START="-0.4613822299053924" LOG_EFFECT_SIZE="0.03476210625921191" ORDER="1367" O_E="0.0" SE="0.5828752780343234" STUDY_ID="STD-Clark-1977" TOTAL_1="12" TOTAL_2="13" VAR="0.33974358974358976" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.7880014673166584" CI_START="0.33488852782483586" DF="0" EFFECT_SIZE="0.7738095238095238" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="7" I2="0.0" ID="CMP-004.07.08" LOG_CI_END="0.25236787086217316" LOG_CI_START="-0.4750997297002253" LOG_EFFECT_SIZE="-0.11136592941902607" NO="8" P_CHI2="1.0" P_Z="0.5484459034028546" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="13" WEIGHT="100.0" Z="0.6000905348839612">
<NAME>rigidity - 12 weeks</NAME>
<DICH_DATA CI_END="1.7880014673166587" CI_START="0.3348885278248358" EFFECT_SIZE="0.7738095238095238" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="7" LOG_CI_END="0.2523678708621732" LOG_CI_START="-0.47509972970022535" LOG_EFFECT_SIZE="-0.11136592941902607" ORDER="1368" O_E="0.0" SE="0.42731806959305224" STUDY_ID="STD-Clark-1977" TOTAL_1="12" TOTAL_2="13" VAR="0.18260073260073262" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.199389321490883" CI_START="0.3705609134707083" DF="0" EFFECT_SIZE="0.9027777777777778" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="6" I2="0.0" ID="CMP-004.07.09" LOG_CI_END="0.3423021121300315" LOG_CI_START="-0.43114039170685714" LOG_EFFECT_SIZE="-0.04441913978841288" NO="9" P_CHI2="1.0" P_Z="0.8218834565529245" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="13" WEIGHT="100.0" Z="0.22512317018434622">
<NAME>tremor - 12 weeks</NAME>
<DICH_DATA CI_END="2.199389321490883" CI_START="0.3705609134707082" EFFECT_SIZE="0.9027777777777778" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="6" LOG_CI_END="0.3423021121300315" LOG_CI_START="-0.4311403917068573" LOG_EFFECT_SIZE="-0.04441913978841288" ORDER="1369" O_E="0.0" SE="0.45432395535592934" STUDY_ID="STD-Clark-1977" TOTAL_1="12" TOTAL_2="13" VAR="0.20641025641025645" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.0909819198036397" CI_START="0.7103607871652409" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.21875" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="8" I2="0.0" I2_Q="0.0" ID="CMP-004.08" LOG_CI_END="0.32035027759841855" LOG_CI_START="-0.1485210201852321" LOG_EFFECT_SIZE="0.08591462870659324" METHOD="MH" NO="8" P_CHI2="1.0" P_Q="1.0" P_Z="0.47258692579659756" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="12" TOTAL_2="13" WEIGHT="100.0" Z="0.718276332145002">
<NAME>Adverse effects: 5. Sleep problems</NAME>
<GROUP_LABEL_1>High dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Low dose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours high dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours low dose</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.0909819198036397" CI_START="0.7103607871652409" DF="0" EFFECT_SIZE="1.21875" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="8" I2="0.0" ID="CMP-004.08.01" LOG_CI_END="0.32035027759841855" LOG_CI_START="-0.1485210201852321" LOG_EFFECT_SIZE="0.08591462870659324" NO="1" P_CHI2="1.0" P_Z="0.47258692579659756" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="13" WEIGHT="100.0" Z="0.718276332145002">
<NAME>drowsiness - 12 weeks</NAME>
<DICH_DATA CI_END="2.0909819198036397" CI_START="0.7103607871652409" EFFECT_SIZE="1.21875" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="8" LOG_CI_END="0.32035027759841855" LOG_CI_START="-0.1485210201852321" LOG_EFFECT_SIZE="0.08591462870659324" ORDER="1370" O_E="0.0" SE="0.27541732126847224" STUDY_ID="STD-Clark-1977" TOTAL_1="12" TOTAL_2="13" VAR="0.07585470085470086" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.22126656022758012" CI_END="3.2631708079460076" CI_START="0.20230514700379193" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8124999999999998" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-004.09" LOG_CI_END="0.5136398071641889" LOG_CI_START="-0.6939930678623653" LOG_EFFECT_SIZE="-0.09017663034908813" METHOD="MH" NO="9" P_CHI2="0.6380765704795643" P_Q="0.6387024865325062" P_Z="0.7697440307113994" Q="0.2204431475624688" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="24" TOTAL_2="26" WEIGHT="200.0" Z="0.2927097322147809">
<NAME>Adverse effects: 6. Weight changes</NAME>
<GROUP_LABEL_1>High dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Low dose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours high dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours low dose</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="6.528029811075432" CI_START="0.17978029284118258" DF="0" EFFECT_SIZE="1.0833333333333333" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" I2="0.0" ID="CMP-004.09.01" LOG_CI_END="0.814782129011123" LOG_CI_START="-0.7452579164926992" LOG_EFFECT_SIZE="0.03476210625921191" NO="1" P_CHI2="1.0" P_Z="0.9303956275096956" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="13" WEIGHT="100.0" Z="0.08734708636637084">
<NAME>weight increase - 12 weeks</NAME>
<DICH_DATA CI_END="6.528029811075431" CI_START="0.17978029284118263" EFFECT_SIZE="1.0833333333333333" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.814782129011123" LOG_CI_START="-0.7452579164926991" LOG_EFFECT_SIZE="0.03476210625921191" ORDER="1371" O_E="0.0" SE="0.9163752450517144" STUDY_ID="STD-Clark-1977" TOTAL_1="12" TOTAL_2="13" VAR="0.8397435897435896" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="5.235701242768925" CI_START="0.05603886932681634" DF="0" EFFECT_SIZE="0.5416666666666666" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" I2="0.0" ID="CMP-004.09.02" LOG_CI_END="0.718974857069199" LOG_CI_START="-1.2515106358787376" LOG_EFFECT_SIZE="-0.2662678894047693" NO="2" P_CHI2="1.0" P_Z="0.5963253058676485" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="13" WEIGHT="100.0" Z="0.5296922766907484">
<NAME>weight loss - 12 weeks</NAME>
<DICH_DATA CI_END="5.235701242768925" CI_START="0.05603886932681634" EFFECT_SIZE="0.5416666666666666" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.718974857069199" LOG_CI_START="-1.2515106358787376" LOG_EFFECT_SIZE="-0.2662678894047693" ORDER="1372" O_E="0.0" SE="1.1574729326181195" STUDY_ID="STD-Clark-1977" TOTAL_1="12" TOTAL_2="13" VAR="1.3397435897435899" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="3.01693511884425" CI_START="0.043223082178133254" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.36111111111111116" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-004.10" LOG_CI_END="0.47956597048956995" LOG_CI_START="-1.364284267410471" LOG_EFFECT_SIZE="-0.44235914846045044" METHOD="MH" NO="10" P_CHI2="1.0" P_Q="1.0" P_Z="0.34699596142186206" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="12" TOTAL_2="13" WEIGHT="100.0" Z="0.9404321255523707">
<NAME>Adverse effects: 7. Others - abnormal blood results - 12 weeks</NAME>
<GROUP_LABEL_1>High dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Low dose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours high dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours low dose</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.01693511884425" CI_START="0.043223082178133254" EFFECT_SIZE="0.3611111111111111" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.47956597048956995" LOG_CI_START="-1.364284267410471" LOG_EFFECT_SIZE="-0.4423591484604505" ORDER="1373" O_E="0.0" SE="1.0830867569483633" STUDY_ID="STD-Clark-1977" TOTAL_1="12" TOTAL_2="13" VAR="1.1730769230769231" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-005" NO="5">
<NAME>LOXAPINE versus ATYPICAL ANTIPSYCHOTICS</NAME>
<DICH_OUTCOME CHI2="2.5802756555388497" CI_END="4.999121601380751" CI_START="0.31898740331172837" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="1.2627972198512376" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" I2="22.488901691306637" I2_Q="0.0" ID="CMP-005.01" LOG_CI_END="0.6988937008986889" LOG_CI_START="-0.49622646672408083" LOG_EFFECT_SIZE="0.10133361708730403" METHOD="MH" NO="1" P_CHI2="0.2752329729415618" P_Q="1.0" P_Z="0.7396109065335809" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="110" TOTAL_2="108" WEIGHT="99.99999999999999" Z="0.33236865261732956">
<NAME>Leaving the study early-any reason - 8 weeks</NAME>
<GROUP_LABEL_1>Loxapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Atypicals</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Loxapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Atypicals</GRAPH_LABEL_2>
<DICH_DATA CI_END="70.08142337334066" CI_START="0.12277782085855314" EFFECT_SIZE="2.933333333333333" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.845602913892187" LOG_CI_START="-0.910880079031175" LOG_EFFECT_SIZE="0.46736141743050613" ORDER="1374" O_E="0.0" SE="1.6191717548540585" STUDY_ID="STD-Li-2005a" TOTAL_1="44" TOTAL_2="43" VAR="2.6217171717171714" WEIGHT="14.26655285940739"/>
<DICH_DATA CI_END="100.42750446643518" CI_START="0.2489357883860937" EFFECT_SIZE="5.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.0018526709975903" LOG_CI_START="-0.603912662325553" LOG_EFFECT_SIZE="0.6989700043360189" ORDER="1375" O_E="0.0" SE="1.5306394555404428" STUDY_ID="STD-Li-2005b" TOTAL_1="34" TOTAL_2="34" VAR="2.342857142857143" WEIGHT="14.108035605413974"/>
<DICH_DATA CI_END="3.8843813103531986" CI_START="0.009683006254130959" EFFECT_SIZE="0.19393939393939394" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.5893218558533486" LOG_CI_START="-2.013989787641349" LOG_EFFECT_SIZE="-0.7123339658940003" ORDER="1376" O_E="0.0" SE="1.5291981459892532" STUDY_ID="STD-Wang-2005b" TOTAL_1="32" TOTAL_2="31" VAR="2.3384469696969696" WEIGHT="71.62541153517863"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="100.42750446643518" CI_START="0.24893578838609381" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="5.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-005.02" LOG_CI_END="2.0018526709975903" LOG_CI_START="-0.6039126623255529" LOG_EFFECT_SIZE="0.6989700043360189" METHOD="MH" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.29303786444150803" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="34" TOTAL_2="34" WEIGHT="100.0" Z="1.0514807432987772">
<NAME>Removed from analysis - 8 weeks</NAME>
<GROUP_LABEL_1>Loxapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Atypicals</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Loxapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Atypicals</GRAPH_LABEL_2>
<DICH_DATA CI_END="100.42750446643518" CI_START="0.2489357883860937" EFFECT_SIZE="5.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.0018526709975903" LOG_CI_START="-0.603912662325553" LOG_EFFECT_SIZE="0.6989700043360189" ORDER="1377" O_E="0.0" SE="1.5306394555404428" STUDY_ID="STD-Wang-2005b" TOTAL_1="34" TOTAL_2="34" VAR="2.342857142857143" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.5072819430541484" CI_END="1.5307542711650153" CI_START="0.7530808425143924" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0736767279826152" ESTIMABLE="YES" EVENTS_1="49" EVENTS_2="45" I2="0.0" I2_Q="0.0" ID="CMP-005.03" LOG_CI_END="0.1849054798933721" LOG_CI_START="-0.12315840019590915" LOG_EFFECT_SIZE="0.030873539848731497" METHOD="MH" NO="3" P_CHI2="0.9122279839189057" P_Q="1.0" P_Z="0.6944322947498336" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="236" TOTAL_2="232" WEIGHT="99.99999999999999" Z="0.39284726376385953">
<NAME>Mental state: 1. Not Improved, up to 8 weeks (PANSS)</NAME>
<GROUP_LABEL_1>Loxapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Atypicals</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Loxapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Atypicals</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.7529106241982273" CI_START="0.47445145421675067" EFFECT_SIZE="1.1428571428571428" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="7" LOG_CI_END="0.43979211184824923" LOG_CI_START="-0.3238082178928758" LOG_EFFECT_SIZE="0.05799194697768673" ORDER="1378" O_E="0.0" SE="0.4485426135725302" STUDY_ID="STD-Li-2004" TOTAL_1="30" TOTAL_2="30" VAR="0.2011904761904762" WEIGHT="15.442723107480603"/>
<DICH_DATA CI_END="2.7728622099598397" CI_START="0.612323239328879" EFFECT_SIZE="1.303030303030303" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="9" LOG_CI_END="0.44292828900054126" LOG_CI_START="-0.21301925759714319" LOG_EFFECT_SIZE="0.11495451570169904" ORDER="1379" O_E="0.0" SE="0.3853068358642023" STUDY_ID="STD-Li-2005a" TOTAL_1="44" TOTAL_2="43" VAR="0.1484613577636833" WEIGHT="20.08314729248709"/>
<DICH_DATA CI_END="2.5495527102863056" CI_START="0.6628613690478354" EFFECT_SIZE="1.3" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="10" LOG_CI_END="0.4064639951424194" LOG_CI_START="-0.17857729052874585" LOG_EFFECT_SIZE="0.11394335230683679" ORDER="1380" O_E="0.0" SE="0.34365614720431265" STUDY_ID="STD-Li-2005b" TOTAL_1="34" TOTAL_2="34" VAR="0.11809954751131221" WEIGHT="22.06103301068658"/>
<DICH_DATA CI_END="2.8339972336960395" CI_START="0.33046060968544894" EFFECT_SIZE="0.967741935483871" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="6" LOG_CI_END="0.45239942199078825" LOG_CI_START="-0.4808803002200086" LOG_EFFECT_SIZE="-0.01424043911461023" ORDER="1381" O_E="0.0" SE="0.5482131286357543" STUDY_ID="STD-Lu-2003" TOTAL_1="62" TOTAL_2="60" VAR="0.30053763440860215" WEIGHT="13.453613573730173"/>
<DICH_DATA CI_END="2.725626538430788" CI_START="0.23480839762019057" EFFECT_SIZE="0.8" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" LOG_CI_END="0.43546634914726584" LOG_CI_START="-0.6292863751633786" LOG_EFFECT_SIZE="-0.09691001300805639" ORDER="1382" O_E="0.0" SE="0.6254410208710612" STUDY_ID="STD-Wang-2005a" TOTAL_1="34" TOTAL_2="34" VAR="0.3911764705882353" WEIGHT="11.03051650534329"/>
<DICH_DATA CI_END="1.8529234864693696" CI_START="0.28489739066998254" EFFECT_SIZE="0.7265625" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="8" LOG_CI_END="0.2678574861887238" LOG_CI_START="-0.5453115283765902" LOG_EFFECT_SIZE="-0.13872702109393326" ORDER="1383" O_E="0.0" SE="0.47765950440720595" STUDY_ID="STD-Wang-2005b" TOTAL_1="32" TOTAL_2="31" VAR="0.2281586021505376" WEIGHT="17.928966510272264"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="8.57353332189807" CI_START="-5.813533321898065" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="1.3800000000000026" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-005.04" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="0.7069187808848536" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="30" TOTAL_2="30" UNITS="" WEIGHT="100.0" Z="0.3759974657282342">
<NAME>Mental state: 2a. Average endpoint score, by 8 weeks (BPRS, high score=worse)</NAME>
<GROUP_LABEL_1>Loxapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Atypicals</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="8.57353332189807" CI_START="-5.813533321898065" EFFECT_SIZE="1.3800000000000026" ESTIMABLE="YES" MEAN_1="20.76" MEAN_2="19.38" ORDER="1384" SD_1="15.72" SD_2="12.53" SE="3.6702375036683024" STUDY_ID="STD-Du-2003" TOTAL_1="30" TOTAL_2="30" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.6893691263374736" CI_END="1.812947182723947" CI_START="-4.0803557790757505" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.133704298175902" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-005.05" NO="5" P_CHI2="0.9526334285498281" P_Q="1.0" P_Z="0.4507994304924414" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="206" TOTAL_2="202" UNITS="" WEIGHT="100.0" Z="0.7540829337796223">
<NAME>Mental state: 2b. Average endpoint score, by 8 weeks (PANSS, high score=worse)</NAME>
<GROUP_LABEL_1>Loxapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Atypicals</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="6.199383292207811" CI_START="-6.939383292207806" EFFECT_SIZE="-0.36999999999999744" ESTIMABLE="YES" MEAN_1="46.42" MEAN_2="46.79" ORDER="1385" SD_1="16.04" SD_2="15.22" SE="3.3517877593804095" STUDY_ID="STD-Li-2005a" TOTAL_1="44" TOTAL_2="43" WEIGHT="20.119090353466383"/>
<CONT_DATA CI_END="6.080058467397867" CI_START="-8.240058467397878" EFFECT_SIZE="-1.0800000000000054" ESTIMABLE="YES" MEAN_1="40.69" MEAN_2="41.77" ORDER="1386" SD_1="14.44" SD_2="15.66" SE="3.653158182433708" STUDY_ID="STD-Li-2005b" TOTAL_1="34" TOTAL_2="34" WEIGHT="16.936528876460823"/>
<CONT_DATA CI_END="4.410815366615767" CI_START="-5.230815366615774" EFFECT_SIZE="-0.4100000000000037" ESTIMABLE="YES" MEAN_1="41.76" MEAN_2="42.17" ORDER="1387" SD_1="13.48" SD_2="13.68" SE="2.459644873396525" STUDY_ID="STD-Lu-2003" TOTAL_1="62" TOTAL_2="60" WEIGHT="37.36083267302814"/>
<CONT_DATA CI_END="6.187176927958648" CI_START="-9.347176927958644" EFFECT_SIZE="-1.5799999999999983" ESTIMABLE="YES" MEAN_1="45.74" MEAN_2="47.32" ORDER="1388" SD_1="15.42" SD_2="17.21" SE="3.9629181909591944" STUDY_ID="STD-Wang-2005a" TOTAL_1="34" TOTAL_2="34" WEIGHT="14.392331321270012"/>
<CONT_DATA CI_END="4.378259847796738" CI_START="-13.238259847796737" EFFECT_SIZE="-4.43" ESTIMABLE="YES" MEAN_1="54.95" MEAN_2="59.38" ORDER="1389" SD_1="18.95" SD_2="16.68" SE="4.494092706435" STUDY_ID="STD-Wang-2005b" TOTAL_1="32" TOTAL_2="31" WEIGHT="11.19121677577464"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.1383796711282902" CI_START="-0.038379671128290105" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.050000000000000044" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-005.06" NO="6" P_CHI2="1.0" P_Q="1.0" P_Z="0.26750272112329865" Q="0.0" RANDOM="NO" SCALE="0.5" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="30" TOTAL_2="30" UNITS="" WEIGHT="100.0" Z="1.1088319064318604">
<NAME>Adverse effects: 1. Average change score, by 8 weeks (TESS, high score=worse)</NAME>
<GROUP_LABEL_1>Loxapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Atypicals</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.1383796711282902" CI_START="-0.038379671128290105" EFFECT_SIZE="0.050000000000000044" ESTIMABLE="YES" MEAN_1="0.91" MEAN_2="0.86" ORDER="1390" SD_1="0.13" SD_2="0.21" SE="0.04509249752822894" STUDY_ID="STD-Du-2003" TOTAL_1="30" TOTAL_2="30" WEIGHT="100.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="24.450397244528084" CI_END="1.9246888900315062" CI_START="1.2106369292730552" CI_STUDY="95" CI_TOTAL="95" DF="8" EFFECT_MEASURE="RR" EFFECT_SIZE="1.5264663270553032" ESTIMABLE="YES" EVENTS_1="100" EVENTS_2="64" I2="67.28069519692416" I2_Q="76.68397883117784" ID="CMP-005.07" LOG_CI_END="0.2843605394227178" LOG_CI_START="0.08301391749896156" LOG_EFFECT_SIZE="0.18368722846083968" METHOD="MH" NO="7" P_CHI2="0.0019251944168292567" P_Q="0.0018029263179201171" P_Z="3.487248484616476E-4" Q="17.15558572810331" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="344" TOTAL_2="337" WEIGHT="500.0" Z="3.576125079859103">
<NAME>Adverse effects: 2. Movement disorders - 8 weeks</NAME>
<GROUP_LABEL_1>Loxapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Atypicals</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Loxapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Atypicals</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.9588233823694603" CI_START="0.006025596235575949" DF="0" EFFECT_SIZE="0.10864197530864197" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="4" I2="0.0" ID="CMP-005.07.01" LOG_CI_END="0.29199527952701637" LOG_CI_START="-2.2199999729839788" LOG_EFFECT_SIZE="-0.9640023467284812" NO="1" P_CHI2="1.0" P_Z="0.13250154669376582" STUDIES="1" TAU2="0.0" TOTAL_1="44" TOTAL_2="43" WEIGHT="100.0" Z="1.5043100728086642">
<NAME>agitation</NAME>
<DICH_DATA CI_END="1.9588233823694594" CI_START="0.006025596235575949" EFFECT_SIZE="0.10864197530864197" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="4" LOG_CI_END="0.29199527952701615" LOG_CI_START="-2.2199999729839788" LOG_EFFECT_SIZE="-0.9640023467284812" ORDER="1391" O_E="0.0" SE="1.4755584459020006" STUDY_ID="STD-Li-2005a" TOTAL_1="44" TOTAL_2="43" VAR="2.1772727272727272" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="126.23619543512021" CI_START="0.364992768358703" DF="0" EFFECT_SIZE="6.787878787878788" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" I2="0.0" ID="CMP-005.07.02" LOG_CI_END="2.101183897094496" LOG_CI_START="-0.43771574018194537" LOG_EFFECT_SIZE="0.8317340784562753" NO="2" P_CHI2="1.0" P_Z="0.19908813846518295" STUDIES="1" TAU2="0.0" TOTAL_1="32" TOTAL_2="31" WEIGHT="100.0" Z="1.284153823612851">
<NAME>akathsia</NAME>
<DICH_DATA CI_END="126.23619543512021" CI_START="0.364992768358703" EFFECT_SIZE="6.787878787878788" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="2.101183897094496" LOG_CI_START="-0.43771574018194537" LOG_EFFECT_SIZE="0.8317340784562753" ORDER="1392" O_E="0.0" SE="1.4913622146920764" STUDY_ID="STD-Wang-2005b" TOTAL_1="32" TOTAL_2="31" VAR="2.2241612554112553" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.2480284873077236" CI_END="3.059295704461896" CI_START="1.5540664510034068" DF="3" EFFECT_SIZE="2.180446930792645" ESTIMABLE="YES" EVENTS_1="71" EVENTS_2="32" I2="7.636278076899299" ID="CMP-005.07.03" LOG_CI_END="0.48562145691581604" LOG_CI_START="0.19146958504860456" LOG_EFFECT_SIZE="0.3385455209822103" NO="3" P_CHI2="0.3549419159220285" P_Z="6.436264577533373E-6" STUDIES="4" TAU2="0.0" TOTAL_1="172" TOTAL_2="168" WEIGHT="100.0" Z="4.511526811238658">
<NAME>extraparyamidal</NAME>
<DICH_DATA CI_END="3.275576565569695" CI_START="1.1662825940445911" EFFECT_SIZE="1.9545454545454546" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="13" LOG_CI_END="0.5152877553832209" LOG_CI_START="0.06680379413153954" LOG_EFFECT_SIZE="0.2910457747573803" ORDER="1393" O_E="0.0" SE="0.2634416988706501" STUDY_ID="STD-Li-2005a" TOTAL_1="44" TOTAL_2="43" VAR="0.06940152870385428" WEIGHT="40.758779971163605"/>
<DICH_DATA CI_END="3.1951651857846173" CI_START="1.1497405916461263" EFFECT_SIZE="1.9166666666666667" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="12" LOG_CI_END="0.5044933155211181" LOG_CI_START="0.06059986441881799" LOG_EFFECT_SIZE="0.28254658996996806" ORDER="1394" O_E="0.0" SE="0.2607452104855118" STUDY_ID="STD-Li-2005b" TOTAL_1="34" TOTAL_2="34" VAR="0.06798806479113384" WEIGHT="37.19594955410385"/>
<DICH_DATA CI_END="28.547503547271383" CI_START="1.6074855076214034" EFFECT_SIZE="6.774193548387097" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="2" LOG_CI_END="1.4555681355924117" LOG_CI_START="0.20614706620688125" LOG_EFFECT_SIZE="0.8308576008996466" ORDER="1395" O_E="0.0" SE="0.7339161208911004" STUDY_ID="STD-Lu-2003" TOTAL_1="62" TOTAL_2="60" VAR="0.5386328725038402" WEIGHT="6.3009532031542035"/>
<DICH_DATA CI_END="4.222838974473222" CI_START="0.5689300526311685" EFFECT_SIZE="1.55" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="5" LOG_CI_END="0.6256045211997021" LOG_CI_START="-0.2449411248591192" LOG_EFFECT_SIZE="0.1903316981702915" ORDER="1396" O_E="0.0" SE="0.5113628217653987" STUDY_ID="STD-Wang-2005b" TOTAL_1="32" TOTAL_2="31" VAR="0.26149193548387095" WEIGHT="15.744317271578348"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.9871616742106097" CI_START="0.0062127199676644" DF="0" EFFECT_SIZE="0.1111111111111111" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="4" I2="0.0" ID="CMP-005.07.04" LOG_CI_END="0.2982332024702401" LOG_CI_START="-2.20671822134889" LOG_EFFECT_SIZE="-0.9542425094393249" NO="4" P_CHI2="1.0" P_Z="0.13536724699486954" STUDIES="1" TAU2="0.0" TOTAL_1="34" TOTAL_2="34" WEIGHT="100.0" Z="1.4932672412199584">
<NAME>increased activity</NAME>
<DICH_DATA CI_END="1.9871616742106106" CI_START="0.006212719967664394" EFFECT_SIZE="0.1111111111111111" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="4" LOG_CI_END="0.29823320247024027" LOG_CI_START="-2.2067182213488903" LOG_EFFECT_SIZE="-0.9542425094393249" ORDER="1397" O_E="0.0" SE="1.4714208660608852" STUDY_ID="STD-Li-2005b" TOTAL_1="34" TOTAL_2="34" VAR="2.1650793650793654" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.3177162696663112" CI_END="1.4177321265918814" CI_START="0.8223016494124997" DF="1" EFFECT_SIZE="1.0797237915881983" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="24" I2="24.111129002510328" ID="CMP-005.07.05" LOG_CI_END="0.15159418082388115" LOG_CI_START="-0.08496883861104643" LOG_EFFECT_SIZE="0.03331267110641739" NO="5" P_CHI2="0.25100245474410243" P_Z="0.5809469526470974" STUDIES="2" TAU2="0.0" TOTAL_1="62" TOTAL_2="61" WEIGHT="99.99999999999999" Z="0.5520020479394181">
<NAME>tremor</NAME>
<DICH_DATA CI_END="1.2879222518327607" CI_START="0.7764443844160338" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="24" LOG_CI_END="0.10988964670457298" LOG_CI_START="-0.109889646704573" LOG_EFFECT_SIZE="0.0" ORDER="1398" O_E="0.0" SE="0.12909944487358055" STUDY_ID="STD-Du-2003" TOTAL_1="30" TOTAL_2="30" VAR="0.016666666666666663" WEIGHT="97.92843691148775"/>
<DICH_DATA CI_END="97.10953275882997" CI_START="0.24207515635327403" EFFECT_SIZE="4.848484848484849" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.9872618645253863" LOG_CI_START="-0.6160497789693115" LOG_EFFECT_SIZE="0.6856060427780373" ORDER="1399" O_E="0.0" SE="1.5291981459892532" STUDY_ID="STD-Wang-2005b" TOTAL_1="32" TOTAL_2="31" VAR="2.3384469696969696" WEIGHT="2.071563088512241"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.4893420545991176" CI_END="4.633122399905311" CI_START="0.7028554709919715" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.8045540796963944" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="6" I2="32.85625710279379" I2_Q="0.0" ID="CMP-005.08" LOG_CI_END="0.6658737737410971" LOG_CI_START="-0.1531339702913627" LOG_EFFECT_SIZE="0.25636990172486723" METHOD="MH" NO="8" P_CHI2="0.22231892408619613" P_Q="1.0" P_Z="0.21980928462042215" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="78" TOTAL_2="77" WEIGHT="100.0" Z="1.227035465200432">
<NAME>Adverse effects: 3. Cardiovascular - 8 weeks</NAME>
<GROUP_LABEL_1>Loxapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Atypicals</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Loxapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Atypicals</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.4893420545991176" CI_END="4.633122399905311" CI_START="0.7028554709919715" DF="1" EFFECT_SIZE="1.8045540796963944" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="6" I2="32.85625710279379" ID="CMP-005.08.01" LOG_CI_END="0.6658737737410971" LOG_CI_START="-0.1531339702913627" LOG_EFFECT_SIZE="0.25636990172486723" NO="1" P_CHI2="0.22231892408619613" P_Z="0.21980928462042215" STUDIES="2" TAU2="0.0" TOTAL_1="78" TOTAL_2="77" WEIGHT="100.0" Z="1.227035465200432">
<NAME>ECG abnormal</NAME>
<DICH_DATA CI_END="3.558142668686456" CI_START="0.3865188622990366" EFFECT_SIZE="1.1727272727272726" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" LOG_CI_END="0.5512233577392106" LOG_CI_START="-0.41282930745716284" LOG_EFFECT_SIZE="0.06919702514102388" ORDER="1400" O_E="0.0" SE="0.5662893076740065" STUDY_ID="STD-Li-2005a" TOTAL_1="44" TOTAL_2="43" VAR="0.32068357998590563" WEIGHT="83.49146110056925"/>
<DICH_DATA CI_END="40.57638819608976" CI_START="0.6161218657309964" EFFECT_SIZE="5.0" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="1" LOG_CI_END="1.6082733867998966" LOG_CI_START="-0.21033337812785904" LOG_EFFECT_SIZE="0.6989700043360189" ORDER="1401" O_E="0.0" SE="1.0682586159672365" STUDY_ID="STD-Li-2005b" TOTAL_1="34" TOTAL_2="34" VAR="1.1411764705882355" WEIGHT="16.50853889943074"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.023369785111085048" CI_END="0.5216419990058095" CI_START="0.06660412059919527" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.18639610138462726" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="21" I2="0.0" I2_Q="0.0" ID="CMP-005.09" LOG_CI_END="-0.282627449480561" LOG_CI_START="-1.176498901488343" LOG_EFFECT_SIZE="-0.7295631754844518" METHOD="MH" NO="9" P_CHI2="0.9883831114431545" P_Q="0.9425862779693832" P_Z="0.001377231601855466" Q="0.0051868285607636205" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="110" TOTAL_2="108" WEIGHT="200.0" Z="3.199380727920938">
<NAME>Adverse effects: 4. Sleep problems - 8 weeks</NAME>
<GROUP_LABEL_1>Loxapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Atypicals</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Loxapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Atypicals</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.018660987137884874" CI_END="0.7835365087417433" CI_START="0.04118891907387008" DF="1" EFFECT_SIZE="0.17964693665628245" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="11" I2="0.0" ID="CMP-005.09.01" LOG_CI_END="-0.10594076285119007" LOG_CI_START="-1.385219605140288" LOG_EFFECT_SIZE="-0.7455801839957391" NO="1" P_CHI2="0.8913428540073773" P_Z="0.02233720254997993" STUDIES="2" TAU2="0.0" TOTAL_1="78" TOTAL_2="77" WEIGHT="100.0" Z="2.284584501692495">
<NAME>insomnia</NAME>
<DICH_DATA CI_END="1.2970790099988676" CI_START="0.020453264092899263" EFFECT_SIZE="0.16287878787878787" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="6" LOG_CI_END="0.11296643141285129" LOG_CI_START="-1.6892373739933406" LOG_EFFECT_SIZE="-0.7881354712902445" ORDER="1402" O_E="0.0" SE="1.0586234363483107" STUDY_ID="STD-Li-2005a" TOTAL_1="44" TOTAL_2="43" VAR="1.1206835799859056" WEIGHT="54.82866043613707"/>
<DICH_DATA CI_END="1.6230555278435903" CI_START="0.024644874629239855" EFFECT_SIZE="0.2" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="5" LOG_CI_END="0.21033337812785904" LOG_CI_START="-1.6082733867998966" LOG_EFFECT_SIZE="-0.6989700043360187" ORDER="1403" O_E="0.0" SE="1.0682586159672365" STUDY_ID="STD-Li-2005b" TOTAL_1="34" TOTAL_2="34" VAR="1.1411764705882355" WEIGHT="45.17133956386293"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.8141594574996772" CI_START="0.04610775217828246" DF="0" EFFECT_SIZE="0.19375" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="10" I2="0.0" ID="CMP-005.09.02" LOG_CI_END="-0.08929052787477304" LOG_CI_START="-1.336226049768531" LOG_EFFECT_SIZE="-0.712758288821652" NO="2" P_CHI2="1.0" P_Z="0.02504797155237598" STUDIES="1" TAU2="0.0" TOTAL_1="32" TOTAL_2="31" WEIGHT="100.0" Z="2.240662089169134">
<NAME>sleep disturbance</NAME>
<DICH_DATA CI_END="0.8141594574996772" CI_START="0.04610775217828246" EFFECT_SIZE="0.19375" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="10" LOG_CI_END="-0.08929052787477304" LOG_CI_START="-1.336226049768531" LOG_EFFECT_SIZE="-0.712758288821652" ORDER="1404" O_E="0.0" SE="0.7324560979907745" STUDY_ID="STD-Wang-2005b" TOTAL_1="32" TOTAL_2="31" VAR="0.536491935483871" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.2883401320856023" CI_END="0.9216204897506445" CI_START="0.15809240289012197" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="RR" EFFECT_SIZE="0.3817082626528412" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="14" I2="0.0" I2_Q="0.0" ID="CMP-005.10" LOG_CI_END="-0.035447878444819676" LOG_CI_START="-0.80108899953125" LOG_EFFECT_SIZE="-0.4182684389880349" METHOD="MH" NO="10" P_CHI2="0.6556273343811367" P_Q="0.5539858216212641" P_Z="0.032237769253915034" Q="3.022988379134253" RANDOM="NO" SCALE="5.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="222" TOTAL_2="215" WEIGHT="500.0" Z="2.1414499658092274">
<NAME>Adverse effects: 5. Others - 8 weeks</NAME>
<GROUP_LABEL_1>Loxapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Atypicals</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Loxapine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Atypicals</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="7.645133861275818" CI_START="0.013666096196349616" DF="0" EFFECT_SIZE="0.32323232323232326" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-005.10.01" LOG_CI_END="0.8833850940262291" LOG_CI_START="-1.8643555265815168" LOG_EFFECT_SIZE="-0.4904852162776439" NO="1" P_CHI2="1.0" P_Z="0.48409817628420715" STUDIES="1" TAU2="0.0" TOTAL_1="32" TOTAL_2="31" WEIGHT="100.0" Z="0.6997264236978039">
<NAME>amenhorrhea</NAME>
<DICH_DATA CI_END="7.645133861275818" CI_START="0.013666096196349616" EFFECT_SIZE="0.32323232323232326" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8833850940262291" LOG_CI_START="-1.8643555265815168" LOG_EFFECT_SIZE="-0.4904852162776439" ORDER="1405" O_E="0.0" SE="1.6140364420804247" STUDY_ID="STD-Wang-2005b" TOTAL_1="32" TOTAL_2="31" VAR="2.6051136363636362" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.5365483847930164" CI_START="0.26536511320908346" DF="0" EFFECT_SIZE="0.96875" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" I2="0.0" ID="CMP-005.10.02" LOG_CI_END="0.5485796041984375" LOG_CI_START="-0.576156173169704" LOG_EFFECT_SIZE="-0.013788284485633297" NO="2" P_CHI2="1.0" P_Z="0.9616724774062447" STUDIES="1" TAU2="0.0" TOTAL_1="32" TOTAL_2="31" WEIGHT="100.0" Z="0.048054914841724895">
<NAME>anxiety</NAME>
<DICH_DATA CI_END="3.5365483847930164" CI_START="0.26536511320908346" EFFECT_SIZE="0.96875" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" LOG_CI_END="0.5485796041984375" LOG_CI_START="-0.576156173169704" LOG_EFFECT_SIZE="-0.013788284485633297" ORDER="1406" O_E="0.0" SE="0.6606753631579363" STUDY_ID="STD-Wang-2005b" TOTAL_1="32" TOTAL_2="31" VAR="0.436491935483871" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="7.645133861275818" CI_START="0.013666096196349616" DF="0" EFFECT_SIZE="0.32323232323232326" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-005.10.03" LOG_CI_END="0.8833850940262291" LOG_CI_START="-1.8643555265815168" LOG_EFFECT_SIZE="-0.4904852162776439" NO="3" P_CHI2="1.0" P_Z="0.48409817628420715" STUDIES="1" TAU2="0.0" TOTAL_1="32" TOTAL_2="31" WEIGHT="100.0" Z="0.6997264236978039">
<NAME>dermatitis</NAME>
<DICH_DATA CI_END="7.645133861275818" CI_START="0.013666096196349616" EFFECT_SIZE="0.32323232323232326" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8833850940262291" LOG_CI_START="-1.8643555265815168" LOG_EFFECT_SIZE="-0.4904852162776439" ORDER="1407" O_E="0.0" SE="1.6140364420804247" STUDY_ID="STD-Wang-2005b" TOTAL_1="32" TOTAL_2="31" VAR="2.6051136363636362" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="7.645133861275818" CI_START="0.013666096196349616" DF="0" EFFECT_SIZE="0.32323232323232326" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-005.10.04" LOG_CI_END="0.8833850940262291" LOG_CI_START="-1.8643555265815168" LOG_EFFECT_SIZE="-0.4904852162776439" NO="4" P_CHI2="1.0" P_Z="0.48409817628420715" STUDIES="1" TAU2="0.0" TOTAL_1="32" TOTAL_2="31" WEIGHT="100.0" Z="0.6997264236978039">
<NAME>enuresis</NAME>
<DICH_DATA CI_END="7.645133861275818" CI_START="0.013666096196349616" EFFECT_SIZE="0.32323232323232326" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8833850940262291" LOG_CI_START="-1.8643555265815168" LOG_EFFECT_SIZE="-0.4904852162776439" ORDER="1408" O_E="0.0" SE="1.6140364420804247" STUDY_ID="STD-Wang-2005b" TOTAL_1="32" TOTAL_2="31" VAR="2.6051136363636362" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.48135817437082523" CI_END="0.951143249589027" CI_START="0.015417023022172202" DF="1" EFFECT_SIZE="0.12109416739173576" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="7" I2="0.0" ID="CMP-005.10.05" LOG_CI_END="-0.021754070001629305" LOG_CI_START="-1.8119994790646539" LOG_EFFECT_SIZE="-0.9168767745331414" NO="5" P_CHI2="0.4878078040786076" P_Z="0.0446861573743848" STUDIES="2" TAU2="0.0" TOTAL_1="94" TOTAL_2="91" WEIGHT="100.00000000000001" Z="2.0075967766751526">
<NAME>haematological - leucopenia</NAME>
<DICH_DATA CI_END="1.2938256380657014" CI_START="0.004287618279190153" EFFECT_SIZE="0.07448107448107448" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="6" LOG_CI_END="0.11187575274058126" LOG_CI_START="-2.3677838862398843" LOG_EFFECT_SIZE="-1.1279540667496515" ORDER="1409" O_E="0.0" SE="1.4565643464502993" STUDY_ID="STD-Lu-2003" TOTAL_1="62" TOTAL_2="60" VAR="2.1215796953501873" WEIGHT="81.26116224756149"/>
<DICH_DATA CI_END="7.645133861275818" CI_START="0.013666096196349616" EFFECT_SIZE="0.32323232323232326" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8833850940262291" LOG_CI_START="-1.8643555265815168" LOG_EFFECT_SIZE="-0.4904852162776439" ORDER="1410" O_E="0.0" SE="1.6140364420804247" STUDY_ID="STD-Wang-2005b" TOTAL_1="32" TOTAL_2="31" VAR="2.6051136363636362" WEIGHT="18.738837752438524"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES>
<FIGURE FILENAME="Other figure.jpg" FILE_TYPE="JPG" ID="FIG-01" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Loxapine - structure</P>
</CAPTION>
<FILE>/9j/4AAQSkZJRgABAgAAAQABAAD/2wBDAAgGBgcGBQgHBwcJCQgKDBQNDAsLDBkSEw8UHRofHh0a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==
</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK>
<FEEDBACK_ITEM ID="FBK-01" NO="1">
<TITLE>Included studies</TITLE>
<DATE_SUBMITTED>
<DATE DAY="" MONTH="" YEAR=""/>
</DATE_SUBMITTED>
<FEEDBACK_SUMMARY>
<P>Category: Included studies<BR/>This review does not include Clark 1972 which is included in the Cochrane Library Chlorpromazine review. In addition to a chlorpromazine and<BR/>placebo arm, this study has a loxapine arm.</P>
</FEEDBACK_SUMMARY>
<FEEDBACK_REPLY>
<P>The reviewers would like to thank the commentator for drawing our attention to the omission of the study, which had been identified in the original electronic search. The study will be included in the next update of the review and placed in the 'awaiting assessment' section in the interim.</P>
</FEEDBACK_REPLY>
<FEEDBACK_CONTRIBUTORS>
<P>Comment received from Paul Waraich, University of British Columbia,Canada, November 2000.<BR/>Reply by Mark Fenton, Scarborough, UK, November 2000.</P>
</FEEDBACK_CONTRIBUTORS>
</FEEDBACK_ITEM>
</FEEDBACK>
<APPENDICES/>
<EXTENSIONS/>
</COCHRANE_REVIEW>